

Medicare Part D: 5 Tier Closed Performance Formulary 2025

Por favor haga clic aquí.

Para Medicare Part D: Criterios de autorización previa

Por favor haga clic aquí.

Para Medicare Part D: Criterios de terapia escalonada

Por favor haga clic aquí.

Para obtener información más reciente o hacer otras preguntas, comuníquese con:

Servicio de farmacia Freedom Blue PPO (DE) al 1-844-576-1246

Servicio de farmacia Freedom Blue PPO (PA) al 1-800-550-8722

Servicio de farmacia Freedom Blue PPO (WV) al 1-888-459-4020

Servicio de farmacia Security Blue HMO-POS al 1-800-935-2583

Servicio de farmacia Community Blue Medicare HMO al 1-888-234-5397

Servicio de farmacia Community Blue Medicare PPO al 1-888-757-2946

Servicio de farmacia Community Blue Medicare Plus PPO al 1-888-757-2946

Servicio de farmacia Complete Blue PPO al 1-833-227-9375

Servicio de farmacia Together Blue Medicare HMO al 1-888-328-5704

Los usuarios de TTY deben llamar al 711, los siete días de la semana, de 8 a. m. a 8 p. m., o visitar **[medicare.highmark.com/formulary](https://www.medicare.highmark.com/formulary)**.

ID del formulario: 25023 Versión: 8

Actualizado: 10/2024

Nota a los miembros actuales: Este formulario ha cambiado desde el año pasado. Revise este documento para asegurarse de que aún contenga los medicamentos que toma.

Cuando esta Lista de medicamentos (Formulario) se refiere a “nosotros” o “nuestro”, significa Highmark Senior Health Company, Highmark Choice Company, Highmark Senior Solutions Company, Highmark BCBSD Inc., o Highmark Health Insurance Company.

Cuando se refiere a “plan” o “nuestro plan”, significa Freedom Blue PPO, Security Blue HMO-POS, Community Blue Medicare HMO, Community Blue Medicare PPO, Community Blue Medicare Plus PPO, Complete Blue PPO, Complete Blue Plus PPO o Together Blue Medicare HMO.

Este documento incluye una Lista de medicamentos (formulario) para nuestro plan, en vigor a partir del 1 de enero de 2025. Para obtener una Lista de medicamentos (formulario) actualizada, comuníquese con nosotros. Nuestra información de contacto, junto con la fecha de la última actualización de la lista de medicamentos cubiertos, aparece en la portada y en la contracubierta.

Generalmente, debe utilizar las farmacias de la red para recibir el beneficio de los medicamentos con receta. Los beneficios, el formulario, la red de farmacias o los copagos/coseguros pueden cambiar el 1 de enero de 2026 y ocasionalmente durante el año.

¿Qué es el formulario de Freedom Blue PPO, Security Blue HMO-POS, Community Blue Medicare HMO, Community Blue Medicare PPO, Community Blue Medicare Plus PPO, Complete Blue PPO, Complete Blue Plus PPO y Together Blue Medicare HMO?

En este documento, usamos los términos Lista de medicamentos y formulario para referirnos a lo mismo: una lista de medicamentos cubiertos que selecciona nuestro plan junto con un equipo de proveedores de atención médica, que representa a las terapias recetadas que se consideran parte necesaria de un programa de tratamiento de calidad. Nuestro plan generalmente cubrirá los medicamentos mencionados en nuestra lista de medicamentos cubiertos (formulario) siempre que el medicamento sea medicamento necesario, la receta se surta en una de las farmacias de la red de nuestro plan y se sigan otras reglas del plan. Para obtener más información sobre cómo surtir sus recetas, consulte su Evidencia de cobertura.

¿Puede cambiar el formulario?

La mayoría de los cambios en la cobertura de medicamentos ocurre el 1 de enero, pero es posible que agreguemos o eliminemos medicamentos del formulario durante el año, que los movamos a diferentes niveles de costo compartido o que agreguemos nuevas restricciones. Debemos seguir las reglas de Medicare al hacer estos cambios. Las actualizaciones del formulario se publican mensualmente en nuestro sitio web aquí: [medicare.highmark.com/formulary](https://www.medicare.highmark.com/formulary).

Cambios que pueden afectarlo este año: En los casos que se mencionan abajo, los cambios de cobertura lo afectarán durante el año:

- **Sustituciones inmediatas de ciertas nuevas versiones de medicamentos de marca y productos biológicos originales.** Podemos eliminar inmediatamente un medicamento de nuestro formulario si vamos a reemplazarlo con una nueva versión de ese medicamento que aparecerá en el mismo o en un nivel de costo compartido más bajo y con las mismas o menos restricciones. Cuando agregamos una nueva versión de un medicamento a nuestro formulario, podemos decidir mantener el medicamento de marca o el producto biológico original en nuestro formulario, pero moverlo inmediatamente a un nivel diferente de costo compartido o agregar nuevas restricciones.

Solo podemos hacer estos cambios inmediatos si vamos a agregar una nueva versión genérica de un medicamento de marca, o ciertas nuevas versiones biosimilares de un producto biológico original que ya estaba en el formulario (por ejemplo, si se agrega un biosimilar intercambiable que puede sustituir un producto biológico original en una farmacia sin una nueva receta).

Si actualmente está tomando el medicamento de marca o el producto biológico original, es posible que no le avisemos por adelantado antes de hacer un cambio inmediato, pero después le daremos información sobre el cambio específico que hicimos.

Si hacemos dicho cambio, usted o su médico pueden solicitarnos una excepción para que continuemos cubriendo el medicamento que se va a cambiar. Para obtener más información, consulte la sección de abajo titulada “¿Cómo solicito una excepción al formulario de Freedom Blue PPO, Security Blue HMO-POS, Community Blue Medicare HMO, Community Blue Medicare PPO, Community Blue Medicare Plus PPO, Complete Blue PPO, Complete Blue Plus PPO o Together Blue Medicare HMO?”

Algunos de estos tipos de medicamentos pueden ser nuevos para usted. Para obtener más información, consulte la sección debajo titulada “¿Qué son los productos biológicos originales y cómo están relacionados con los biosimilares?”

- **Medicamentos sacados del mercado.** Si un fabricante retira un medicamento de la venta o la Administración de Alimentos y Medicamentos (FDA) determina que se debe retirar por razones de seguridad o efectividad, podemos eliminar inmediatamente el medicamento de nuestro formulario y posteriormente informar a los miembros que lo están tomando.
- **Otros cambios.** Es posible que hagamos otros cambios que afecten a los miembros que actualmente toman un medicamento. Por ejemplo, podemos retirar un medicamento de marca de nuestro formulario al agregar un equivalente genérico o eliminar un producto biológico original al agregar un biosimilar. También podemos aplicar nuevas restricciones al medicamento de marca o al producto biológico original, moverlo a un nivel de costo compartido diferente, o las dos cosas. Estos cambios pueden hacerse de acuerdo con nuevas directrices clínicas. Si eliminamos medicamentos de nuestro formulario, agregamos autorización previa, límites de cantidad o restricciones de terapia escalonada a un medicamento, o movemos un medicamento a un nivel de costo compartido más alto, debemos informar a los miembros afectados sobre el cambio al menos 31 días antes de que el cambio entre en vigor. Alternativamente, cuando un miembro solicita un resurtido del medicamento, puede recibir un suministro de 31 días del medicamento junto con el aviso del cambio.

Si hacemos estos otros cambios, usted o su médico pueden solicitarnos una excepción para que continuemos cubriendo el medicamento que toma. El aviso que le enviemos también incluirá información sobre cómo solicitar una excepción, y también puede encontrar esta información en la sección de abajo titulada “¿Cómo solicito una excepción al formulario de Freedom Blue PPO, Security Blue HMO-POS, Community Blue Medicare HMO, Community Blue Medicare PPO, Community Blue Medicare Plus PPO, Complete Blue PPO, Complete Blue Plus PPO o Together Blue Medicare HMO?”

Cambios que no lo afectarán si actualmente está tomando el medicamento. Por lo general, si está tomando un medicamento de nuestra lista de medicamentos cubiertos de 2025 que estaba cubierto al inicio del año, no descontinuaremos ni reduciremos la cobertura del medicamento durante el año de cobertura del 2025, excepto como se describe arriba. Esto significa que estos medicamentos seguirán disponibles con el mismo costo compartido y sin nuevas restricciones para los miembros que los estén tomando durante el resto del año de cobertura. No recibirá un aviso directo este año sobre los cambios que no lo afecten. Pero, el 1 de enero del próximo año, dichos cambios lo afectarán y es importante consultar el formulario para el nuevo año de beneficios para conocer si hay cambios en los medicamentos.

La lista de medicamentos cubiertos adjunta está actualizada al 30 de agosto de 2024. Para recibir información actualizada sobre los medicamentos que cubre nuestro plan, comuníquese con nosotros. Nuestra información de contacto está en la portada y en la contracubierta. Si hay cambios a medio año en la lista de medicamentos cubiertos, que no sean cambios de mantenimiento, se les avisará por correo a los miembros y los miembros potenciales recibirán una actualización de esta lista de medicamentos cubiertos. El formulario más actualizado está disponible en nuestro sitio web: [medicare.highmark.com/formulary](https://www.medicare.highmark.com/formulary).

¿Cómo uso el formulario?

Hay dos formas de buscar su medicamento en el formulario:

Condición médica

El formulario comienza en la página 9. Los medicamentos de este formulario están agrupados en categorías según el tipo de condiciones para los que se usan. Por ejemplo, los medicamentos que se usan para tratar una condición cardíaca se mencionan en la categoría “Cardiovascular, hipertensión y lípidos”. Si sabe para qué se usa su medicamento, busque el nombre de la categoría en la lista que comienza en la página 9. Luego, busque su medicamento debajo del nombre de la categoría.

Lista en orden alfabético

Si no está seguro en qué categoría buscar, debe buscar su medicamento en el Índice que comienza en la página 9. El índice incluye una lista en orden alfabético de todos los medicamentos incluidos en este documento. Los medicamentos de marca y los genéricos se mencionan en el Índice. Consulte el índice y busque su medicamento. Junto a su medicamento, verá el número de página donde puede encontrar información de la cobertura. Vaya a la página incluida en el Índice y busque el nombre de su medicamento en la primera columna de la lista.

¿Qué son los medicamentos genéricos?

Nuestro plan cubre medicamentos de marca y medicamentos genéricos. La FDA aprueba un medicamento genérico siempre que tenga el mismo ingrediente activo que el medicamento de marca. Generalmente, los medicamentos genéricos funcionan tan bien como los productos de marca y pueden costar menos. Hay medicamentos genéricos sustitutos disponibles para muchos medicamentos de marca. Los medicamentos genéricos generalmente pueden sustituirse por el medicamento de marca en la farmacia sin necesidad de una nueva receta, según las leyes estatales.

¿Qué son los productos biológicos originales y cómo se relacionan con los biosimilares?

En el formulario, cuando nos referimos a medicamentos, esto puede significar un medicamento o un producto biológico. Los productos biológicos son medicamentos que son más complejos que los medicamentos habituales. Debido a que los productos biológicos son más complejos que los medicamentos normales, en vez de tener una forma genérica, tienen alternativas llamadas biosimilares. En general, los biosimilares funcionan tan bien como el producto biológico original y pueden costar menos. Existen alternativas biosimilares para algunos productos biológicos originales. Algunos biosimilares son biosimilares intercambiables y, según las leyes estatales, pueden sustituir el producto biológico original en la farmacia sin necesidad de una nueva receta, al igual que los medicamentos genéricos pueden sustituir los medicamentos de marca.

- Para obtener información sobre los tipos de medicamentos, consulte la Evidencia de cobertura, Capítulo 5, Sección 3.1, “La ‘Lista de medicamentos’ menciona qué medicamentos de la Parte D están cubiertos”.

¿Hay alguna restricción en mi cobertura?

Algunos medicamentos cubiertos pueden tener otros requisitos o límites de cobertura. Estos requisitos y límites pueden incluir:

- **Autorización previa:** Nuestro plan exige que usted o su médico obtengan una autorización previa para ciertos medicamentos. Esto significa que necesitará la aprobación de nuestro plan antes de que se le surtan sus recetas médicas. Si no obtiene la aprobación, es posible que nuestro plan no cubra el medicamento.
- **Límites de cantidad:** Para ciertos medicamentos, nuestro plan limita la cantidad del medicamento que cubriremos. Por ejemplo, nuestro plan da 31 tabletas, cada 31 días, por receta de Losartan 100 mg. Esto puede ser además del suministro estándar para uno o tres meses.
- **Terapia escalonada:** En algunos casos, nuestro plan exige que primero pruebe con ciertos medicamentos para tratar su condición antes de cubrir otro medicamento para dicha condición. Por ejemplo, si el Medicamento A y el Medicamento B están recomendados para su condición, es posible que nuestro plan no cubra el Medicamento B, a menos que pruebe primero el Medicamento A. Si el Medicamento A no funciona para usted, entonces nuestro plan cubrirá el Medicamento B.

Puede averiguar si su medicamento tiene más requisitos o límites consultando la lista de medicamentos cubiertos que comienza en la página 9. También puede obtener más información sobre las restricciones aplicadas a medicamentos cubiertos específicos visitando nuestro sitio web. Publicamos documentos en línea que explican nuestra autorización previa y las restricciones de la terapia escalonada. También puede pedirnos que le enviemos una copia. Nuestra información de contacto, junto con la fecha de la última actualización de la lista de medicamentos cubiertos, aparece en la portada y en la contracubierta.

Puede pedir a nuestro plan que hagamos una excepción a estas restricciones o límites, o para una lista de otros medicamentos similares que podrían servir para tratar su condición médica. Consulte la sección, “¿Cómo solicito una excepción al Formulario de Freedom Blue PPO, Security Blue HMO-POS, Community Blue Medicare HMO, Community Blue Medicare PPO, Community Blue Medicare Plus PPO, Complete Blue PPO, Complete Blue Plus PPO o Together Blue Medicare HMO?” en la página 6 para obtener información sobre cómo solicitar una excepción.

¿Qué pasa si mi medicamento no está en el Formulario?

Si su medicamento no está incluido en esta Lista de medicamentos cubiertos (Formulario), primero debe comunicarse con Servicios de Farmacia y preguntar si su medicamento está cubierto.

Si usted se entera que de nuestro plan no cubre su medicamento, tiene dos opciones:

- Puede pedir a Servicios de Farmacia una lista de medicamentos similares que estén cubiertos por nuestro plan. Cuando reciba la lista, preséntesela al médico y pídale que le recete algún medicamento similar que cubra nuestro plan.
- Puede solicitar a nuestro plan que haga una excepción y cubra su medicamento. Consulte más abajo para obtener información sobre cómo solicitar una excepción.

¿Cómo solicito una excepción al Formulario de Freedom Blue PPO, Security Blue HMO-POS, Community Blue Medicare HMO, Community Blue Medicare PPO, Community Blue Medicare Plus PPO, Complete Blue PPO, Complete Blue Plus PPO o Together Blue Medicare HMO?

Puede solicitar a nuestro plan que haga una excepción a nuestras reglas de cobertura. Hay varios tipos de excepciones que puede pedirnos.

- Puede pedirnos que cubramos un medicamento aunque no esté en nuestro formulario. Si se aprueba, este medicamento estará cubierto a un nivel de costo compartido predeterminado, y no podrá pedirnos que le demos el medicamento a un nivel de costo compartido más bajo.

- Puede solicitarnos que eliminemos una restricción de cobertura, incluyendo la autorización previa, la terapia escalonada o un límite de cantidad del medicamento. Por ejemplo, para ciertos medicamentos, nuestro plan limita la cantidad del medicamento que cubriremos. Si su medicamento tiene un límite de cantidad, puede pedirnos que no apliquemos el límite y cubramos una cantidad mayor.
- Puede pedirnos que cubramos un medicamento del formulario a un menor nivel de costo compartido, a menos que el medicamento esté en el nivel de especialidad. Si se aprueba, esto reduciría la cantidad que debe pagar por el medicamento.

Generalmente, nuestro plan solo aprobará su solicitud de excepción si los medicamentos alternativos incluidos en el formulario del plan, el medicamento de menor costo compartido, o la aplicación de la restricción no serían tan efectivos para usted o le causarían efectos adversos.

Usted o su médico deben comunicarse con nosotros para solicitar una excepción de nivel o del formulario, incluyendo una excepción a una restricción de cobertura. **Cuando solicite una excepción, su médico deberá explicar las razones médicas por las que necesita la excepción.** Por lo general, debemos tomar nuestra decisión en un plazo de 72 horas después de recibir la declaración de respaldo de la persona que receta. Puede solicitar una decisión expedita (rápida) si cree, y estamos de acuerdo, que su salud podría verse gravemente afectada al esperar hasta 72 horas para una decisión. Si estamos de acuerdo, o si su médico solicita una decisión rápida, debemos tomar una decisión a más tardar 24 horas después de recibir la declaración de apoyo de su médico.

¿Qué puedo hacer si mi medicamento no está en el formulario o tiene una restricción?

Como miembro nuevo o actual de nuestro plan, es posible que esté tomando medicamentos que no se encuentran en nuestra lista de medicamentos cubiertos. O puede que esté tomando un medicamento que está en nuestro formulario pero que tiene una restricción de cobertura, como la autorización previa. Debe hablar con su médico sobre solicitar una decisión de cobertura para demostrar que cumple los criterios de aprobación, cambiar a un medicamento alternativo que cubrimos o solicitar una excepción al formulario para que cubramos el medicamento que toma. Mientras usted y su médico determinan el mejor curso de acción para usted, podemos cubrir su medicamento en ciertos casos durante los primeros 90 días en que sea miembro de nuestro plan.

Para cada uno de sus medicamentos que no esté en nuestro formulario o tenga una restricción de cobertura, cubriremos un suministro temporal de 31 días. Si su receta es para menos días, permitiremos resurtidos para que tenga un suministro máximo de medicamentos para 31 días. Si la cobertura no se aprueba después de su primer suministro de 31 días, no pagaremos por estos medicamentos, incluso si fue miembro del plan durante menos de 90 días.

Si usted es residente de un centro de atención a largo plazo y necesita un medicamento que no está en nuestra lista de medicamentos cubiertos o si su capacidad para obtener sus medicamentos es limitada, pero ya cumplió los primeros 90 días de membresía en nuestro plan, cubriremos un suministro de emergencia para 31 días de ese medicamento mientras pida una excepción a la lista de medicamentos cubiertos.

El proceso de transición de arriba se implementará como una adaptación para usted si necesita inmediatamente un medicamento que no está en el formulario o un medicamento que necesite autorización previa debido a un cambio en su nivel de atención mientras espera que se procese una solicitud de excepción.

Para obtener más información

Para obtener más información detallada sobre la cobertura de medicamentos con receta de su plan, revise su Evidencia de cobertura y otro material del plan.

Si tiene alguna pregunta sobre su plan, comuníquese con nosotros. Nuestra información de contacto, junto con la fecha de la última actualización de la lista de medicamentos cubiertos, aparece en la portada y en la contracubierta.

Si tiene preguntas generales sobre la cobertura de medicamentos con receta de Medicare, llame a Medicare al 1-800-MEDICARE (1-800-633-4227) las 24 horas del día, los siete días de la semana. Los usuarios de TTY deberán llamar al 1-877-486-2048. O visite <http://www.medicare.gov>.

Formulario de Freedom Blue PPO, Security Blue HMO-POS, Community Blue Medicare HMO, Community Blue Medicare PPO, Community Blue Medicare Plus PPO, Complete Blue PPO, Complete Blue Plus PPO o Together Blue Medicare HMO

El formulario que empieza en la siguiente página da información de cobertura sobre los medicamentos cubiertos por su plan. Si tiene problemas para encontrar su medicamento en la lista, consulte el índice en la página 9.

La primera columna de la tabla muestra el nombre del medicamento. Los medicamentos de marca están en mayúsculas (por ejemplo, ABELCET) y los medicamentos genéricos están en cursiva minúscula (por ejemplo, *abacavir*).

La información en la columna Requisitos/Límites le dice si su plan tiene algún requisito especial de cobertura de su medicamento.

El siguiente es solo un ejemplo del formato del formulario:

| Nombre del medicamento | Nivel del medicamento | Requisitos/Límites |
|-------------------------------|------------------------------|---------------------------|
| Antiinfecciosos | | |
| <i>MEDICAMENTO XYZ</i> | NF | QL-28 |

Table of Contents

| | |
|---|----|
| Anti-Infeciosos | 3 |
| Cardiovascular, Hipertensión / Lípidos | 11 |
| Dermatológicos/Terapia Tópica | 17 |
| Diagnósticos / Agentes Varios | 21 |
| Endocrino/Diabetes | 23 |
| Gastroenterología | 27 |
| Inmunología, Vacunas / Biotecnología | 29 |
| Medicamentos Antineoplásicos E Inmunosupresores | 32 |
| Medicamentos Autonómicos/Snc, Neurología/Psico | 40 |
| Medicamentos Para Oídos, Nariz Y Garganta | 54 |
| Musculoesquelético / Reumatología | 55 |
| Obstetricia / Ginecología | 56 |
| Oftalmología | 60 |
| Respiratorio Y Alergia | 62 |
| Suministros Variados | 65 |
| Urológicos | 65 |
| Vitaminas, Hematinicos / Electrolitos | 66 |

Nivel de medicamento

T1 = El Nivel 1 de costo compartido incluye medicamentos genéricos preferidos. Este es el nivel de costo compartido más bajo.

T2 = El Nivel 2 de costo compartido incluye medicamentos genéricos.

T3 = El Nivel 3 de costo compartido incluye medicamentos de marca preferidos y puede incluir algunos medicamentos de fuente única (aquellos medicamentos genéricos fabricados por un solo fabricante).

T4 = El Nivel 4 de costo compartido incluye medicamentos de marca no preferidos y puede incluir algunos medicamentos genéricos de una sola fuente (aquellos medicamentos genéricos fabricados por un solo fabricante).

T5 = El Nivel 5 de costo compartido incluye medicamentos especializados. Este es el nivel de costo compartido más alto.

Requisitos/Límites

LA = Acceso limitado

PA = Se requiere autorización previa

PA-BvD = Este medicamento puede estar cubierto por la parte B o D de Medicare según las circunstancias.

Es posible que sea necesario enviar información que describa el uso y la establecimiento del medicamento para tomar la determinación.

PA-NC = Se requiere autorización previa solo para nuevos inicios

QL = Se aplica límite de cantidad.

El límite de cantidad se anota para cada medicamento. Por ejemplo, si el límite de cantidad es LC (90 c/u por 180 días), el límite de cantidad sería 90 unidades por suministro de 180 días.

ST = Se aplica la terapia escalonada

ST-NC = La terapia escalonada se aplica únicamente a los nuevos comienzos.

lowercase italics = Generic drugs

UPPERCASE BOLD = Brand name drugs

| Nombre del medicamento | Nivel de medicamento | Requisitos/Límites |
|---|-----------------------------|---------------------------|
| Anti-Infeciosos | | |
| <i>abacavir</i> | T4 | |
| <i>abacavir-lamivudine</i> | T4 | |
| <i>acyclovir oral capsule</i> | T2 | |
| <i>acyclovir oral suspension 200 mg/5 ml</i> | T4 | |
| <i>acyclovir oral tablet</i> | T2 | |
| <i>acyclovir sodium intravenous solution</i> | T4 | PA-BvD |
| <i>adefovir</i> | T4 | |
| <i>albendazole</i> | T4 | |
| <i>amantadine hcl oral capsule</i> | T3 | QL (124 EA per 31 days) |
| <i>amantadine hcl oral solution</i> | T3 | |
| <i>amantadine hcl oral tablet</i> | T3 | |
| <i>amikacin injection solution 500 mg/2 ml</i> | T4 | |
| <i>amoxicillin oral capsule</i> | T1 | |
| <i>amoxicillin oral suspension for reconstitution</i> | T1 | |
| <i>amoxicillin oral tablet</i> | T2 | |
| <i>amoxicillin oral tablet, chewable 125 mg, 250 mg</i> | T1 | |

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla al principio de esta tabla.

| Nombre del medicamento | Nivel de medicamento | Requisitos/Límites |
|---|-----------------------------|---------------------------|
| <i>amoxicillin-pot clavulanate oral suspension for reconstitution</i> | T2 | |
| <i>amoxicillin-pot clavulanate oral tablet</i> | T2 | |
| <i>amoxicillin-pot clavulanate oral tablet, chewable</i> | T2 | |
| <i>amphotericin b</i> | T4 | PA-BvD |
| <i>amphotericin b liposome</i> | T5 | PA-BvD |
| <i>ampicillin oral capsule 500 mg</i> | T2 | |
| <i>ampicillin sodium injection recon soln 1 gram, 10 gram, 125 mg</i> | T4 | |
| <i>ampicillin-sulbactam injection</i> | T4 | |
| APTIVUS | T5 | |
| ARIKAYCE | T5 | PA |
| <i>atazanavir</i> | T4 | |
| <i>atovaquone</i> | T4 | |
| <i>atovaquone-proguanil</i> | T3 | |
| <i>azithromycin intravenous</i> | T2 | |
| <i>azithromycin oral packet</i> | T2 | |
| <i>azithromycin oral tablet</i> | T2 | |
| <i>aztreonam injection recon soln 1 gram</i> | T4 | |
| <i>aztreonam injection recon soln 2 gram</i> | T5 | |
| BICILLIN C-R | T3 | |
| BICILLIN L-A INTRAMUSCULAR SYRINGE 600,000 UNIT/ML | T3 | |
| BIKTARVY | T5 | QL (31 EA per 31 days) |
| <i>caspofungin</i> | T4 | |
| CAYSTON | T5 | PA |
| <i>cefaclor oral capsule 500 mg</i> | T2 | |
| <i>cefadroxil oral capsule</i> | T2 | |
| <i>cefadroxil oral suspension for reconstitution 250 mg/5 ml</i> | T2 | |
| <i>cefadroxil oral suspension for reconstitution 500 mg/5 ml</i> | T4 | |
| <i>cefadroxil oral tablet</i> | T3 | |
| <i>cefazolin injection recon soln 1 gram, 500 mg</i> | T2 | |
| <i>cefazolin injection recon soln 10 gram</i> | T4 | |
| <i>cefdinir oral capsule</i> | T2 | |
| <i>cefepime injection</i> | T4 | |

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla al principio de esta tabla.

| Nombre del medicamento | Nivel de medicamento | Requisitos/Límites |
|---|-----------------------------|---------------------------|
| <i>cefixime oral capsule</i> | T2 | |
| <i>cefoxitin</i> | T4 | |
| <i>cefpodoxime oral suspension for reconstitution 100 mg/5 ml</i> | T4 | |
| <i>cefpodoxime oral suspension for reconstitution 50 mg/5 ml</i> | T3 | |
| <i>cefpodoxime oral tablet</i> | T3 | |
| <i>cefprozil</i> | T2 | |
| <i>ceftazidime</i> | T4 | |
| <i>ceftriaxone injection recon soln 1 gram, 10 gram, 2 gram, 250 mg, 500 mg</i> | T2 | |
| <i>cefuroxime axetil oral tablet</i> | T2 | |
| <i>cefuroxime sodium injection recon soln 750 mg</i> | T3 | |
| <i>cefuroxime sodium intravenous recon soln 1.5 gram</i> | T3 | |
| <i>cephalexin oral capsule 250 mg, 500 mg</i> | T2 | |
| <i>cephalexin oral suspension for reconstitution</i> | T2 | |
| <i>chloroquine phosphate oral tablet 250 mg</i> | T3 | QL (50 EA per 30 days) |
| <i>chloroquine phosphate oral tablet 500 mg</i> | T3 | QL (25 EA per 30 days) |
| CIMDUO | T5 | QL (31 EA per 31 days) |
| <i>ciprofloxacin hcl oral tablet 250 mg, 500 mg, 750 mg</i> | T1 | |
| <i>ciprofloxacin in 5 % dextrose intravenous piggyback 200 mg/100 ml</i> | T2 | |
| <i>clarithromycin oral suspension for reconstitution</i> | T4 | |
| <i>clarithromycin oral tablet</i> | T2 | |
| <i>clarithromycin oral tablet extended release 24 hr</i> | T2 | |
| <i>clindamycin hcl</i> | T2 | |
| <i>clindamycin in 5 % dextrose</i> | T2 | |
| CLINDAMYCIN PEDIATRIC | T4 | |
| <i>clindamycin phosphate injection</i> | T2 | |
| <i>clotrimazole mucous membrane</i> | T2 | |
| COARTEM | T4 | |
| <i>colistin (colistimethate na)</i> | T4 | |
| COMPLERA | T5 | |
| <i>dapsone oral</i> | T3 | |
| <i>daptomycin</i> | T4 | |

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla al principio de esta tabla.

| Nombre del medicamento | Nivel de medicamento | Requisitos/Límites |
|---|-----------------------------|---------------------------|
| <i>darunavir</i> | T5 | |
| DELSTRIGO | T5 | QL (31 EA per 31 days) |
| DESCOVY | T5 | QL (31 EA per 31 days) |
| <i>dicloxacillin</i> | T2 | |
| DIFICID ORAL TABLET | T5 | QL (20 EA per 10 days) |
| DOVATO | T5 | QL (31 EA per 31 days) |
| DOXY-100 | T4 | |
| <i>doxycycline hyclate oral capsule</i> | T2 | |
| <i>doxycycline hyclate oral tablet 100 mg, 20 mg</i> | T2 | |
| <i>doxycycline hyclate oral tablet, delayed release (dr/ec) 100 mg</i> | T4 | |
| <i>doxycycline monohydrate oral capsule 100 mg, 50 mg</i> | T2 | |
| <i>doxycycline monohydrate oral tablet 100 mg, 50 mg</i> | T2 | |
| E.E.S. 400 ORAL TABLET | T4 | |
| EDURANT | T5 | |
| <i>efavirenz oral tablet</i> | T4 | |
| <i>efavirenz-emtricitabin-tenofovir</i> | T5 | |
| <i>efavirenz-lamivudine-tenofovir disoproxil fumarate</i> | T5 | QL (31 EA per 31 days) |
| <i>emtricitabine</i> | T4 | |
| <i>emtricitabine-tenofovir (tdf) oral tablet 100-150 mg, 133-200 mg, 167-250 mg</i> | T5 | |
| <i>emtricitabine-tenofovir (tdf) oral tablet 200-300 mg</i> | T4 | |
| EMTRIVA ORAL SOLUTION | T3 | |
| EMVERM | T5 | |
| <i>entecavir</i> | T4 | |
| <i>ertapenem</i> | T4 | |
| ERY-TAB ORAL TABLET, DELAYED RELEASE (DR/EC) 250 MG, 333 MG | T4 | |
| ERYTHROCIN (AS STEARATE) ORAL TABLET 250 MG | T4 | |
| <i>erythromycin ethylsuccinate oral tablet</i> | T4 | |
| <i>erythromycin oral tablet</i> | T2 | |
| <i>ethambutol</i> | T2 | |
| <i>etravirine</i> | T5 | |

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla al principio de esta tabla.

| Nombre del medicamento | Nivel de medicamento | Requisitos/Límites |
|---|-----------------------------|---------------------------|
| EVOTAZ | T5 | |
| <i>famciclovir</i> | T3 | |
| <i>fluconazole in nacl (iso-osm) intravenous piggyback 200 mg/100 ml</i> | T2 | |
| <i>fluconazole in nacl (iso-osm) intravenous piggyback 400 mg/200 ml</i> | T3 | |
| <i>fluconazole oral suspension for reconstitution</i> | T3 | |
| <i>fluconazole oral tablet</i> | T2 | |
| <i>flucytosine oral capsule 250 mg</i> | T4 | |
| <i>flucytosine oral capsule 500 mg</i> | T5 | |
| <i>fosamprenavir</i> | T5 | |
| FUZEON SUBCUTANEOUS RECON SOLN | T5 | |
| <i>gentamicin in nacl (iso-osm) intravenous piggyback 100 mg/100 ml, 60 mg/50 ml, 80 mg/100 ml, 80 mg/50 ml</i> | T2 | |
| <i>gentamicin injection solution 40 mg/ml</i> | T4 | |
| GENVOYA | T5 | |
| <i>griseofulvin microsize</i> | T4 | |
| <i>griseofulvin ultramicrosize</i> | T4 | |
| <i>hydroxychloroquine oral tablet 200 mg</i> | T2 | QL (93 EA per 31 days) |
| <i>imipenem-cilastatin</i> | T4 | |
| INTELENCE ORAL TABLET 25 MG | T4 | |
| ISENTRESS HD | T5 | |
| ISENTRESS ORAL POWDER IN PACKET | T5 | |
| ISENTRESS ORAL TABLET | T5 | |
| ISENTRESS ORAL TABLET,CHEWABLE 100 MG | T5 | |
| ISENTRESS ORAL TABLET,CHEWABLE 25 MG | T3 | |
| <i>isoniazid oral solution</i> | T2 | |
| <i>isoniazid oral tablet</i> | T1 | |
| <i>itraconazole oral capsule</i> | T4 | PA |
| <i>ivermectin oral</i> | T3 | PA |
| JULUCA | T5 | |
| <i>ketoconazole oral</i> | T2 | |
| <i>lamivudine</i> | T2 | |
| <i>lamivudine-zidovudine</i> | T2 | |

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla al principio de esta tabla.

| Nombre del medicamento | Nivel de medicamento | Requisitos/Límites |
|---|-----------------------------|-----------------------------|
| <i>levofloxacin in d5w intravenous piggyback 500 mg/100 ml, 750 mg/150 ml</i> | T2 | |
| <i>levofloxacin oral solution</i> | T4 | |
| <i>levofloxacin oral tablet</i> | T2 | |
| <i>linezolid in dextrose 5%</i> | T4 | |
| <i>linezolid oral tablet</i> | T4 | |
| LIVTENCITY | T5 | PA; QL (372 EA per 31 days) |
| <i>lopinavir-ritonavir</i> | T4 | |
| <i>maraviroc oral tablet 150 mg</i> | T5 | |
| <i>maraviroc oral tablet 300 mg</i> | T4 | |
| MAVYRET ORAL PELLETS IN PACKET | T5 | PA; QL (140 EA per 28 days) |
| MAVYRET ORAL TABLET | T5 | PA; QL (84 EA per 28 days) |
| <i>mefloquine</i> | T2 | |
| <i>meropenem intravenous recon soln 1 gram, 500 mg</i> | T3 | |
| <i>methenamine hippurate</i> | T4 | |
| <i>metronidazole in nacl (iso-os)</i> | T2 | |
| <i>metronidazole oral tablet</i> | T2 | |
| <i>micafungin</i> | T4 | |
| <i>minocycline oral capsule</i> | T2 | |
| <i>minocycline oral tablet</i> | T2 | |
| <i>moxifloxacin oral</i> | T3 | |
| <i>moxifloxacin-sod.chloride(iso)</i> | T4 | |
| <i>nafcillin injection</i> | T4 | |
| <i>neomycin</i> | T2 | |
| <i>nevirapine oral suspension</i> | T2 | |
| <i>nevirapine oral tablet</i> | T2 | |
| <i>nevirapine oral tablet extended release 24 hr 400 mg</i> | T4 | |
| <i>nitazoxanide</i> | T5 | |
| <i>nitrofurantoin macrocrystal oral capsule 100 mg</i> | T2 | QL (90 EA per 365 days) |
| <i>nitrofurantoin macrocrystal oral capsule 50 mg</i> | T2 | QL (180 EA per 365 days) |
| <i>nitrofurantoin monohyd/m-cryst</i> | T2 | QL (90 EA per 365 days) |
| NORVIR ORAL POWDER IN PACKET | T4 | |
| <i>nystatin oral</i> | T2 | |
| ODEFSEY | T5 | QL (31 EA per 31 days) |

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla al principio de esta tabla.

| Nombre del medicamento | Nivel de medicamento | Requisitos/Límites |
|--|-----------------------------|----------------------------|
| <i>ofloxacin oral tablet 300 mg</i> | T4 | |
| <i>ofloxacin oral tablet 400 mg</i> | T2 | |
| <i>oseltamivir oral capsule 30 mg</i> | T2 | QL (170 EA per 365 days) |
| <i>oseltamivir oral capsule 45 mg, 75 mg</i> | T2 | QL (90 EA per 365 days) |
| <i>oseltamivir oral suspension for reconstitution</i> | T3 | QL (1080 ML per 365 days) |
| <i>oxacillin in dextrose(iso-osm) intravenous piggyback 1 gram/50 ml</i> | T4 | |
| <i>oxacillin injection recon soln 1 gram</i> | T2 | |
| <i>oxacillin injection recon soln 2 gram</i> | T5 | |
| PAXLOVID ORAL TABLETS,DOSE PACK 150-100 MG | T3 | QL (180 EA per 365 days) |
| PAXLOVID ORAL TABLETS,DOSE PACK 300 MG (150 MG X 2)-100 MG | T3 | QL (270 EA per 365 days) |
| <i>penicillin g pot in dextrose intravenous piggyback 2 million unit/50 ml, 3 million unit/50 ml</i> | T4 | |
| <i>penicillin g potassium injection recon soln 20 million unit</i> | T4 | |
| <i>penicillin v potassium oral tablet</i> | T1 | |
| <i>pentamidine inhalation</i> | T4 | PA-BvD |
| <i>pentamidine injection</i> | T4 | |
| PIFELTRO | T5 | QL (62 EA per 31 days) |
| <i>piperacillin-tazobactam intravenous recon soln 2.25 gram, 3.375 gram, 4.5 gram, 40.5 gram</i> | T4 | |
| <i>posaconazole oral tablet,delayed release (dr/ec)</i> | T5 | PA |
| <i>praziquantel</i> | T4 | |
| PREVYMIS ORAL | T5 | QL (31 EA per 31 days) |
| PREZCOBIX | T5 | |
| PREZISTA ORAL SUSPENSION | T5 | |
| PREZISTA ORAL TABLET 150 MG, 75 MG | T5 | |
| PRIFTIN | T4 | |
| <i>primaquine</i> | T3 | |
| <i>pyrazinamide</i> | T4 | |
| <i>pyrimethamine</i> | T5 | PA |
| <i>quinine sulfate</i> | T4 | PA; QL (42 EA per 28 days) |
| RELENZA DISKHALER | T3 | |
| REYATAZ ORAL POWDER IN PACKET | T5 | |
| <i>ribavirin oral capsule</i> | T3 | |

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla al principio de esta tabla.

| Nombre del medicamento | Nivel de medicamento | Requisitos/Límites |
|--|-----------------------------|-----------------------------|
| <i>ribavirin oral tablet 200 mg</i> | T3 | |
| <i>rifabutin</i> | T4 | |
| <i>rifampin intravenous</i> | T5 | |
| <i>rifampin oral</i> | T4 | |
| <i>rimantadine</i> | T4 | |
| <i>ritonavir</i> | T3 | |
| RUKOBIA | T5 | QL (62 EA per 31 days) |
| SELZENTRY ORAL SOLUTION | T5 | |
| SELZENTRY ORAL TABLET 25 MG | T4 | |
| SELZENTRY ORAL TABLET 75 MG | T5 | |
| SIRTURO | T5 | PA |
| <i>sofosbuvir-velpatasvir</i> | T5 | PA; QL (28 EA per 28 days) |
| <i>streptomycin</i> | T5 | |
| STRIBILD | T5 | |
| <i>sulfadiazine</i> | T4 | |
| <i>sulfamethoxazole-trimethoprim oral suspension</i> | T2 | |
| <i>sulfamethoxazole-trimethoprim oral tablet</i> | T1 | |
| SUNLENCA ORAL | T5 | |
| SYMTUZA | T5 | QL (31 EA per 31 days) |
| TEFLARO | T5 | |
| <i>tenofovir disoproxil fumarate</i> | T3 | |
| <i>terbinafine hcl oral</i> | T1 | QL (90 EA per 180 days) |
| <i>tetracycline oral capsule</i> | T4 | |
| <i>tigecycline</i> | T5 | |
| <i>tinidazole</i> | T2 | |
| TIVICAY ORAL TABLET 10 MG | T4 | |
| TIVICAY ORAL TABLET 25 MG, 50 MG | T5 | |
| TIVICAY PD | T5 | |
| TOBI PODHALER | T5 | PA; QL (224 EA per 56 days) |
| <i>tobramycin in 0.225 % nacl</i> | T5 | PA |
| <i>tobramycin inhalation</i> | T5 | PA |
| <i>tobramycin sulfate injection solution</i> | T4 | |
| TRECATOR | T4 | |
| <i>trimethoprim</i> | T2 | |
| TRIUMEQ | T5 | |
| TRIUMEQ PD | T4 | QL (186 EA per 31 days) |

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla al principio de esta tabla.

| Nombre del medicamento | Nivel de medicamento | Requisitos/Límites |
|--|-----------------------------|-----------------------------|
| TYBOST | T3 | |
| <i>valacyclovir</i> | T2 | |
| <i>valganciclovir oral recon soln</i> | T4 | |
| <i>valganciclovir oral tablet</i> | T3 | |
| <i>vancomycin intravenous recon soln 1,000 mg, 10 gram, 500 mg, 750 mg</i> | T4 | |
| <i>vancomycin oral capsule 125 mg</i> | T4 | PA; QL (124 EA per 31 days) |
| <i>vancomycin oral capsule 250 mg</i> | T4 | PA; QL (248 EA per 31 days) |
| <i>vancomycin oral recon soln 50 mg/ml</i> | T4 | |
| VEMLIDY | T5 | QL (31 EA per 31 days) |
| VIRACEPT ORAL TABLET | T5 | |
| VIREAD ORAL POWDER | T5 | |
| VIREAD ORAL TABLET 150 MG, 200 MG, 250 MG | T5 | |
| VIVJOA | T4 | PA; QL (18 EA per 84 days) |
| <i>voriconazole intravenous</i> | T5 | PA |
| <i>voriconazole oral</i> | T4 | |
| VOSEVI | T5 | PA; QL (28 EA per 28 days) |
| XIFAXAN ORAL TABLET 200 MG | T4 | QL (27 EA per 365 days) |
| XIFAXAN ORAL TABLET 550 MG | T5 | PA; QL (62 EA per 31 days) |
| XOFLUZA ORAL TABLET 40 MG, 80 MG | T3 | QL (9 EA per 365 days) |
| <i>zidovudine</i> | T2 | |
| Cardiovascular, Hipertensión / Lípidos | | |
| <i>acebutolol</i> | T2 | |
| <i>aliskiren</i> | T4 | |
| <i>amiloride</i> | T2 | |
| <i>amiloride-hydrochlorothiazide</i> | T2 | |
| <i>amiodarone oral</i> | T2 | |
| <i>amlodipine</i> | T1 | |
| <i>amlodipine-benazepril</i> | T1 | |
| <i>amlodipine-olmesartan</i> | T3 | QL (31 EA per 31 days) |
| <i>amlodipine-valsartan</i> | T2 | |
| <i>aspirin-dipyridamole</i> | T4 | |
| <i>atenolol</i> | T1 | |
| <i>atenolol-chlorthalidone</i> | T2 | |
| <i>atorvastatin</i> | T1 | |

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla al principio de esta tabla.

| Nombre del medicamento | Nivel de medicamento | Requisitos/Límites |
|--|-----------------------------|-----------------------------|
| <i>benazepril</i> | T1 | |
| <i>benazepril-hydrochlorothiazide</i> | T1 | |
| <i>bisoprolol fumarate</i> | T2 | |
| <i>bisoprolol-hydrochlorothiazide</i> | T1 | |
| BRILINTA | T3 | |
| <i>bumetanide oral</i> | T2 | |
| CABLIVI INJECTION KIT | T5 | PA; QL (31 EA per 31 days) |
| CAMZYOS | T5 | PA; QL (31 EA per 31 days) |
| <i>candesartan</i> | T1 | |
| <i>candesartan-hydrochlorothiazid</i> | T1 | |
| <i>captopril</i> | T1 | |
| CARTIA XT | T2 | |
| <i>carvedilol</i> | T1 | |
| <i>carvedilol phosphate</i> | T4 | |
| <i>chlorthalidone oral tablet 25 mg, 50 mg</i> | T1 | |
| <i>cholestyramine (with sugar) oral powder in packet</i> | T2 | |
| CHOLESTYRAMINE LIGHT ORAL POWDER IN PACKET | T2 | |
| <i>cilostazol</i> | T2 | |
| <i>clonidine</i> | T4 | |
| <i>clonidine hcl oral tablet</i> | T1 | |
| <i>clopidogrel oral tablet 75 mg</i> | T1 | |
| <i>colesevelam</i> | T4 | |
| <i>colestipol oral packet</i> | T4 | |
| <i>colestipol oral tablet</i> | T3 | |
| CORLANOR ORAL SOLUTION | T4 | PA; QL (420 ML per 28 days) |
| CORLANOR ORAL TABLET 5 MG | T4 | PA; QL (93 EA per 31 days) |
| CORLANOR ORAL TABLET 7.5 MG | T4 | PA; QL (62 EA per 31 days) |
| <i>digoxin oral solution</i> | T3 | QL (155 ML per 31 days) |
| <i>digoxin oral tablet 125 mcg (0.125 mg)</i> | T1 | QL (62 EA per 31 days) |
| <i>digoxin oral tablet 250 mcg (0.25 mg)</i> | T2 | QL (31 EA per 31 days) |
| <i>diltiazem hcl oral capsule,extended release 12 hr</i> | T2 | |
| <i>diltiazem hcl oral capsule,extended release 24 hr 360 mg, 420 mg</i> | T2 | |
| <i>diltiazem hcl oral capsule,extended release 24hr 120 mg, 180 mg, 240 mg, 300 mg</i> | T2 | |

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla al principio de esta tabla.

| Nombre del medicamento | Nivel de medicamento | Requisitos/Límites |
|--|-----------------------------|---------------------------|
| <i>diltiazem hcl oral tablet</i> | T2 | |
| <i>diltiazem hcl oral tablet extended release 24 hr</i> | T2 | |
| DILT-XR | T2 | |
| <i>dofetilide</i> | T4 | |
| DOPTELET (10 TAB PACK) | T5 | PA |
| DOPTELET (15 TAB PACK) | T5 | PA |
| DOPTELET (30 TAB PACK) | T5 | PA |
| <i>doxazosin</i> | T2 | |
| ELIQUIS DVT-PE TREAT 30D START | T3 | QL (74 EA per 30 days) |
| ELIQUIS ORAL TABLET 2.5 MG | T3 | QL (60 EA per 30 days) |
| ELIQUIS ORAL TABLET 5 MG | T3 | QL (74 EA per 30 days) |
| <i>enalapril maleate oral tablet</i> | T1 | |
| <i>enalapril-hydrochlorothiazide oral tablet 5-12.5 mg</i> | T1 | |
| <i>enoxaparin subcutaneous syringe</i> | T4 | |
| ENTRESTO ORAL TABLET 24-26 MG | T3 | QL (186 EA per 31 days) |
| ENTRESTO ORAL TABLET 49-51 MG | T3 | QL (93 EA per 31 days) |
| ENTRESTO ORAL TABLET 97-103 MG | T3 | QL (62 EA per 31 days) |
| <i>eplerenone</i> | T4 | |
| <i>ethacrynic acid</i> | T4 | |
| <i>ezetimibe</i> | T2 | |
| <i>ezetimibe-simvastatin</i> | T3 | QL (31 EA per 31 days) |
| <i>felodipine</i> | T2 | |
| <i>fenofibrate micronized oral capsule 134 mg, 200 mg, 67 mg</i> | T2 | |
| <i>fenofibrate nanocrystallized</i> | T2 | |
| <i>fenofibrate oral tablet 160 mg, 54 mg</i> | T2 | |
| <i>flecainide</i> | T2 | |
| <i>fondaparinux subcutaneous syringe 10 mg/0.8 ml, 7.5 mg/0.6 ml</i> | T5 | |
| <i>fondaparinux subcutaneous syringe 2.5 mg/0.5 ml, 5 mg/0.4 ml</i> | T4 | |
| <i>fosinopril</i> | T1 | |
| <i>fosinopril-hydrochlorothiazide</i> | T1 | |
| FUROSCIX | T5 | PA; QL (8 EA per 30 days) |
| <i>furosemide injection solution</i> | T2 | |

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla al principio de esta tabla.

| Nombre del medicamento | Nivel de medicamento | Requisitos/Límites |
|---|-----------------------------|----------------------------|
| <i>furosemide oral solution 10 mg/ml, 40 mg/5 ml (8 mg/ml)</i> | T2 | |
| <i>furosemide oral tablet</i> | T1 | |
| <i>gemfibrozil</i> | T1 | |
| <i>heparin (porcine) injection solution</i> | T3 | PA-BvD |
| <i>hydralazine oral</i> | T1 | |
| <i>hydrochlorothiazide</i> | T1 | |
| <i>icosapent ethyl oral capsule 0.5 gram</i> | T4 | QL (248 EA per 31 days) |
| <i>icosapent ethyl oral capsule 1 gram</i> | T4 | QL (124 EA per 31 days) |
| <i>indapamide</i> | T1 | |
| <i>irbesartan</i> | T1 | QL (31 EA per 31 days) |
| <i>irbesartan-hydrochlorothiazide</i> | T2 | QL (31 EA per 31 days) |
| <i>isosorbide dinitrate oral tablet 10 mg, 20 mg, 30 mg, 5 mg</i> | T2 | |
| <i>isosorbide mononitrate</i> | T2 | |
| <i>isradipine</i> | T4 | |
| JANTOVEN | T1 | |
| KERENDIA | T4 | PA; QL (31 EA per 31 days) |
| <i>labetalol oral</i> | T2 | |
| <i>lisinopril</i> | T1 | |
| <i>lisinopril-hydrochlorothiazide</i> | T1 | |
| <i>losartan oral tablet 100 mg</i> | T1 | QL (31 EA per 31 days) |
| <i>losartan oral tablet 25 mg</i> | T1 | QL (93 EA per 31 days) |
| <i>losartan oral tablet 50 mg</i> | T1 | QL (62 EA per 31 days) |
| <i>losartan-hydrochlorothiazide</i> | T1 | |
| <i>lovastatin</i> | T1 | |
| <i>metolazone</i> | T2 | |
| <i>metoprolol succinate</i> | T2 | |
| <i>metoprolol ta-hydrochlorothiaz</i> | T2 | |
| <i>metoprolol tartrate oral tablet 100 mg, 25 mg, 50 mg</i> | T1 | |
| <i>metoprolol tartrate oral tablet 37.5 mg, 75 mg</i> | T2 | |
| <i>metyrosine</i> | T5 | PA |
| <i>mexiletine</i> | T3 | |
| <i>minoxidil oral</i> | T2 | |
| <i>moexipril</i> | T1 | |

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla al principio de esta tabla.

| Nombre del medicamento | Nivel de medicamento | Requisitos/Límites |
|---|-----------------------------|-----------------------------|
| MULPLETA | T5 | PA |
| MULTAQ | T4 | |
| <i>nadolol</i> | T4 | |
| <i>nebivolol oral tablet 10 mg, 2.5 mg</i> | T2 | QL (93 EA per 31 days) |
| <i>nebivolol oral tablet 20 mg</i> | T2 | QL (62 EA per 31 days) |
| <i>nebivolol oral tablet 5 mg</i> | T2 | QL (217 EA per 31 days) |
| NEXLETOL | T4 | PA; QL (31 EA per 31 days) |
| NEXLIZET | T4 | PA; QL (31 EA per 31 days) |
| <i>niacin oral tablet extended release 24 hr 1,000 mg, 750 mg</i> | T4 | |
| <i>niacin oral tablet extended release 24 hr 500 mg</i> | T4 | QL (31 EA per 31 days) |
| <i>nicardipine oral capsule 20 mg</i> | T4 | |
| <i>nicardipine oral capsule 30 mg</i> | T5 | |
| <i>nifedipine oral tablet extended release</i> | T2 | |
| <i>nifedipine oral tablet extended release 24hr</i> | T2 | |
| <i>nimodipine</i> | T4 | |
| NITRO-BID | T2 | |
| <i>nitroglycerin sublingual</i> | T2 | |
| <i>nitroglycerin transdermal patch 24 hour</i> | T2 | |
| <i>nitroglycerin translingual</i> | T4 | |
| <i>olmesartan oral tablet 20 mg, 40 mg</i> | T2 | QL (31 EA per 31 days) |
| <i>olmesartan oral tablet 5 mg</i> | T2 | QL (93 EA per 31 days) |
| <i>olmesartan-amlodipin-hcthiazyd</i> | T3 | |
| <i>olmesartan-hydrochlorothiazide</i> | T2 | QL (31 EA per 31 days) |
| <i>omega-3 acid ethyl esters</i> | T3 | QL (124 EA per 31 days) |
| ORENITRAM ORAL TABLET EXTENDED RELEASE 0.125 MG | T4 | PA; QL (93 EA per 31 days) |
| ORENITRAM ORAL TABLET EXTENDED RELEASE 0.25 MG, 1 MG | T5 | PA; QL (186 EA per 31 days) |
| ORENITRAM ORAL TABLET EXTENDED RELEASE 2.5 MG | T5 | PA; QL (521 EA per 31 days) |
| ORENITRAM ORAL TABLET EXTENDED RELEASE 5 MG | T5 | PA; QL (261 EA per 31 days) |
| PACERONE ORAL TABLET 100 MG, 200 MG, 400 MG | T2 | |
| <i>pentoxifylline</i> | T2 | |
| <i>perindopril erbumine</i> | T2 | |

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla al principio de esta tabla.

| Nombre del medicamento | Nivel de medicamento | Requisitos/Límites |
|---|-----------------------------|-----------------------------|
| <i>pindolol</i> | T4 | |
| <i>pitavastatin calcium</i> | T3 | |
| <i>prasugrel</i> | T3 | |
| <i>pravastatin</i> | T1 | |
| <i>prazosin</i> | T2 | |
| PREVALITE ORAL POWDER IN PACKET | T4 | |
| PROMACTA ORAL POWDER IN PACKET 12.5 MG | T5 | PA; QL (372 EA per 31 days) |
| PROMACTA ORAL POWDER IN PACKET 25 MG | T5 | PA; QL (31 EA per 31 days) |
| PROMACTA ORAL TABLET 12.5 MG, 25 MG | T5 | PA; QL (31 EA per 31 days) |
| PROMACTA ORAL TABLET 50 MG, 75 MG | T5 | PA; QL (62 EA per 31 days) |
| <i>propafenone oral capsule, extended release 12 hr</i> | T4 | |
| <i>propafenone oral tablet</i> | T2 | |
| <i>propranolol oral capsule, extended release 24 hr</i> | T2 | |
| <i>propranolol oral tablet</i> | T2 | |
| <i>quinapril</i> | T1 | |
| <i>quinidine sulfate oral tablet</i> | T2 | |
| <i>ramipril</i> | T1 | |
| <i>ranolazine</i> | T4 | QL (62 EA per 31 days) |
| REPATHA PUSHTRONEX | T3 | PA; QL (7 ML per 28 days) |
| REPATHA SURECLICK | T3 | PA; QL (3 ML per 28 days) |
| REPATHA SYRINGE | T3 | PA; QL (3 ML per 28 days) |
| <i>rosuvastatin</i> | T1 | |
| <i>simvastatin</i> | T1 | |
| SOTALOL AF | T2 | |
| <i>sotalol oral</i> | T2 | |
| <i>spironolactone oral tablet</i> | T1 | |
| <i>spironolacton-hydrochlorothiaz</i> | T2 | |
| <i>telmisartan</i> | T2 | |
| <i>telmisartan-amlodipine</i> | T4 | |
| <i>telmisartan-hydrochlorothiazid</i> | T2 | |
| <i>terazosin</i> | T1 | |
| TIADYL T ER | T2 | |
| <i>timolol maleate oral</i> | T3 | |

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla al principio de esta tabla.

| Nombre del medicamento | Nivel de medicamento | Requisitos/Límites |
|--|-----------------------------|------------------------------|
| <i>torse mide oral</i> | T1 | |
| <i>trandolapril</i> | T1 | |
| <i>triamterene-hydrochlorothiazid</i> | T1 | |
| UPTRAVI ORAL TABLET 1,000 MCG, 1,200 MCG, 1,400 MCG, 1,600 MCG, 400 MCG, 600 MCG, 800 MCG | T5 | PA; QL (62 EA per 31 days) |
| UPTRAVI ORAL TABLET 200 MCG | T5 | PA; QL (224 EA per 28 days) |
| UPTRAVI ORAL TABLETS,DOSE PACK | T5 | PA; QL (400 EA per 365 days) |
| <i>valsartan oral tablet 160 mg, 40 mg, 80 mg</i> | T1 | QL (62 EA per 31 days) |
| <i>valsartan oral tablet 320 mg</i> | T1 | QL (31 EA per 31 days) |
| <i>valsartan-hydrochlorothiazide</i> | T2 | QL (31 EA per 31 days) |
| <i>verapamil oral capsule, 24 hr er pellet ct</i> | T4 | |
| <i>verapamil oral capsule,ext rel. pellets 24 hr 120 mg, 180 mg, 240 mg</i> | T2 | |
| <i>verapamil oral capsule,ext rel. pellets 24 hr 360 mg</i> | T4 | |
| <i>verapamil oral tablet</i> | T2 | |
| <i>verapamil oral tablet extended release</i> | T2 | |
| VERQUVO | T4 | PA; QL (31 EA per 31 days) |
| VYNDAQEL | T5 | PA; QL (124 EA per 31 days) |
| <i>warfarin</i> | T1 | |
| XARELTO DVT-PE TREAT 30D START | T3 | QL (51 EA per 30 days) |
| XARELTO ORAL SUSPENSION FOR RECONSTITUTION | T3 | QL (930 ML per 31 days) |
| XARELTO ORAL TABLET 10 MG, 20 MG | T3 | QL (31 EA per 31 days) |
| XARELTO ORAL TABLET 15 MG | T3 | QL (52 EA per 31 days) |
| XARELTO ORAL TABLET 2.5 MG | T3 | QL (62 EA per 31 days) |
| Dermatológicos/Terapia Tópica | | |
| ACUTANE ORAL CAPSULE 10 MG, 20 MG, 40 MG | T4 | |
| <i>acitretin</i> | T4 | PA |
| <i>acyclovir topical ointment</i> | T3 | QL (30 GM per 30 days) |
| ADBRY SUBCUTANEOUS SYRINGE | T5 | PA; QL (4 ML per 28 days) |
| ALA-CORT TOPICAL CREAM 1 % | T1 | |
| ALA-CORT TOPICAL CREAM 2.5 % | T1 | QL (30 GM per 28 days) |
| <i>alclometasone</i> | T3 | |
| <i>ammonium lactate</i> | T2 | |

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla al principio de esta tabla.

| Nombre del medicamento | Nivel de medicamento | Requisitos/Límites |
|---|-----------------------------|-----------------------------|
| AMNESTEEM | T4 | |
| <i>betamethasone dipropionate topical cream</i> | T2 | |
| <i>betamethasone dipropionate topical lotion</i> | T2 | |
| <i>betamethasone valerate topical cream</i> | T2 | |
| <i>betamethasone valerate topical lotion</i> | T3 | |
| <i>betamethasone valerate topical ointment</i> | T2 | |
| <i>betamethasone, augmented topical cream</i> | T2 | |
| <i>betamethasone, augmented topical gel</i> | T4 | |
| <i>betamethasone, augmented topical lotion</i> | T4 | |
| <i>betamethasone, augmented topical ointment</i> | T3 | |
| <i>calcipotriene scalp</i> | T3 | QL (60 ML per 28 days) |
| <i>calcipotriene topical cream</i> | T4 | QL (60 GM per 28 days) |
| <i>calcipotriene topical ointment</i> | T3 | QL (60 GM per 28 days) |
| CIBINQO | T5 | PA; QL (31 EA per 31 days) |
| <i>ciclopirox topical cream</i> | T2 | QL (90 GM per 28 days) |
| <i>ciclopirox topical gel</i> | T3 | QL (45 GM per 28 days) |
| <i>ciclopirox topical shampoo</i> | T3 | QL (120 ML per 28 days) |
| <i>ciclopirox topical solution</i> | T2 | |
| <i>ciclopirox topical suspension</i> | T3 | QL (60 ML per 28 days) |
| CLARAVIS | T4 | |
| <i>clindamycin phosphate topical gel</i> | T2 | QL (60 GM per 28 days) |
| <i>clindamycin phosphate topical lotion</i> | T2 | QL (60 ML per 28 days) |
| <i>clindamycin phosphate topical solution</i> | T2 | QL (60 ML per 28 days) |
| <i>clindamycin phosphate topical swab</i> | T2 | |
| <i>clotrimazole topical cream</i> | T2 | QL (45 GM per 28 days) |
| <i>clotrimazole topical solution</i> | T3 | QL (30 ML per 28 days) |
| <i>clotrimazole-betamethasone topical cream</i> | T2 | QL (45 GM per 28 days) |
| <i>clotrimazole-betamethasone topical lotion</i> | T3 | QL (60 ML per 28 days) |
| COSENTYX (2 SYRINGES) | T5 | PA; QL (2 ML per 28 days) |
| COSENTYX PEN (2 PENS) | T5 | PA; QL (2 ML per 28 days) |
| COSENTYX SUBCUTANEOUS SYRINGE 75 MG/0.5 ML | T5 | PA; QL (0.5 ML per 28 days) |
| COSENTYX UNOREADY PEN | T5 | PA; QL (2 ML per 28 days) |
| <i>desoximetasone topical cream</i> | T4 | QL (100 GM per 28 days) |
| <i>desoximetasone topical gel</i> | T4 | QL (60 GM per 28 days) |
| <i>diclofenac sodium topical gel 3 %</i> | T4 | PA; QL (100 GM per 28 days) |

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla al principio de esta tabla.

| Nombre del medicamento | Nivel de medicamento | Requisitos/Límites |
|--|-----------------------------|------------------------------|
| DUPIXENT PEN SUBCUTANEOUS PEN INJECTOR 200 MG/1.14 ML | T5 | PA; QL (2.28 ML per 28 days) |
| DUPIXENT PEN SUBCUTANEOUS PEN INJECTOR 300 MG/2 ML | T5 | PA; QL (8 ML per 28 days) |
| DUPIXENT SYRINGE SUBCUTANEOUS SYRINGE 100 MG/0.67 ML | T5 | PA; QL (1.34 ML per 28 days) |
| DUPIXENT SYRINGE SUBCUTANEOUS SYRINGE 200 MG/1.14 ML | T5 | PA; QL (2.28 ML per 28 days) |
| DUPIXENT SYRINGE SUBCUTANEOUS SYRINGE 300 MG/2 ML | T5 | PA; QL (8 ML per 28 days) |
| ERY PADS | T3 | |
| <i>erythromycin with ethanol topical gel</i> | T2 | QL (60 GM per 28 days) |
| <i>erythromycin with ethanol topical solution</i> | T2 | QL (60 ML per 28 days) |
| <i>erythromycin-benzoyl peroxide</i> | T4 | |
| FILSUEZ | T5 | PA |
| <i>fluocinolone and shower cap</i> | T4 | QL (118.28 ML per 28 days) |
| <i>fluocinolone topical cream 0.01 %</i> | T3 | QL (60 GM per 28 days) |
| <i>fluocinolone topical cream 0.025 %</i> | T3 | QL (120 GM per 28 days) |
| <i>fluocinolone topical ointment</i> | T3 | QL (120 GM per 28 days) |
| <i>fluocinolone topical solution</i> | T3 | QL (90 ML per 28 days) |
| <i>fluocinonide topical cream 0.05 %</i> | T2 | QL (60 GM per 28 days) |
| <i>fluocinonide topical gel</i> | T3 | QL (60 GM per 28 days) |
| <i>fluocinonide topical ointment</i> | T2 | QL (60 GM per 28 days) |
| <i>fluocinonide topical solution</i> | T2 | QL (60 ML per 28 days) |
| <i>fluocinonide-emollient</i> | T4 | QL (60 GM per 28 days) |
| <i>fluorouracil topical cream 5 %</i> | T3 | |
| <i>fluorouracil topical solution 2 %</i> | T2 | |
| <i>fluorouracil topical solution 5 %</i> | T3 | |
| <i>fluticasone propionate topical cream</i> | T2 | |
| <i>gentamicin topical</i> | T3 | QL (60 GM per 28 days) |
| <i>halobetasol propionate topical cream</i> | T4 | QL (50 GM per 28 days) |
| <i>halobetasol propionate topical ointment</i> | T4 | QL (50 GM per 28 days) |
| <i>hydrocortisone butyrate topical lotion</i> | T4 | QL (118 ML per 28 days) |
| <i>hydrocortisone topical cream 1 %</i> | T1 | |
| <i>hydrocortisone topical lotion 2.5 %</i> | T2 | QL (118 ML per 28 days) |
| <i>hydrocortisone topical ointment 1 %, 2.5 %</i> | T1 | |
| <i>imiquimod topical cream in packet 5 %</i> | T2 | |

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla al principio de esta tabla.

| Nombre del medicamento | Nivel de medicamento | Requisitos/Límites |
|--|-----------------------------|-----------------------------|
| <i>ketoconazole topical cream</i> | T2 | QL (60 GM per 28 days) |
| <i>ketoconazole topical shampoo</i> | T2 | QL (120 ML per 28 days) |
| <i>lidocaine hcl mucous membrane solution 4 % (40 mg/ml)</i> | T2 | PA; QL (50 ML per 28 days) |
| <i>lidocaine topical adhesive patch,medicated 5 %</i> | T4 | PA; QL (93 EA per 31 days) |
| <i>lidocaine topical ointment</i> | T4 | PA; QL (50 GM per 28 days) |
| LIDOCAINE VISCOUS | T2 | |
| <i>lidocaine-prilocaine topical cream</i> | T2 | PA; QL (30 GM per 28 days) |
| <i>malathion</i> | T4 | |
| <i>metronidazole topical cream</i> | T3 | |
| <i>metronidazole topical gel 0.75 %</i> | T3 | |
| <i>metronidazole topical gel 1 %</i> | T4 | |
| <i>metronidazole topical lotion</i> | T4 | |
| <i>mometasone topical</i> | T2 | |
| <i>mupirocin</i> | T2 | |
| NYAMYC | T2 | QL (60 GM per 28 days) |
| <i>nystatin topical cream</i> | T2 | QL (30 GM per 28 days) |
| <i>nystatin topical ointment</i> | T2 | QL (30 GM per 28 days) |
| <i>nystatin topical powder</i> | T2 | QL (60 GM per 28 days) |
| NYSTOP | T2 | QL (60 GM per 28 days) |
| PANRETIN | T5 | PA-NC |
| <i>penciclovir</i> | T4 | QL (5 GM per 28 days) |
| <i>permethrin</i> | T2 | |
| <i>podofilox topical solution</i> | T4 | |
| REGRANEX | T5 | PA |
| <i>selenium sulfide topical lotion</i> | T1 | |
| SILIQ | T5 | PA; QL (6 ML per 28 days) |
| <i>silver sulfadiazine</i> | T1 | |
| SKYRIZI SUBCUTANEOUS PEN INJECTOR | T5 | PA; QL (1 ML per 84 days) |
| SKYRIZI SUBCUTANEOUS SYRINGE 150 MG/ML | T5 | PA; QL (1 ML per 84 days) |
| SSD | T4 | |
| STELARA SUBCUTANEOUS SOLUTION | T5 | PA; QL (0.5 ML per 84 days) |
| STELARA SUBCUTANEOUS SYRINGE 45 MG/0.5 ML | T5 | PA; QL (0.5 ML per 84 days) |

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla al principio de esta tabla.

| Nombre del medicamento | Nivel de medicamento | Requisitos/Límites |
|---|-----------------------------|----------------------------|
| STELARA SUBCUTANEOUS SYRINGE 90 MG/ML | T5 | PA; QL (1 ML per 56 days) |
| <i>sulfacetamide sodium (acne)</i> | T2 | |
| SULFAMYLON TOPICAL CREAM | T3 | |
| <i>tacrolimus topical</i> | T4 | QL (100 GM per 28 days) |
| TALTZ AUTOINJECTOR | T5 | PA; QL (1 ML per 28 days) |
| TALTZ SYRINGE SUBCUTANEOUS SYRINGE 80 MG/ML | T5 | PA; QL (1 ML per 28 days) |
| <i>tazarotene topical cream</i> | T4 | PA; QL (60 GM per 28 days) |
| TAZORAC TOPICAL CREAM 0.05 % | T4 | PA; QL (60 GM per 28 days) |
| <i>tretinoin topical cream</i> | T2 | PA; QL (45 GM per 28 days) |
| <i>tretinoin topical gel 0.01 %, 0.025 %</i> | T4 | PA; QL (45 GM per 28 days) |
| <i>triamcinolone acetonide topical cream</i> | T2 | |
| <i>triamcinolone acetonide topical lotion</i> | T2 | |
| <i>triamcinolone acetonide topical ointment 0.025 %, 0.1 %, 0.5 %</i> | T2 | |
| <i>triamcinolone acetonide topical ointment 0.05 %</i> | T4 | |
| TRIDERM TOPICAL CREAM | T4 | |
| VALCHLOR | T5 | PA-NC |
| Diagnósticos / Agentes Varios | | |
| <i>acamprosate</i> | T4 | |
| <i>anagrelide</i> | T4 | |
| <i>bupropion hcl (smoking deter)</i> | T2 | QL (62 EA per 31 days) |
| <i>carglumic acid</i> | T5 | PA |
| <i>cevimeline</i> | T4 | |
| CHEMET | T4 | |
| CLINIMIX 4.25%/D5W SULFIT FREE | T4 | PA-BvD |
| <i>d10 %-0.45 % sodium chloride</i> | T2 | |
| <i>d2.5 %-0.45 % sodium chloride</i> | T2 | |
| <i>d5 % and 0.9 % sodium chloride</i> | T2 | |
| <i>d5 %-0.45 % sodium chloride</i> | T2 | |
| <i>deferasirox oral tablet, dispersible 125 mg</i> | T3 | PA |
| <i>deferasirox oral tablet, dispersible 250 mg, 500 mg</i> | T5 | PA |
| <i>deferiprone</i> | T5 | PA |
| <i>dextrose 10 % in water (d10w)</i> | T2 | |

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla al principio de esta tabla.

| Nombre del medicamento | Nivel de medicamento | Requisitos/Límites |
|--|-----------------------------|-----------------------------|
| <i>dextrose 5 % in water (d5w) intravenous piggyback</i> | T2 | |
| <i>disulfiram</i> | T3 | |
| <i>droxidopa oral capsule 100 mg</i> | T5 | PA; QL (465 EA per 31 days) |
| <i>droxidopa oral capsule 200 mg, 300 mg</i> | T5 | PA; QL (186 EA per 31 days) |
| FABHALTA | T5 | PA; QL (62 EA per 31 days) |
| INCRELEX | T5 | PA |
| JOENJA | T5 | PA; QL (60 EA per 30 days) |
| KIONEX (WITH SORBITOL) | T2 | |
| <i>levocarnitine (with sugar)</i> | T4 | PA-BvD |
| <i>levocarnitine oral tablet</i> | T4 | PA-BvD |
| LITFULO | T5 | PA; QL (28 EA per 28 days) |
| LOKELMA | T3 | PA; QL (93 EA per 31 days) |
| <i>midodrine</i> | T2 | |
| NICOTROL | T4 | |
| NICOTROL NS | T4 | |
| <i>nitisinone</i> | T5 | PA |
| PHEBURANE | T5 | PA; QL (620 GM per 31 days) |
| <i>pilocarpine hcl oral</i> | T3 | |
| PROLASTIN-C INTRAVENOUS SOLUTION | T5 | PA |
| RAVICTI | T5 | PA |
| REZDIFFRA | T5 | PA; QL (31 EA per 31 days) |
| <i>riluzole</i> | T4 | |
| <i>risedronate oral tablet 30 mg</i> | T4 | |
| <i>sodium chloride 0.9 % intravenous parenteral solution</i> | T2 | |
| <i>sodium chloride irrigation</i> | T2 | |
| <i>sodium phenylbutyrate</i> | T5 | PA |
| <i>sodium polystyrene sulfonate oral powder</i> | T2 | |
| SOHONOS ORAL CAPSULE 1 MG, 1.5 MG, 2.5 MG, 5 MG | T5 | PA; QL (31 EA per 31 days) |
| SOHONOS ORAL CAPSULE 10 MG | T5 | PA; QL (62 EA per 31 days) |
| SPS (WITH SORBITOL) ORAL | T2 | |
| <i>trientine oral capsule 250 mg</i> | T5 | QL (248 EA per 31 days) |
| <i>varenicline oral tablet</i> | T4 | QL (60 EA per 30 days) |
| <i>varenicline oral tablets,dose pack</i> | T4 | QL (106 EA per 365 days) |

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla al principio de esta tabla.

| Nombre del medicamento | Nivel de medicamento | Requisitos/Límites |
|---|----------------------|---------------------------------|
| Endocrino/Diabetes | | |
| <i>acarbose</i> | T2 | QL (93 EA per 31 days) |
| ALCOHOL PADS | T2 | PA |
| BAQSIMI | T3 | |
| BASAGLAR KWIKPEN U-100 INSULIN | T4 | |
| BASAGLAR TEMPO PEN(U-100)INSLN | T4 | |
| BYDUREON BCISE | T3 | PA; QL (3.4 ML per 28 days) |
| <i>cabergoline</i> | T3 | |
| <i>calcitonin (salmon) nasal</i> | T3 | PA-BvD |
| <i>calcitriol oral capsule</i> | T2 | PA-BvD |
| <i>calcitriol oral solution</i> | T4 | PA-BvD |
| CERDELGA | T5 | PA; QL (62 EA per 31 days) |
| <i>cinacalcet oral tablet 30 mg, 60 mg</i> | T4 | PA-BvD; QL (62 EA per 31 days) |
| <i>cinacalcet oral tablet 90 mg</i> | T4 | PA-BvD; QL (124 EA per 31 days) |
| <i>danazol</i> | T4 | |
| <i>desmopressin nasal spray,non-aerosol 10 mcg/spray (0.1 ml)</i> | T4 | |
| <i>desmopressin oral</i> | T2 | |
| <i>dexamethasone oral solution</i> | T2 | |
| <i>dexamethasone oral tablet</i> | T1 | |
| <i>diazoxide</i> | T5 | |
| <i>doxercalciferol oral</i> | T4 | PA-BvD |
| FARXIGA | T3 | QL (31 EA per 31 days) |
| FIASP FLEXTOUCH U-100 INSULIN | T3 | |
| FIASP PENFILL U-100 INSULIN | T3 | |
| FIASP U-100 INSULIN | T3 | |
| <i>fludrocortisone</i> | T2 | |
| <i>glimepiride</i> | T1 | |
| <i>glipizide oral tablet 10 mg, 5 mg</i> | T1 | |
| <i>glipizide oral tablet extended release 24hr</i> | T1 | |
| <i>glipizide-metformin</i> | T1 | |
| GLUCAGON EMERGENCY KIT (HUMAN) | T3 | |
| <i>glyburide</i> | T2 | |
| <i>glyburide micronized</i> | T2 | |
| <i>glyburide-metformin</i> | T2 | |

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla al principio de esta tabla.

| Nombre del medicamento | Nivel de medicamento | Requisitos/Límites |
|--|-----------------------------|---------------------------|
| GLYXAMBI | T3 | QL (31 EA per 31 days) |
| GVOKE | T3 | |
| GVOKE HYPOPEN 2-PACK | T3 | |
| GVOKE PFS 1-PACK SYRINGE SUBCUTANEOUS SYRINGE 1 MG/0.2 ML | T3 | |
| HUMALOG JUNIOR KWIKPEN U-100 | T3 | |
| HUMALOG KWIKPEN INSULIN | T3 | |
| HUMALOG MIX 50-50 KWIKPEN | T3 | |
| HUMALOG MIX 75-25 KWIKPEN | T3 | |
| HUMALOG MIX 75-25(U-100)INSULN | T3 | |
| HUMALOG TEMPO PEN(U-100)INSULN | T3 | |
| HUMALOG U-100 INSULIN | T3 | |
| HUMULIN 70/30 U-100 INSULIN | T3 | |
| HUMULIN 70/30 U-100 KWIKPEN | T3 | |
| HUMULIN N NPH INSULIN KWIKPEN | T3 | |
| HUMULIN N NPH U-100 INSULIN | T3 | |
| HUMULIN R REGULAR U-100 INSULN | T3 | |
| HUMULIN R U-500 (CONC) INSULIN | T3 | |
| HUMULIN R U-500 (CONC) KWIKPEN | T3 | |
| <i>hydrocortisone oral</i> | T1 | |
| <i>insulin asp prt-insulin aspart</i> | T3 | |
| <i>insulin aspart u-100</i> | T3 | |
| <i>insulin lispro</i> | T3 | |
| <i>insulin lispro protamin-lispro</i> | T3 | |
| JANUMET | T3 | QL (62 EA per 31 days) |
| JANUMET XR ORAL TABLET, ER MULTIPHASE 24 HR 100-1,000 MG, 50-500 MG | T3 | QL (31 EA per 31 days) |
| JANUMET XR ORAL TABLET, ER MULTIPHASE 24 HR 50-1,000 MG | T3 | QL (62 EA per 31 days) |
| JANUVIA ORAL TABLET 100 MG, 50 MG | T3 | QL (31 EA per 31 days) |
| JANUVIA ORAL TABLET 25 MG | T3 | QL (93 EA per 31 days) |
| JARDIANCE ORAL TABLET 10 MG | T3 | QL (62 EA per 31 days) |
| JARDIANCE ORAL TABLET 25 MG | T3 | QL (31 EA per 31 days) |
| JAVYGTOR | T5 | PA |
| JENTADUETO ORAL TABLET 2.5-1,000 MG, 2.5-500 MG | T3 | QL (62 EA per 31 days) |

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla al principio de esta tabla.

| Nombre del medicamento | Nivel de medicamento | Requisitos/Límites |
|--|-----------------------------|-----------------------------|
| JENTADUETO XR ORAL TABLET, IR - ER, BIPHASIC 24HR 2.5-1,000 MG | T3 | QL (62 EA per 31 days) |
| JENTADUETO XR ORAL TABLET, IR - ER, BIPHASIC 24HR 5-1,000 MG | T3 | QL (31 EA per 31 days) |
| LANTUS SOLOSTAR U-100 INSULIN | T3 | |
| LANTUS U-100 INSULIN | T3 | |
| <i>levothyroxine oral tablet</i> | T1 | |
| LEVOXYL ORAL TABLET 100 MCG, 112 MCG, 125 MCG, 137 MCG, 150 MCG, 175 MCG, 200 MCG, 25 MCG, 50 MCG, 75 MCG, 88 MCG | T3 | |
| <i>liothyronine oral</i> | T2 | |
| <i>metformin oral tablet 1,000 mg, 500 mg, 850 mg</i> | T1 | |
| <i>metformin oral tablet extended release 24 hr</i> | T1 | |
| <i>methimazole oral tablet 10 mg, 5 mg</i> | T2 | |
| <i>methylprednisolone</i> | T2 | |
| <i>mifepristone oral tablet 300 mg</i> | T5 | PA; QL (124 EA per 31 days) |
| <i>miglustat</i> | T5 | PA; QL (93 EA per 31 days) |
| MOUNJARO | T3 | PA; QL (2 ML per 28 days) |
| <i>nateglinide</i> | T1 | QL (93 EA per 31 days) |
| NOVOLIN 70/30 U-100 INSULIN | T3 | |
| NOVOLIN 70-30 FLEXPEN U-100 | T3 | |
| NOVOLIN N FLEXPEN | T3 | |
| NOVOLIN N NPH U-100 INSULIN | T3 | |
| NOVOLIN R FLEXPEN | T3 | |
| NOVOLIN R REGULAR U100 INSULIN | T3 | |
| NOVOLOG FLEXPEN U-100 INSULIN | T3 | |
| NOVOLOG MIX 70-30 U-100 INSULIN | T3 | |
| NOVOLOG MIX 70-30FLEXPEN U-100 | T3 | |
| NOVOLOG PENFILL U-100 INSULIN | T3 | |
| NOVOLOG U-100 INSULIN ASPART | T3 | |
| OZEMPIC SUBCUTANEOUS PEN INJECTOR 0.25 MG OR 0.5 MG (2 MG/3 ML), 1 MG/DOSE (4 MG/3 ML), 2 MG/DOSE (8 MG/3 ML) | T3 | PA; QL (3 ML per 28 days) |
| <i>paricalcitol oral</i> | T4 | PA-BvD |
| <i>pioglitazone</i> | T1 | QL (31 EA per 31 days) |
| <i>pioglitazone-metformin</i> | T2 | QL (93 EA per 31 days) |

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla al principio de esta tabla.

| Nombre del medicamento | Nivel de medicamento | Requisitos/Límites |
|---|-----------------------------|-----------------------------|
| <i>prednisolone oral solution</i> | T2 | |
| <i>prednisolone sodium phosphate oral solution 25 mg/5 ml (5 mg/ml), 5 mg base/5 ml (6.7 mg/5 ml)</i> | T2 | |
| <i>prednisone oral solution</i> | T3 | |
| <i>prednisone oral tablet</i> | T1 | |
| <i>prednisone oral tablets,dose pack</i> | T2 | |
| <i>propylthiouracil</i> | T2 | |
| RECORLEV | T5 | PA; QL (248 EA per 31 days) |
| <i>repaglinide oral tablet 0.5 mg, 1 mg</i> | T2 | QL (124 EA per 31 days) |
| <i>repaglinide oral tablet 2 mg</i> | T2 | QL (248 EA per 31 days) |
| RYBELSUS | T3 | PA; QL (31 EA per 31 days) |
| <i>sapropterin</i> | T5 | PA |
| SOLQUA 100/33 | T3 | QL (18 ML per 30 days) |
| SOMAVERT | T5 | PA |
| SYMLINPEN 120 | T5 | QL (10.8 ML per 28 days) |
| SYMLINPEN 60 | T5 | QL (6 ML per 28 days) |
| SYNAREL | T5 | PA |
| SYNJARDY | T3 | QL (62 EA per 31 days) |
| SYNJARDY XR ORAL TABLET, IR - ER, BIPHASIC 24HR 10-1,000 MG, 12.5-1,000 MG, 5-1,000 MG | T3 | QL (62 EA per 31 days) |
| SYNJARDY XR ORAL TABLET, IR - ER, BIPHASIC 24HR 25-1,000 MG | T3 | QL (31 EA per 31 days) |
| SYNTHROID | T3 | |
| <i>testosterone cypionate</i> | T2 | PA |
| <i>testosterone enanthate</i> | T3 | PA |
| <i>testosterone transdermal gel in metered-dose pump 20.25 mg/1.25 gram (1.62 %)</i> | T3 | PA |
| <i>testosterone transdermal gel in packet 1.62 % (20.25 mg/1.25 gram), 1.62 % (40.5 mg/2.5 gram)</i> | T3 | PA |
| <i>tolvaptan</i> | T5 | PA |
| TOUJEO MAX U-300 SOLOSTAR | T3 | |
| TOUJEO SOLOSTAR U-300 INSULIN | T3 | |
| TRADJENTA | T3 | QL (31 EA per 31 days) |
| TRESIBA FLEXTOUCH U-100 | T3 | |
| TRESIBA FLEXTOUCH U-200 | T3 | |
| TRESIBA U-100 INSULIN | T3 | |

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla al principio de esta tabla.

| Nombre del medicamento | Nivel de medicamento | Requisitos/Límites |
|--|-----------------------------|----------------------------|
| TRIJARDY XR ORAL TABLET, IR - ER, BIPHASIC 24HR 10-5-1,000 MG, 25-5-1,000 MG | T3 | QL (31 EA per 31 days) |
| TRIJARDY XR ORAL TABLET, IR - ER, BIPHASIC 24HR 12.5-2.5-1,000 MG, 5-2.5-1,000 MG | T3 | QL (62 EA per 31 days) |
| TRULICITY | T3 | PA; QL (2 ML per 28 days) |
| UNITHROID | T3 | |
| XIGDUO XR ORAL TABLET, IR - ER, BIPHASIC 24HR 10-1,000 MG, 10-500 MG, 5-500 MG | T3 | QL (31 EA per 31 days) |
| XIGDUO XR ORAL TABLET, IR - ER, BIPHASIC 24HR 2.5-1,000 MG, 5-1,000 MG | T3 | QL (62 EA per 31 days) |
| XULTOPHY 100/3.6 | T3 | QL (15 ML per 30 days) |
| YARGESA | T5 | PA; QL (93 EA per 31 days) |
| ZEGALOGUE AUTOINJECTOR | T3 | |
| ZEGALOGUE SYRINGE | T3 | |
| Gastroenterología | | |
| <i>alose tron oral tablet 0.5 mg</i> | T4 | PA; QL (93 EA per 31 days) |
| <i>alose tron oral tablet 1 mg</i> | T5 | PA; QL (62 EA per 31 days) |
| <i>aprepitant oral capsule 125 mg</i> | T5 | PA-BvD |
| <i>aprepitant oral capsule 40 mg, 80 mg</i> | T4 | PA-BvD |
| <i>aprepitant oral capsule, dose pack</i> | T4 | PA-BvD |
| <i>balsalazide</i> | T4 | |
| <i>betaine</i> | T5 | |
| <i>budesonide oral capsule, delayed, extend. release</i> | T4 | |
| <i>budesonide oral tablet, delayed and ext. release</i> | T5 | |
| CIMZIA | T5 | PA; QL (2 EA per 28 days) |
| CIMZIA POWDER FOR RECONST | T5 | PA; QL (2 EA per 28 days) |
| COMPRO | T4 | |
| CONSTULOSE | T2 | |
| CREON | T3 | |
| <i>cromolyn oral</i> | T4 | |
| <i>dicyclomine oral capsule</i> | T2 | |
| <i>dicyclomine oral solution</i> | T2 | |
| <i>dicyclomine oral tablet</i> | T2 | |
| <i>diphenoxylate-atropine oral liquid</i> | T4 | |

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla al principio de esta tabla.

| Nombre del medicamento | Nivel de medicamento | Requisitos/Límites |
|--|-----------------------------|----------------------------|
| <i>diphenoxylate-atropine oral tablet</i> | T2 | |
| <i>dronabinol</i> | T4 | PA-BvD |
| ENULOSE | T2 | |
| <i>esomeprazole magnesium oral capsule, delayed release(dr/ec)</i> | T2 | QL (31 EA per 31 days) |
| <i>famotidine oral suspension for reconstitution</i> | T2 | |
| <i>famotidine oral tablet 20 mg, 40 mg</i> | T1 | |
| GATTEX 30-VIAL | T5 | PA |
| GAVILYTE-C | T1 | |
| GAVILYTE-G | T1 | |
| GENERLAC | T2 | |
| <i>glycopyrrolate oral tablet 1 mg, 2 mg</i> | T2 | |
| <i>granisetron hcl oral</i> | T4 | PA-BvD |
| <i>hydrocortisone rectal</i> | T4 | |
| <i>hydrocortisone topical cream with perineal applicator 2.5 %</i> | T1 | |
| <i>hydrocortisone-pramoxine rectal cream 1-1 %</i> | T4 | |
| IBSRELA | T5 | PA; QL (62 EA per 31 days) |
| <i>lactulose oral solution 10 gram/15 ml</i> | T2 | |
| LINZESS | T3 | QL (31 EA per 31 days) |
| <i>loperamide oral capsule</i> | T2 | |
| <i>lubiprostone</i> | T3 | QL (62 EA per 31 days) |
| <i>meclizine oral tablet 12.5 mg, 25 mg</i> | T2 | |
| <i>mesalamine oral capsule (with del rel tablets)</i> | T4 | QL (186 EA per 31 days) |
| <i>mesalamine oral capsule, extended release 24hr</i> | T4 | QL (124 EA per 31 days) |
| <i>mesalamine oral tablet, delayed release (dr/ec) 1.2 gram</i> | T4 | QL (124 EA per 31 days) |
| <i>mesalamine rectal enema</i> | T4 | QL (1860 ML per 31 days) |
| <i>metoclopramide hcl oral solution</i> | T2 | |
| <i>metoclopramide hcl oral tablet</i> | T2 | |
| <i>misoprostol</i> | T2 | |
| MOVANTIK | T3 | QL (31 EA per 31 days) |
| <i>nitroglycerin rectal</i> | T4 | |
| OCALIVA | T5 | PA; QL (31 EA per 31 days) |
| <i>omeprazole oral capsule, delayed release(dr/ec)</i> | T1 | |
| <i>ondansetron hcl oral solution</i> | T3 | PA-BvD |

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla al principio de esta tabla.

| Nombre del medicamento | Nivel de medicamento | Requisitos/Límites |
|---|-----------------------------|------------------------------|
| <i>ondansetron hcl oral tablet 4 mg, 8 mg</i> | T2 | PA-BvD |
| <i>ondansetron oral tablet, disintegrating 4 mg, 8 mg</i> | T2 | PA-BvD |
| <i>pantoprazole oral tablet, delayed release (dr/ec)</i> | T1 | |
| <i>peg 3350-electrolytes</i> | T1 | |
| <i>peg3350-sod sul-nacl-kcl-asb-c</i> | T4 | |
| <i>peg-electrolyte soln</i> | T1 | |
| <i>prochlorperazine</i> | T4 | |
| <i>prochlorperazine maleate</i> | T2 | |
| PROCTOSOL HC TOPICAL | T2 | |
| PROCTOZONE-HC | T2 | |
| <i>rabeprazole oral tablet, delayed release (dr/ec)</i> | T2 | QL (62 EA per 31 days) |
| <i>scopolamine base</i> | T3 | QL (10 EA per 30 days) |
| SKYRIZI SUBCUTANEOUS WEARABLE INJECTOR 180 MG/1.2 ML (150 MG/ML) | T5 | PA; QL (1.2 ML per 56 days) |
| SKYRIZI SUBCUTANEOUS WEARABLE INJECTOR 360 MG/2.4 ML (150 MG/ML) | T5 | PA; QL (2.4 ML per 56 days) |
| <i>sodium, potassium, mag sulfates</i> | T4 | |
| <i>sucralfate</i> | T2 | |
| <i>sulfasalazine</i> | T2 | |
| <i>ursodiol oral capsule 300 mg</i> | T4 | |
| <i>ursodiol oral tablet</i> | T3 | |
| VIBERZI | T5 | PA; QL (62 EA per 31 days) |
| VOWST | T5 | PA; QL (12 EA per 14 days) |
| Immunología, Vacunas / Biotecnología | | |
| ABRYSVO (PF) | T3 | QL (1 EA per 365 days) |
| ACTHIB (PF) | T3 | |
| ACTIMMUNE | T5 | PA |
| ADACEL(TDAP ADOLESN/ADULT)(PF) | T3 | |
| AREXVY (PF) | T3 | QL (1 EA per 365 days) |
| AVONEX INTRAMUSCULAR PEN INJECTOR KIT | T5 | PA; QL (1 EA per 28 days) |
| AVONEX INTRAMUSCULAR SYRINGE KIT | T5 | PA; QL (1 EA per 28 days) |
| <i>bcg vaccine, live (pf)</i> | T4 | |
| BESREMI | T5 | PA-NC; QL (2 ML per 28 days) |
| BETASERON SUBCUTANEOUS KIT | T5 | PA; QL (14 EA per 28 days) |
| BEXSERO | T3 | |

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla al principio de esta tabla.

| Nombre del medicamento | Nivel de medicamento | Requisitos/Límites |
|---|-----------------------------|---------------------------|
| BIVIGAM | T5 | PA |
| BOOSTRIX TDAP | T3 | |
| DAPTACEL (DTAP PEDIATRIC) (PF) | T3 | |
| ENGERIX-B (PF) | T3 | PA-BvD |
| ENGERIX-B PEDIATRIC (PF) | T3 | PA-BvD |
| FULPHILA | T5 | |
| GAMMAGARD LIQUID | T5 | PA |
| GAMMAGARD S-D (IGA < 1 MCG/ML) | T5 | PA |
| GAMMAKED INJECTION SOLUTION 1 GRAM/10 ML (10 %) | T5 | PA |
| GAMMAPLEX | T5 | PA |
| GAMMAPLEX (WITH SORBITOL) | T5 | PA |
| GAMUNEX-C INJECTION SOLUTION 1 GRAM/10 ML (10 %) | T5 | PA |
| GARDASIL 9 (PF) | T3 | |
| HAVRIX (PF) | T3 | |
| HEPLISAV-B (PF) | T3 | PA-BvD |
| HIBERIX (PF) | T3 | |
| IMOVAX RABIES VACCINE (PF) | T3 | PA-BvD |
| INFANRIX (DTAP) (PF) | T3 | |
| IPOL | T3 | |
| IXCHIQ (PF) | T3 | |
| IXIARO (PF) | T3 | |
| JYNNEOS (PF) | T3 | PA-BvD |
| KINRIX (PF) | T3 | |
| LEUKINE INJECTION RECON SOLN | T5 | PA |
| MENACTRA (PF) INTRAMUSCULAR SOLUTION | T3 | |
| MENQUADFI (PF) | T4 | |
| MENVEO A-C-Y-W-135-DIP (PF) INTRAMUSCULAR KIT | T3 | |
| M-M-R II (PF) | T3 | |
| NEULASTA | T5 | |
| NIVESTYM | T5 | |
| NORDITROPIN FLEXPPO | T5 | PA |
| OCTAGAM | T5 | PA |
| PANZYGA | T5 | PA |

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla al principio de esta tabla.

| Nombre del medicamento | Nivel de medicamento | Requisitos/Límites |
|---|-----------------------------|-----------------------------|
| PEDIARIX (PF) | T3 | PA-BvD |
| PEDVAX HIB (PF) | T3 | |
| PEGASYS | T5 | PA |
| PENBRAYA (PF) | T3 | |
| PENTACEL (PF) INTRAMUSCULAR KIT 15LF-48MCG-62DU -10 MCG/0.5ML | T3 | |
| PLEGRIDY SUBCUTANEOUS PEN INJECTOR 125 MCG/0.5 ML | T5 | PA; QL (1 ML per 28 days) |
| PLEGRIDY SUBCUTANEOUS SYRINGE 125 MCG/0.5 ML | T5 | PA; QL (1 ML per 28 days) |
| PREHEVBRIO (PF) | T3 | PA-BvD |
| PRIORIX (PF) | T3 | |
| PRIVIGEN | T5 | PA |
| PROCRIT INJECTION SOLUTION 10,000 UNIT/ML, 2,000 UNIT/ML, 3,000 UNIT/ML, 4,000 UNIT/ML | T3 | PA-BvD |
| PROCRIT INJECTION SOLUTION 20,000 UNIT/ML, 40,000 UNIT/ML | T5 | PA-BvD |
| PROQUAD (PF) | T3 | |
| QUADRACEL (PF) | T3 | |
| RABAVERT (PF) | T3 | PA-BvD |
| RECOMBIVAX HB (PF) | T3 | PA-BvD |
| RETACRIT | T3 | PA-BvD |
| ROTARIX | T3 | |
| ROTATEQ VACCINE | T3 | |
| SHINGRIX (PF) | T3 | QL (2 EA per 999 days) |
| TDVAX | T3 | |
| TENIVAC (PF) | T3 | |
| <i>tetanus,diphtheria tox ped(pf)</i> | T4 | |
| TICOVAC | T3 | |
| TRUMENBA | T3 | |
| TWINRIX (PF) | T3 | |
| TYPHIM VI | T3 | |
| VAQTA (PF) | T3 | |
| VARIVAX (PF) | T3 | |
| XOLREMDI | T5 | PA; QL (124 EA per 31 days) |
| YF-VAX (PF) | T3 | |

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla al principio de esta tabla.

| Nombre del medicamento | Nivel de medicamento | Requisitos/Límites |
|--|----------------------|--------------------------------|
| ZARXIO | T5 | |
| ZIEXTENZO | T5 | |
| Medicamentos Antineoplásicos E Inmunosupresores | | |
| <i>abiraterone oral tablet 250 mg</i> | T5 | PA-NC; QL (124 EA per 31 days) |
| <i>abiraterone oral tablet 500 mg</i> | T5 | PA-NC; QL (62 EA per 31 days) |
| AKEEGA | T5 | PA-NC; QL (62 EA per 31 days) |
| ALECENSA | T5 | PA-NC; QL (248 EA per 31 days) |
| ALUNBRIG ORAL TABLET 180 MG, 90 MG | T5 | PA-NC; QL (31 EA per 31 days) |
| ALUNBRIG ORAL TABLET 30 MG | T5 | PA-NC; QL (186 EA per 31 days) |
| ALUNBRIG ORAL TABLETS,DOSE PACK | T5 | PA-NC; QL (60 EA per 365 days) |
| <i>anastrozole</i> | T2 | |
| AUGTYRO | T5 | PA-NC; QL (248 EA per 31 days) |
| AYVAKIT | T5 | PA-NC; QL (31 EA per 31 days) |
| <i>azathioprine oral tablet 50 mg</i> | T2 | PA-BvD |
| BALVERSA | T5 | PA-NC |
| <i>bexarotene oral</i> | T5 | PA-NC |
| <i>bexarotene topical</i> | T5 | PA-NC; QL (60 GM per 28 days) |
| <i>bicalutamide</i> | T2 | |
| BOSULIF ORAL CAPSULE 100 MG | T5 | PA-NC; QL (186 EA per 31 days) |
| BOSULIF ORAL CAPSULE 50 MG | T5 | PA-NC; QL (341 EA per 31 days) |
| BOSULIF ORAL TABLET 100 MG | T5 | PA-NC; QL (93 EA per 31 days) |
| BOSULIF ORAL TABLET 400 MG, 500 MG | T5 | PA-NC; QL (31 EA per 31 days) |
| BRAFTOVI | T5 | PA-NC; QL (186 EA per 31 days) |
| BRUKINSA | T5 | PA-NC; QL (124 EA per 31 days) |
| CABOMETYX | T5 | PA-NC; QL (31 EA per 31 days) |
| CALQUENCE | T5 | PA-NC; QL (62 EA per 31 days) |
| CALQUENCE (ACALABRUTINIB MAL) | T5 | PA-NC; QL (62 EA per 31 days) |
| CAPRELSA ORAL TABLET 100 MG | T5 | PA-NC; QL (62 EA per 31 days) |
| CAPRELSA ORAL TABLET 300 MG | T5 | PA-NC; QL (31 EA per 31 days) |
| COMETRIQ ORAL CAPSULE 100 MG/DAY(80 MG X1-20 MG X1) | T5 | PA-NC; QL (56 EA per 28 days) |
| COMETRIQ ORAL CAPSULE 140 MG/DAY(80 MG X1-20 MG X3) | T5 | PA-NC; QL (112 EA per 28 days) |
| COMETRIQ ORAL CAPSULE 60 MG/DAY (20 MG X 3/DAY) | T5 | PA-NC; QL (84 EA per 28 days) |

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla al principio de esta tabla.

| Nombre del medicamento | Nivel de medicamento | Requisitos/Límites |
|--|-----------------------------|-----------------------------------|
| COPIKTRA | T5 | PA-NC; QL (62 EA per 31 days) |
| COTELLIC | T5 | PA-NC; LA; QL (63 EA per 28 days) |
| <i>cyclophosphamide oral</i> | T3 | PA-BvD |
| <i>cyclosporine modified oral capsule</i> | T2 | PA-BvD |
| <i>cyclosporine modified oral solution</i> | T4 | PA-BvD |
| <i>cyclosporine oral capsule</i> | T2 | PA-BvD |
| DAURISMO ORAL TABLET 100 MG | T5 | PA-NC; QL (31 EA per 31 days) |
| DAURISMO ORAL TABLET 25 MG | T5 | PA-NC; QL (62 EA per 31 days) |
| ELIGARD | T4 | ST-NC; QL (1 EA per 30 days) |
| ELIGARD (3 MONTH) | T4 | ST-NC; QL (1 EA per 90 days) |
| ELIGARD (4 MONTH) | T4 | ST-NC; QL (1 EA per 120 days) |
| ELIGARD (6 MONTH) | T4 | ST-NC; QL (1 EA per 180 days) |
| ENVARUSUS XR | T4 | PA-BvD |
| ERIVEDGE | T5 | PA-NC; QL (31 EA per 31 days) |
| ERLEADA ORAL TABLET 240 MG | T5 | PA-NC; QL (31 EA per 31 days) |
| ERLEADA ORAL TABLET 60 MG | T5 | PA-NC; QL (93 EA per 31 days) |
| <i>erlotinib</i> | T5 | PA-NC; QL (31 EA per 31 days) |
| <i>everolimus (antineoplastic) oral tablet 10 mg, 2.5 mg, 7.5 mg</i> | T5 | PA-NC; QL (31 EA per 31 days) |
| <i>everolimus (antineoplastic) oral tablet 5 mg</i> | T5 | PA-NC; QL (62 EA per 31 days) |
| <i>everolimus (antineoplastic) oral tablet for suspension 2 mg, 5 mg</i> | T5 | PA-NC; QL (62 EA per 31 days) |
| <i>everolimus (antineoplastic) oral tablet for suspension 3 mg</i> | T5 | PA-NC; QL (93 EA per 31 days) |
| <i>everolimus (immunosuppressive)</i> | T5 | PA-BvD |
| <i>exemestane</i> | T4 | |
| FIRMAGON KIT W DILUENT SYRINGE SUBCUTANEOUS RECON SOLN 120 MG | T5 | PA-NC |
| FIRMAGON KIT W DILUENT SYRINGE SUBCUTANEOUS RECON SOLN 80 MG | T4 | PA-NC |
| FOTIVDA | T5 | PA-NC; QL (21 EA per 28 days) |
| FRUZAQLA ORAL CAPSULE 1 MG | T5 | PA-NC; QL (84 EA per 28 days) |
| FRUZAQLA ORAL CAPSULE 5 MG | T5 | PA-NC; QL (21 EA per 28 days) |
| GAVRETO | T5 | PA-NC; QL (124 EA per 31 days) |
| <i>gefitinib</i> | T5 | PA-NC; QL (31 EA per 31 days) |
| GENGRAF ORAL CAPSULE | T2 | PA-BvD |

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla al principio de esta tabla.

| Nombre del medicamento | Nivel de medicamento | Requisitos/Límites |
|---|-----------------------------|--------------------------------|
| GENGRAF ORAL SOLUTION | T5 | PA-BvD |
| GILOTRIF | T5 | PA-NC; QL (31 EA per 31 days) |
| GLEOSTINE ORAL CAPSULE 10 MG, 100 MG | T5 | PA-NC |
| GLEOSTINE ORAL CAPSULE 40 MG | T4 | PA-NC |
| <i>hydroxyurea</i> | T2 | |
| IBRANCE | T5 | PA-NC; QL (21 EA per 28 days) |
| ICLUSIG | T5 | PA-NC; QL (31 EA per 31 days) |
| IDHIFA ORAL TABLET 100 MG | T5 | PA-NC; QL (31 EA per 31 days) |
| IDHIFA ORAL TABLET 50 MG | T5 | PA-NC; QL (62 EA per 31 days) |
| <i>imatinib oral tablet 100 mg</i> | T5 | PA-NC; QL (93 EA per 31 days) |
| <i>imatinib oral tablet 400 mg</i> | T5 | PA-NC; QL (62 EA per 31 days) |
| IMBRUVICA ORAL CAPSULE 140 MG | T5 | PA-NC; QL (124 EA per 31 days) |
| IMBRUVICA ORAL CAPSULE 70 MG | T5 | PA-NC; QL (31 EA per 31 days) |
| IMBRUVICA ORAL SUSPENSION | T5 | PA-NC; QL (216 ML per 25 days) |
| IMBRUVICA ORAL TABLET 140 MG, 280 MG, 420 MG | T5 | PA-NC; QL (31 EA per 31 days) |
| INLYTA | T5 | PA-NC; QL (124 EA per 31 days) |
| INQOVI | T5 | PA-NC; QL (5 EA per 28 days) |
| INREBIC | T5 | PA-NC; QL (124 EA per 31 days) |
| IWILFIN | T5 | PA-NC; QL (248 EA per 31 days) |
| JAKAFI | T5 | PA-NC; QL (62 EA per 31 days) |
| JAYPIRCA ORAL TABLET 100 MG | T5 | PA-NC; QL (62 EA per 31 days) |
| JAYPIRCA ORAL TABLET 50 MG | T5 | PA-NC; QL (31 EA per 31 days) |
| KISQALI FEMARA CO-PACK ORAL TABLET 200 MG/DAY(200 MG X 1)-2.5 MG | T5 | PA-NC; QL (49 EA per 28 days) |
| KISQALI FEMARA CO-PACK ORAL TABLET 400 MG/DAY(200 MG X 2)-2.5 MG | T5 | PA-NC; QL (70 EA per 28 days) |
| KISQALI FEMARA CO-PACK ORAL TABLET 600 MG/DAY(200 MG X 3)-2.5 MG | T5 | PA-NC; QL (91 EA per 28 days) |
| KISQALI ORAL TABLET 200 MG/DAY (200 MG X 1) | T5 | PA-NC; QL (21 EA per 28 days) |
| KISQALI ORAL TABLET 400 MG/DAY (200 MG X 2) | T5 | PA-NC; QL (42 EA per 28 days) |
| KISQALI ORAL TABLET 600 MG/DAY (200 MG X 3) | T5 | PA-NC; QL (63 EA per 28 days) |
| KLISYRI | T5 | PA |
| KOSELUGO ORAL CAPSULE 10 MG | T5 | PA; QL (279 EA per 31 days) |

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla al principio de esta tabla.

| Nombre del medicamento | Nivel de medicamento | Requisitos/Límites |
|--|-----------------------------|--------------------------------|
| KOSELUGO ORAL CAPSULE 25 MG | T5 | PA; QL (124 EA per 31 days) |
| KRAZATI | T5 | PA-NC; QL (186 EA per 31 days) |
| <i>lapatinib</i> | T5 | PA-NC; QL (186 EA per 31 days) |
| <i>lenalidomide</i> | T5 | PA-NC; QL (21 EA per 28 days) |
| LENVIMA | T5 | PA-NC |
| <i>letrozole</i> | T2 | |
| <i>leucovorin calcium oral tablet 10 mg, 15 mg, 25 mg</i> | T3 | |
| <i>leucovorin calcium oral tablet 5 mg</i> | T2 | |
| LEUKERAN | T5 | |
| <i>leuprolide (3 month)</i> | T4 | QL (1 EA per 84 days) |
| <i>leuprolide subcutaneous kit</i> | T3 | QL (2 EA per 28 days) |
| LONSURF | T5 | PA-NC |
| LORBRENA ORAL TABLET 100 MG | T5 | PA-NC; QL (31 EA per 31 days) |
| LORBRENA ORAL TABLET 25 MG | T5 | PA-NC; QL (93 EA per 31 days) |
| LUMAKRAS ORAL TABLET 120 MG | T5 | PA-NC; QL (124 EA per 31 days) |
| LUMAKRAS ORAL TABLET 320 MG | T5 | PA-NC; QL (93 EA per 31 days) |
| LUPRON DEPOT (3 MONTH) INTRAMUSCULAR SYRINGE KIT 11.25 MG | T5 | QL (1 EA per 90 days) |
| LUPRON DEPOT (3 MONTH) INTRAMUSCULAR SYRINGE KIT 22.5 MG | T5 | QL (1 EA per 84 days) |
| LUPRON DEPOT (4 MONTH) | T5 | QL (1 EA per 112 days) |
| LUPRON DEPOT (6 MONTH) | T5 | QL (1 EA per 168 days) |
| LUPRON DEPOT INTRAMUSCULAR SYRINGE KIT 3.75 MG | T5 | QL (1 EA per 30 days) |
| LUPRON DEPOT INTRAMUSCULAR SYRINGE KIT 7.5 MG | T5 | QL (1 EA per 28 days) |
| LUPRON DEPOT-PED (3 MONTH) INTRAMUSCULAR SYRINGE KIT 11.25 MG | T5 | PA; QL (1 EA per 90 days) |
| LUPRON DEPOT-PED INTRAMUSCULAR KIT 7.5 MG (PED) | T5 | PA; QL (1 EA per 30 days) |
| LUPRON DEPOT-PED INTRAMUSCULAR SYRINGE KIT | T5 | PA; QL (1 EA per 168 days) |
| LYNPARZA | T5 | PA-NC; QL (124 EA per 31 days) |
| LYSODREN | T5 | |

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla al principio de esta tabla.

| Nombre del medicamento | Nivel de medicamento | Requisitos/Límites |
|---|-----------------------------|-----------------------------------|
| LYTGOBI ORAL TABLET 12 MG/DAY (4 MG X 3) | T5 | PA-NC; QL (93 EA per 31 days) |
| LYTGOBI ORAL TABLET 16 MG/DAY (4 MG X 4) | T5 | PA-NC; QL (124 EA per 31 days) |
| LYTGOBI ORAL TABLET 20 MG/DAY (4 MG X 5) | T5 | PA-NC; QL (155 EA per 31 days) |
| MATULANE | T5 | |
| <i>megestrol oral suspension 400 mg/10 ml (40 mg/ml)</i> | T2 | PA |
| <i>megestrol oral suspension 625 mg/5 ml (125 mg/ml)</i> | T4 | PA |
| <i>megestrol oral tablet</i> | T2 | PA-NC |
| MEKINIST ORAL RECON SOLN | T5 | PA-NC; QL (1260 ML per 31 days) |
| MEKINIST ORAL TABLET 0.5 MG | T5 | PA-NC; QL (93 EA per 31 days) |
| MEKINIST ORAL TABLET 2 MG | T5 | PA-NC; QL (31 EA per 31 days) |
| MEKTOVI | T5 | PA-NC; QL (186 EA per 31 days) |
| <i>mercaptopurine</i> | T2 | |
| MESNEX ORAL | T4 | |
| <i>methotrexate sodium</i> | T2 | PA-BvD |
| <i>methotrexate sodium (pf) injection solution</i> | T2 | PA-BvD |
| <i>mycophenolate mofetil oral capsule</i> | T2 | PA-BvD |
| <i>mycophenolate mofetil oral suspension for reconstitution</i> | T4 | PA-BvD |
| <i>mycophenolate mofetil oral tablet</i> | T2 | PA-BvD |
| <i>mycophenolate sodium</i> | T4 | PA-BvD |
| NERLYNX | T5 | PA-NC; QL (186 EA per 31 days) |
| <i>nilutamide</i> | T5 | |
| NINLARO | T5 | PA-NC; QL (3 EA per 28 days) |
| NUBEQA | T5 | PA-NC; QL (124 EA per 31 days) |
| <i>octreotide acetate injection solution</i> | T4 | PA |
| ODOMZO | T5 | PA-NC; LA; QL (31 EA per 31 days) |
| OGSIVEO ORAL TABLET 100 MG, 150 MG | T5 | PA-NC; QL (62 EA per 31 days) |
| OGSIVEO ORAL TABLET 50 MG | T5 | PA-NC; QL (186 EA per 31 days) |
| OJEMDA ORAL SUSPENSION FOR RECONSTITUTION | T5 | PA-NC; QL (96 ML per 28 days) |

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla al principio de esta tabla.

| Nombre del medicamento | Nivel de medicamento | Requisitos/Límites |
|--|-----------------------------|--------------------------------|
| OJEMDA ORAL TABLET 500 MG/WEEK (100 MG X 5) | T5 | PA-NC; QL (20 EA per 28 days) |
| OJJAARA | T5 | PA-NC; QL (31 EA per 31 days) |
| ONUREG | T5 | PA-NC; QL (14 EA per 28 days) |
| ORGOVYX | T5 | PA-NC; QL (31 EA per 31 days) |
| ORSERDU ORAL TABLET 345 MG | T5 | PA-NC; QL (31 EA per 31 days) |
| ORSERDU ORAL TABLET 86 MG | T5 | PA-NC; QL (93 EA per 31 days) |
| <i>pazopanib</i> | T5 | PA-NC; QL (124 EA per 31 days) |
| PEMAZYRE | T5 | PA-NC; QL (14 EA per 21 days) |
| PIQRAY ORAL TABLET 200 MG/DAY (200 MG X 1) | T5 | PA-NC; QL (28 EA per 28 days) |
| PIQRAY ORAL TABLET 250 MG/DAY (200 MG X1-50 MG X1), 300 MG/DAY (150 MG X 2) | T5 | PA-NC; QL (56 EA per 28 days) |
| POMALYST | T5 | PA-NC; QL (21 EA per 28 days) |
| PROGRAF ORAL GRANULES IN PACKET | T4 | PA-BvD |
| PURIXAN | T5 | |
| QINLOCK | T5 | PA-NC; QL (93 EA per 31 days) |
| RETEVMO ORAL CAPSULE 40 MG | T5 | PA-NC; QL (186 EA per 31 days) |
| RETEVMO ORAL CAPSULE 80 MG | T5 | PA-NC; QL (124 EA per 31 days) |
| REZLIDHIA | T5 | PA-NC; QL (62 EA per 31 days) |
| ROZLYTREK ORAL CAPSULE 100 MG | T5 | PA-NC; QL (155 EA per 31 days) |
| ROZLYTREK ORAL CAPSULE 200 MG | T5 | PA-NC; QL (93 EA per 31 days) |
| ROZLYTREK ORAL PELLETS IN PACKET | T5 | PA-NC; QL (372 EA per 31 days) |
| RUBRACA | T5 | PA-NC; QL (124 EA per 31 days) |
| RYDAPT | T5 | PA-NC; QL (248 EA per 31 days) |
| SANDIMMUNE ORAL SOLUTION | T3 | PA-BvD |
| SCEMBLIX ORAL TABLET 100 MG | T5 | PA-NC; QL (124 EA per 31 days) |
| SCEMBLIX ORAL TABLET 20 MG | T5 | PA-NC; QL (62 EA per 31 days) |
| SCEMBLIX ORAL TABLET 40 MG | T5 | PA-NC; QL (310 EA per 31 days) |
| SIGNIFOR | T5 | PA |
| <i>sirolimus oral solution</i> | T5 | PA-BvD |
| <i>sirolimus oral tablet</i> | T4 | PA-BvD |
| SOLTAMOX | T4 | |
| <i>sorafenib</i> | T5 | PA-NC; QL (124 EA per 31 days) |
| SPRYCEL | T5 | PA-NC; QL (31 EA per 31 days) |
| STIVARGA | T5 | PA-NC; QL (84 EA per 28 days) |

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla al principio de esta tabla.

| Nombre del medicamento | Nivel de medicamento | Requisitos/Límites |
|--|-----------------------------|-----------------------------------|
| <i>sunitinib malate</i> | T5 | PA-NC; QL (31 EA per 31 days) |
| TABLOID | T4 | |
| TABRECTA | T5 | PA-NC; QL (124 EA per 31 days) |
| <i>tacrolimus oral capsule 0.5 mg, 1 mg</i> | T2 | PA-BvD |
| <i>tacrolimus oral capsule 5 mg</i> | T4 | PA-BvD |
| TAFINLAR ORAL CAPSULE | T5 | PA-NC; QL (124 EA per 31 days) |
| TAFINLAR ORAL TABLET FOR SUSPENSION | T5 | PA-NC; QL (930 EA per 31 days) |
| TAGRISSE | T5 | PA-NC; LA; QL (31 EA per 31 days) |
| TALZENNA | T5 | PA-NC; QL (31 EA per 31 days) |
| <i>tamoxifen</i> | T1 | |
| TASIGNA | T5 | PA-NC; QL (124 EA per 31 days) |
| TAZVERIK | T5 | PA-NC; QL (248 EA per 31 days) |
| TEPMETKO | T5 | PA-NC; QL (62 EA per 31 days) |
| THALOMID ORAL CAPSULE 100 MG, 150 MG, 50 MG | T5 | PA-NC; QL (28 EA per 28 days) |
| THALOMID ORAL CAPSULE 200 MG | T5 | PA-NC; QL (56 EA per 28 days) |
| TIBSOVO | T5 | PA-NC; QL (62 EA per 31 days) |
| <i>toremifene</i> | T4 | |
| TRELSTAR INTRAMUSCULAR SUSPENSION FOR RECONSTITUTION 11.25 MG | T4 | ST-NC; QL (1 EA per 84 days) |
| TRELSTAR INTRAMUSCULAR SUSPENSION FOR RECONSTITUTION 22.5 MG | T4 | ST-NC; QL (1 EA per 168 days) |
| TRELSTAR INTRAMUSCULAR SUSPENSION FOR RECONSTITUTION 3.75 MG | T4 | ST-NC; QL (1 EA per 28 days) |
| <i>tretinoin (antineoplastic)</i> | T5 | |
| TRUQAP | T5 | PA-NC; QL (64 EA per 28 days) |
| TUKYSA ORAL TABLET 150 MG | T5 | PA-NC; QL (124 EA per 31 days) |
| TUKYSA ORAL TABLET 50 MG | T5 | PA-NC; QL (248 EA per 31 days) |
| TURALIO ORAL CAPSULE 125 MG | T5 | PA-NC; QL (124 EA per 31 days) |
| VANFLYTA | T5 | PA-NC; QL (62 EA per 31 days) |
| VENCLEXTA ORAL TABLET 10 MG | T3 | PA-NC; QL (62 EA per 31 days) |
| VENCLEXTA ORAL TABLET 100 MG | T5 | PA-NC; QL (186 EA per 31 days) |
| VENCLEXTA ORAL TABLET 50 MG | T5 | PA-NC; QL (31 EA per 31 days) |

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla al principio de esta tabla.

| Nombre del medicamento | Nivel de medicamento | Requisitos/Límites |
|--|-----------------------------|--------------------------------|
| VENCLEXTA STARTING PACK | T5 | PA-NC; QL (84 EA per 365 days) |
| VERZENIO | T5 | PA-NC; QL (62 EA per 31 days) |
| VIJOICE ORAL GRANULES IN PACKET | T5 | PA-NC; QL (31 EA per 31 days) |
| VIJOICE ORAL TABLET 125 MG, 50 MG | T5 | PA-NC; QL (28 EA per 28 days) |
| VIJOICE ORAL TABLET 250 MG/DAY (200 MG X1-50 MG X1) | T5 | PA-NC; QL (56 EA per 28 days) |
| VITRAKVI ORAL CAPSULE 100 MG | T5 | PA-NC; QL (62 EA per 31 days) |
| VITRAKVI ORAL CAPSULE 25 MG | T5 | PA-NC; QL (186 EA per 31 days) |
| VITRAKVI ORAL SOLUTION | T5 | PA-NC; QL (310 ML per 31 days) |
| VIZIMPRO | T5 | PA-NC; QL (31 EA per 31 days) |
| VONJO | T5 | PA-NC; QL (124 EA per 31 days) |
| WELIREG | T5 | PA-NC; QL (93 EA per 31 days) |
| XALKORI ORAL CAPSULE | T5 | PA-NC; QL (124 EA per 31 days) |
| XALKORI ORAL PELLETT 150 MG | T5 | PA-NC; QL (186 EA per 31 days) |
| XALKORI ORAL PELLETT 20 MG, 50 MG | T5 | PA-NC; QL (124 EA per 31 days) |
| XATMEP | T4 | PA-BvD |
| XERMELO | T5 | PA; QL (93 EA per 31 days) |
| XGEVA | T5 | PA-NC |
| XOSPATA | T5 | PA-NC; QL (124 EA per 31 days) |
| XPOVIO ORAL TABLET 100 MG/WEEK (50 MG X 2), 40MG TWICE WEEK (40 MG X 2), 80 MG/WEEK (40 MG X 2) | T5 | PA-NC; QL (8 EA per 28 days) |
| XPOVIO ORAL TABLET 40 MG/WEEK (40 MG X 1), 60 MG/WEEK (60 MG X 1) | T5 | PA-NC; QL (4 EA per 28 days) |
| XPOVIO ORAL TABLET 60MG TWICE WEEK (120 MG/WEEK) | T5 | PA-NC; QL (24 EA per 28 days) |
| XPOVIO ORAL TABLET 80MG TWICE WEEK (160 MG/WEEK) | T5 | PA-NC; QL (32 EA per 28 days) |
| XTANDI ORAL CAPSULE | T5 | PA-NC; QL (124 EA per 31 days) |
| XTANDI ORAL TABLET 40 MG | T5 | PA-NC; QL (124 EA per 31 days) |
| XTANDI ORAL TABLET 80 MG | T5 | PA-NC; QL (62 EA per 31 days) |
| YONSA | T5 | PA-NC; QL (124 EA per 31 days) |
| ZEJULA ORAL TABLET | T5 | PA-NC; QL (31 EA per 31 days) |
| ZELBORAF | T5 | PA-NC; QL (248 EA per 31 days) |
| ZOLINZA | T5 | PA-NC |
| ZYDELIG | T5 | PA-NC; QL (62 EA per 31 days) |
| ZYKADIA | T5 | PA-NC; QL (93 EA per 31 days) |

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla al principio de esta tabla.

| Nombre del medicamento | Nivel de medicamento | Requisitos/Límites |
|--|-----------------------------|-------------------------------|
| Medicamentos Autonómicos/Snc, Neurología/Psico | | |
| ABILIFY MAINTENA | T5 | QL (1 EA per 28 days) |
| <i>acetaminophen-codeine oral solution 120-12 mg/5 ml</i> | T2 | PA; QL (5167 ML per 31 days) |
| <i>acetaminophen-codeine oral tablet</i> | T2 | PA; QL (403 EA per 31 days) |
| AIMOVIG AUTOINJECTOR SUBCUTANEOUS AUTO-INJECTOR 140 MG/ML | T3 | PA; QL (1 ML per 28 days) |
| AIMOVIG AUTOINJECTOR SUBCUTANEOUS AUTO-INJECTOR 70 MG/ML | T3 | PA; QL (2 ML per 28 days) |
| AJOVY AUTOINJECTOR | T3 | PA; QL (1.5 ML per 28 days) |
| AJOVY SYRINGE | T3 | PA; QL (1.5 ML per 28 days) |
| <i>alprazolam oral tablet 0.25 mg, 0.5 mg</i> | T2 | PA; QL (93 EA per 31 days) |
| <i>alprazolam oral tablet 1 mg, 2 mg</i> | T2 | PA; QL (155 EA per 31 days) |
| <i>amitriptyline</i> | T2 | PA-NC |
| <i>amoxapine</i> | T2 | |
| <i>apomorphine</i> | T5 | PA; QL (60 ML per 30 days) |
| APTIOM ORAL TABLET 200 MG | T4 | QL (186 EA per 31 days) |
| APTIOM ORAL TABLET 400 MG | T5 | QL (93 EA per 31 days) |
| APTIOM ORAL TABLET 600 MG, 800 MG | T5 | QL (62 EA per 31 days) |
| <i>aripiprazole oral solution</i> | T4 | PA-NC |
| <i>aripiprazole oral tablet</i> | T3 | |
| <i>aripiprazole oral tablet, disintegrating</i> | T5 | PA-NC |
| <i>armodafinil</i> | T4 | PA; QL (31 EA per 31 days) |
| <i>asenapine maleate</i> | T4 | PA-NC; QL (62 EA per 31 days) |
| <i>atomoxetine oral capsule 10 mg, 25 mg, 40 mg</i> | T4 | QL (62 EA per 31 days) |
| <i>atomoxetine oral capsule 100 mg, 60 mg, 80 mg</i> | T4 | QL (31 EA per 31 days) |
| <i>atomoxetine oral capsule 18 mg</i> | T4 | QL (124 EA per 31 days) |
| AUSTEDO ORAL TABLET 12 MG, 6 MG | T5 | PA; QL (124 EA per 31 days) |
| AUSTEDO ORAL TABLET 9 MG | T5 | PA; QL (155 EA per 31 days) |
| AUSTEDO XR ORAL TABLET EXTENDED RELEASE 24 HR 12 MG | T5 | PA; QL (93 EA per 31 days) |
| AUSTEDO XR ORAL TABLET EXTENDED RELEASE 24 HR 24 MG | T5 | PA; QL (62 EA per 31 days) |

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla al principio de esta tabla.

| Nombre del medicamento | Nivel de medicamento | Requisitos/Límites |
|---|-----------------------------|-------------------------------|
| AUSTEDO XR ORAL TABLET EXTENDED RELEASE 24 HR 30 MG, 36 MG, 42 MG, 48 MG | T5 | PA; QL (31 EA per 31 days) |
| AUSTEDO XR ORAL TABLET EXTENDED RELEASE 24 HR 6 MG | T5 | PA; QL (217 EA per 31 days) |
| AUSTEDO XR TITRATION KT(WK1-4) ORAL TABLET, EXT REL 24HR DOSE PACK 6 MG (14)-12 MG (14)-24 MG (14) | T5 | PA; QL (84 EA per 365 days) |
| AUVELITY | T5 | PA-NC; QL (62 EA per 31 days) |
| <i>baclofen oral tablet 10 mg, 20 mg</i> | T2 | |
| BAFIERTAM | T5 | PA; QL (124 EA per 31 days) |
| <i>benztropine oral</i> | T2 | PA |
| BRIVIACT ORAL SOLUTION | T5 | QL (620 ML per 31 days) |
| BRIVIACT ORAL TABLET | T5 | QL (62 EA per 31 days) |
| <i>bromocriptine</i> | T4 | |
| <i>buprenorphine</i> | T4 | PA; QL (4 EA per 28 days) |
| <i>buprenorphine hcl sublingual tablet 2 mg</i> | T3 | QL (93 EA per 31 days) |
| <i>buprenorphine hcl sublingual tablet 8 mg</i> | T3 | QL (62 EA per 31 days) |
| <i>buprenorphine-naloxone sublingual film 12-3 mg, 4-1 mg, 8-2 mg</i> | T2 | QL (62 EA per 31 days) |
| <i>buprenorphine-naloxone sublingual film 2-0.5 mg</i> | T2 | QL (93 EA per 31 days) |
| <i>buprenorphine-naloxone sublingual tablet</i> | T4 | QL (93 EA per 31 days) |
| <i>bupropion hcl oral tablet</i> | T2 | |
| <i>bupropion hcl oral tablet extended release 24 hr 150 mg</i> | T2 | QL (93 EA per 31 days) |
| <i>bupropion hcl oral tablet extended release 24 hr 300 mg</i> | T2 | QL (31 EA per 31 days) |
| <i>bupropion hcl oral tablet sustained-release 12 hr</i> | T2 | QL (62 EA per 31 days) |
| <i>buspirone</i> | T2 | |
| <i>butorphanol nasal</i> | T4 | QL (5 ML per 28 days) |
| CAPLYTA | T5 | PA-NC; QL (31 EA per 31 days) |
| <i>carbamazepine oral capsule, er multiphase 12 hr</i> | T3 | |
| <i>carbamazepine oral suspension 100 mg/5 ml</i> | T2 | |
| <i>carbamazepine oral tablet</i> | T2 | |
| <i>carbamazepine oral tablet extended release 12 hr</i> | T3 | |
| <i>carbamazepine oral tablet, chewable</i> | T2 | |
| <i>carbidopa-levodopa</i> | T2 | |
| <i>carbidopa-levodopa-entacapone</i> | T4 | |

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla al principio de esta tabla.

| Nombre del medicamento | Nivel de medicamento | Requisitos/Límites |
|---|-----------------------------|--------------------------------|
| <i>celecoxib oral capsule 100 mg, 200 mg, 50 mg</i> | T2 | QL (62 EA per 31 days) |
| <i>celecoxib oral capsule 400 mg</i> | T3 | QL (62 EA per 31 days) |
| <i>chlorpromazine oral</i> | T4 | |
| <i>citalopram oral solution</i> | T3 | |
| <i>citalopram oral tablet</i> | T1 | |
| <i>clobazam oral suspension</i> | T4 | PA-NC; QL (496 ML per 31 days) |
| <i>clobazam oral tablet</i> | T3 | PA-NC; QL (62 EA per 31 days) |
| <i>clomipramine</i> | T4 | PA-NC |
| <i>clonazepam oral tablet 0.5 mg</i> | T2 | PA-NC; QL (93 EA per 31 days) |
| <i>clonazepam oral tablet 1 mg</i> | T2 | PA-NC; QL (124 EA per 31 days) |
| <i>clonazepam oral tablet 2 mg</i> | T2 | PA-NC; QL (310 EA per 31 days) |
| <i>clonazepam oral tablet, disintegrating 0.125 mg, 0.25 mg, 0.5 mg</i> | T2 | PA-NC; QL (93 EA per 31 days) |
| <i>clonazepam oral tablet, disintegrating 1 mg</i> | T2 | PA-NC; QL (124 EA per 31 days) |
| <i>clonazepam oral tablet, disintegrating 2 mg</i> | T2 | PA-NC; QL (310 EA per 31 days) |
| <i>clorazepate dipotassium oral tablet 15 mg</i> | T3 | PA-NC; QL (186 EA per 31 days) |
| <i>clorazepate dipotassium oral tablet 3.75 mg, 7.5 mg</i> | T3 | PA-NC; QL (93 EA per 31 days) |
| <i>clozapine oral tablet 100 mg</i> | T3 | QL (279 EA per 31 days) |
| <i>clozapine oral tablet 200 mg</i> | T3 | QL (124 EA per 31 days) |
| <i>clozapine oral tablet 25 mg</i> | T2 | QL (279 EA per 31 days) |
| <i>clozapine oral tablet 50 mg</i> | T2 | QL (93 EA per 31 days) |
| <i>clozapine oral tablet, disintegrating 100 mg, 25 mg</i> | T4 | QL (279 EA per 31 days) |
| <i>clozapine oral tablet, disintegrating 12.5 mg</i> | T4 | QL (93 EA per 31 days) |
| <i>clozapine oral tablet, disintegrating 150 mg</i> | T4 | QL (186 EA per 31 days) |
| <i>clozapine oral tablet, disintegrating 200 mg</i> | T4 | QL (124 EA per 31 days) |
| COPAXONE SUBCUTANEOUS SYRINGE 20 MG/ML | T5 | PA; QL (31 ML per 31 days) |
| COPAXONE SUBCUTANEOUS SYRINGE 40 MG/ML | T5 | PA; QL (12 ML per 28 days) |
| <i>cyclobenzaprine oral tablet 10 mg</i> | T2 | QL (93 EA per 31 days) |
| <i>cyclobenzaprine oral tablet 5 mg</i> | T2 | QL (155 EA per 31 days) |
| <i>dalfampridine</i> | T5 | PA; QL (62 EA per 31 days) |
| <i>dantrolene oral</i> | T4 | |
| DAYBUE | T5 | PA; QL (3600 ML per 30 days) |
| <i>desipramine oral tablet 10 mg, 25 mg</i> | T3 | |

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla al principio de esta tabla.

| Nombre del medicamento | Nivel de medicamento | Requisitos/Límites |
|---|-----------------------------|---------------------------------|
| <i>desipramine oral tablet 100 mg, 150 mg, 50 mg, 75 mg</i> | T4 | |
| <i>desvenlafaxine succinate</i> | T3 | QL (31 EA per 31 days) |
| <i>dexmethylphenidate oral capsule,er biphasic 50-50</i> | T2 | QL (31 EA per 31 days) |
| <i>dexmethylphenidate oral tablet 10 mg</i> | T2 | QL (62 EA per 31 days) |
| <i>dexmethylphenidate oral tablet 2.5 mg, 5 mg</i> | T2 | QL (93 EA per 31 days) |
| <i>dextroamphetamine-amphetamine oral capsule,extended release 24hr</i> | T4 | QL (31 EA per 31 days) |
| <i>dextroamphetamine-amphetamine oral tablet 10 mg, 12.5 mg, 15 mg, 30 mg, 5 mg, 7.5 mg</i> | T2 | QL (62 EA per 31 days) |
| <i>dextroamphetamine-amphetamine oral tablet 20 mg</i> | T2 | QL (93 EA per 31 days) |
| DIACOMIT ORAL CAPSULE 250 MG | T5 | PA-NC; QL (341 EA per 31 days) |
| DIACOMIT ORAL CAPSULE 500 MG | T5 | PA-NC; QL (186 EA per 31 days) |
| DIACOMIT ORAL POWDER IN PACKET 250 MG | T5 | PA-NC; QL (341 EA per 31 days) |
| DIACOMIT ORAL POWDER IN PACKET 500 MG | T5 | PA-NC; QL (186 EA per 31 days) |
| DIAZEPAM INTENSOL | T2 | PA-NC; QL (248 ML per 31 days) |
| <i>diazepam oral solution 5 mg/5 ml (1 mg/ml)</i> | T2 | PA-NC; QL (1500 ML per 31 days) |
| <i>diazepam oral tablet</i> | T2 | PA-NC; QL (124 EA per 31 days) |
| <i>diazepam rectal</i> | T4 | |
| <i>diclofenac epolamine</i> | T4 | PA; QL (62 EA per 31 days) |
| <i>diclofenac potassium oral tablet 50 mg</i> | T2 | |
| <i>diclofenac sodium oral</i> | T2 | |
| <i>diclofenac sodium topical drops</i> | T2 | QL (450 ML per 28 days) |
| <i>diflunisal</i> | T2 | |
| <i>dihydroergotamine nasal</i> | T5 | PA; QL (8 ML per 31 days) |
| DILANTIN | T4 | |
| DILANTIN EXTENDED | T4 | |
| DILANTIN INFATABS | T4 | |
| <i>dimethyl fumarate oral capsule,delayed release(dr/ec) 120 mg (14)- 240 mg (46)</i> | T5 | PA; QL (120 EA per 365 days) |
| <i>dimethyl fumarate oral capsule,delayed release(dr/ec) 120 mg, 240 mg</i> | T5 | PA; QL (62 EA per 31 days) |
| <i>divalproex oral capsule, delayed rel sprinkle</i> | T2 | |

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla al principio de esta tabla.

| Nombre del medicamento | Nivel de medicamento | Requisitos/Límites |
|--|-----------------------------|--------------------------------|
| <i>divalproex oral tablet extended release 24 hr 250 mg</i> | T2 | |
| <i>divalproex oral tablet extended release 24 hr 500 mg</i> | T3 | |
| <i>divalproex oral tablet, delayed release (dr/ec)</i> | T2 | |
| <i>donepezil oral tablet 10 mg, 5 mg</i> | T1 | |
| <i>donepezil oral tablet 23 mg</i> | T3 | QL (31 EA per 31 days) |
| <i>donepezil oral tablet, disintegrating</i> | T2 | |
| <i>doxepin oral capsule</i> | T2 | PA-NC |
| <i>doxepin oral concentrate</i> | T2 | PA-NC |
| <i>doxepin oral tablet</i> | T3 | PA |
| <i>duloxetine oral capsule, delayed release(dr/ec) 20 mg, 60 mg</i> | T2 | QL (62 EA per 31 days) |
| <i>duloxetine oral capsule, delayed release(dr/ec) 30 mg</i> | T2 | QL (31 EA per 31 days) |
| EC-NAPROXEN ORAL TABLET, DELAYED RELEASE (DR/EC) 500 MG | T4 | |
| EMGALITY PEN | T3 | PA; QL (1 ML per 28 days) |
| EMGALITY SYRINGE SUBCUTANEOUS SYRINGE 120 MG/ML | T3 | PA; QL (1 ML per 28 days) |
| EMGALITY SYRINGE SUBCUTANEOUS SYRINGE 300 MG/3 ML (100 MG/ML X 3) | T5 | PA; QL (3 ML per 28 days) |
| EMSAM | T5 | QL (30 EA per 30 days) |
| ENDOCET | T3 | PA; QL (372 EA per 31 days) |
| <i>entacapone</i> | T3 | |
| EPIDIOLEX | T5 | PA-NC |
| EPITOL | T2 | |
| EPRONTIA | T4 | PA-NC; QL (496 ML per 31 days) |
| <i>ergotamine-caffeine</i> | T3 | PA |
| <i>escitalopram oxalate oral solution</i> | T4 | QL (620 ML per 31 days) |
| <i>escitalopram oxalate oral tablet 10 mg</i> | T2 | QL (45 EA per 30 days) |
| <i>escitalopram oxalate oral tablet 20 mg, 5 mg</i> | T2 | QL (30 EA per 30 days) |
| <i>ethosuximide oral capsule</i> | T3 | |
| <i>ethosuximide oral solution</i> | T4 | |
| <i>etodolac oral capsule</i> | T3 | |
| <i>etodolac oral tablet</i> | T2 | |
| <i>etodolac oral tablet extended release 24 hr 400 mg, 500 mg</i> | T3 | |

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla al principio de esta tabla.

| Nombre del medicamento | Nivel de medicamento | Requisitos/Límites |
|--|-----------------------------|--------------------------------|
| <i>etodolac oral tablet extended release 24 hr 600 mg</i> | T4 | |
| EVRYSDI | T5 | PA; QL (240 ML per 31 days) |
| FANAPT ORAL TABLET 1 MG | T4 | PA-NC; QL (62 EA per 31 days) |
| FANAPT ORAL TABLET 10 MG, 12 MG, 2 MG, 4 MG, 6 MG, 8 MG | T5 | PA-NC; QL (62 EA per 31 days) |
| FANAPT ORAL TABLETS,DOSE PACK | T4 | PA-NC; QL (16 EA per 365 days) |
| <i>felbamate</i> | T4 | |
| <i>fentanyl citrate buccal lozenge on a handle</i> | T5 | PA; QL (124 EA per 31 days) |
| <i>fentanyl transdermal patch 72 hour 100 mcg/hr, 12 mcg/hr, 75 mcg/hr</i> | T4 | PA; QL (10 EA per 30 days) |
| <i>fentanyl transdermal patch 72 hour 25 mcg/hr, 50 mcg/hr</i> | T2 | PA; QL (10 EA per 30 days) |
| FETZIMA ORAL CAPSULE,EXT REL 24HR DOSE PACK 20 MG (2)- 40 MG (26) | T4 | PA-NC; QL (56 EA per 365 days) |
| FETZIMA ORAL CAPSULE,EXTENDED RELEASE 24 HR 120 MG, 40 MG, 80 MG | T4 | PA-NC; QL (31 EA per 31 days) |
| FETZIMA ORAL CAPSULE,EXTENDED RELEASE 24 HR 20 MG | T4 | PA-NC; QL (93 EA per 31 days) |
| <i> fingolimod</i> | T5 | PA; QL (31 EA per 31 days) |
| FINTEPLA | T5 | PA-NC; QL (360 ML per 30 days) |
| FIRDAPSE | T5 | PA; QL (248 EA per 31 days) |
| FLECTOR | T4 | PA; QL (62 EA per 31 days) |
| <i>fluoxetine (pmdd)</i> | T2 | |
| <i>fluoxetine oral capsule</i> | T1 | |
| <i>fluoxetine oral solution</i> | T3 | |
| <i>fluoxetine oral tablet 10 mg, 20 mg</i> | T2 | |
| <i>fluphenazine decanoate</i> | T3 | |
| <i>fluphenazine hcl injection</i> | T4 | |
| <i>fluphenazine hcl oral concentrate</i> | T4 | |
| <i>fluphenazine hcl oral tablet</i> | T2 | |
| <i>flurbiprofen oral tablet 100 mg</i> | T2 | |
| <i>fluvoxamine oral tablet</i> | T2 | |
| FYCOMPA ORAL SUSPENSION | T5 | QL (744 ML per 31 days) |
| FYCOMPA ORAL TABLET 10 MG, 12 MG, 4 MG, 6 MG, 8 MG | T5 | QL (31 EA per 31 days) |
| FYCOMPA ORAL TABLET 2 MG | T4 | QL (31 EA per 31 days) |
| <i>gabapentin oral capsule 100 mg, 400 mg</i> | T2 | PA-NC; QL (270 EA per 30 days) |

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla al principio de esta tabla.

| Nombre del medicamento | Nivel de medicamento | Requisitos/Límites |
|--|-----------------------------|---------------------------------|
| <i>gabapentin oral capsule 300 mg</i> | T2 | PA-NC; QL (360 EA per 30 days) |
| <i>gabapentin oral solution 250 mg/5 ml</i> | T4 | PA-NC; QL (2160 ML per 30 days) |
| <i>gabapentin oral tablet 600 mg</i> | T2 | PA-NC; QL (180 EA per 30 days) |
| <i>gabapentin oral tablet 800 mg</i> | T2 | PA-NC; QL (120 EA per 30 days) |
| <i>galantamine oral capsule, ext rel. pellets 24 hr</i> | T3 | |
| <i>galantamine oral solution</i> | T4 | |
| <i>galantamine oral tablet</i> | T3 | |
| <i>glatiramer subcutaneous syringe 20 mg/ml</i> | T5 | PA; QL (31 ML per 31 days) |
| <i>glatiramer subcutaneous syringe 40 mg/ml</i> | T5 | PA; QL (12 ML per 28 days) |
| GLATOPA SUBCUTANEOUS SYRINGE 20 MG/ML | T5 | PA; QL (31 ML per 31 days) |
| GLATOPA SUBCUTANEOUS SYRINGE 40 MG/ML | T5 | PA; QL (12 ML per 28 days) |
| <i>guanfacine oral tablet extended release 24 hr</i> | T2 | PA |
| <i>haloperidol</i> | T2 | |
| <i>haloperidol decanoate</i> | T2 | |
| <i>haloperidol lactate injection</i> | T1 | |
| <i>haloperidol lactate oral</i> | T2 | |
| <i>hydrocodone-acetaminophen oral tablet 10-325 mg, 5-325 mg, 7.5-325 mg</i> | T2 | PA; QL (372 EA per 31 days) |
| <i>hydromorphone oral liquid</i> | T4 | PA; QL (1240 ML per 31 days) |
| <i>hydromorphone oral tablet 2 mg, 4 mg</i> | T2 | PA; QL (186 EA per 31 days) |
| <i>hydromorphone oral tablet 8 mg</i> | T3 | PA; QL (155 EA per 31 days) |
| IBU ORAL TABLET 600 MG, 800 MG | T1 | |
| <i>ibuprofen oral tablet 400 mg, 600 mg, 800 mg</i> | T1 | |
| <i>imipramine hcl</i> | T2 | PA-NC |
| <i>indomethacin oral capsule</i> | T2 | |
| <i>indomethacin oral capsule, extended release</i> | T2 | |
| INGREZZA INITIATION PK(TARDIV) | T5 | PA; QL (56 EA per 365 days) |
| INGREZZA ORAL CAPSULE 40 MG | T5 | PA; QL (62 EA per 31 days) |
| INGREZZA ORAL CAPSULE 60 MG, 80 MG | T5 | PA; QL (31 EA per 31 days) |
| INGREZZA SPRINKLE | T5 | PA; QL (31 EA per 31 days) |
| INVEGA HAFYERA INTRAMUSCULAR SYRINGE 1,092 MG/3.5 ML | T5 | QL (3.5 ML per 180 days) |
| INVEGA HAFYERA INTRAMUSCULAR SYRINGE 1,560 MG/5 ML | T5 | QL (5 ML per 180 days) |

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla al principio de esta tabla.

| Nombre del medicamento | Nivel de medicamento | Requisitos/Límites |
|---|-----------------------------|-------------------------------|
| INVEGA SUSTENNA INTRAMUSCULAR SYRINGE 117 MG/0.75 ML | T5 | QL (0.75 ML per 28 days) |
| INVEGA SUSTENNA INTRAMUSCULAR SYRINGE 156 MG/ML | T5 | QL (1 ML per 28 days) |
| INVEGA SUSTENNA INTRAMUSCULAR SYRINGE 234 MG/1.5 ML | T5 | QL (1.5 ML per 28 days) |
| INVEGA SUSTENNA INTRAMUSCULAR SYRINGE 39 MG/0.25 ML | T4 | QL (0.25 ML per 28 days) |
| INVEGA SUSTENNA INTRAMUSCULAR SYRINGE 78 MG/0.5 ML | T5 | QL (0.5 ML per 28 days) |
| INVEGA TRINZA INTRAMUSCULAR SYRINGE 273 MG/0.88 ML | T5 | QL (0.88 ML per 84 days) |
| INVEGA TRINZA INTRAMUSCULAR SYRINGE 410 MG/1.32 ML | T5 | QL (1.32 ML per 84 days) |
| INVEGA TRINZA INTRAMUSCULAR SYRINGE 546 MG/1.75 ML | T5 | QL (1.75 ML per 84 days) |
| INVEGA TRINZA INTRAMUSCULAR SYRINGE 819 MG/2.63 ML | T5 | QL (2.63 ML per 84 days) |
| KESIMPTA PEN | T5 | PA; QL (0.4 ML per 28 days) |
| KLOXXADO | T3 | |
| <i>lacosamide oral</i> | T4 | |
| <i>lamotrigine oral tablet</i> | T2 | |
| <i>lamotrigine oral tablet extended release 24hr</i> | T4 | |
| <i>lamotrigine oral tablet, chewable dispersible</i> | T2 | |
| <i>levetiracetam oral solution 100 mg/ml</i> | T2 | |
| <i>levetiracetam oral tablet</i> | T2 | |
| <i>levetiracetam oral tablet extended release 24 hr</i> | T2 | |
| LIBERVANT | T5 | PA-NC; QL (10 EA per 30 days) |
| <i>lithium carbonate oral capsule</i> | T1 | |
| <i>lithium carbonate oral tablet</i> | T1 | |
| <i>lithium carbonate oral tablet extended release</i> | T2 | |
| <i>lithium citrate</i> | T2 | |
| LORAZEPAM INTENSOL | T2 | PA; QL (155 ML per 31 days) |
| <i>lorazepam oral tablet 0.5 mg</i> | T2 | PA; QL (124 EA per 31 days) |
| <i>lorazepam oral tablet 1 mg</i> | T2 | PA; QL (186 EA per 31 days) |
| <i>lorazepam oral tablet 2 mg</i> | T2 | PA; QL (155 EA per 31 days) |
| <i>loxapine succinate</i> | T2 | |
| LUCEMYRA | T5 | |

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla al principio de esta tabla.

| Nombre del medicamento | Nivel de medicamento | Requisitos/Límites |
|--|-----------------------------|-------------------------------|
| <i>lurasidone oral tablet 120 mg, 20 mg, 40 mg, 60 mg</i> | T4 | PA-NC; QL (31 EA per 31 days) |
| <i>lurasidone oral tablet 80 mg</i> | T4 | PA-NC; QL (62 EA per 31 days) |
| MARPLAN | T4 | |
| MAVENCLAD (10 TABLET PACK) | T5 | PA; QL (40 EA per 365 days) |
| MAVENCLAD (4 TABLET PACK) | T5 | PA; QL (40 EA per 365 days) |
| MAVENCLAD (5 TABLET PACK) | T5 | PA; QL (40 EA per 365 days) |
| MAVENCLAD (6 TABLET PACK) | T5 | PA; QL (40 EA per 365 days) |
| MAVENCLAD (7 TABLET PACK) | T5 | PA; QL (40 EA per 365 days) |
| MAVENCLAD (8 TABLET PACK) | T5 | PA; QL (40 EA per 365 days) |
| MAVENCLAD (9 TABLET PACK) | T5 | PA; QL (40 EA per 365 days) |
| <i>meloxicam oral tablet</i> | T1 | |
| <i>memantine oral capsule, sprinkle, er 24hr</i> | T4 | |
| <i>memantine oral solution</i> | T4 | |
| <i>memantine oral tablet</i> | T2 | |
| <i>memantine oral tablets, dose pack</i> | T4 | |
| <i>methadone oral solution 10 mg/5 ml</i> | T2 | PA; QL (620 ML per 31 days) |
| <i>methadone oral solution 5 mg/5 ml</i> | T2 | PA; QL (1240 ML per 31 days) |
| <i>methadone oral tablet 10 mg</i> | T2 | PA; QL (124 EA per 31 days) |
| <i>methadone oral tablet 5 mg</i> | T2 | PA; QL (248 EA per 31 days) |
| <i>methsuximide</i> | T4 | |
| <i>methylphenidate hcl oral tablet</i> | T2 | QL (93 EA per 31 days) |
| <i>mirtazapine oral tablet 15 mg, 30 mg, 45 mg</i> | T2 | |
| <i>mirtazapine oral tablet 7.5 mg</i> | T3 | |
| <i>mirtazapine oral tablet, disintegrating</i> | T3 | |
| <i>modafinil</i> | T3 | PA; QL (31 EA per 31 days) |
| <i>molindone</i> | T4 | |
| <i>morphine concentrate oral solution</i> | T2 | PA; QL (310 ML per 31 days) |
| <i>morphine oral solution 10 mg/5 ml</i> | T2 | PA; QL (2800 ML per 31 days) |
| <i>morphine oral solution 20 mg/5 ml (4 mg/ml)</i> | T2 | PA; QL (1400 ML per 31 days) |
| <i>morphine oral tablet</i> | T2 | PA; QL (186 EA per 31 days) |
| <i>morphine oral tablet extended release 100 mg</i> | T3 | PA; QL (62 EA per 31 days) |
| <i>morphine oral tablet extended release 15 mg, 30 mg, 60 mg</i> | T3 | PA; QL (100 EA per 31 days) |
| <i>morphine oral tablet extended release 200 mg</i> | T3 | PA; QL (31 EA per 31 days) |
| <i>nabumetone</i> | T2 | |

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla al principio de esta tabla.

| Nombre del medicamento | Nivel de medicamento | Requisitos/Límites |
|--|-----------------------------|-------------------------------|
| <i>naloxone injection solution</i> | T2 | |
| <i>naloxone injection syringe</i> | T2 | |
| <i>naloxone nasal</i> | T3 | |
| <i>naltrexone</i> | T2 | |
| NAMZARIC | T4 | PA |
| <i>naproxen oral tablet</i> | T1 | |
| <i>naproxen oral tablet, delayed release (dr/ec) 375 mg</i> | T2 | |
| <i>naproxen sodium oral tablet 550 mg</i> | T2 | |
| <i>naratriptan oral tablet 1 mg</i> | T3 | QL (20 EA per 28 days) |
| <i>naratriptan oral tablet 2.5 mg</i> | T3 | QL (9 EA per 28 days) |
| NAYZILAM | T4 | PA-NC; QL (10 EA per 30 days) |
| <i>nefazodone</i> | T4 | |
| NEUPRO | T4 | |
| <i>nortriptyline</i> | T2 | |
| NUEDEXTA | T3 | PA; QL (62 EA per 31 days) |
| NUPLAZID | T5 | PA-NC; QL (31 EA per 31 days) |
| NURTEC ODT | T4 | PA; QL (18 EA per 28 days) |
| <i>olanzapine intramuscular</i> | T4 | |
| <i>olanzapine oral tablet</i> | T2 | QL (31 EA per 31 days) |
| <i>olanzapine oral tablet, disintegrating</i> | T4 | QL (31 EA per 31 days) |
| <i>oxcarbazepine oral suspension</i> | T4 | |
| <i>oxcarbazepine oral tablet</i> | T2 | |
| <i>oxycodone oral capsule</i> | T2 | PA; QL (186 EA per 31 days) |
| <i>oxycodone oral concentrate</i> | T4 | PA; QL (180 ML per 31 days) |
| <i>oxycodone oral tablet 10 mg, 15 mg, 20 mg, 5 mg</i> | T2 | PA; QL (186 EA per 31 days) |
| <i>oxycodone oral tablet 30 mg</i> | T3 | PA; QL (138 EA per 31 days) |
| <i>oxycodone-acetaminophen oral tablet 10-325 mg, 2.5-325 mg</i> | T3 | PA; QL (372 EA per 31 days) |
| <i>oxycodone-acetaminophen oral tablet 5-325 mg, 7.5-325 mg</i> | T2 | PA; QL (372 EA per 31 days) |
| <i>paliperidone oral tablet extended release 24hr 1.5 mg, 3 mg, 9 mg</i> | T4 | QL (31 EA per 31 days) |
| <i>paliperidone oral tablet extended release 24hr 6 mg</i> | T4 | QL (62 EA per 31 days) |
| <i>paroxetine hcl oral suspension</i> | T4 | |
| <i>paroxetine hcl oral tablet</i> | T1 | |

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla al principio de esta tabla.

| Nombre del medicamento | Nivel de medicamento | Requisitos/Límites |
|---|-----------------------------|--------------------------------|
| <i>perphenazine</i> | T4 | |
| PERSERIS | T5 | QL (1 EA per 28 days) |
| <i>phenelzine</i> | T2 | |
| <i>phenobarbital</i> | T2 | PA-NC |
| <i>phenytoin oral suspension 125 mg/5 ml</i> | T2 | |
| <i>phenytoin oral tablet, chewable</i> | T2 | |
| <i>phenytoin sodium extended</i> | T2 | |
| <i>pimozide</i> | T4 | |
| <i>piroxicam</i> | T2 | |
| <i>pramipexole oral tablet</i> | T2 | |
| <i>pregabalin oral capsule 100 mg, 150 mg, 200 mg, 25 mg, 50 mg, 75 mg</i> | T2 | PA-NC; QL (93 EA per 31 days) |
| <i>pregabalin oral capsule 225 mg, 300 mg</i> | T2 | PA-NC; QL (62 EA per 31 days) |
| <i>pregabalin oral solution</i> | T2 | PA-NC; QL (930 ML per 31 days) |
| <i>primidone oral tablet 125 mg</i> | T4 | |
| <i>primidone oral tablet 250 mg, 50 mg</i> | T2 | |
| <i>protriptyline</i> | T4 | |
| <i>pyridostigmine bromide oral tablet 60 mg</i> | T3 | |
| <i>pyridostigmine bromide oral tablet extended release</i> | T4 | |
| <i>quetiapine oral tablet 100 mg, 200 mg, 300 mg, 400 mg, 50 mg</i> | T2 | QL (62 EA per 31 days) |
| <i>quetiapine oral tablet 150 mg</i> | T3 | QL (62 EA per 31 days) |
| <i>quetiapine oral tablet 25 mg</i> | T1 | QL (62 EA per 31 days) |
| <i>quetiapine oral tablet extended release 24 hr</i> | T3 | QL (62 EA per 31 days) |
| QULIPTA | T5 | PA; QL (31 EA per 31 days) |
| <i>ramelteon</i> | T4 | QL (31 EA per 31 days) |
| <i>rasagiline</i> | T4 | |
| REXULTI ORAL TABLET | T5 | PA-NC; QL (31 EA per 31 days) |
| <i>risperidone microspheres intramuscular suspension, extended rel recon 12.5 mg/2 ml, 25 mg/2 ml, 37.5 mg/2 ml</i> | T4 | QL (2 EA per 28 days) |
| <i>risperidone microspheres intramuscular suspension, extended rel recon 50 mg/2 ml</i> | T5 | QL (2 EA per 28 days) |
| <i>risperidone oral solution</i> | T2 | QL (496 ML per 31 days) |
| <i>risperidone oral tablet 0.25 mg, 0.5 mg, 1 mg, 2 mg</i> | T2 | QL (31 EA per 31 days) |

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla al principio de esta tabla.

| Nombre del medicamento | Nivel de medicamento | Requisitos/Límites |
|---|-----------------------------|-------------------------------|
| <i>risperidone oral tablet 3 mg</i> | T2 | QL (93 EA per 31 days) |
| <i>risperidone oral tablet 4 mg</i> | T2 | QL (124 EA per 31 days) |
| <i>risperidone oral tablet,disintegrating 0.25 mg, 0.5 mg, 1 mg, 2 mg</i> | T4 | QL (31 EA per 31 days) |
| <i>risperidone oral tablet,disintegrating 3 mg</i> | T4 | QL (93 EA per 31 days) |
| <i>risperidone oral tablet,disintegrating 4 mg</i> | T4 | QL (124 EA per 31 days) |
| <i>rivastigmine</i> | T4 | QL (30 EA per 30 days) |
| <i>rivastigmine tartrate</i> | T3 | |
| <i>rizatriptan oral tablet 10 mg</i> | T2 | QL (12 EA per 28 days) |
| <i>rizatriptan oral tablet 5 mg</i> | T2 | QL (24 EA per 28 days) |
| <i>rizatriptan oral tablet,disintegrating 10 mg</i> | T2 | QL (12 EA per 28 days) |
| <i>rizatriptan oral tablet,disintegrating 5 mg</i> | T2 | QL (24 EA per 28 days) |
| <i>ropinirole oral tablet</i> | T2 | |
| ROWEEPRA ORAL TABLET 500 MG | T2 | |
| <i>rufinamide oral suspension</i> | T5 | PA-NC |
| <i>rufinamide oral tablet 200 mg</i> | T4 | PA-NC |
| <i>rufinamide oral tablet 400 mg</i> | T5 | PA-NC |
| RYTARY | T3 | ST |
| SECUADO | T5 | PA-NC; QL (31 EA per 31 days) |
| <i>selegiline hcl</i> | T2 | |
| <i>sertraline oral concentrate</i> | T2 | |
| <i>sertraline oral tablet</i> | T1 | |
| SKYCLARYS | T5 | PA; QL (93 EA per 31 days) |
| <i>sodium oxybate</i> | T5 | PA; QL (540 ML per 30 days) |
| SPRITAM | T4 | |
| SUBVENITE | T2 | |
| <i>sulindac</i> | T2 | |
| <i>sumatriptan nasal spray,non-aerosol 20 mg/actuation</i> | T4 | QL (8 EA per 28 days) |
| <i>sumatriptan nasal spray,non-aerosol 5 mg/actuation</i> | T4 | QL (32 EA per 28 days) |
| <i>sumatriptan succinate oral tablet 100 mg</i> | T2 | QL (9 EA per 28 days) |
| <i>sumatriptan succinate oral tablet 25 mg</i> | T2 | QL (36 EA per 28 days) |
| <i>sumatriptan succinate oral tablet 50 mg</i> | T2 | QL (18 EA per 28 days) |
| <i>sumatriptan succinate subcutaneous cartridge 6 mg/0.5 ml</i> | T4 | QL (4 ML per 28 days) |

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla al principio de esta tabla.

| Nombre del medicamento | Nivel de medicamento | Requisitos/Límites |
|---|-----------------------------|-------------------------------|
| <i>sumatriptan succinate subcutaneous pen injector 4 mg/0.5 ml</i> | T4 | QL (6 ML per 28 days) |
| <i>sumatriptan succinate subcutaneous pen injector 6 mg/0.5 ml</i> | T4 | QL (4 ML per 28 days) |
| <i>sumatriptan succinate subcutaneous solution</i> | T4 | QL (4 ML per 28 days) |
| SUNOSI | T4 | PA; QL (31 EA per 31 days) |
| SYMPAZAN ORAL FILM 10 MG, 20 MG | T5 | PA-NC; QL (62 EA per 31 days) |
| SYMPAZAN ORAL FILM 5 MG | T4 | PA-NC; QL (62 EA per 31 days) |
| TASCENSO ODT | T5 | PA; QL (31 EA per 31 days) |
| <i>tasimelteon</i> | T5 | PA; QL (31 EA per 31 days) |
| TEGRETOL ORAL TABLET | T4 | |
| TEGRETOL XR | T4 | |
| <i>teriflunomide</i> | T5 | PA; QL (31 EA per 31 days) |
| <i>tetrabenazine oral tablet 12.5 mg</i> | T5 | PA; QL (93 EA per 31 days) |
| <i>tetrabenazine oral tablet 25 mg</i> | T5 | PA; QL (124 EA per 31 days) |
| <i>thioridazine</i> | T2 | |
| <i>thiothixene</i> | T3 | |
| <i>tiagabine</i> | T4 | |
| <i>tizanidine oral tablet</i> | T2 | |
| <i>topiramate oral capsule, sprinkle</i> | T2 | |
| <i>topiramate oral tablet</i> | T2 | |
| <i>tramadol oral tablet 50 mg</i> | T2 | PA; QL (240 EA per 30 days) |
| <i>tramadol-acetaminophen</i> | T2 | PA; QL (372 EA per 31 days) |
| <i>tranylcypromine</i> | T4 | |
| <i>trazodone oral tablet 100 mg, 150 mg, 50 mg</i> | T1 | |
| <i>trifluoperazine</i> | T2 | |
| <i>trimipramine</i> | T3 | PA-NC |
| TRINTELLIX | T4 | PA-NC |
| UBRELVY ORAL TABLET 100 MG | T5 | PA; QL (17 EA per 28 days) |
| UBRELVY ORAL TABLET 50 MG | T5 | PA; QL (34 EA per 28 days) |
| <i>valproic acid</i> | T2 | |
| <i>valproic acid (as sodium salt) oral solution 250 mg/5 ml</i> | T2 | |
| VALTOCO NASAL SPRAY, NON-AEROSOL 10 MG/SPRAY (0.1 ML), 5 MG/SPRAY (0.1 ML) | T4 | PA-NC; QL (10 EA per 30 days) |

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla al principio de esta tabla.

| Nombre del medicamento | Nivel de medicamento | Requisitos/Límites |
|--|-----------------------------|--------------------------------|
| VALTOCO NASAL SPRAY, NON-AEROSOL 15 MG/2 SPRAY (7.5/0.1ML X 2), 20 MG/2 SPRAY (10MG/0.1ML X2) | T5 | PA-NC; QL (10 EA per 30 days) |
| <i>venlafaxine oral capsule, extended release 24hr 150 mg, 37.5 mg</i> | T2 | QL (31 EA per 31 days) |
| <i>venlafaxine oral capsule, extended release 24hr 75 mg</i> | T2 | QL (93 EA per 31 days) |
| <i>venlafaxine oral tablet</i> | T2 | |
| VERSACLOZ | T5 | QL (558 ML per 31 days) |
| <i>vigabatrin</i> | T5 | PA-NC |
| VIGADRONE | T5 | PA-NC |
| VIGPODER | T5 | PA-NC |
| <i>vilazodone</i> | T3 | PA-NC; QL (31 EA per 31 days) |
| VIVITROL | T5 | |
| VRAYLAR ORAL CAPSULE | T5 | PA-NC; QL (31 EA per 31 days) |
| VUMERITY | T5 | PA; QL (124 EA per 31 days) |
| XCOPRI | T5 | PA-NC |
| XCOPRI MAINTENANCE PACK | T5 | PA-NC |
| XCOPRI TITRATION PACK ORAL TABLETS, DOSE PACK 12.5 MG (14)- 25 MG (14) | T4 | PA-NC |
| XCOPRI TITRATION PACK ORAL TABLETS, DOSE PACK 150 MG (14)- 200 MG (14), 50 MG (14)- 100 MG (14) | T5 | PA-NC |
| XYREM | T5 | PA; QL (540 ML per 30 days) |
| <i>zaleplon oral capsule 10 mg</i> | T2 | PA; QL (62 EA per 31 days) |
| <i>zaleplon oral capsule 5 mg</i> | T2 | PA; QL (93 EA per 31 days) |
| ZAVZPRET | T5 | PA; QL (8 EA per 30 days) |
| ZEPOSIA | T5 | PA; QL (31 EA per 31 days) |
| ZEPOSIA STARTER KIT (28-DAY) | T5 | PA; QL (56 EA per 365 days) |
| ZEPOSIA STARTER PACK (7-DAY) | T5 | PA; QL (14 EA per 365 days) |
| ZILBRYSQ SUBCUTANEOUS SYRINGE 16.6 MG/0.416 ML | T5 | PA; QL (11.648 ML per 28 days) |
| ZILBRYSQ SUBCUTANEOUS SYRINGE 23 MG/0.574 ML | T5 | PA; QL (16 ML per 28 days) |
| ZILBRYSQ SUBCUTANEOUS SYRINGE 32.4 MG/0.81 ML | T5 | PA; QL (22.68 ML per 28 days) |
| <i>ziprasidone hcl</i> | T3 | QL (62 EA per 31 days) |

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla al principio de esta tabla.

| Nombre del medicamento | Nivel de medicamento | Requisitos/Límites |
|--|-----------------------------|---------------------------------|
| <i>ziprasidone mesylate</i> | T3 | |
| <i>zolpidem oral tablet</i> | T4 | PA; QL (31 EA per 31 days) |
| ZONISADE | T4 | PA-NC; QL (930 ML per 31 days) |
| <i>zonisamide</i> | T2 | |
| ZTALMY | T5 | PA-NC; QL (1100 ML per 30 days) |
| ZUBSOLV SUBLINGUAL TABLET 0.7-0.18 MG, 2.9-0.71 MG, 8.6-2.1 MG | T3 | QL (62 EA per 31 days) |
| ZUBSOLV SUBLINGUAL TABLET 1.4-0.36 MG | T3 | QL (93 EA per 31 days) |
| ZUBSOLV SUBLINGUAL TABLET 11.4-2.9 MG, 5.7-1.4 MG | T3 | QL (31 EA per 31 days) |
| ZURZUVAE ORAL CAPSULE 20 MG, 25 MG | T5 | PA-NC; QL (28 EA per 180 days) |
| ZURZUVAE ORAL CAPSULE 30 MG | T5 | PA-NC; QL (14 EA per 180 days) |
| ZYPREXA RELPREVV INTRAMUSCULAR SUSPENSION FOR RECONSTITUTION 210 MG | T4 | QL (2 EA per 28 days) |
| Medicamentos Para Oídos, Nariz Y Garganta | | |
| <i>acetic acid otic (ear)</i> | T2 | |
| <i>azelastine nasal spray,non-aerosol 137 mcg (0.1 %)</i> | T2 | QL (30 ML per 25 days) |
| <i>chlorhexidine gluconate mucous membrane</i> | T1 | |
| CIPRO HC | T4 | |
| <i>ciprofloxacin-dexamethasone</i> | T4 | |
| <i>fluocinolone acetonide oil</i> | T4 | |
| <i>ipratropium bromide nasal spray,non-aerosol 21 mcg (0.03 %)</i> | T2 | QL (30 ML per 28 days) |
| <i>ipratropium bromide nasal spray,non-aerosol 42 mcg (0.06 %)</i> | T2 | QL (15 ML per 28 days) |
| KOURZEQ | T2 | |
| <i>neomycin-polymyxin-hc otic (ear)</i> | T3 | |
| <i>ofloxacin otic (ear)</i> | T2 | |
| <i>olopatadine nasal</i> | T3 | QL (30.5 GM per 30 days) |
| PERIOGARD | T1 | |
| <i>triamcinolone acetonide dental</i> | T2 | |

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla al principio de esta tabla.

| Nombre del medicamento | Nivel de medicamento | Requisitos/Límites |
|---|----------------------|-------------------------------|
| Musculoesquelético / Reumatología | | |
| ACTEMRA ACTPEN | T5 | PA; QL (3.6 ML per 28 days) |
| ACTEMRA SUBCUTANEOUS | T5 | PA; QL (3.6 ML per 28 days) |
| <i>alendronate oral tablet 10 mg, 35 mg, 70 mg</i> | T1 | |
| <i>allopurinol oral tablet 100 mg, 300 mg</i> | T1 | |
| BENLYSTA SUBCUTANEOUS | T5 | PA; QL (4 ML per 28 days) |
| <i>colchicine oral tablet</i> | T2 | QL (62 EA per 31 days) |
| CYLTEZO(CF) | T5 | PA; QL (2 EA per 28 days) |
| CYLTEZO(CF) PEN | T5 | PA; QL (2 EA per 28 days) |
| CYLTEZO(CF) PEN CROHN'S-UC-HS | T5 | PA; QL (12 EA per 365 days) |
| CYLTEZO(CF) PEN PSORIASIS-UV | T5 | PA; QL (8 EA per 365 days) |
| ENBREL MINI | T5 | PA; QL (8 ML per 28 days) |
| ENBREL SUBCUTANEOUS SOLUTION | T5 | PA; QL (4 ML per 28 days) |
| ENBREL SUBCUTANEOUS SYRINGE 25 MG/0.5 ML (0.5) | T5 | PA; QL (4 ML per 28 days) |
| ENBREL SUBCUTANEOUS SYRINGE 50 MG/ML (1 ML) | T5 | PA; QL (8 ML per 28 days) |
| ENBREL SURECLICK | T5 | PA; QL (8 ML per 28 days) |
| EVENTY SUBCUTANEOUS SYRINGE 210MG/2.34ML (105MG/1.17MLX2) | T5 | PA; QL (2.34 ML per 28 days) |
| HUMIRA PEN | T5 | PA; QL (2 EA per 28 days) |
| HUMIRA SUBCUTANEOUS SYRINGE KIT 40 MG/0.8 ML | T5 | PA; QL (2 EA per 28 days) |
| HUMIRA(CF) | T5 | PA; QL (2 EA per 28 days) |
| HUMIRA(CF) PEN | T5 | PA; QL (2 EA per 28 days) |
| HUMIRA(CF) PEN CROHNS-UC-HS | T5 | PA; QL (6 EA per 365 days) |
| HUMIRA(CF) PEN PEDIATRIC UC | T5 | PA; QL (8 EA per 365 days) |
| HUMIRA(CF) PEN PSOR-UV-ADOL HS | T5 | PA; QL (6 EA per 365 days) |
| <i>ibandronate oral</i> | T2 | |
| KEVZARA | T5 | PA; QL (2.28 ML per 28 days) |
| KINERET | T5 | PA; QL (18.76 ML per 28 days) |
| <i>leflunomide</i> | T3 | |
| OLUMIANT | T5 | PA; QL (31 EA per 31 days) |
| ORENCIA CLICKJECT | T5 | PA; QL (4 ML per 28 days) |
| ORENCIA SUBCUTANEOUS SYRINGE 125 MG/ML | T5 | PA; QL (4 ML per 28 days) |

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla al principio de esta tabla.

| Nombre del medicamento | Nivel de medicamento | Requisitos/Límites |
|---|-----------------------------|------------------------------|
| ORENCIA SUBCUTANEOUS SYRINGE 50 MG/0.4 ML | T5 | PA; QL (1.6 ML per 28 days) |
| ORENCIA SUBCUTANEOUS SYRINGE 87.5 MG/0.7 ML | T5 | PA; QL (2.8 ML per 28 days) |
| OTEZLA ORAL TABLET 30 MG | T5 | PA; QL (62 EA per 31 days) |
| OTEZLA STARTER ORAL TABLETS,DOSE PACK 10 MG (4)-20 MG (4)-30 MG (47) | T5 | PA; QL (55 EA per 28 days) |
| <i>penicillamine oral tablet</i> | T5 | |
| <i>probenecid</i> | T2 | |
| <i>probenecid-colchicine</i> | T2 | |
| PROLIA | T4 | PA; QL (1 ML per 180 days) |
| <i>raloxifene</i> | T3 | |
| RINVOQ ORAL TABLET EXTENDED RELEASE 24 HR 15 MG, 30 MG | T5 | PA; QL (31 EA per 31 days) |
| RINVOQ ORAL TABLET EXTENDED RELEASE 24 HR 45 MG | T5 | PA; QL (168 EA per 365 days) |
| <i>risedronate oral tablet 150 mg, 35 mg, 35 mg (12 pack), 35 mg (4 pack), 5 mg</i> | T4 | |
| <i>risedronate oral tablet, delayed release (dr/ec)</i> | T4 | |
| SIMPONI SUBCUTANEOUS PEN INJECTOR 100 MG/ML | T5 | PA; QL (1 ML per 28 days) |
| SIMPONI SUBCUTANEOUS PEN INJECTOR 50 MG/0.5 ML | T5 | PA; QL (0.5 ML per 28 days) |
| SIMPONI SUBCUTANEOUS SYRINGE 100 MG/ML | T5 | PA; QL (1 ML per 28 days) |
| SIMPONI SUBCUTANEOUS SYRINGE 50 MG/0.5 ML | T5 | PA; QL (0.5 ML per 28 days) |
| <i>teriparatide subcutaneous pen injector 20 mcg/dose (620mcg/2.48ml)</i> | T5 | PA; QL (2.48 ML per 28 days) |
| TYMLOS | T5 | PA; QL (1.56 ML per 30 days) |
| XELJANZ ORAL SOLUTION | T5 | PA; QL (310 ML per 31 days) |
| XELJANZ ORAL TABLET | T5 | PA; QL (62 EA per 31 days) |
| XELJANZ XR | T5 | PA; QL (31 EA per 31 days) |
| YUFLYMA(CF) | T5 | PA; QL (2 EA per 28 days) |
| YUFLYMA(CF) AI CROHN'S-UC-HS | T5 | PA; QL (6 EA per 365 days) |
| YUFLYMA(CF) AUTOINJECTOR | T5 | PA; QL (2 EA per 28 days) |
| Obstetricia / Ginecología | | |
| ALTAVERA (28) | T2 | |

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla al principio de esta tabla.

| Nombre del medicamento | Nivel de medicamento | Requisitos/Límites |
|--|-----------------------------|---------------------------|
| ALYACEN 1/35 (28) | T2 | |
| APRI | T2 | |
| ARANELLE (28) | T2 | |
| AVIANE | T2 | |
| BALZIVA (28) | T2 | |
| BLISOVI FE 1.5/30 (28) | T2 | |
| BRIELLYN | T2 | |
| CAMILA | T2 | |
| <i>clindamycin phosphate vaginal</i> | T2 | |
| CRYSELLE (28) | T2 | |
| CYRED EQ | T2 | |
| DEPO-SUBQ PROVERA 104 | T3 | |
| <i>desog-e.estradiol/e.estradiol</i> | T2 | |
| <i>desogestrel-ethinyl estradiol</i> | T2 | |
| <i>drospirenone-ethinyl estradiol</i> | T2 | |
| ENPRESSE | T2 | |
| ENSKYCE | T2 | |
| ERRIN | T2 | |
| ESTARYLLA | T2 | |
| <i>estradiol oral</i> | T2 | |
| <i>estradiol transdermal patch weekly 0.025 mg/24 hr, 0.06 mg/24 hr, 0.1 mg/24 hr</i> | T3 | |
| <i>estradiol transdermal patch weekly 0.0375 mg/24 hr, 0.05 mg/24 hr, 0.075 mg/24 hr</i> | T2 | |
| <i>estradiol vaginal</i> | T4 | |
| <i>estradiol-norethindrone acet</i> | T2 | |
| <i>ethynodiol diac-eth estradiol</i> | T2 | |
| <i>etonogestrel-ethinyl estradiol</i> | T3 | |
| HAILEY 24 FE | T2 | |
| HALOETTE | T4 | |
| HEATHER | T2 | |
| ICLEVIA | T2 | |
| IMVEXXY MAINTENANCE PACK | T3 | |
| IMVEXXY STARTER PACK | T3 | |
| INCASSIA | T2 | |
| INTROVALE | T2 | |

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla al principio de esta tabla.

| Nombre del medicamento | Nivel de medicamento | Requisitos/Límites |
|--|-----------------------------|---------------------------|
| ISIBLOOM | T2 | |
| JASMIEL (28) | T2 | |
| JINTELI | T4 | |
| JULEBER | T2 | |
| JUNEL 1.5/30 (21) | T2 | |
| JUNEL 1/20 (21) | T2 | |
| JUNEL FE 1.5/30 (28) | T2 | |
| JUNEL FE 1/20 (28) | T2 | |
| JUNEL FE 24 | T2 | |
| KARIVA (28) | T2 | |
| KELNOR 1/35 (28) | T2 | |
| KELNOR 1/50 (28) | T2 | |
| KURVELO (28) | T2 | |
| LESSINA | T2 | |
| LEVONEST (28) | T2 | |
| <i>levonorgestrel-ethinyl estrad oral tablet 0.1-20 mg-mcg, 0.15-0.03 mg</i> | T2 | |
| <i>levonorgestrel-ethinyl estrad oral tablets,dose pack,3 month</i> | T2 | |
| <i>levonorg-eth estrad triphasic</i> | T2 | |
| LEVORA-28 | T2 | |
| LILETTA | T3 | |
| LORYNA (28) | T2 | |
| LOW-OGESTREL (28) | T2 | |
| LUTERA (28) | T2 | |
| LYLEQ | T2 | |
| LYZA | T2 | |
| MARLISSA (28) | T2 | |
| <i>medroxyprogesterone</i> | T2 | |
| <i>metronidazole vaginal gel 0.75 % (37.5mg/5 gram)</i> | T3 | |
| MICONAZOLE-3 VAGINAL SUPPOSITORY | T2 | |
| MICROGESTIN 1.5/30 (21) | T2 | |
| MICROGESTIN 1/20 (21) | T2 | |
| MICROGESTIN FE 1.5/30 (28) | T2 | |
| MICROGESTIN FE 1/20 (28) | T2 | |

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla al principio de esta tabla.

| Nombre del medicamento | Nivel de medicamento | Requisitos/Límites |
|--|-----------------------------|---------------------------|
| MILI | T2 | |
| NECON 0.5/35 (28) | T2 | |
| NEXPLANON | T3 | |
| <i>noreth-ethinyl estradiol-iron</i> | T2 | |
| <i>norethindrone (contraceptive)</i> | T2 | |
| <i>norethindrone acetate</i> | T2 | |
| <i>norethindrone ac-eth estradiol oral tablet 0.5-2.5 mg-mcg, 1-5 mg-mcg</i> | T3 | |
| <i>norethindrone ac-eth estradiol oral tablet 1-20 mg-mcg</i> | T2 | |
| <i>norethindrone-e.estradiol-iron oral tablet 1 mg-20 mcg (21)/75 mg (7)</i> | T2 | |
| <i>norgestimate-ethinyl estradiol oral tablet 0.18/0.215/0.25 mg-35 mcg (28), 0.25-35 mg-mcg</i> | T2 | |
| NORTREL 0.5/35 (28) | T2 | |
| NORTREL 1/35 (21) | T2 | |
| NORTREL 1/35 (28) | T2 | |
| NORTREL 7/7/7 (28) | T2 | |
| NYLIA 1/35 (28) | T2 | |
| NYLIA 7/7/7 (28) | T2 | |
| NYMYO | T2 | |
| PIMTREA (28) | T2 | |
| PORTIA 28 | T2 | |
| PREMARIN VAGINAL | T3 | |
| RECLIPSEN (28) | T2 | |
| SETLAKIN | T2 | |
| SPRINTEC (28) | T2 | |
| SRONYX | T2 | |
| SYEDA | T2 | |
| <i>terconazole</i> | T2 | |
| <i>tranexamic acid oral</i> | T3 | |
| TRI-ESTARYLLA | T2 | |
| TRI-MILI | T2 | |
| TRI-NYMYO | T2 | |
| TRI-SPRINTEC (28) | T2 | |
| TRIVORA (28) | T2 | |
| TRI-VYLIBRA | T2 | |

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla al principio de esta tabla.

| Nombre del medicamento | Nivel de medicamento | Requisitos/Límites |
|--|----------------------|----------------------------|
| TURQOZ (28) | T2 | |
| VELIVET TRIPHASIC REGIMEN (28) | T2 | |
| VESTURA (28) | T2 | |
| VIENVA | T2 | |
| VYFEMLA (28) | T2 | |
| VYLIBRA | T2 | |
| YUVAFEM | T4 | |
| ZAFEMY | T3 | |
| ZOVIA 1-35 (28) | T2 | |
| Oftalmología | | |
| <i>acetazolamide</i> | T3 | |
| ALOMIDE | T4 | |
| <i>apraclonidine</i> | T3 | |
| <i>azelastine ophthalmic (eye)</i> | T2 | |
| <i>bacitracin ophthalmic (eye)</i> | T2 | |
| <i>bacitracin-polymyxin b</i> | T2 | |
| BESIVANCE | T4 | |
| <i>betaxolol ophthalmic (eye)</i> | T3 | |
| <i>brimonidine ophthalmic (eye) drops 0.1 %</i> | T3 | |
| <i>brimonidine ophthalmic (eye) drops 0.15 %</i> | T4 | |
| <i>brimonidine ophthalmic (eye) drops 0.2 %</i> | T2 | |
| <i>brimonidine-timolol</i> | T3 | |
| <i>brinzolamide</i> | T4 | |
| <i>carteolol</i> | T2 | |
| CILOXAN OPHTHALMIC (EYE) OINTMENT | T4 | |
| <i>ciprofloxacin hcl ophthalmic (eye)</i> | T2 | |
| <i>cromolyn ophthalmic (eye)</i> | T2 | |
| <i>cyclosporine ophthalmic (eye)</i> | T3 | QL (60 EA per 30 days) |
| CYSTARAN | T5 | PA; QL (60 ML per 28 days) |
| <i>dexamethasone sodium phosphate ophthalmic (eye)</i> | T2 | |
| <i>diclofenac sodium ophthalmic (eye)</i> | T2 | |
| <i>difluprednate</i> | T4 | |
| <i>dorzolamide</i> | T2 | |
| <i>dorzolamide-timolol</i> | T2 | |

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla al principio de esta tabla.

| Nombre del medicamento | Nivel de medicamento | Requisitos/Límites |
|--|-----------------------------|---------------------------|
| <i>erythromycin ophthalmic (eye)</i> | T2 | |
| <i>fluorometholone</i> | T3 | |
| <i>flurbiprofen sodium</i> | T2 | |
| <i>gatifloxacin</i> | T3 | |
| <i>gentamicin ophthalmic (eye) drops</i> | T2 | |
| <i>ketorolac ophthalmic (eye) drops 0.4 %</i> | T3 | |
| <i>ketorolac ophthalmic (eye) drops 0.5 %</i> | T2 | |
| <i>latanoprost</i> | T1 | |
| <i>levobunolol ophthalmic (eye) drops 0.5 %</i> | T1 | |
| LUMIGAN OPHTHALMIC (EYE) DROPS 0.01 % | T3 | QL (5 ML per 31 days) |
| <i>methazolamide</i> | T4 | |
| <i>moxifloxacin ophthalmic (eye) drops</i> | T3 | |
| NATACYN | T4 | |
| <i>neomycin-bacitracin-poly-hc</i> | T3 | |
| <i>neomycin-bacitracin-polymyxin</i> | T2 | |
| <i>neomycin-polymyxin b-dexameth</i> | T2 | |
| <i>neomycin-polymyxin-gramicidin</i> | T3 | |
| <i>neomycin-polymyxin-hc ophthalmic (eye)</i> | T3 | |
| NEO-POLYCIN | T2 | |
| NEO-POLYCIN HC | T2 | |
| <i>ofloxacin ophthalmic (eye)</i> | T2 | |
| <i>pilocarpine hcl ophthalmic (eye) drops 1 %, 2 %, 4 %</i> | T3 | |
| POLYCIN | T2 | |
| <i>polymyxin b sulf-trimethoprim</i> | T1 | |
| <i>prednisolone acetate</i> | T2 | |
| <i>prednisolone sodium phosphate ophthalmic (eye)</i> | T2 | |
| RESTASIS | T3 | QL (60 EA per 30 days) |
| RESTASIS MULTIDOSE | T3 | QL (5.5 ML per 27 days) |
| SIMBRINZA | T4 | |
| <i>sulfacetamide sodium ophthalmic (eye)</i> | T2 | |
| <i>sulfacetamide-prednisolone</i> | T2 | |
| <i>timolol maleate ophthalmic (eye) drops</i> | T1 | |
| <i>timolol maleate ophthalmic (eye) gel forming solution</i> | T3 | |

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla al principio de esta tabla.

| Nombre del medicamento | Nivel de medicamento | Requisitos/Límites |
|---|----------------------|----------------------------|
| <i>tobramycin ophthalmic (eye)</i> | T1 | |
| <i>tobramycin-dexamethasone</i> | T3 | |
| TOBREX OPHTHALMIC (EYE) OINTMENT | T4 | |
| <i>travoprost</i> | T3 | |
| <i>trifluridine</i> | T3 | |
| XDEMVY | T5 | PA; QL (10 ML per 42 days) |
| XIIDRA | T3 | QL (60 EA per 30 days) |
| ZIRGAN | T4 | ST |
| Respiratorio Y Alergia | | |
| <i>acetylcysteine</i> | T2 | PA-BvD |
| ADEMPAS | T5 | PA; QL (93 EA per 31 days) |
| <i>albuterol sulfate inhalation hfa aerosol inhaler 90 mcg/actuation</i> | T3 | QL (17 GM per 30 days) |
| <i>albuterol sulfate inhalation hfa aerosol inhaler 90 mcg/actuation (nda020503)</i> | T3 | QL (13.4 GM per 30 days) |
| <i>albuterol sulfate inhalation solution for nebulization 0.63 mg/3 ml, 1.25 mg/3 ml, 2.5 mg /3 ml (0.083 %), 2.5 mg/0.5 ml</i> | T2 | PA-BvD |
| <i>albuterol sulfate oral syrup</i> | T1 | |
| ALYQ | T5 | PA; QL (62 EA per 31 days) |
| <i>ambrisentan</i> | T5 | PA; QL (31 EA per 31 days) |
| ANORO ELLIPTA | T3 | QL (60 EA per 30 days) |
| ASMANEX HFA | T3 | QL (13 GM per 30 days) |
| ASMANEX TWISTHALER INHALATION AEROSOL POWDR BREATH ACTIVATED 110 MCG/ ACTUATION (30), 220 MCG/ ACTUATION (120), 220 MCG/ ACTUATION (30), 220 MCG/ ACTUATION (60) | T3 | QL (1 EA per 30 days) |
| ATROVENT HFA | T4 | QL (25.8 GM per 30 days) |
| <i>azelastine-fluticasone</i> | T4 | QL (23 GM per 30 days) |
| BERINERT INTRAVENOUS KIT | T5 | PA |
| BREO ELLIPTA | T3 | QL (60 EA per 30 days) |
| BREYNA | T3 | QL (10.3 GM per 30 days) |
| BREZTRI AEROSPHERE | T3 | QL (10.7 GM per 30 days) |
| <i>budesonide inhalation</i> | T4 | PA-BvD |
| <i>budesonide-formoterol</i> | T3 | QL (10.2 GM per 30 days) |
| CINRYZE | T5 | PA; QL (20 EA per 28 days) |

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla al principio de esta tabla.

| Nombre del medicamento | Nivel de medicamento | Requisitos/Límites |
|--|-----------------------------|------------------------------|
| COMBIVENT RESPIMAT | T3 | QL (4 GM per 30 days) |
| <i>cromolyn inhalation</i> | T4 | PA-BvD |
| <i>cyproheptadine</i> | T2 | PA |
| <i>desloratadine oral tablet</i> | T2 | QL (31 EA per 31 days) |
| DULERA | T3 | QL (13 GM per 30 days) |
| <i>epinephrine injection auto-injector</i> | T3 | |
| FASENRA PEN | T5 | PA; QL (1 ML per 56 days) |
| FASENRA SUBCUTANEOUS SYRINGE 10 MG/0.5 ML | T5 | PA; QL (0.5 ML per 56 days) |
| FASENRA SUBCUTANEOUS SYRINGE 30 MG/ML | T5 | PA; QL (1 ML per 56 days) |
| <i>flunisolide</i> | T3 | QL (50 ML per 25 days) |
| <i>fluticasone propionate inhalation blister with device 100 mcg/actuation, 50 mcg/actuation</i> | T4 | ST; QL (60 EA per 30 days) |
| <i>fluticasone propionate inhalation blister with device 250 mcg/actuation</i> | T4 | ST; QL (240 EA per 30 days) |
| <i>fluticasone propionate inhalation hfa aerosol inhaler 110 mcg/actuation</i> | T4 | ST; QL (12 GM per 30 days) |
| <i>fluticasone propionate inhalation hfa aerosol inhaler 220 mcg/actuation</i> | T4 | ST; QL (24 GM per 30 days) |
| <i>fluticasone propionate inhalation hfa aerosol inhaler 44 mcg/actuation</i> | T4 | ST; QL (10.6 GM per 30 days) |
| <i>fluticasone propionate nasal</i> | T1 | QL (16 GM per 30 days) |
| <i>fluticasone propion-salmeterol inhalation aerosol powdr breath activated</i> | T3 | QL (1 EA per 30 days) |
| <i>fluticasone propion-salmeterol inhalation blister with device</i> | T3 | QL (60 EA per 30 days) |
| HAEGARDA | T5 | PA |
| <i>hydroxyzine hcl oral solution 10 mg/5 ml</i> | T2 | PA |
| <i>hydroxyzine hcl oral tablet</i> | T2 | PA |
| <i>icatibant</i> | T5 | PA; QL (18 ML per 30 days) |
| <i>ipratropium bromide inhalation</i> | T2 | PA-BvD |
| <i>ipratropium-albuterol</i> | T2 | PA-BvD |
| KALYDECO ORAL GRANULES IN PACKET 13.4 MG, 5.8 MG, 50 MG, 75 MG | T5 | PA; QL (56 EA per 28 days) |
| KALYDECO ORAL GRANULES IN PACKET 25 MG | T5 | PA; QL (62 EA per 31 days) |
| KALYDECO ORAL TABLET | T5 | PA; QL (62 EA per 31 days) |

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla al principio de esta tabla.

| Nombre del medicamento | Nivel de medicamento | Requisitos/Límites |
|--|-----------------------------|-----------------------------|
| <i>levalbuterol hcl inhalation solution for nebulization 1.25 mg/3 ml</i> | T3 | PA-BvD |
| <i>levalbuterol tartrate</i> | T3 | QL (30 GM per 30 days) |
| <i>levocetirizine oral solution</i> | T4 | QL (310 ML per 31 days) |
| <i>levocetirizine oral tablet</i> | T1 | QL (31 EA per 31 days) |
| <i>mometasone nasal</i> | T3 | QL (34 GM per 30 days) |
| <i>montelukast oral tablet</i> | T2 | QL (31 EA per 31 days) |
| <i>montelukast oral tablet, chewable</i> | T2 | QL (31 EA per 31 days) |
| NUCALA SUBCUTANEOUS AUTO-INJECTOR | T5 | PA; QL (3 ML per 28 days) |
| NUCALA SUBCUTANEOUS RECON SOLN | T5 | PA; QL (3 EA per 28 days) |
| NUCALA SUBCUTANEOUS SYRINGE 100 MG/ML | T5 | PA; QL (3 ML per 28 days) |
| NUCALA SUBCUTANEOUS SYRINGE 40 MG/0.4 ML | T5 | PA; QL (0.4 ML per 28 days) |
| OFEV | T5 | PA; QL (62 EA per 31 days) |
| OPSUMIT | T5 | PA; QL (31 EA per 31 days) |
| ORKAMBI ORAL GRANULES IN PACKET | T5 | PA; QL (62 EA per 31 days) |
| ORKAMBI ORAL TABLET | T5 | PA; QL (124 EA per 31 days) |
| <i>pirfenidone oral capsule</i> | T5 | PA; QL (279 EA per 31 days) |
| <i>pirfenidone oral tablet</i> | T5 | PA; QL (93 EA per 31 days) |
| <i>promethazine oral tablet</i> | T4 | PA |
| PULMOZYME | T5 | PA |
| QVAR REDIHALER INHALATION HFA AEROSOL BREATH ACTIVATED 40 MCG/ACTUATION | T3 | QL (10.6 GM per 30 days) |
| QVAR REDIHALER INHALATION HFA AEROSOL BREATH ACTIVATED 80 MCG/ACTUATION | T3 | QL (21.2 GM per 30 days) |
| <i>roflumilast</i> | T4 | QL (31 EA per 31 days) |
| SAJAZIR | T5 | PA; QL (18 ML per 30 days) |
| SEREVENT DISKUS | T3 | QL (60 EA per 30 days) |
| <i>sildenafil (pulm.hypertension) oral suspension for reconstitution</i> | T5 | PA; QL (784 ML per 31 days) |
| <i>sildenafil (pulm.hypertension) oral tablet</i> | T3 | PA; QL (372 EA per 31 days) |
| SPIRIVA RESPIMAT | T3 | QL (4 GM per 30 days) |
| SPIRIVA WITH HANDIHALER | T3 | QL (30 EA per 30 days) |
| STIOLTO RESPIMAT | T3 | QL (4 GM per 30 days) |

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla al principio de esta tabla.

| Nombre del medicamento | Nivel de medicamento | Requisitos/Límites |
|--|----------------------|----------------------------|
| STRIVERDI RESPIMAT | T4 | QL (4 GM per 30 days) |
| SYMDEKO | T5 | PA; QL (56 EA per 28 days) |
| <i>tadalafil (pulm. hypertension)</i> | T5 | PA; QL (62 EA per 31 days) |
| TAKHZYRO SUBCUTANEOUS SOLUTION | T5 | PA; QL (4 ML per 28 days) |
| TAKHZYRO SUBCUTANEOUS SYRINGE 150 MG/ML | T5 | PA; QL (2 ML per 28 days) |
| TAKHZYRO SUBCUTANEOUS SYRINGE 300 MG/2 ML (150 MG/ML) | T5 | PA; QL (4 ML per 28 days) |
| <i>terbutaline oral</i> | T4 | |
| THEO-24 | T4 | |
| <i>theophylline oral solution</i> | T2 | |
| <i>theophylline oral tablet extended release 12 hr</i> | T2 | |
| <i>theophylline oral tablet extended release 24 hr</i> | T2 | |
| TRELEGY ELLIPTA | T3 | QL (60 EA per 30 days) |
| TRIKAFTA ORAL GRANULES IN PACKET, SEQUENTIAL | T5 | PA; QL (56 EA per 28 days) |
| TRIKAFTA ORAL TABLETS, SEQUENTIAL | T5 | PA; QL (84 EA per 28 days) |
| VENTOLIN HFA | T3 | QL (36 GM per 30 days) |
| WIXELA INHUB | T3 | QL (60 EA per 30 days) |
| XOLAIR | T5 | PA |
| <i>zafirlukast oral tablet 10 mg</i> | T4 | QL (93 EA per 31 days) |
| <i>zafirlukast oral tablet 20 mg</i> | T4 | QL (62 EA per 31 days) |
| Suministros Variados | | |
| ASSURE ID INSULIN SAFETY SYRINGE 1 ML 29 GAUGE X 1/2" | T4 | PA |
| GAUZE PAD TOPICAL BANDAGE 2 X 2 " | T2 | PA |
| <i>insulin syringe-needle u-100 syringe 0.3 ml 29 gauge, 1 ml 29 gauge x 1/2", 1/2 ml 28 gauge</i> | T3 | PA |
| <i>pen needle, diabetic needle 29 gauge x 1/2"</i> | T4 | PA |
| Urológicos | | |
| <i>alfuzosin</i> | T2 | QL (31 EA per 31 days) |
| <i>bethanechol chloride oral tablet 10 mg, 25 mg, 5 mg</i> | T2 | |
| <i>bethanechol chloride oral tablet 50 mg</i> | T3 | |
| CYSTAGON | T4 | |
| <i>darifenacin</i> | T4 | QL (31 EA per 31 days) |

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla al principio de esta tabla.

| Nombre del medicamento | Nivel de medicamento | Requisitos/Límites |
|--|-----------------------------|-----------------------------|
| <i>dutasteride</i> | T2 | QL (31 EA per 31 days) |
| <i>dutasteride-tamsulosin</i> | T4 | QL (31 EA per 31 days) |
| ELMIRON | T4 | |
| <i>finasteride oral tablet 5 mg</i> | T2 | |
| MYRBETRIQ ORAL SUSPENSION,EXTENDED REL RECON | T3 | QL (300 ML per 30 days) |
| MYRBETRIQ ORAL TABLET EXTENDED RELEASE 24 HR | T3 | QL (31 EA per 31 days) |
| <i>oxybutynin chloride oral syrup</i> | T2 | |
| <i>oxybutynin chloride oral tablet 5 mg</i> | T2 | |
| <i>oxybutynin chloride oral tablet extended release 24hr 10 mg, 5 mg</i> | T2 | QL (31 EA per 31 days) |
| <i>oxybutynin chloride oral tablet extended release 24hr 15 mg</i> | T3 | QL (62 EA per 31 days) |
| <i>potassium citrate oral tablet extended release</i> | T3 | |
| RIVFLOZA SUBCUTANEOUS SOLUTION | T5 | PA; QL (1 ML per 28 days) |
| RIVFLOZA SUBCUTANEOUS SYRINGE 128 MG/0.8 ML | T5 | PA; QL (0.8 ML per 28 days) |
| RIVFLOZA SUBCUTANEOUS SYRINGE 160 MG/ML | T5 | PA; QL (1 ML per 28 days) |
| <i>silodosin</i> | T4 | |
| <i>solifenacin</i> | T4 | QL (31 EA per 31 days) |
| <i>tadalafil oral tablet 2.5 mg</i> | T4 | PA; QL (62 EA per 31 days) |
| <i>tadalafil oral tablet 5 mg</i> | T4 | PA; QL (31 EA per 31 days) |
| <i>tamsulosin</i> | T1 | |
| <i>tolterodine oral capsule,extended release 24hr</i> | T3 | QL (31 EA per 31 days) |
| <i>tolterodine oral tablet</i> | T3 | QL (62 EA per 31 days) |
| <i>trospium oral capsule,extended release 24hr</i> | T3 | QL (31 EA per 31 days) |
| <i>trospium oral tablet</i> | T2 | QL (93 EA per 31 days) |
| Vitaminas, Hematinicos / Electrolitos | | |
| CLINIMIX 5%/D15W SULFITE FREE | T4 | PA-BvD |
| CLINIMIX 4.25%/D10W SULF FREE | T4 | PA-BvD |
| CLINIMIX 5%-D20W(SULFITE-FREE) | T4 | PA-BvD |
| <i>fluoride (sodium) oral tablet</i> | T2 | |
| INTRALIPID INTRAVENOUS EMULSION 20 %, 30 % | T4 | PA-BvD |
| ISOLYTE S PH 7.4 | T3 | PA-BvD |

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla al principio de esta tabla.

| Nombre del medicamento | Nivel de medicamento | Requisitos/Límites |
|--|-----------------------------|---------------------------|
| ISOLYTE-P IN 5 % DEXTROSE | T4 | PA-BvD |
| KLOR-CON | T4 | |
| KLOR-CON M10 | T2 | |
| KLOR-CON M15 | T2 | |
| KLOR-CON M20 | T2 | |
| <i>magnesium sulfate injection</i> | T2 | |
| PLENAMINE | T3 | PA-BvD |
| <i>potassium chlorid-d5-0.45%nacl</i> | T2 | |
| <i>potassium chloride in 0.9%nacl intravenous parenteral solution 20 meq/l, 40 meq/l</i> | T2 | |
| <i>potassium chloride in 5 % dex intravenous parenteral solution 20 meq/l</i> | T2 | |
| <i>potassium chloride in lr-d5 intravenous parenteral solution 20 meq/l</i> | T2 | |
| <i>potassium chloride in water intravenous piggyback 10 meq/100 ml, 20 meq/100 ml, 40 meq/100 ml</i> | T2 | |
| <i>potassium chloride intravenous</i> | T2 | |
| <i>potassium chloride oral capsule, extended release</i> | T2 | |
| <i>potassium chloride oral liquid</i> | T2 | |
| <i>potassium chloride oral tablet extended release</i> | T2 | |
| <i>potassium chloride oral tablet,er particles/crystals</i> | T2 | |
| <i>potassium chloride-0.45 % nacl</i> | T2 | |
| <i>potassium chloride-d5-0.2%nacl intravenous parenteral solution 20 meq/l</i> | T2 | |
| <i>potassium chloride-d5-0.9%nacl</i> | T2 | |
| PRENATAL VITAMIN PLUS LOW IRON | T2 | PA |
| PROSOL 20 % | T4 | PA-BvD |
| <i>sodium chloride 0.45 % intravenous</i> | T2 | |
| <i>sodium chloride 3 % hypertonic</i> | T2 | |
| <i>sodium chloride 5 % hypertonic</i> | T2 | |
| TRAVASOL 10 % | T3 | PA-BvD |
| TROPHAMINE 10 % | T4 | PA-BvD |

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla al principio de esta tabla.

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla al principio de esta tabla.

Índice de drogas

| | | | | | |
|--|-------|--|--------|--|--------|
| <i>abacavir</i> | 3 | <i>amiodarone</i> | 11 | AVONEX | 29 |
| <i>abacavir-lamivudine</i> | 3 | <i>amitriptyline</i> | 40 | AYVAKIT | 32 |
| ABILIFY MANTENA | 40 | <i>amlodipine</i> | 11 | <i>azathioprine</i> | 32 |
| <i>abiraterone</i> | 32 | <i>amlodipine-benazepril</i> | 11 | <i>azelastine</i> | 54, 60 |
| ABRYSVO (PF) | 29 | <i>amlodipine-olmesartan</i> | 11 | <i>azelastine-fluticasone</i> | 62 |
| <i>acamprosate</i> | 21 | <i>amlodipine-valsartan</i> | 11 | <i>azithromycin</i> | 4 |
| <i>acarbose</i> | 23 | <i>ammonium lactate</i> | 17 | <i>aztreonam</i> | 4 |
| ACCUTANE | 17 | AMNESTEEM | 18 | <i>bacitracin</i> | 60 |
| <i>acebutolol</i> | 11 | <i>amoxapine</i> | 40 | <i>bacitracin-polymyxin b</i> | 60 |
| <i>acetaminophen-codeine</i> | 40 | <i>amoxicillin</i> | 3 | <i>baclofen</i> | 41 |
| <i>acetazolamide</i> | 60 | <i>amoxicillin-pot clavulanate</i> | 4 | BAFIERTAM | 41 |
| <i>acetic acid</i> | 54 | <i>amphotericin b</i> | 4 | <i>balsalazide</i> | 27 |
| <i>acetylcysteine</i> | 62 | <i>amphotericin b liposome</i> | 4 | BALVERSA | 32 |
| <i>acitretin</i> | 17 | <i>ampicillin</i> | 4 | BALZIVA (28) | 57 |
| ACTEMRA | 55 | <i>ampicillin sodium</i> | 4 | BAQSIMI | 23 |
| ACTEMRA ACTPEN | 55 | <i>ampicillin-sulbactam</i> | 4 | BASAGLAR KWIKPEN U- | |
| ACTHIB (PF) | 29 | <i>anagrelide</i> | 21 | 100 INSULIN | 23 |
| ACTIMMUNE | 29 | <i>anastrozole</i> | 32 | BASAGLAR TEMPO | |
| <i>acyclovir</i> | 3, 17 | ANORO ELLIPTA | 62 | PEN(U-100)INSLN | 23 |
| <i>acyclovir sodium</i> | 3 | <i>apomorphine</i> | 40 | <i>bcg vaccine, live (pf)</i> | 29 |
| ADACEL(TDAP | | <i>apraclonidine</i> | 60 | <i>benazepril</i> | 12 |
| ADOLESN/ADULT)(PF) | 29 | <i>aprepitant</i> | 27 | <i>benazepril-hydrochlorothiazide</i> .. | 12 |
| ADBRY | 17 | APRI | 57 | BENLYSTA | 55 |
| <i>adefovir</i> | 3 | APTIOM | 40 | <i>benztropine</i> | 41 |
| ADEMPAS | 62 | APTIVUS | 4 | BERINERT | 62 |
| AIMOVIG AUTOINJECTOR | 40 | ARANELLE (28) | 57 | BESIVANCE | 60 |
| AJOVY AUTOINJECTOR | 40 | AREXVY (PF) | 29 | BESREMI | 29 |
| AJOVY SYRINGE | 40 | ARIKAYCE | 4 | <i>betaine</i> | 27 |
| AKEEGA | 32 | <i>aripiprazole</i> | 40 | <i>betamethasone dipropionate</i> | 18 |
| ALA-CORT | 17 | <i>armodafinil</i> | 40 | <i>betamethasone valerate</i> | 18 |
| <i>albendazole</i> | 3 | <i>asenapine maleate</i> | 40 | <i>betamethasone, augmented</i> | 18 |
| <i>albuterol sulfate</i> | 62 | ASMANEX HFA | 62 | BETASERON | 29 |
| <i>alclometasone</i> | 17 | ASMANEX TWISTHALER | 62 | <i>betaxolol</i> | 60 |
| ALCOHOL PADS | 23 | <i>aspirin-dipyridamole</i> | 11 | <i>bethanechol chloride</i> | 65 |
| ALECENSA | 32 | ASSURE ID INSULIN | | <i>bexarotene</i> | 32 |
| <i>alendronate</i> | 55 | SAFETY | 65 | BEXSERO | 29 |
| <i>alfuzosin</i> | 65 | <i>atazanavir</i> | 4 | <i>bicalutamide</i> | 32 |
| <i>aliskiren</i> | 11 | <i>atenolol</i> | 11 | BICILLIN C-R | 4 |
| <i>allopurinol</i> | 55 | <i>atenolol-chlorthalidone</i> | 11 | BICILLIN L-A | 4 |
| ALOMIDE | 60 | <i>atomoxetine</i> | 40 | BIKTARVY | 4 |
| <i>alosetron</i> | 27 | <i>atorvastatin</i> | 11 | <i>bisoprolol fumarate</i> | 12 |
| <i>alprazolam</i> | 40 | <i>atovaquone</i> | 4 | <i>bisoprolol-hydrochlorothiazide</i> .. | 12 |
| ALTAVERA (28) | 56 | <i>atovaquone-proguanil</i> | 4 | BIVIGAM | 30 |
| ALUNBRIG | 32 | ATROVENT HFA | 62 | BLISOVI FE 1.5/30 (28) | 57 |
| ALYACEN 1/35 (28) | 57 | AUGTYRO | 32 | BOOSTRIX TDAP | 30 |
| ALYQ | 62 | AUSTEDO | 40 | BOSULIF | 32 |
| <i>amantadine hcl</i> | 3 | AUSTEDO XR | 40, 41 | BRAFTOVI | 32 |
| <i>ambrisentan</i> | 62 | AUSTEDO XR TITRATION | | BREO ELLIPTA | 62 |
| <i>amikacin</i> | 3 | KT(WK1-4) | 41 | BREYNA | 62 |
| <i>amiloride</i> | 11 | AUVELITY | 41 | BREZTRI AEROSPHERE | 62 |
| <i>amiloride-hydrochlorothiazide</i> ... | 11 | AVIANE | 57 | BRIELLYN | 57 |

| | | | | | |
|---|--------|--|-----------|---|------------|
| BRILINTA | 12 | <i>cefprozil</i> | 5 | <i>clopidogrel</i> | 12 |
| <i>brimonidine</i> | 60 | <i>ceftazidime</i> | 5 | <i>clorazepate dipotassium</i> | 42 |
| <i>brimonidine-timolol</i> | 60 | <i>ceftriaxone</i> | 5 | <i>clotrimazole</i> | 5, 18 |
| <i>brinzolamide</i> | 60 | <i>cefuroxime axetil</i> | 5 | <i>clotrimazole-betamethasone</i> | 18 |
| BRIVIACT | 41 | <i>cefuroxime sodium</i> | 5 | <i>clozapine</i> | 42 |
| <i>bromocriptine</i> | 41 | <i>celecoxib</i> | 42 | COARTEM | 5 |
| BRUKINSA | 32 | <i>cephalexin</i> | 5 | <i>colchicine</i> | 55 |
| <i>budesonide</i> | 27, 62 | CERDELGA | 23 | <i>colesevelam</i> | 12 |
| <i>budesonide-formoterol</i> | 62 | <i>cevimeline</i> | 21 | <i>colestipol</i> | 12 |
| <i>bumetanide</i> | 12 | CHEMET | 21 | <i>colistin (colistimethate na)</i> | 5 |
| <i>buprenorphine</i> | 41 | <i>chlorhexidine gluconate</i> | 54 | COMBIVENT RESPIMAT | 63 |
| <i>buprenorphine hcl</i> | 41 | <i>chloroquine phosphate</i> | 5 | COMETRIQ | 32 |
| <i>buprenorphine-naloxone</i> | 41 | <i>chlorpromazine</i> | 42 | COMPLERA | 5 |
| <i>bupropion hcl</i> | 41 | <i>chlorthalidone</i> | 12 | COMPRO | 27 |
| <i>bupropion hcl (smoking deter)</i> | 21 | <i>cholestyramine (with sugar)</i> | 12 | CONSTULOSE | 27 |
| <i>bupirone</i> | 41 | CHOLESTYRAMINE | | COPAXONE | 42 |
| <i>butorphanol</i> | 41 | LIGHT | 12 | COPIKTRA | 33 |
| BYDUREON BCISE | 23 | CIBINQO | 18 | CORLANOR | 12 |
| <i>cabergoline</i> | 23 | <i>ciclopirox</i> | 18 | COSENTYX | 18 |
| CABLIVI | 12 | <i>cilostazol</i> | 12 | COSENTYX (2 SYRINGES) .. | 18 |
| CABOMETYX | 32 | CILOXAN | 60 | COSENTYX PEN (2 PENS) ... | 18 |
| <i>calcipotriene</i> | 18 | CIMDUO | 5 | COSENTYX UNOREADY | |
| <i>calcitonin (salmon)</i> | 23 | CIMZIA | 27 | PEN | 18 |
| <i>calcitriol</i> | 23 | CIMZIA POWDER FOR | | COTELLIC | 33 |
| CALQUENCE | 32 | RECONST | 27 | CREON | 27 |
| CALQUENCE | | <i>cinacalcet</i> | 23 | <i>cromolyn</i> | 27, 60, 63 |
| (ACALABRUTINIB MAL) | 32 | CINRYZE | 62 | CRYSELLE (28) | 57 |
| CAMILA | 57 | CIPRO HC | 54 | <i>cyclobenzaprine</i> | 42 |
| CAMZYOS | 12 | <i>ciprofloxacin hcl</i> | 5, 60 | <i>cyclophosphamide</i> | 33 |
| <i>candesartan</i> | 12 | <i>ciprofloxacin in 5 % dextrose</i> | 5 | <i>cyclosporine</i> | 33, 60 |
| <i>candesartan-hydrochlorothiazid</i> | 12 | <i>ciprofloxacin-dexamethasone</i> | 54 | <i>cyclosporine modified</i> | 33 |
| CAPLYTA | 41 | <i>citalopram</i> | 42 | CYLTEZO(CF) | 55 |
| CAPRELSA | 32 | CLARAVIS | 18 | CYLTEZO(CF) PEN | 55 |
| <i>captopril</i> | 12 | <i>clarithromycin</i> | 5 | CYLTEZO(CF) PEN | |
| <i>carbamazepine</i> | 41 | <i>clindamycin hcl</i> | 5 | CROHN'S-UC-HS | 55 |
| <i>carbidopa-levodopa</i> | 41 | <i>clindamycin in 5 % dextrose</i> | 5 | CYLTEZO(CF) PEN | |
| <i>carbidopa-levodopa-entacapone</i> | 41 | CLINDAMYCIN | | PSORIASIS-UV | 55 |
| <i>carglumic acid</i> | 21 | PEDIATRIC | 5 | <i>cyproheptadine</i> | 63 |
| <i>carteolol</i> | 60 | <i>clindamycin phosphate</i> | 5, 18, 57 | CYRED EQ | 57 |
| CARTIA XT | 12 | CLINIMIX 5%/D15W | | CYSTAGON | 65 |
| <i>carvedilol</i> | 12 | SULFITE FREE | 66 | CYSTARAN | 60 |
| <i>carvedilol phosphate</i> | 12 | CLINIMIX 4.25%/D10W | | <i>d10 %-0.45 % sodium chloride</i> ... | 21 |
| <i>caspofungin</i> | 4 | SULF FREE | 66 | <i>d2.5 %-0.45 % sodium chloride</i> .. | 21 |
| CAYSTON | 4 | CLINIMIX 4.25%/D5W | | <i>d5 % and 0.9 % sodium</i> | |
| <i>cefaclor</i> | 4 | SULFIT FREE | 21 | <i>chloride</i> | 21 |
| <i>cefadroxil</i> | 4 | CLINIMIX 5%- | | <i>d5 %-0.45 % sodium chloride</i> | 21 |
| <i>cefazolin</i> | 4 | D20W(SULFITE-FREE) | 66 | <i>dalfampridine</i> | 42 |
| <i>cefdinir</i> | 4 | <i>clobazam</i> | 42 | <i>danazol</i> | 23 |
| <i>cefepime</i> | 4 | <i>clomipramine</i> | 42 | <i>dantrolene</i> | 42 |
| <i>cefixime</i> | 5 | <i>clonazepam</i> | 42 | <i>dapsone</i> | 5 |
| <i>cefoxitin</i> | 5 | <i>clonidine</i> | 12 | DAPTACEL (DTAP | |
| <i>cefpodoxime</i> | 5 | <i>clonidine hcl</i> | 12 | PEDIATRIC) (PF) | 30 |

| | | | | | |
|---|------------|---|----|---|--------|
| <i>daptomycin</i> | 5 | DOPTELET (30 TAB PACK) | 13 | <i>entacapone</i> | 44 |
| <i>darifenacin</i> | 65 | <i>dorzolamide</i> | 60 | <i>entecavir</i> | 6 |
| <i>darunavir</i> | 6 | <i>dorzolamide-timolol</i> | 60 | ENTRESTO | 13 |
| DAURISMO | 33 | DOVATO | 6 | ENULOSE | 28 |
| DAYBUE | 42 | <i>doxazosin</i> | 13 | ENVARBUS XR | 33 |
| <i>deferasirox</i> | 21 | <i>doxepin</i> | 44 | EPIDIOLEX | 44 |
| <i>deferiprone</i> | 21 | <i>doxercalciferol</i> | 23 | <i>epinephrine</i> | 63 |
| DELSTRIGO | 6 | DOXY-100 | 6 | EPITOL | 44 |
| DEPO-SUBQ PROVERA 104 | 57 | <i>doxycycline hyclate</i> | 6 | <i>eplerenone</i> | 13 |
| DESCOVY | 6 | <i>doxycycline monohydrate</i> | 6 | EPRONTIA | 44 |
| <i>desipramine</i> | 42, 43 | <i>dronabinol</i> | 28 | <i>ergotamine-caffeine</i> | 44 |
| <i>desloratadine</i> | 63 | <i>drospirenone-ethinyl estradiol</i> | 57 | ERIVEDGE | 33 |
| <i>desmopressin</i> | 23 | <i>droxidopa</i> | 22 | ERLEADA | 33 |
| <i>desog-e.estradiol/e.estradiol</i> | 57 | DULERA | 63 | <i>erlotinib</i> | 33 |
| <i>desogestrel-ethinyl estradiol</i> | 57 | <i>duloxetine</i> | 44 | ERRIN | 57 |
| <i>desoximetasone</i> | 18 | DUPIXENT PEN | 19 | <i>ertapenem</i> | 6 |
| <i>desvenlafaxine succinate</i> | 43 | DUPIXENT SYRINGE | 19 | ERY PADS | 19 |
| <i>dexamethasone</i> | 23 | <i>dutasteride</i> | 66 | ERY-TAB | 6 |
| <i>dexamethasone sodium phosphate</i> | 60 | <i>dutasteride-tamsulosin</i> | 66 | ERYTHROCIN (AS STEARATE) | 6 |
| <i>dexmethylphenidate</i> | 43 | E.E.S. 400 | 6 | <i>erythromycin</i> | 6, 61 |
| <i>dextroamphetamine-amphetamine</i> | 43 | EC-NAPROXEN | 44 | <i>erythromycin ethylsuccinate</i> | 6 |
| <i>dextrose 10 % in water (d10w)</i> | 21 | EDURANT | 6 | <i>erythromycin with ethanol</i> | 19 |
| <i>dextrose 5 % in water (d5w)</i> | 22 | <i>efavirenz</i> | 6 | <i>erythromycin-benzoyl peroxide</i> | 19 |
| DIACOMIT | 43 | <i>efavirenz-emtricitabin-tenofov</i> | 6 | <i>escitalopram oxalate</i> | 44 |
| <i>diazepam</i> | 43 | <i>efavirenz-lamivu-tenofov disop</i> | 6 | <i>esomeprazole magnesium</i> | 28 |
| DIAZEPAM INTENSOL | 43 | ELIGARD | 33 | ESTARYLLA | 57 |
| <i>diazoxide</i> | 23 | ELIGARD (3 MONTH) | 33 | <i>estradiol</i> | 57 |
| <i>diclofenac epolamine</i> | 43 | ELIGARD (4 MONTH) | 33 | <i>estradiol-norethindrone acet</i> | 57 |
| <i>diclofenac potassium</i> | 43 | ELIGARD (6 MONTH) | 33 | <i>ethacrynic acid</i> | 13 |
| <i>diclofenac sodium</i> | 18, 43, 60 | ELIQUIS | 13 | <i>ethambutol</i> | 6 |
| <i>dicloxacillin</i> | 6 | ELIQUIS DVT-PE TREAT 30D START | 13 | <i>ethosuximide</i> | 44 |
| <i>dicyclomine</i> | 27 | ELMIRON | 66 | <i>ethynodiol diac-eth estradiol</i> | 57 |
| DIFICID | 6 | EMGALITY PEN | 44 | <i>etodolac</i> | 44, 45 |
| <i>diflunisal</i> | 43 | EMGALITY SYRINGE | 44 | <i>etonogestrel-ethinyl estradiol</i> | 57 |
| <i>difluprednate</i> | 60 | EMSAM | 44 | <i>etravirine</i> | 6 |
| <i>digoxin</i> | 12 | <i>emtricitabine</i> | 6 | EVENITY | 55 |
| <i>dihydroergotamine</i> | 43 | <i>emtricitabine-tenofovir (tdf)</i> | 6 | <i>everolimus (antineoplastic)</i> | 33 |
| DILANTIN | 43 | EMTRIVA | 6 | <i>everolimus (immunosuppressive)</i> | 33 |
| DILANTIN EXTENDED | 43 | EMVERM | 6 | EVOTAZ | 7 |
| DILANTIN INFATABS | 43 | <i>enalapril maleate</i> | 13 | EVRYSDI | 45 |
| <i>diltiazem hcl</i> | 12, 13 | <i>enalapril-hydrochlorothiazide</i> | 13 | <i>exemestane</i> | 33 |
| DILT-XR | 13 | ENBREL | 55 | <i>ezetimibe</i> | 13 |
| <i>dimethyl fumarate</i> | 43 | ENBREL MINI | 55 | <i>ezetimibe-simvastatin</i> | 13 |
| <i>diphenoxylate-atropine</i> | 27, 28 | ENBREL SURECLICK | 55 | FABHALTA | 22 |
| <i>disulfiram</i> | 22 | ENDOCET | 44 | <i>famciclovir</i> | 7 |
| <i>divalproex</i> | 43, 44 | ENGERIX-B (PF) | 30 | <i>famotidine</i> | 28 |
| <i>dofetilide</i> | 13 | ENGERIX-B PEDIATRIC (PF) | 30 | FANAPT | 45 |
| <i>donepezil</i> | 44 | <i>enoxaparin</i> | 13 | FARXIGA | 23 |
| DOPTELET (10 TAB PACK) | 13 | ENPRESSE | 57 | FASENRA | 63 |
| DOPTELET (15 TAB PACK) | 13 | ENSKYCE | 57 | FASENRA PEN | 63 |

| | | | | | |
|--|--------|---|-----------|--|------------|
| <i>felbamate</i> | 45 | <i>furosemide</i> | 13, 14 | HALOETTE | 57 |
| <i>felodipine</i> | 13 | FUZEON | 7 | <i>haloperidol</i> | 46 |
| <i>fenofibrate</i> | 13 | FYCOMPA | 45 | <i>haloperidol decanoate</i> | 46 |
| <i>fenofibrate micronized</i> | 13 | <i>gabapentin</i> | 45, 46 | <i>haloperidol lactate</i> | 46 |
| <i>fenofibrate nanocrystallized</i> | 13 | <i>galantamine</i> | 46 | HAVRIX (PF) | 30 |
| <i>fentanyl</i> | 45 | GAMMAGARD LIQUID | 30 | HEATHER | 57 |
| <i>fentanyl citrate</i> | 45 | GAMMAGARD S-D (IGA < 1 | | <i>heparin (porcine)</i> | 14 |
| FETZIMA | 45 | MCG/ML) | 30 | HEPLISAV-B (PF) | 30 |
| FIASP FLEXTOUCH U-100 | | GAMMAKED | 30 | HIBERIX (PF) | 30 |
| INSULIN | 23 | GAMMAPLEX | 30 | HUMALOG JUNIOR | |
| FIASP PENFILL U-100 | | GAMMAPLEX (WITH | | KWIKPEN U-100 | 24 |
| INSULIN | 23 | SORBITOL) | 30 | HUMALOG KWIKPEN | |
| FIASP U-100 INSULIN | 23 | GAMUNEX-C | 30 | INSULIN | 24 |
| FILSUVEZ | 19 | GARDASIL 9 (PF) | 30 | HUMALOG MIX 50-50 | |
| <i>finasteride</i> | 66 | <i>gatifloxacin</i> | 61 | KWIKPEN | 24 |
| <i>fingolimod</i> | 45 | GATTEX 30-VIAL | 28 | HUMALOG MIX 75-25 | |
| FINTEPLA | 45 | GAUZE PAD | 65 | KWIKPEN | 24 |
| FIRDAPSE | 45 | GAVILYTE-C | 28 | HUMALOG MIX 75-25(U- | |
| FIRMAGON KIT W | | GAVILYTE-G | 28 | 100)INSULN | 24 |
| DILUENT SYRINGE | 33 | GAVRETO | 33 | HUMALOG TEMPO PEN(U- | |
| <i>flecainide</i> | 13 | <i>gefitinib</i> | 33 | 100)INSULN | 24 |
| FLECTOR | 45 | <i>gemfibrozil</i> | 14 | HUMALOG U-100 INSULIN .. | 24 |
| <i>fluconazole</i> | 7 | GENERLAC | 28 | HUMIRA | 55 |
| <i>fluconazole in nacl (iso-osm)</i> | 7 | GENGRAF | 33, 34 | HUMIRA PEN | 55 |
| <i>flucytosine</i> | 7 | <i>gentamicin</i> | 7, 19, 61 | HUMIRA (CF) | 55 |
| <i>fludrocortisone</i> | 23 | <i>gentamicin in nacl (iso-osm)</i> | 7 | HUMIRA (CF) PEN | 55 |
| <i>flunisolide</i> | 63 | GENVOYA | 7 | HUMIRA (CF) PEN | |
| <i>fluocinolone</i> | 19 | GILOTRIF | 34 | CROHNS-UC-HS | 55 |
| <i>fluocinolone acetonide oil</i> | 54 | <i>glatiramer</i> | 46 | HUMIRA (CF) PEN | |
| <i>fluocinolone and shower cap</i> | 19 | GLATOPA | 46 | PEDIATRIC UC | 55 |
| <i>fluocinonide</i> | 19 | GLEOSTINE | 34 | HUMIRA (CF) PEN PSOR- | |
| <i>fluocinonide-emollient</i> | 19 | <i>glimepiride</i> | 23 | UV-ADOL HS | 55 |
| <i>fluoride (sodium)</i> | 66 | <i>glipizide</i> | 23 | HUMULIN 70/30 U-100 | |
| <i>fluorometholone</i> | 61 | <i>glipizide-metformin</i> | 23 | INSULIN | 24 |
| <i>fluorouracil</i> | 19 | GLUCAGON EMERGENCY | | HUMULIN 70/30 U-100 | |
| <i>fluoxetine</i> | 45 | KIT (HUMAN) | 23 | KWIKPEN | 24 |
| <i>fluoxetine (pmdd)</i> | 45 | <i>glyburide</i> | 23 | HUMULIN N NPH INSULIN | |
| <i>fluphenazine decanoate</i> | 45 | <i>glyburide micronized</i> | 23 | KWIKPEN | 24 |
| <i>fluphenazine hcl</i> | 45 | <i>glyburide-metformin</i> | 23 | HUMULIN N NPH U-100 | |
| <i>flurbiprofen</i> | 45 | <i>glycopyrrolate</i> | 28 | INSULIN | 24 |
| <i>flurbiprofen sodium</i> | 61 | GLYXAMBI | 24 | HUMULIN R REGULAR U- | |
| <i>fluticasone propionate</i> | 19, 63 | <i>granisetron hcl</i> | 28 | 100 INSULN | 24 |
| <i>fluticasone propion-salmeterol</i> ... | 63 | <i>griseofulvin microsize</i> | 7 | HUMULIN R U-500 (CONC) | |
| <i>fluvoxamine</i> | 45 | <i>griseofulvin ultramicrosize</i> | 7 | INSULIN | 24 |
| <i>fondaparinux</i> | 13 | <i>guanfacine</i> | 46 | HUMULIN R U-500 (CONC) | |
| <i>fosamprenavir</i> | 7 | GVOKE | 24 | KWIKPEN | 24 |
| <i>fosinopril</i> | 13 | GVOKE HYPOPEN 2-PACK .. | 24 | <i>hydralazine</i> | 14 |
| <i>fosinopril-hydrochlorothiazide</i> ... | 13 | GVOKE PFS 1-PACK | | <i>hydrochlorothiazide</i> | 14 |
| FOTIVDA | 33 | SYRINGE | 24 | <i>hydrocodone-acetaminophen</i> | 46 |
| FRUZAQLA | 33 | HAEGARDA | 63 | <i>hydrocortisone</i> | 19, 24, 28 |
| FULPHILA | 30 | HAILEY 24 FE | 57 | <i>hydrocortisone butyrate</i> | 19 |
| FUROSCIX | 13 | <i>halobetasol propionate</i> | 19 | <i>hydrocortisone-pramoxine</i> | 28 |

| | | | | | |
|---|--------|-------------------------------------|-------|--|--------|
| <i>hydromorphone</i> | 46 | ISENTRESS | 7 | KLISYRI | 34 |
| <i>hydroxychloroquine</i> | 7 | ISENTRESS HD | 7 | KLOR-CON | 67 |
| <i>hydroxyurea</i> | 34 | ISIBLOOM | 58 | KLOR-CON M10 | 67 |
| <i>hydroxyzine hcl</i> | 63 | ISOLYTE S PH 7.4 | 66 | KLOR-CON M15 | 67 |
| <i>ibandronate</i> | 55 | ISOLYTE-P IN 5 % | | KLOR-CON M20 | 67 |
| IBRANCE | 34 | DEXTROSE | 67 | KLOXXADO | 47 |
| IBSRELA | 28 | <i>isoniazid</i> | 7 | KOSELUGO | 34, 35 |
| IBU | 46 | <i>isosorbide dinitrate</i> | 14 | KOURZEQ | 54 |
| <i>ibuprofen</i> | 46 | <i>isosorbide mononitrate</i> | 14 | KRAZATI | 35 |
| <i>icatibant</i> | 63 | <i>isradipine</i> | 14 | KURVELO (28) | 58 |
| ICLEVIA | 57 | <i>itraconazole</i> | 7 | <i>labetalol</i> | 14 |
| ICLUSIG | 34 | <i>ivermectin</i> | 7 | <i>lacosamide</i> | 47 |
| <i>icosapent ethyl</i> | 14 | IWILFIN | 34 | <i>lactulose</i> | 28 |
| IDHIFA | 34 | IXCHIQ (PF) | 30 | <i>lamivudine</i> | 7 |
| <i>imatinib</i> | 34 | IXIARO (PF) | 30 | <i>lamivudine-zidovudine</i> | 7 |
| IMBRUVICA | 34 | JAKAFI | 34 | <i>lamotrigine</i> | 47 |
| <i>imipenem-cilastatin</i> | 7 | JANTOVEN | 14 | LANTUS SOLOSTAR U-100 | |
| <i>imipramine hcl</i> | 46 | JANUMET | 24 | INSULIN | 25 |
| <i>imiquimod</i> | 19 | JANUMET XR | 24 | LANTUS U-100 INSULIN | 25 |
| IMOVAX RABIES | | JANUVIA | 24 | <i>lapatinib</i> | 35 |
| VACCINE (PF) | 30 | JARDIANCE | 24 | <i>latanoprost</i> | 61 |
| IMVEXXY MAINTENANCE | | JASMIEL (28) | 58 | <i>leflunomide</i> | 55 |
| PACK | 57 | JAVYGTOR | 24 | <i>lenalidomide</i> | 35 |
| IMVEXXY STARTER PACK | 57 | JAYPIRCA | 34 | LENVIMA | 35 |
| INCASSIA | 57 | JENTADUETO | 24 | LESSINA | 58 |
| INCRELEX | 22 | JENTADUETO XR | 25 | <i>letrozole</i> | 35 |
| <i>indapamide</i> | 14 | JINTELI | 58 | <i>leucovorin calcium</i> | 35 |
| <i>indomethacin</i> | 46 | JOENJA | 22 | LEUKERAN | 35 |
| INFANRIX (DTAP) (PF) | 30 | JULEBER | 58 | LEUKINE | 30 |
| INGREZZA | 46 | JULUCA | 7 | <i>leuprolide</i> | 35 |
| INGREZZA INITIATION | | JUNEL 1.5/30 (21) | 58 | <i>leuprolide (3 month)</i> | 35 |
| PK(TARDIV) | 46 | JUNEL 1/20 (21) | 58 | <i>levalbuterol hcl</i> | 64 |
| INGREZZA SPRINKLE | 46 | JUNEL FE 1.5/30 (28) | 58 | <i>levalbuterol tartrate</i> | 64 |
| INLYTA | 34 | JUNEL FE 1/20 (28) | 58 | <i>levetiracetam</i> | 47 |
| INQOVI | 34 | JUNEL FE 24 | 58 | <i>levobunolol</i> | 61 |
| INREBIC | 34 | JYNNEOS (PF) | 30 | <i>levocarnitine</i> | 22 |
| <i>insulin asp prt-insulin aspart</i> | 24 | KALYDECO | 63 | <i>levocarnitine (with sugar)</i> | 22 |
| <i>insulin aspart u-100</i> | 24 | KARIVA (28) | 58 | <i>levocetirizine</i> | 64 |
| <i>insulin lispro</i> | 24 | KELNOR 1/35 (28) | 58 | <i>levofloxacin</i> | 8 |
| <i>insulin lispro protamin-lispro</i> | 24 | KELNOR 1/50 (28) | 58 | <i>levofloxacin in d5w</i> | 8 |
| <i>insulin syringe-needle u-100</i> | 65 | KERENDIA | 14 | LEVONEST (28) | 58 |
| INTELENCE | 7 | KESIMPTA PEN | 47 | <i>levonorgestrel-ethinyl estrad</i> | 58 |
| INTRALIPID | 66 | <i>ketoconazole</i> | 7, 20 | <i>levonorg-eth estrad triphasic</i> | 58 |
| INTROVALE | 57 | <i>ketorolac</i> | 61 | LEVORA-28 | 58 |
| INVEGA HAFYERA | 46 | KEVZARA | 55 | <i>levothyroxine</i> | 25 |
| INVEGA SUSTENNA | 47 | KINERET | 55 | LEVOXYL | 25 |
| INVEGA TRINZA | 47 | KINRIX (PF) | 30 | LIBERVANT | 47 |
| IPOL | 30 | KIONEX (WITH | | <i>lidocaine</i> | 20 |
| <i>ipratropium bromide</i> | 54, 63 | SORBITOL) | 22 | <i>lidocaine hcl</i> | 20 |
| <i>ipratropium-albuterol</i> | 63 | KISQALI | 34 | LIDOCAINE VISCOUS | 20 |
| <i>irbesartan</i> | 14 | KISQALI FEMARA CO- | | <i>lidocaine-prilocaine</i> | 20 |
| <i>irbesartan-hydrochlorothiazide</i> .. | 14 | PACK | 34 | LILETTA | 58 |

| | | | |
|--|----|---|-----------------------------------|
| <i>linezolid</i> | 8 | MAVENCLAD (4 TABLET | MICROGESTIN FE 1.5/30 |
| <i>linezolid in dextrose 5%</i> | 8 | PACK) | (28) |
| LINZESS | 28 | MAVENCLAD (5 TABLET | MICROGESTIN FE 1/20 (28) . |
| <i>liothyronine</i> | 25 | PACK) | 58 |
| <i>lisinopril</i> | 14 | MAVENCLAD (6 TABLET | <i>midodrine</i> |
| <i>lisinopril-hydrochlorothiazide</i> | 14 | PACK) | 22 |
| LITFULO | 22 | MAVENCLAD (7 TABLET | <i>mifepristone</i> |
| <i>lithium carbonate</i> | 47 | PACK) | 25 |
| <i>lithium citrate</i> | 47 | MAVENCLAD (8 TABLET | <i>miglustat</i> |
| LIVTENCITY | 8 | PACK) | 25 |
| LOKELMA | 22 | MAVENCLAD (9 TABLET | MILI |
| LONSURF | 35 | PACK) | 59 |
| <i>loperamide</i> | 28 | MAVYRET | <i>minocycline</i> |
| <i>lopinavir-ritonavir</i> | 8 | <i>meclizine</i> | 8 |
| <i>lorazepam</i> | 47 | <i>medroxyprogesterone</i> | 14 |
| LORAZEPAM INTENSOL | 47 | <i>mefloquine</i> | 48 |
| LORBRENA | 35 | <i>megestrol</i> | 48 |
| LORYNA (28) | 58 | MEKINIST | 28 |
| <i>losartan</i> | 14 | MEKTOVI | 8 |
| <i>losartan-hydrochlorothiazide</i> | 14 | <i>meloxicam</i> | 36 |
| <i>lovastatin</i> | 14 | <i>memantine</i> | 36 |
| LOW-OGESTREL (28) | 58 | MENACTRA (PF) | 48 |
| <i>loxapine succinate</i> | 47 | MENQUADFI (PF) | 30 |
| <i>lubiprostone</i> | 28 | MENVEO A-C-Y-W-135-DIP | 30 |
| LUCEMYRA | 47 | (PF) | 36 |
| LUMAKRAS | 35 | <i>mercaptopurine</i> | 8 |
| LUMIGAN | 61 | <i>meropenem</i> | 28 |
| LUPRON DEPOT | 35 | <i>mesalamine</i> | 36 |
| LUPRON DEPOT (3 | 35 | MESNEX | 25 |
| MONTH) | 35 | <i>metformin</i> | 48 |
| LUPRON DEPOT (4 | 35 | <i>methadone</i> | 61 |
| MONTH) | 35 | <i>methazolamide</i> | 8 |
| LUPRON DEPOT (6 | 35 | <i>methenamine hippurate</i> | 25 |
| MONTH) | 35 | <i>methimazole</i> | 36 |
| LUPRON DEPOT-PED | 35 | <i>methotrexate sodium</i> | 36 |
| LUPRON DEPOT-PED (3 | 35 | <i>methotrexate sodium (pf)</i> | 48 |
| MONTH) | 35 | <i>methsuximide</i> | 48 |
| <i>lurasidone</i> | 48 | <i>methylphenidate hcl</i> | 25 |
| LUTERA (28) | 58 | <i>methylprednisolone</i> | 28 |
| LYLEQ | 58 | <i>metoclopramide hcl</i> | 14 |
| LYNPARZA | 35 | <i>metolazone</i> | 14 |
| LYSODREN | 35 | <i>metoprolol succinate</i> | 14 |
| LYTGOBI | 36 | <i>metoprolol ta-hydrochlorothiaz.</i> | 14 |
| LYZA | 58 | <i>metoprolol tartrate</i> | 8, 20, 58 |
| <i>magnesium sulfate</i> | 67 | <i>metronidazole</i> | 8 |
| <i>malathion</i> | 20 | <i>metronidazole in nacl (iso-os)</i> | 14 |
| <i>maraviroc</i> | 8 | <i>metirosine</i> | 14 |
| MARLISSA (28) | 58 | <i>mexiletine</i> | 8 |
| MARPLAN | 48 | <i>micafungin</i> | 58 |
| MATULANE | 36 | MICONAZOLE-3 | 58 |
| MAVENCLAD (10 TABLET | 48 | MICROGESTIN 1.5/30 (21) | 58 |
| PACK) | 48 | MICROGESTIN 1/20 (21) | 58 |

| | | | | | |
|--|--------|---|-----------|---|--------|
| NEO-POLYCIN HC | 61 | NOVOLOG PENFILL U-100 | | OZEMPIC | 25 |
| NERLYNX | 36 | INSULIN | 25 | PACERONE | 15 |
| NEULASTA | 30 | NOVOLOG U-100 INSULIN | | <i>paliperidone</i> | 49 |
| NEUPRO | 49 | ASPART | 25 | PANRETIN | 20 |
| <i>nevirapine</i> | 8 | NUBEQA | 36 | <i>pantoprazole</i> | 29 |
| NEXLETOL | 15 | NUCALA | 64 | PANZYGA | 30 |
| NEXLIZET | 15 | NUEDEXTA | 49 | <i>paricalcitol</i> | 25 |
| NEXPLANON | 59 | NUPLAZID | 49 | <i>paroxetine hcl</i> | 49 |
| <i>niacin</i> | 15 | NURTEC ODT | 49 | PAXLOVID | 9 |
| <i>nicardipine</i> | 15 | NYAMYC | 20 | <i>pazopanib</i> | 37 |
| NICOTROL | 22 | NYLIA 1/35 (28) | 59 | PEDIARIX (PF) | 31 |
| NICOTROL NS | 22 | NYLIA 7/7/7 (28) | 59 | PEDVAX HIB (PF) | 31 |
| <i>nifedipine</i> | 15 | NYMYO | 59 | <i>peg 3350-electrolytes</i> | 29 |
| <i>nilutamide</i> | 36 | <i>nystatin</i> | 8, 20 | <i>peg3350-sod sul-nacl-kcl-asb-c</i> .. | 29 |
| <i>nimodipine</i> | 15 | NYSTOP | 20 | PEGASYS | 31 |
| NINLARO | 36 | OCALIVA | 28 | <i>peg-electrolyte soln</i> | 29 |
| <i>nitazoxanide</i> | 8 | OCTAGAM | 30 | PEMAZYRE | 37 |
| <i>nitisinone</i> | 22 | <i>octreotide acetate</i> | 36 | <i>pen needle, diabetic</i> | 65 |
| NITRO-BID | 15 | ODEFSEY | 8 | PENBRAYA (PF) | 31 |
| <i>nitrofurantoin macrocrystal</i> | 8 | ODOMZO | 36 | <i>penciclovir</i> | 20 |
| <i>nitrofurantoin monohyd/m-cryst</i> ... | 8 | OFEV | 64 | <i>penicillamine</i> | 56 |
| <i>nitroglycerin</i> | 15, 28 | <i>ofloxacin</i> | 9, 54, 61 | <i>penicillin g pot in dextrose</i> | 9 |
| NIVESTYM | 30 | OGSIVEO | 36 | <i>penicillin g potassium</i> | 9 |
| NORDITROPIN FLEXPRO ... | 30 | OJEMDA | 36, 37 | <i>penicillin v potassium</i> | 9 |
| <i>noreth-ethinyl estradiol-iron</i> | 59 | OJJAARA | 37 | PENTACEL (PF) | 31 |
| <i>norethindrone (contraceptive)</i> ... | 59 | <i>olanzapine</i> | 49 | <i>pentamidine</i> | 9 |
| <i>norethindrone acetate</i> | 59 | <i>olmesartan</i> | 15 | <i>pentoxifylline</i> | 15 |
| <i>norethindrone ac-eth estradiol</i> ... | 59 | <i>olmesartan-amlodipin-hcthiiazid</i> .15 | | <i>perindopril erbumine</i> | 15 |
| <i>norethindrone-e.estradiol-iron</i> ... | 59 | <i>olmesartan-hydrochlorothiazide</i> .15 | | PERIOGARD | 54 |
| <i>norgestimate-ethinyl estradiol</i> ... | 59 | <i>olopatadine</i> | 54 | <i>permethrin</i> | 20 |
| NORTREL 0.5/35 (28) | 59 | OLUMIANT | 55 | <i>perphenazine</i> | 50 |
| NORTREL 1/35 (21) | 59 | <i>omega-3 acid ethyl esters</i> | 15 | PERSERIS | 50 |
| NORTREL 1/35 (28) | 59 | <i>omeprazole</i> | 28 | PHEBURANE | 22 |
| NORTREL 7/7/7 (28) | 59 | <i>ondansetron</i> | 29 | <i>phenelzine</i> | 50 |
| <i>nortriptyline</i> | 49 | <i>ondansetron hcl</i> | 28, 29 | <i>phenobarbital</i> | 50 |
| NORVIR | 8 | ONUREG | 37 | <i>phenytoin</i> | 50 |
| NOVOLIN 70/30 U-100 | | OPSUMIT | 64 | <i>phenytoin sodium extended</i> | 50 |
| INSULIN | 25 | ORENCIA | 55, 56 | PIFELTRO | 9 |
| NOVOLIN 70-30 FLEXPEN | | ORENCIA CLICKJECT | 55 | <i>pilocarpine hcl</i> | 22, 61 |
| U-100 | 25 | ORENITRAM | 15 | <i>pimozide</i> | 50 |
| NOVOLIN N FLEXPEN | 25 | ORGOVYX | 37 | PIMTREA (28) | 59 |
| NOVOLIN N NPH U-100 | | ORKAMBI | 64 | <i>pindolol</i> | 16 |
| INSULIN | 25 | ORSERDU | 37 | <i>pioglitazone</i> | 25 |
| NOVOLIN R FLEXPEN | 25 | <i>oseltamivir</i> | 9 | <i>pioglitazone-metformin</i> | 25 |
| NOVOLIN R REGULAR | | OTEZLA | 56 | <i>piperacillin-tazobactam</i> | 9 |
| U100 INSULIN | 25 | OTEZLA STARTER | 56 | PIQRAY | 37 |
| NOVOLOG FLEXPEN U-100 | | <i>oxacillin</i> | 9 | <i>pirfenidone</i> | 64 |
| INSULIN | 25 | <i>oxacillin in dextrose(iso-osm)</i> | 9 | <i>piroxicam</i> | 50 |
| NOVOLOG MIX 70-30 U-100 | | <i>oxcarbazepine</i> | 49 | <i>pitavastatin calcium</i> | 16 |
| INSULN | 25 | <i>oxybutynin chloride</i> | 66 | PLEGRIDY | 31 |
| NOVOLOG MIX 70- | | <i>oxycodone</i> | 49 | PLENAMINE | 67 |
| 30FLEXPEN U-100 | 25 | <i>oxycodone-acetaminophen</i> | 49 | <i>podofilox</i> | 20 |

| | | | | | |
|---|--------|-------------------------------------|-------|---|--------|
| POLYCIN | 61 | PROMACTA | 16 | <i>risedronate</i> | 22, 56 |
| <i>polymyxin b sulf-trimethoprim</i> | 61 | <i>promethazine</i> | 64 | <i>risperidone</i> | 50, 51 |
| POMALYST | 37 | <i>propafenone</i> | 16 | <i>risperidone microspheres</i> | 50 |
| PORTIA 28 | 59 | <i>propranolol</i> | 16 | <i>ritonavir</i> | 10 |
| <i>posaconazole</i> | 9 | <i>propylthiouracil</i> | 26 | <i>rivastigmine</i> | 51 |
| <i>potassium chlorid-d5-</i> | | PROQUAD (PF) | 31 | <i>rivastigmine tartrate</i> | 51 |
| <i>0.45%nacl</i> | 67 | PROSOL 20 % | 67 | RIVFLOZA | 66 |
| <i>potassium chloride</i> | 67 | <i>protriptyline</i> | 50 | <i>rizatriptan</i> | 51 |
| <i>potassium chloride in 0.9%nacl</i> | 67 | PULMOZYME | 64 | <i>roflumilast</i> | 64 |
| <i>potassium chloride in 5 % dex</i> | 67 | PURIXAN | 37 | <i>ropinirole</i> | 51 |
| <i>potassium chloride in lr-d5</i> | 67 | <i>pyrazinamide</i> | 9 | <i>rosuvastatin</i> | 16 |
| <i>potassium chloride in water</i> | 67 | <i>pyridostigmine bromide</i> | 50 | ROTARIX | 31 |
| <i>potassium chloride-0.45 % nacl</i> | 67 | <i>pyrimethamine</i> | 9 | ROTATEQ VACCINE | 31 |
| <i>potassium chloride-d5-</i> | | QINLOCK | 37 | ROWEEPRA | 51 |
| <i>0.2%nacl</i> | 67 | QUADRACEL (PF) | 31 | ROZLYTREK | 37 |
| <i>potassium chloride-d5-</i> | | <i>quetiapine</i> | 50 | RUBRACA | 37 |
| <i>0.9%nacl</i> | 67 | <i>quinapril</i> | 16 | <i>rufinamide</i> | 51 |
| <i>potassium citrate</i> | 66 | <i>quinidine sulfate</i> | 16 | RUKOBIA | 10 |
| <i>pramipexole</i> | 50 | <i>quinine sulfate</i> | 9 | RYBELSUS | 26 |
| <i>prasugrel</i> | 16 | QULIPTA | 50 | RYDAPT | 37 |
| <i>pravastatin</i> | 16 | QVAR REDIHALER | 64 | RYTARY | 51 |
| <i>praziquantel</i> | 9 | RABAVERT (PF) | 31 | SAJAZIR | 64 |
| <i>prazosin</i> | 16 | <i>rabeprazole</i> | 29 | SANDIMMUNE | 37 |
| <i>prednisolone</i> | 26 | <i>raloxifene</i> | 56 | <i>sapropterin</i> | 26 |
| <i>prednisolone acetate</i> | 61 | <i>ramelteon</i> | 50 | SCSEMBLIX | 37 |
| <i>prednisolone sodium phosphate</i> | | <i>ramipril</i> | 16 | <i>scopolamine base</i> | 29 |
| | 26, 61 | <i>ranolazine</i> | 16 | SECUADO | 51 |
| <i>prednisone</i> | 26 | <i>rasagiline</i> | 50 | <i>selegiline hcl</i> | 51 |
| <i>pregabalin</i> | 50 | RAVICTI | 22 | <i>selenium sulfide</i> | 20 |
| PREHEVBRIO (PF) | 31 | RECLIPSEN (28) | 59 | SELZENTRY | 10 |
| PREMARIN | 59 | RECOMBIVAX HB (PF) | 31 | SEREVENT DISKUS | 64 |
| PRENATAL VITAMIN | | RECORLEV | 26 | <i>sertraline</i> | 51 |
| PLUS LOW IRON | 67 | REGANEX | 20 | SETLAKIN | 59 |
| PREVALITE | 16 | RELENZA DISKHALER | 9 | SHINGRIX (PF) | 31 |
| PREVYMIS | 9 | <i>repaglinide</i> | 26 | SIGNIFOR | 37 |
| PREZCOBIX | 9 | REPATHA PUSHTRONEX | 16 | <i>sildenafil (pulm.hypertension)</i> | 64 |
| PREZISTA | 9 | REPATHA SURECLICK | 16 | SILIQ | 20 |
| PRIFTIN | 9 | REPATHA SYRINGE | 16 | <i>silodosin</i> | 66 |
| <i>primaquine</i> | 9 | RESTASIS | 61 | <i>silver sulfadiazine</i> | 20 |
| <i>primidone</i> | 50 | RESTASIS MULTIDOSE | 61 | SIMBRINZA | 61 |
| PRIORIX (PF) | 31 | RETACRIT | 31 | SIMPONI | 56 |
| PRIVIGEN | 31 | RETEVMO | 37 | <i>simvastatin</i> | 16 |
| <i>probenecid</i> | 56 | REXULTI | 50 | <i>sirolimus</i> | 37 |
| <i>probenecid-colchicine</i> | 56 | REYATAZ | 9 | SIRTURO | 10 |
| <i>prochlorperazine</i> | 29 | REZDIFFRA | 22 | SKYCLARYS | 51 |
| <i>prochlorperazine maleate</i> | 29 | REZLIDHIA | 37 | SKYRIZI | 20, 29 |
| PROCRIT | 31 | <i>ribavirin</i> | 9, 10 | <i>sodium chloride</i> | 22 |
| PROCTOSOL HC | 29 | <i>rifabutin</i> | 10 | <i>sodium chloride 0.45 %</i> | 67 |
| PROCTOZONE-HC | 29 | <i>rifampin</i> | 10 | <i>sodium chloride 0.9 %</i> | 22 |
| PROGRAF | 37 | <i>riluzole</i> | 22 | <i>sodium chloride 3 % hypertonic</i> | 67 |
| PROLASTIN-C | 22 | <i>rimantadine</i> | 10 | <i>sodium chloride 5 % hypertonic</i> | 67 |
| PROLIA | 56 | RINVOQ | 56 | <i>sodium oxybate</i> | 51 |

| | | | | | |
|---|--------|--|--------|--|--------|
| <i>sodium phenylbutyrate</i> | 22 | SYNJARDY XR | 26 | <i>tigecycline</i> | 10 |
| <i>sodium polystyrene sulfonate</i> | 22 | SYNTHROID | 26 | <i>timolol maleate</i> | 16, 61 |
| <i>sodium, potassium, magnesium sulfates</i> .. | 29 | TABLOID | 38 | <i>tinidazole</i> | 10 |
| <i>sofosbuvir-velpatasvir</i> | 10 | TABRECTA | 38 | TIVICAY | 10 |
| SOHONOS | 22 | <i>tacrolimus</i> | 21, 38 | TIVICAY PD | 10 |
| <i>solifenacin</i> | 66 | <i>tadalafil</i> | 66 | <i>tizanidine</i> | 52 |
| SOLQUA 100/33 | 26 | <i>tadalafil (pulm. hypertension)</i> | 65 | TOBI PODHALER | 10 |
| SOLTAMOX | 37 | TAFINLAR | 38 | <i>tobramycin</i> | 10, 62 |
| SOMAVERT | 26 | TAGRISO | 38 | <i>tobramycin in 0.225 % nacl</i> | 10 |
| <i>sorafenib</i> | 37 | TAKHZYRO | 65 | <i>tobramycin sulfate</i> | 10 |
| <i>sotalol</i> | 16 | TALTZ AUTOINJECTOR | 21 | <i>tobramycin-dexamethasone</i> | 62 |
| SOTALOL AF | 16 | TALTZ SYRINGE | 21 | TOBREX | 62 |
| SPIRIVA RESPIMAT | 64 | TALZENNA | 38 | <i>tolterodine</i> | 66 |
| SPIRIVA WITH | | <i>tamoxifen</i> | 38 | <i>tolvaptan</i> | 26 |
| HANDIHALER | 64 | <i>tamsulosin</i> | 66 | <i>topiramate</i> | 52 |
| <i>spironolactone</i> | 16 | TASCENSO ODT | 52 | <i>toremifene</i> | 38 |
| <i>spironolactone-hydrochlorothiazid</i> .. | 16 | TASIGNA | 38 | <i>torse mide</i> | 17 |
| SPRINTEC (28) | 59 | <i>tasimelteon</i> | 52 | TOUJEO MAX U-300 | |
| SPRITAM | 51 | <i>tazarotene</i> | 21 | SOLOSTAR | 26 |
| SPRYCEL | 37 | TAZORAC | 21 | TOUJEO SOLOSTAR U-300 | |
| SPS (WITH SORBITOL) | 22 | TAZVERIK | 38 | INSULIN | 26 |
| SRONYX | 59 | TDVAX | 31 | TRADJENTA | 26 |
| SSD | 20 | TEFLARO | 10 | <i>tramadol</i> | 52 |
| STELARA | 20, 21 | TEGRETOL | 52 | <i>tramadol-acetaminophen</i> | 52 |
| STIOLTO RESPIMAT | 64 | TEGRETOL XR | 52 | <i>trandolapril</i> | 17 |
| STIVARGA | 37 | <i>telmisartan</i> | 16 | <i>tranexamic acid</i> | 59 |
| <i>streptomycin</i> | 10 | <i>telmisartan-amlodipine</i> | 16 | <i>tranylcypromine</i> | 52 |
| STRIBILD | 10 | <i>telmisartan-hydrochlorothiazid</i> .. | 16 | TRAVASOL 10 % | 67 |
| STRIVERDI RESPIMAT | 65 | TENIVAC (PF) | 31 | <i>travoprost</i> | 62 |
| SUBVENITE | 51 | <i>tenofovir disoproxil fumarate</i> | 10 | <i>trazodone</i> | 52 |
| <i>sucralfate</i> | 29 | TEPMETKO | 38 | TRECATOR | 10 |
| <i>sulfacetamide sodium</i> | 61 | <i>terazosin</i> | 16 | TRELEGY ELLIPTA | 65 |
| <i>sulfacetamide sodium (acne)</i> | 21 | <i>terbinafine hcl</i> | 10 | TRELSTAR | 38 |
| <i>sulfacetamide-prednisolone</i> | 61 | <i>terbutaline</i> | 65 | TRESIBA FLEXTOUCH U- | |
| <i>sulfadiazine</i> | 10 | <i>terconazole</i> | 59 | 100 | 26 |
| <i>sulfamethoxazole-trimethoprim</i> .. | 10 | <i>teriflunomide</i> | 52 | TRESIBA FLEXTOUCH U- | |
| SULFAMYLON | 21 | <i>teriparatide</i> | 56 | 200 | 26 |
| <i>sulfasalazine</i> | 29 | <i>testosterone</i> | 26 | TRESIBA U-100 INSULIN | 26 |
| <i>sulindac</i> | 51 | <i>testosterone cypionate</i> | 26 | <i>tretinoin</i> | 21 |
| <i>sumatriptan</i> | 51 | <i>testosterone enanthate</i> | 26 | <i>tretinoin (antineoplastic)</i> | 38 |
| <i>sumatriptan succinate</i> | 51, 52 | <i>tetanus, diphtheria tox ped(pf)</i> | 31 | <i>triamcinolone acetonide</i> | 21, 54 |
| <i>sunitinib maleate</i> | 38 | <i>tetrabenazine</i> | 52 | <i>triamterene-hydrochlorothiazid</i> .. | 17 |
| SUNLENCA | 10 | <i>tetracycline</i> | 10 | TRIDERM | 21 |
| SUNOSI | 52 | THALOMID | 38 | <i>trientine</i> | 22 |
| SYEDA | 59 | THEO-24 | 65 | TRI-ESTARYLLA | 59 |
| SYMDEKO | 65 | <i>theophylline</i> | 65 | <i>trifluoperazine</i> | 52 |
| SYMLINPEN 120 | 26 | <i>thioridazine</i> | 52 | <i>trifluridine</i> | 62 |
| SYMLINPEN 60 | 26 | <i>thiothixene</i> | 52 | TRIJARDY XR | 27 |
| SYMPAZAN | 52 | TIADYLT ER | 16 | TRIKAFTA | 65 |
| SYMTUZA | 10 | <i>tiagabine</i> | 52 | <i>trimethoprim</i> | 10 |
| SYNAREL | 26 | TIBSOVO | 38 | TRI-MILI | 59 |
| SYNJARDY | 26 | TICOVAC | 31 | <i>trimipramine</i> | 52 |

| | | | | | |
|---|--------|-------------------------------|----|-----------------------------------|----|
| TRINTELLIX | 52 | VIGADRONE | 53 | YUFLYMA(CF) AI | |
| TRI-NYMYO | 59 | VIGPODER | 53 | CROHN'S-UC-HS | 56 |
| TRI-SPRINTEC (28) | 59 | VIJOICE | 39 | YUFLYMA(CF) | |
| TRIUMEQ | 10 | <i>vilazodone</i> | 53 | AUTOINJECTOR | 56 |
| TRIUMEQ PD | 10 | VIRACEPT | 11 | YUVAFEM | 60 |
| TRIVORA (28) | 59 | VIREAD | 11 | ZAFEMY | 60 |
| TRI-VYLIBRA | 59 | VITRAKVI | 39 | <i>zafirlukast</i> | 65 |
| TROPHAMINE 10 % | 67 | VIVITROL | 53 | <i>zaleplon</i> | 53 |
| <i>trospium</i> | 66 | VIVJOA | 11 | ZARXIO | 32 |
| TRULICITY | 27 | VIZIMPRO | 39 | ZAVZPRET | 53 |
| TRUMENBA | 31 | VONJO | 39 | ZEGALOGUE | |
| TRUQAP | 38 | <i>voriconazole</i> | 11 | AUTOINJECTOR | 27 |
| TUKYSA | 38 | VOSEVI | 11 | ZEGALOGUE SYRINGE | 27 |
| TURALIO | 38 | VOWST | 29 | ZEJULA | 39 |
| TURQOZ (28) | 60 | VRAYLAR | 53 | ZELBORAF | 39 |
| TWINRIX (PF) | 31 | VUMERITY | 53 | ZEPOSIA | 53 |
| TYBOST | 11 | VYFEMLA (28) | 60 | ZEPOSIA STARTER KIT | |
| TYMLOS | 56 | VYLIBRA | 60 | (28-DAY) | 53 |
| TYPHIM VI | 31 | VYNDAQEL | 17 | ZEPOSIA STARTER PACK | |
| UBRELVY | 52 | <i>warfarin</i> | 17 | (7-DAY) | 53 |
| UNITHROID | 27 | WELIREG | 39 | <i>zidovudine</i> | 11 |
| UPTRAVI | 17 | WIXELA INHUB | 65 | ZIEXTENZO | 32 |
| <i>ursodiol</i> | 29 | XALKORI | 39 | ZILBRYSQ | 53 |
| <i>valacyclovir</i> | 11 | XARELTO | 17 | <i>ziprasidone hcl</i> | 53 |
| VALCHLOR | 21 | XARELTO DVT-PE TREAT | | <i>ziprasidone mesylate</i> | 54 |
| <i>valganciclovir</i> | 11 | 30D START | 17 | ZIRGAN | 62 |
| <i>valproic acid</i> | 52 | XATMEP | 39 | ZOLINZA | 39 |
| <i>valproic acid (as sodium salt)</i> | 52 | XCOPRI | 53 | <i>zolpidem</i> | 54 |
| <i>valsartan</i> | 17 | XCOPRI MAINTENANCE | | ZONISADE | 54 |
| <i>valsartan-hydrochlorothiazide</i> ... 17 | | PACK | 53 | <i>zonisamide</i> | 54 |
| VALTOCO | 52, 53 | XCOPRI TITRATION PACK | 53 | ZOVIA 1-35 (28) | 60 |
| <i>vancomycin</i> | 11 | XDEMVI | 62 | ZTALMY | 54 |
| VANFLYTA | 38 | XELJANZ | 56 | ZUBSOLV | 54 |
| VAQTA (PF) | 31 | XELJANZ XR | 56 | ZURZUVAE | 54 |
| <i>varenicline</i> | 22 | XERMELO | 39 | ZYDELIG | 39 |
| VARIVAX (PF) | 31 | XGEVA | 39 | ZYKADIA | 39 |
| VELIVET TRIPHASIC | | XIFAXAN | 11 | ZYPREXA RELPREVV | 54 |
| REGIMEN (28) | 60 | XIGDUO XR | 27 | | |
| VEMLIDY | 11 | XIIDRA | 62 | | |
| VENCLEXTA | 38 | XOFLUZA | 11 | | |
| VENCLEXTA STARTING | | XOLAIR | 65 | | |
| PACK | 39 | XOLREMDI | 31 | | |
| <i>venlafaxine</i> | 53 | XOSPATA | 39 | | |
| VENTOLIN HFA | 65 | XPOVIO | 39 | | |
| <i>verapamil</i> | 17 | XTANDI | 39 | | |
| VERQUVO | 17 | XULTOPHY 100/3.6 | 27 | | |
| VERSACLOZ | 53 | XYREM | 53 | | |
| VERZENIO | 39 | YARGESA | 27 | | |
| VESTURA (28) | 60 | YF-VAX (PF) | 31 | | |
| VIBERZI | 29 | YONSA | 39 | | |
| VIENVA | 60 | YUFLYMA(CF) | 56 | | |
| <i>vigabatrin</i> | 53 | | | | |

Acitretin

Products Affected

- *acitretin*

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Actemra

Products Affected

- **ACTEMRA ACTPEN**
- **ACTEMRA SUBCUTANEOUS**

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | Part A covered for Covid-19 in hospitalized patients |
| Required Medical Information | Documentation of diagnosis. For rheumatoid arthritis, patients must have an inadequate response or intolerance to at least one DMARD (e.g., methotrexate, leflunomide). For giant cell arteritis, patients must have therapeutic failure or intolerance to one systemic corticosteroid (e.g., prednisone). For polyarticular juvenile idiopathic arthritis, patients must have an inadequate response or intolerance to at least one DMARD (e.g., methotrexate, leflunomide) -OR- requires initial biologic therapy due to involvement of high-risk joints, high disease activity or at high risk of disabling joint damage. For systemic sclerosis-associated interstitial lung disease (SSc-ILD), patients must have therapeutic failure or intolerance to one immunosuppressant (e.g., mycophenolate mofetil, corticosteroids, cyclophosphamide). Documentation of systemic juvenile idiopathic arthritis. |
| Age Restrictions | Deny if less than 18 years of age for systemic sclerosis-associated interstitial lung disease (SSc-ILD), Rheumatoid Arthritis, and Giant Cell Arteritis or less than 2 years of age for Polyarticular Juvenile Idiopathic Arthritis and Systemic Juvenile Idiopathic Arthritis |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Actimmune

Products Affected

- ACTIMMUNE

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Adbry

Products Affected

- **ADBRY SUBCUTANEOUS SYRINGE**

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis. For moderate to severe atopic dermatitis, documentation of one of the following (1 or 2): 1) trial & failure or intolerance to at least one topical corticosteroid or one topical calcineurin inhibitor (e.g., tacrolimus, pimecrolimus) -OR- 2) severe atopic dermatitis and the member is incapable of applying topical therapies due to the extent of body surface area involvement or severe atopic dermatitis and topical therapies are contraindicated due to severely damaged skin. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | For Atopic Dermatitis, patients must have a trial/failure, intolerance, or contraindication to both preferred products: Dupixent and Rinvoq. For induction therapy, doses above plan quantity limit will be approved when aligned with recommended induction therapy dosing regimen. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

ADHD Drugs

Products Affected

- *guanfacine oral tablet extended release 24 hr*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of ADHD -AND- trial/failure, intolerance or contraindication to a stimulant |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Afinitor

Products Affected

- *everolimus (antineoplastic) oral tablet 10 mg, 2.5 mg, 5 mg, 7.5 mg*
- *everolimus (antineoplastic) oral tablet for suspension 2 mg, 3 mg, 5 mg*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | <p>For everolimus only, documentation of advanced, hormone receptor-positive, HER2-negative breast cancer -AND- all of the following (1-3): 1) member is a postmenopausal woman 2) using in combination with exemestane 3) therapeutic failure or intolerance to prior treatment with letrozole or anastrozole. For everolimus only, documentation of non-functional neuroendocrine tumors -AND- all of the following (1-2): 1) disease is classified as progressive, well-differentiated, non-functional 2) disease is of gastrointestinal or lung origin that are unresectable, locally advanced or metastatic. For everolimus only, documentation of advanced renal cell carcinoma -AND- therapeutic failure or intolerance to prior treatment with sunitinib or sorafenib. For everolimus only, documentation of renal angiomyolipoma and tuberous sclerosis complex (TSC), member does not require immediate surgery. For everolimus and everolimus tablets for oral suspension, documentation of TSC with Subependymal Giant Cell Astrocytoma -AND- member is not a candidate for curative surgical resection. For everolimus only, documentation of progressive neuroendocrine tumors of pancreatic origin. For everolimus tablets for oral suspension only, documentation of use for adjunctive treatment of TSC-associated partial-onset seizures.</p> |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

| PA Criteria | Criteria Details |
|--------------------------------|-------------------------|
| Part B Prerequisite | No |

Aimovig

Products Affected

- **AIMOVIG AUTOINJECTOR
SUBCUTANEOUS AUTO-INJECTOR
140 MG/ML, 70 MG/ML**

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis. For Episodic Migraine, defined as 4-14 migraine days per month OR Chronic Migraine, defined as 15 or more headaches per month, the following criteria will apply (1-3). 1) Documentation of average monthly migraine days. 2) Attestation that headaches are not caused by medication rebound or overutilization (e.g. not taking triptans exceeding more than 18 doses per month) or lifestyle factors (e.g. sleep patterns, caffeine use). 3) Trial and failure or intolerance to one agent from 2 unique prophylactic migraine medication classes: e.g. Anti-epileptic drugs (e.g. topiramate), beta-blockers (e.g. propranolol), calcium-channel blockers (e.g. verapamil), tricyclic antidepressants (e.g. amitriptyline) -OR- contraindication to all prophylactic medication classes. |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 6 months initial authorization, 12 months reauthorization |
| Other Criteria | For reauthorization, attestation of reduction in migraine frequency |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Ajovy

Products Affected

- AJOVY AUTOINJECTOR
- AJOVY SYRINGE

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis. For Episodic Migraine, defined as 4-14 migraine days per month OR Chronic Migraine, defined as 15 or more headaches per month, the following criteria will apply (1-3). 1) Documentation of average monthly migraine days. 2) Attestation that headaches are not caused by medication rebound or overutilization (e.g. not taking triptans exceeding more than 18 doses per month) or lifestyle factors (e.g. sleep patterns, caffeine use). 3) Trial and failure or intolerance to one agent from 2 unique prophylactic migraine medication classes: e.g. Anti-epileptic drugs (e.g. topiramate), beta-blockers (e.g. propranolol), calcium-channel blockers (e.g. verapamil), tricyclic antidepressants (e.g. amitriptyline) -OR- contraindication to all prophylactic medication classes. |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 6 months initial authorization, 12 months reauthorization |
| Other Criteria | For reauthorization, attestation of reduction in migraine frequency |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Akeega

Products Affected

- **AKEEGA**

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis -AND- All of the following: 1) BRCA mutations, 2) Comcomitant therapy with prednisone, 3) Concomitant therapy with a gonadotropin-releasing hormone analog or a bilateral orchiectomy. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Alecensa

Products Affected

- ALECENSA

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------|
| Exclusion Criteria | Pending CMS Review |
| Required Medical Information | Pending CMS Review |
| Age Restrictions | Pending CMS Review |
| Prescriber Restrictions | Pending CMS Review |
| Coverage Duration | Pending CMS Review |
| Other Criteria | Pending CMS Review |
| Indications | Pending CMS Review |
| Off Label Uses | Pending CMS Review |
| Part B Prerequisite | No |

Alpha1-Proteinase Inhibitors

Products Affected

- **PROLASTIN-C INTRAVENOUS SOLUTION**

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Diagnosis of panacinar emphysema AND documentation of a decline in forced expiratory volume in 1 second (fev1) despite medical therapy (bronchodilators, corticosteroids) AND documentation of phenotype (pi*zz, pi*znull or pi*nullnull) associated with causing serum alpha 1-antitrypsin of less than 80 mg/dl AND documentation of an alpha 1-antitrypsin serum level below the value of 35% of normal (less than 80 mg/dl). |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | Covered under Part B when furnished incident to a physician service and is not self-administered. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Alunbrig

Products Affected

- ALUNBRIG ORAL TABLET 180 MG, 30 MG, 90 MG
- ALUNBRIG ORAL TABLETS,DOSE PACK

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK) positive |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Ampyra

Products Affected

- *dalfampridine*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | History of seizure disorder, Cr Cl less than 50ml/min |
| Required Medical Information | Documentation of diagnosis -AND- documentation that the patient is ambulatory and has walking impairment as evidenced by one of the following. 1. Functional status score (EDSS score). 2. Timed 25-foot Walk Test (T25W). |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 3 months initial authorization, 12 months reauthorization |
| Other Criteria | For reauthorization, documentation supporting improvement in walking impairment from baseline is required. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Apokyn

Products Affected

- *apomorphine*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of Parkinson's disease -AND- for use in acute, intermittent treatment of hypomobility off episodes -AND- experiencing off episodes despite the use of oral carbidopa/levodopa -AND- Therapeutic failure, intolerance, or contraindication to one of the following generic products: pramipexole, ropinirole, entacapone, selegiline or rasagiline |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Arikayce

Products Affected

- ARIKAYCE

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of Mycobacterium avium complex lung disease -AND- Attestation of not achieving negative sputum cultures despite at least 6 months with a multidrug background regimen containing 2 of the following: 1) macrolide 2) rifamycin or 3) ethambutal -AND- Arikayce will be used in conjunction with a background multidrug regimen. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | For reauthorization, attestation of positive sputum cultures -OR- negative sputum cultures for insufficient period of time (e.g. less than 12 months). |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

ATTR-CM drugs

Products Affected

- VYNDAQEL

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Concomitantly with transthyretin-lowering agents |
| Required Medical Information | Documentation of cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) with amyloid deposits on cardiac biopsy or scintigraphy with heart contralateral greater than 1.5 (Grade III) -AND- Cardiac involvement supported by cardiac magnetic resonance, echocardiography or serum cardiac biomarker (e.g. B-type natriuretic peptide, cardiac troponin) - AND- Primary (light chain) amyloidosis has been ruled out by immunohistochemistry, mass spectrometry or scintigraphy. |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | For reauthorization, attestation of improvement or delayed disease progression from baseline demonstrated by 6-minute walk test, cardiac function (e.g. LVEF, NYHA class), Kansas City Cardiomyopathy Questionnaire-Overall Summary, number of cardiovascular-related hospitalizations or serum cardiac biomarkers (e.g. B-type natriuretic peptide, cardiac troponin) |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Atypical Antipsychotics

Products Affected

- *aripiprazole oral solution*
- *aripiprazole oral tablet, disintegrating*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis. If medication is being used for major depressive disorder, documentation of adjunctive therapy and therapeutic failure, contraindication or intolerance to one other generic antidepressant in addition to the antidepressant currently being used for the treatment of MDD (e.g. SSRI, SNRI, NDRIs, TCA, MAOI). |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Aubagio

Products Affected

- *teriflunomide*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | Concomitant use with other disease modifying agents such as fingolimod, interferons, Copaxone, Tysabri |
| Required Medical Information | Documentation of relapsing form of multiple sclerosis (e.g. relapsing-remitting, clinically isolated syndrome, or active secondary progressive disease) |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 5 years |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Augtyro

Products Affected

- AUGTYRO

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------|
| Exclusion Criteria | Pending CMS Review |
| Required Medical Information | Pending CMS Review |
| Age Restrictions | Pending CMS Review |
| Prescriber Restrictions | Pending CMS Review |
| Coverage Duration | Pending CMS Review |
| Other Criteria | Pending CMS Review |
| Indications | Pending CMS Review |
| Off Label Uses | Pending CMS Review |
| Part B Prerequisite | No |

Austedo

Products Affected

- AUSTEDO ORAL TABLET 12 MG, 6 MG, 9 MG
- AUSTEDO XR ORAL TABLET EXTENDED RELEASE 24 HR 12 MG, 24 MG, 30 MG, 36 MG, 42 MG, 48 MG, 6 MG
- AUSTEDO XR TITRATION KT(WK1-4) ORAL TABLET, EXT REL 24HR DOSE PACK 6 MG (14)-12 MG (14)-24 MG (14)

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of all of the following (1-3) 1) Chorea associated with Huntington's disease 2) In patients with comorbid depression, attestation of adequate treatment for depression is required. 3) Attestation that patient is not actively suicidal. -OR- 4) Tardive Dyskinesia |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Auvelity

Products Affected

- AUVELITY

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of major depressive disorder (MDD) -AND- Therapeutic failure or intolerance to generic bupropion hydrochloride tablets -AND- Therapeutic failure, intolerance or contraindication to one other generic antidepressant (e.g. SNRI, SSRI). |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Ayvakit

Products Affected

- AYVAKIT

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of unresectable or metastatic gastrointestinal stromal tumor -AND- tumors harbor a PDGFRA exon 18 mutation. Documentation of aggressive systemic mastocytosis, systemic mastocytosis with an associated hematological neoplasm, mast cell leukemia, or indolent systemic mastocytosis -AND- platelet count greater than or equal to $50 \times 10^9/L$. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Bafiertam

Products Affected

- **BAFIERTAM**

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | Concomitant use with other disease modifying agents such as interferons, Copaxone, Tysabri, Aubagio, Gilenya |
| Required Medical Information | Documentation of relapsing form of multiple sclerosis (e.g. relapsing-remitting, clinically isolated syndrome, or active secondary progressive disease) -AND- Therapeutic failure or intolerance to generic dimethyl fumarate |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 5 years |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Balversa

Products Affected

- **BALVERSA**

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis -AND- all of the following: 1) FGFR3 mutation status as detected by an FDA approved test 2) disease progression on or after at least on prior line of systemic therapy. |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Banzel

Products Affected

- *rufinamide*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | Patients with familial short QT syndrome |
| Required Medical Information | Documentation of seizures due to Lennox-Gastaut Syndrome -AND- documentation of adjunctive therapy -AND- therapeutic failure or intolerance of a previous antiepileptic therapy |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Benlysta

Products Affected

- **BENLYSTA SUBCUTANEOUS**

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------|
| Exclusion Criteria | Pending CMS Review |
| Required Medical Information | Pending CMS Review |
| Age Restrictions | Pending CMS Review |
| Prescriber Restrictions | Pending CMS Review |
| Coverage Duration | Pending CMS Review |
| Other Criteria | Pending CMS Review |
| Indications | Pending CMS Review |
| Off Label Uses | Pending CMS Review |
| Part B Prerequisite | No |

Berinert

Products Affected

- **BERINERT INTRAVENOUS KIT**

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | Member should not be on two acute therapies simultaneously and acute therapy should not be used as prophylactic therapy |
| Required Medical Information | <p>For the treatment of acute abdominal, facial, or laryngeal attacks of hereditary angioedema (HAE) type I & II with the following (1-4): 1) Low C4 level of less than or equal to 14mg/dL or C4 below lower limit of laboratory reference range and 1 of the following (A or B). A) C1 inhibitor (C1INH) antigen level less than or equal to 19mg/dL or below lower limit of laboratory reference range. B) Normal C1INH antigen level and a low C1INH functional level below laboratory reference range. 2) Past medical history of at least 1 symptom of moderate or severe angioedema attack (e.g. airway swelling, painful facial distortion) in absence of concomitant hives. 3) Medications known to cause angioedema have been evaluated and discontinued. 4) Documentation of member's weight. For the treatment of acute abdominal, facial, or laryngeal attacks of hereditary angioedema (HAE) type III with the following (5-9): 5) Documentation of clinical laboratory performance C4, C1INH antigen, or C1INH functional level are within normal limits of laboratory reference ranges. 6) Documentation of family history of HAE or FXII mutation 7) Past medical history of at least 1 symptom of moderate or severe angioedema attack (e.g. airway swelling, painful facial distortion) in absence of concomitant hives. 8) Medications known to cause angioedema have been evaluated and discontinued. 9) Documentation of member's weight.</p> |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | For 18 years of age or older, therapeutic failure, intolerance or contraindication to icatibant. |

| PA Criteria | Criteria Details |
|----------------------------|-------------------------------|
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Besremi

Products Affected

- **BESREMI**

| PA Criteria | Criteria Details |
|-------------------------------------|--------------------------------|
| Exclusion Criteria | |
| Required Medical Information | Diagnosis of polycythemia vera |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Bosulif

Products Affected

- **BOSULIF ORAL CAPSULE 100 MG, 50 MG**
- **BOSULIF ORAL TABLET 100 MG, 400 MG, 500 MG**

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis. For members 18 years of age and older, one of the following (1, 2): 1) newly diagnosed Philadelphia chromosome (PH) -positive CML in the chronic phase 2) diagnosis of Ph-positive CML in the chronic, accelerated, or blast phase and no longer responding to or intolerant to at least 1 prior therapy. For pediatric patients 1 year of age and older, one of the following (3, 4): 3) newly diagnosed PH-positive CML in the chronic phase 4) diagnosis of Ph-positive CML in the chronic phase and no longer responding to or intolerant to at least 1 prior therapy. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | For Bosutinib capsules and 18 years of age or older, inability to swallow tablets is required. For Bosutinib 100mg capsules and pediatric 1 year of age or older, inability to swallow tablets is required. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Braftovi

Products Affected

- BRAFTOVI

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Use in wild-type BRAF melanoma or wild-type BRAF CRC |
| Required Medical Information | Documentation of diagnosis. For metastatic colorectal cancer (mCRC), all of the following (1-3): 1) BRAF V600E mutation status 2) using in combination with cetuximab 3) member has received prior therapy for CRC. For unresectable or metastatic melanoma, all of the following (1-2): 1) BRAF V600E or V600K mutation status 2) using in combination with binimetinib. For metastatic non-small cell lung cancer, all of the following (1-2): 1) BRAF V600E mutation status 2) using in combination with binimetinib. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Brukinsa

Products Affected

- BRUKINSA

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis. For mantle cell lymphoma (MCL), previous treatment with at least 1 prior therapy. For marginal zone lymphoma (MZL), previous treatment with at least 1 anti-CD20-based regimen. For follicular lymphoma (FL), using in combination with obinutuzumab and previous treatment with at least 2 prior lines of systemic therapy. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Buphenyl

Products Affected

- *sodium phenylbutyrate*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Treatment of acute hyperammonemia in urea cycle disorders |
| Required Medical Information | Documentation of chronic management of urea cycle disorders involving deficiencies of carbamylphosphate synthetase, argininosuccinic acid synthetase, or ornithine transcarbamylase. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Cablivi

Products Affected

- CABLIVI INJECTION KIT

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Diagnosis of acquired thrombocytopenic purpura (aTTP) -AND- Used in conjunction with plasma exchange and immunosuppressive therapy (i.e. systemic corticosteroids or rituximab) |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 75 days initial authorization, 28 days reauthorization |
| Other Criteria | For reauthorization, attestation of remaining signs and symptoms of persistent disease (e.g. suppressed ADAMTS 13 activity level remain present) |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Cabometyx

Products Affected

- CABOMETYX

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------|
| Exclusion Criteria | Pending CMS Review |
| Required Medical Information | Pending CMS Review |
| Age Restrictions | Pending CMS Review |
| Prescriber Restrictions | Pending CMS Review |
| Coverage Duration | Pending CMS Review |
| Other Criteria | Pending CMS Review |
| Indications | Pending CMS Review |
| Off Label Uses | Pending CMS Review |
| Part B Prerequisite | No |

Calquence

Products Affected

- CALQUENCE
- CALQUENCE (ACALABRUTINIB MAL)

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis. For mantle cell lymphoma, member has received at least one prior therapy. |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Camzyos

Products Affected

- CAMZYOS

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy -AND- Left ventricular ejection fraction of greater than or equal to 55% -AND- Valsalva left ventricular outflow tract peak gradient of greater than or equal to 50 mmHg at rest or after provocation -AND- Therapeutic failure or intolerance to one of the following (1 or 2) or contraindication to all: 1) Non-vasodilating beta blocker (e.g. metoprolol) 2) non-dihydropyridine calcium channel blocker (e.g. diltiazem) -AND- Not currently treated with and attestation Camzyos will not be used concomitantly with disopyramide, ranolazine, or combination therapy of beta-blocker and calcium channel blocker |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | For reauthorization, prescriber attestation of no NYHA class worsening - AND- Not currently treated with and attestation Camzyos will not be used concomitantly with disopyramide, ranolazine, or combination therapy of beta-blocker and calcium channel blocker |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Caplyta

Products Affected

- CAPLYTA

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis -AND- therapeutic failure, intolerance, or contraindication to one other generic atypical antipsychotic (e.g. quetiapine). |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Caprelsa

Products Affected

- CAPRELSA ORAL TABLET 100 MG, 300 MG

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease. |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Carbaglu

Products Affected

- *carglumic acid*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of use as an adjunct therapy for acute hyperammonemia due to hepatic enzyme N-acetylglutamate synthase (NAGS) deficiency, propionic acidemia (PA), or methylmalonic acidemia (MMA) -OR- maintenance therapy for chronic hyperammonemia due to hepatic enzyme N-acetylglutamate synthase (NAGS) deficiency |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Cayston

Products Affected

- CAYSTON

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Diagnosis of cystic fibrosis |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | For reauthorization, attestation of decrease in sputum density of pseudomonas aeruginosa, increase in FEV1 or decrease in number of hospitalizations or pulmonary exacerbations |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Cerdelga

Products Affected

- CERDELGA

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of type 1 Gaucher disease confirmed by the following A. or B. A) With one of the following symptoms (1, 2, 3, 4, or, 5): 1)Hepatomegaly. 2)Splenomegaly. 3)Bone disease (i.e. osteonecrosis, osteopenia, secondary pathologic fractures, bone infarct). 4)Bone marrow complications as defined by anemia with hemoglobin less than or equal to 11.5 g/dL for females or 12.5 g/dL for males or thrombocytopenia with platelet count less than or equal to 120,000/mm ³ . 5)Symptomatic disease (e.g. bone pain, exertional limitation, cachexia). -OR- B) Attestation of deficiency in glucocerebrosidase activity in peripheral leukocytes or genetic testing confirms mutant alleles -AND- Documentation of CYP2D6 metabolizer status (e.g. intermediate metabolizer). |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

CF drugs

Products Affected

- **TOBI PODHALER**
- *tobramycin in 0.225 % nacl*
- *tobramycin inhalation*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Diagnosis of cystic fibrosis. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | Inhalation solutions covered under Part B when administered in the home setting using a covered nebulizer (i.e. DME). For reauthorization of tobramycin products, attestation of decrease in sputum density of pseudomonas aeruginosa, increase in FEV1 or decrease in number of hospitalizations or pulmonary exacerbations. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Cialis

Products Affected

- *tadalafil oral tablet 2.5 mg, 5 mg*

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------|
| Exclusion Criteria | Pending CMS Review |
| Required Medical Information | Pending CMS Review |
| Age Restrictions | Pending CMS Review |
| Prescriber Restrictions | Pending CMS Review |
| Coverage Duration | Pending CMS Review |
| Other Criteria | Pending CMS Review |
| Indications | Pending CMS Review |
| Off Label Uses | Pending CMS Review |
| Part B Prerequisite | No |

Cibinqo

Products Affected

- CIBINQO

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis. For moderate to severe atopic dermatitis, documentation of one of the following (1 or 2): 1) trial & failure or intolerance to at least one topical corticosteroid or one topical calcineurin inhibitor (e.g., tacrolimus, pimecrolimus) -OR- 2) severe atopic dermatitis and the member is incapable of applying topical therapies due to the extent of body surface area involvement or severe atopic dermatitis and topical therapies are contraindicated due to severely damaged skin. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | For Atopic Dermatitis, patients must have a trial/failure, intolerance, or contraindication to both preferred products: Dupixent and Rinvoq. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Cimzia

Products Affected

- CIMZIA
- CIMZIA POWDER FOR RECONST

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis. For moderate to severe rheumatoid arthritis, inadequate response or intolerance to at least one DMARD (e.g. leflunomide). For ankylosing spondylitis, inadequate response or intolerance to one nonsteroidal anti-inflammatory drug (NSAID). For non-radiographic axial spondyloarthritis, inadequate response or intolerance to two nonsteroidal anti-inflammatory drugs (NSAIDs). For moderate to severe psoriasis, inadequate response or intolerance to one systemic therapy (e.g. methotrexate) -OR- inadequate response to phototherapy -OR- contraindication to phototherapy and systemic therapy. |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |

| PA Criteria | Criteria Details |
|----------------------------|---|
| Other Criteria | <p>For Crohn's disease, patients must have therapeutic failure or intolerance to 2 of the following preferred biologic products: a preferred adalimumab product, Stelara , Rinvoq, and Skyrizi SC. For Rheumatoid arthritis, patients must have therapeutic failure or intolerance to 2 of the following preferred products: a preferred adalimumab product, Enbrel, Actemra SC, Xeljanz/Xeljanz XR and Rinvoq. For plaque psoriasis, patients must have therapeutic failure or intolerance to 2 of the following preferred products: a preferred adalimumab product, Cosentyx, Otezla, Stelara SC, Skyrizi SC, and Enbrel. For ankylosing spondylitis, patients must have therapeutic failure or intolerance to 2 of the following preferred products: a preferred adalimumab product, Enbrel, Cosentyx, Rinvoq, and Xeljanz/Xeljanz XR. For Psoriatic arthritis, patients must have therapeutic failure or intolerance to 2 of the following preferred products: Cosentyx, Enbrel, a preferred adalimumab product, Xeljanz/Xeljanz XR, Otezla, Stelara SC, Rinvoq, and Skyrizi SC. Please Note: preferred adalimumab products include Humira with NDC starting with 00074, Cyltezo with NDC starting 00597 and Yuflyma with NDC starting 72606. For initial and induction therapy dosing, doses above plan quantity limit will be approved aligned with recommended initial and induction therapy dosing regimens per indication.</p> |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Cinryze

Products Affected

- CINRYZE

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Member should not be on two prophylactic therapies simultaneously. |
| Required Medical Information | For the prophylactic treatment of abdominal, facial, or laryngeal attacks of hereditary angioedema (HAE) type I & II with the following (1-3): 1) Low C4 level of less than or equal to 14mg/dL or C4 below lower limit of laboratory reference range and 1 of the following (A or B). A) C1 inhibitor (C1INH) antigen level less than or equal to 19mg/dL or below lower limit of laboratory reference range. B) Normal C1INH antigen level and a low C1INH functional level below laboratory reference range. 2) Past medical history of at least 1 symptom of moderate or severe angioedema attack (e.g. airway swelling, painful facial distortion) in absence of concomitant hives. 3) Medications known to cause angioedema have been evaluated and discontinued. For the prophylactic treatment of acute abdominal, facial, or laryngeal attacks of hereditary angioedema (HAE) type III with the following (4-7): 4) Documentation of clinical laboratory performance C4, C1INH antigen, or C1INH functional level are within normal limits of laboratory reference ranges. 5) Documentation of family history of HAE or FXII mutation 6) Past medical history of at least 1 symptom of moderate or severe angioedema attack (e.g. airway swelling, painful facial distortion) in absence of concomitant hives. 7) Medications known to cause angioedema have been evaluated and discontinued. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |

| PA Criteria | Criteria Details |
|----------------------------|-------------------------|
| Off Label Uses | |
| Part B Prerequisite | No |

Cometriq

Products Affected

- **COMETRIQ ORAL CAPSULE 100 MG/DAY(80 MG X1-20 MG X1), 140 MG/DAY(80 MG X1-20 MG X3), 60 MG/DAY (20 MG X 3/DAY)**

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of progressive, metastatic medullary thyroid cancer |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Copiktra

Products Affected

- **COPIKTRA**

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis -AND- member is no longer responding or is intolerant to at least 2 prior therapies for chronic lymphocytic leukemia and small lymphocytic leukemia. |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Corlanor

Products Affected

- **CORLANOR ORAL SOLUTION**
- **CORLANOR ORAL TABLET 5 MG, 7.5 MG**

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis AND all of the following: 1) Normal sinus rhythm. 2) Resting heart rate greater than or equal to 70 beats per minute. 3) Left ventricular ejection fraction less than or equal to 35 percent, when applicable. 4) In adult patients (greater than or equal to 18 years), trial/failure of maximum tolerated dose of one beta-blocker used for treatment of heart failure (e.g., bisoprolol, carvedilol, metoprolol succinate) OR contraindication to beta-blocker use. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | For oral solution, attestation of inability to swallow tablets is required. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Cosentyx

Products Affected

- COSENTYX (2 SYRINGES)
- COSENTYX PEN (2 PENS)
- COSENTYX SUBCUTANEOUS SYRINGE 75 MG/0.5 ML
- COSENTYX UNOREADY PEN

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis. For moderate to severe psoriasis, inadequate response or intolerance to one systemic therapy (e.g. methotrexate) -OR- inadequate response to phototherapy -OR- contraindication to phototherapy and systemic therapy. For ankylosing spondylitis, inadequate response or intolerance to one nonsteroidal anti-inflammatory drug (NSAID). For non-radiographic axial spondyloarthritis, inadequate response or intolerance to 2 NSAIDs. For enthesitis-related arthritis, inadequate response or intolerance to at least 1 non-biologic disease modifying anti-rheumatic drugs (DMARD), or all are contraindicated. |
| Age Restrictions | Deny if less than 6 years of age for moderate to severe plaque psoriasis -OR- less than 2 years of age for psoriatic arthritis -OR- less than 4 years of age for enthesitis-related arthritis -OR- less than 18 years of age for all other indications |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | For induction therapy dosing, doses above plan quantity limit will be approved aligned with recommended induction therapy dosing regimens per indication. For hidradenitis suppurativa, doses above plan quantity limit will be approved to align with recommended dosing regimen. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Cotellic

Products Affected

- COTELLIC

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis -AND- all of the following for unresectable or metastatic melanoma (1-2): 1) BRAF V600E or V600K mutation status 2) Concomitant therapy with vemurafenib. For cobimetinib monotherapy, documentation of histiocytic neoplasms. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Cysteamine Ophthalmic Drops

Products Affected

- CYSTARAN

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of cystinosis -AND- Attestation of accumulation of corneal cystine crystals |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Daraprim

Products Affected

- *pyrimethamine*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis. For primary prophylaxis of toxoplasmosis gondii infection, CD4 count less than 100 cells/mm ³ -AND- Toxoplasma IgG positive -AND- failure, intolerance or contraindication to trimethoprim-sulfamethoxazole. For secondary prophylaxis of toxoplasmosis gondii infection, CD4 count less than 200 cells/mm ³ . For secondary prophylaxis of cystoisosporiasis with CD4 count less than 200 cells/mm ³ or acute cystoisosporiasis infection: failure, intolerance or contraindication to trimethoprim-sulfamethoxazole. For primary prophylaxis of Pneumocystis jirovecii pneumonia: diagnosis of HIV - AND- CD4 count less than 200 cells/mm ³ -AND- failure, intolerance or contraindication to trimethoprim-sulfamethoxazole. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Daurismo

Products Affected

- DAURISMO ORAL TABLET 100 MG, 25 MG

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of newly diagnosed Acute Myeloid Leukemia -AND- Used in combination with cytarabine -AND- At least one comorbidity that preclude use of intensive induction chemotherapy defined as one of the following: 1) Age greater than or equal to 75 2) Severe cardiac or pulmonary comorbidity 3) Reduced renal function 4) Hepatic impairment 5.) Physician attests patient is not a candidate for intensive induction therapy |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Daybue

Products Affected

- DAYBUE

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of Rett syndrome confirmed by all of the following (1 thru 4): 1) Partial or complete loss of acquired purposeful hand skills, 2) Partial or complete loss of acquired spoken language, 3) Gait abnormalities: impaired or absence of ability, 4) Stereotypic hand movements such as hand wringing/squeezing, clapping/tapping, mouthing, and washing/rubbing automatisms |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Deferasirox

Products Affected

- *deferasirox oral tablet, dispersible*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis. For chronic iron overload due to blood transfusions, transfusion history of greater than or equal to 100 mL/kg of packed red blood cells (i.e. at least 20 units of packed red blood cells for a 40 kg person or more in individuals weighing more than 40 kg) -And- history of serum ferritin consistently greater than 1,000 mcg/L or liver iron concentration (LIC) greater than or equal to 7 iron per gram of liver dry weight (mg Fe/g dw). For Chronic Iron Overload in Non-Transfusion-Dependent Thalassemia (NTDT) Syndrome, LIC of at least 5 mg Fe/g dw -AND- serum ferritin greater than 300 mcg/L. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | For reauthorization of chronic iron overload due to blood transfusion, continued requirement for regular blood transfusions -AND- serum ferritin level greater than or equal to 500mcg/L or LIC greater than or equal to 3 mg Fe/g dw. For reauthorization of chronic iron overload in NTDT syndrome, LIC greater than or equal to 3 mg Fe/g dw. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Diacomit

Products Affected

- **DIACOMIT ORAL CAPSULE 250 MG, 500 MG**
- **DIACOMIT ORAL POWDER IN PACKET 250 MG, 500 MG**

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of Dravets syndrome - AND- Used in combination with clobazam |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | For reauthorization, attestation supporting reduction in seizure frequency |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Dihydroergotamine

Products Affected

- *dihydroergotamine nasal*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of acute migraine headaches with or without aura -AND- requires non-oral route of administration -AND- therapeutic failure or intolerance to generic sumatriptan nasal spray. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Doptelet

Products Affected

- **DOPTELET (10 TAB PACK)**
- **DOPTELET (15 TAB PACK)**
- **DOPTELET (30 TAB PACK)**

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of thrombocytopenia and chronic liver disease - AND- beneficiary is scheduled to undergo a procedure -OR- Documentation of chronic immune thrombocytopenia -AND- Trial, intolerance, or inadequate response to corticosteroid therapy, immunoglobulin therapy or splenectomy -AND- One of the following (1 or 2): 1) Platelet count less than or equal to $50 \times 10^9/L$ and has significant mucous member bleeding or at least one risk factor for bleeding (e.g. hypertension, peptic ulcer disease). 2) Platelets count of less than or equal to $30 \times 10^9/L$ |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | For thrombocytopenia with chronic liver disease- 1 mo. For chronic immune thrombocytopenia- 12 mo. |
| Other Criteria | Platelet count is provided for applicable dosing. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Dupixent

Products Affected

- **DUPIXENT PEN SUBCUTANEOUS PEN INJECTOR 200 MG/1.14 ML, 300 MG/2 ML**
- **DUPIXENT SYRINGE**
- **SUBCUTANEOUS SYRINGE 100 MG/0.67 ML, 200 MG/1.14 ML, 300 MG/2 ML**

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | <p>Documentation of all of the following (1-2): 1) moderate to severe atopic dermatitis 2) trial/failure, or intolerance to at least 1 topical corticosteroid -OR- If 2 years of age or older, topical calcineurin inhibitor (e.g. tacrolimus, pimecrolimus) -OR- The member has severe atopic dermatitis and is incapable of applying topical therapies due to the extent of body surface area involvement or topical therapies are contraindicated due to severely damaged skin -OR- Documentation of the following (3-8): 3) moderate-to-severe asthma 4) documented pretreatment FEV1 less than 80% predicted in adults or less than 90% predicted in adolescents or FEV1 reversibility of at least 12% and 200mL after albuterol administration 5) history of at least 2 asthma exacerbations requiring oral or injectable corticosteroid treatment in past 12 mos or at least 1 asthma exacerbation requiring hospitalization in past 12 mos 6) Blood eosinophils greater than or equal to 150cells/uL -OR- current daily or alternate-day oral corticosteroid (OCS) therapy 7) inadequate symptom control despite regular treatment with medium- or high-dose inhaled corticosteroids (ICS) and at least 1 add'l asthma controller medication (e.g. long-acting beta2-agonist [LABA], leukotriene receptor antagonist [LTRA], theophylline) with or without OCS 8) will continue treatment with a medium- or high-dose ICS and at least 1 add'l asthma controller medication with or without OCS -OR- Documentation of the following (9-10): 9) chronic rhinosinusitis with nasal polyposis (CRSwNP) 10) trial/ failure, intolerance or contraindication to intra-nasal corticosteroid and 14 day course of OCS. -OR- Documentation of the following (11-13): 11) eosinophilic esophagitis 12) esophageal eosinophil count greater than or equal to 15 eos/hpf on esophageal biopsy 13) clinical symptoms of esophageal dysfunction -OR- Documentation of the following (14): 14) prurigo nodularis.</p> |
| Age Restrictions | |

| PA Criteria | Criteria Details |
|--------------------------------|--|
| Prescriber Restrictions | |
| Coverage Duration | 6 months initial authorization, 12 months reauthorization |
| Other Criteria | For induction therapy, doses above plan quantity limit will be approved aligned with recommended induction therapy dosing regimen. For atopic dermatitis reauthorization, attestation of positive clinical response to therapy. For asthma reauthorization, attestation of one of the following is required (1-4): 1) decreased rescue medication or oral corticosteroid use, 2) decreased frequency of severe asthma exacerbation, 3) increased pulmonary function from baseline (e.g. FEV1), or 4) reduction in reported asthma related symptoms. For CRSwNP reauthorization, attestation of decrease in nasal polyp score or reduction in nasal congestion/obstruction severity score. For EoE reauthorization, attestation of histological remission (less than 15 eos/hpf) on esophageal biopsy or reduced severity or frequency of clinical symptoms of esophageal dysfunction. For prurigo nodularis reauthorization, attestation of reduction in itch or number of nodules or lesions from baseline. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

EGFR Tyrosine Kinase Inhibitors

Products Affected

- *erlotinib*
- **GILOTRIF**

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------|
| Exclusion Criteria | Pending CMS Review |
| Required Medical Information | Pending CMS Review |
| Age Restrictions | Pending CMS Review |
| Prescriber Restrictions | Pending CMS Review |
| Coverage Duration | Pending CMS Review |
| Other Criteria | Pending CMS Review |
| Indications | Pending CMS Review |
| Off Label Uses | Pending CMS Review |
| Part B Prerequisite | No |

Emgality

Products Affected

- **EMGALITY PEN**
- **EMGALITY SYRINGE
SUBCUTANEOUS SYRINGE 120
MG/ML, 300 MG/3 ML (100 MG/ML X 3)**

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis. For Episodic Migraine, defined as 4-14 migraine days per month OR Chronic Migraine, defined as 15 or more headaches per month, the following criteria will apply (1-3). 1) Documentation of average monthly migraine days. 2) Attestation that headaches are not caused by medication rebound or overutilization (e.g. not taking triptans exceeding more than 18 doses per month) or lifestyle factors (e.g. sleep patterns, caffeine use). 3) Trial and failure or intolerance to one agent from 2 unique prophylactic migraine medication classes: e.g. Anti-epileptic drugs (e.g. topiramate), beta-blockers (e.g. propranolol), calcium-channel blockers (e.g. verapamil), tricyclic antidepressants (e.g. amitriptyline) -OR- contraindication to all prophylactic medication classes. For episodic cluster headaches, characterized by severe or very severe unilateral orbital, supraorbital, and/or temporal pain lasting 15 to 180 minutes when left untreated -AND- Attack frequency of at least one attack every other day during the cluster period. |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 6 months initial authorization, 12 months reauthorization |
| Other Criteria | For induction therapy, doses above plan quantity limit will be approved aligned with recommended induction therapy dosing regimen. For reauthorization of episodic migraine prevention, attestation of reduction in migraine frequency is required. For reauthorization of cluster headache, attestation of reduction in the number of mean weekly cluster headaches from baseline is required. |
| Indications | All FDA-approved Indications. |

| PA Criteria | Criteria Details |
|----------------------------|-------------------------|
| Off Label Uses | |
| Part B Prerequisite | No |

Enbrel

Products Affected

- ENBREL MINI
- ENBREL SUBCUTANEOUS SOLUTION
- ENBREL SUBCUTANEOUS SYRINGE
25 MG/0.5 ML (0.5), 50 MG/ML (1 ML)
- ENBREL SURECLICK

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis. For rheumatoid arthritis, inadequate response or intolerance to at least one DMARD (e.g. methotrexate, leflunomide). For ankylosing spondylitis, inadequate response or intolerance to one nonsteroidal anti-inflammatory drug (NSAID). For juvenile idiopathic rheumatoid arthritis, inadequate response or intolerance to at least one DMARD (e.g., methotrexate, leflunomide) -OR- requires initial biologic therapy due to involvement of high-risk joints, high disease activity or at high risk of disabling joint damage. For moderate to severe plaque psoriasis, inadequate response or intolerance to one systemic therapy (e.g. methotrexate) -OR- inadequate response to phototherapy -OR- contraindication to phototherapy and systemic therapy. |
| Age Restrictions | Deny if less than 18 years of age for Rheumatoid Arthritis and Ankylosing Spondylitis or less than 2 years of age for Juvenile Idiopathic Arthritis and Psoriatic Arthritis or Less than 4 years of age for Plaque Psoriasis |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | For plaque psoriasis induction therapy, doses above plan quantity limit will be approved aligned with recommended induction therapy dosing regimen. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Epclusa

Products Affected

- *sofosbuvir-velpatasvir*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Criteria will be applied consistent with current AASLD/IDSA guidance |
| Age Restrictions | Deny if less than 3 years of age |
| Prescriber Restrictions | |
| Coverage Duration | Criteria/duration applied consistent with current AASLD-IDSA guidance |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Epidiolex

Products Affected

- EPIDIOLEX

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of Lennox-Gastaut, Dravet syndromes or Tuberous Sclerosis Complex. For Lennox-Gastaut, trial and failure or intolerance of at least two standard of care treatments (e.g. lamotrigine, clobazam). For Lennox-Gastaut and Dravet syndromes, treatment is in combination with other conventional agents. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Eprontia

Products Affected

- **EPRONTIA**

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis -AND- inability to swallow pills or food. For migraine, therapeutic failure, intolerance, or contraindication to two generic preventive migraine therapies. For partial onset seizures, primary generalized tonic-clonic seizures, or adjunctive treatment of Lennox-Gastaut Syndrome, therapeutic failure, contraindication, or intolerance to two generic anti-epileptic drugs. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Ergotamine

Products Affected

- *ergotamine-caffeine*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of use to abort a vascular headache -AND- therapeutic failure or intolerance to a generic triptan -OR- documentation of use to prevent a vascular headache -AND- therapeutic failure or intolerance to generic prophylactic migraine medication |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Erivedge

Products Affected

- ERIVEDGE

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis -AND- if disease is locally advanced all of the following: 1) disease has recurred following surgery, or is not a candidate for surgery, 2) is not a candidate for radiation. |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Erleada

Products Affected

- **ERLEADA ORAL TABLET 240 MG, 60 MG**

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis -AND- the member meets one of the following (1 or 2) 1. Documentation of use in combination with a GnRH analog -OR- 2. The member has had a bilateral orchiectomy |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Evenity

Products Affected

- **EVENITY SUBCUTANEOUS SYRINGE
210MG/2.34ML (105MG/1.17MLX2)**

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis -AND- Postmenopausal woman at high risk for fracture, meeting one of the following (1. thru 3.) 1) History of previous hip or vertebral fracture. 2) T-score less than or equal to -2.5. 3) T-score between -1.0 and -2.5 -AND- meets FRAX calculation (A. or B.) A) 10-year risk of major osteoporotic fracture is greater than or equal to 20 percent or B) 10-year risk of hip fracture is greater than or equal to 3 percent. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | Documentation of trial/failure or intolerance to at least one oral bisphosphonate or all are contraindicated. Covered under Part B for patients eligible for home health services when provider certifies that patient sustained bone fracture related to post-menopausal osteoporosis and is unable to learn the skills needed to self-administer the drug or is otherwise physically or mentally incapable of administering the drug or family/caregivers are unable or unwilling to administer the drug. A cumulative lifetime approval of romosozumab will be limited to a coverage duration of 12 months. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Evrysdi

Products Affected

- EVRYSDI

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of spinal muscular atrophy (SMA) -AND- Baseline motor function test results (e.g. MFM, CHOP, HINE, RULM, HFMSE, 6MWT) -AND- Not using concomitantly with Spinraza (nusinersen) -AND- Molecular genetic testing of 5q SMA showing Homozygous gene deletion, Homozygous conversion mutation or Compound heterozygote - AND- No history of gene replacement therapy to treat of SMA or experienced a decline in clinical status following gene replacement therapy. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 6 months |
| Other Criteria | For reauthorization, attestation of stable or clinically significant improvement in SMA-associated symptoms (e.g. stabilization or decreased decline in motor function compared to the predicted natural history trajectory of disease) or stable or improved motor function results compared to baseline (e.g. MFM, CHOP, HINE, RULM, HFMSE, 6MWT) -AND- Not using concomitantly with Spinraza (nusinersen) - AND- No history of gene replacement therapy to treat of SMA or experienced a decline in clinical status following gene replacement therapy. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Fabhalta

Products Affected

- **FABHALTA**

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------|
| Exclusion Criteria | Pending CMS Review |
| Required Medical Information | Pending CMS Review |
| Age Restrictions | Pending CMS Review |
| Prescriber Restrictions | Pending CMS Review |
| Coverage Duration | Pending CMS Review |
| Other Criteria | Pending CMS Review |
| Indications | Pending CMS Review |
| Off Label Uses | Pending CMS Review |
| Part B Prerequisite | No |

Fanapt

Products Affected

- FANAPT ORAL TABLET
- FANAPT ORAL TABLETS,DOSE PACK

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis - AND - trial and failure of one of the following: olanzapine, quetiapine, or risperidone. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Fasenra

Products Affected

- **FASENRA PEN**
- **FASENRA SUBCUTANEOUS SYRINGE**
10 MG/0.5 ML, 30 MG/ML

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of severe asthma and all of the following (1-5): 1) history of at least 2 asthma exacerbations requiring oral or injectable corticosteroid treatment in past 12 mos or at least 1 asthma exacerbation requiring hospitalization in past 12 mos 2) documented pretreatment FEV1 less than 80% predicted in adults or less than 90% predicted in adolescents or FEV1 reversibility of at least 12% and 200mL after albuterol administration 3) Blood eosinophils greater than or equal to 150cells/uL within the past 6 weeks or greater than or equal to 300cells/uL within the past 12 mos in without other potential causes of eosinophilia (e.g. hypereosinophilic syndromes, neoplastic disease, known suspected parasitic infection) 4) inadequate symptom control despite regular treatment with medium or high dose inhaled corticosteroid (ICS) and at least 1 add'l asthma controller medication (e.g. long-acting beta2-agonist [LABA], leukotriene receptor antagonist [LTRA], theophylline), with or without oral corticosteroids (OCS) 5) will continue treatment with medium or high dose ICS and at least 1 add'l asthma controller medication, with or without OCS. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | For induction therapy, doses above plan quantity limit will be approved aligned with recommended induction therapy dosing regimen. For reauthorization, attestation of one of the following is required (1-4): 1) decreased rescue medication or oral corticosteroid use, 2) decreased frequency of severe asthma exacerbation, 3) increased pulmonary function from baseline (e.g. FEV1), or 4) reduction in reported asthma related symptoms. |

| PA Criteria | Criteria Details |
|----------------------------|-------------------------------|
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Fecal Microbiota Products

Products Affected

- VOWST

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of a recent diagnosis of recurrent <i>Clostridioides difficile</i> infection (CDI) -AND- Will be used for prophylaxis and not treatment of recurrent CDI -AND- Attestation that antibiotic treatment for the most recent recurrent CDI is complete or will be completed. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 1 month |
| Other Criteria | For reauthorization, attestation of recurrent CDI episodes after administration of the initial fecal microbiota product -AND- Will be used for prophylaxis and not treatment of recurrent CDI -AND- Attestation that antibiotic treatment for the most recent recurrent CDI is complete or will be completed. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Ferriprox

Products Affected

- *deferiprone*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of transfusional iron overload due to thalassemia syndromes, sickle cell disease and other anemias -AND- transfusion history of greater than or equal to 100 mL/kg of packed red blood cells (i.e. at least 20 units of packed red blood cells for a 40 kg person or more in individuals weighing more than 40 kg) -AND- history of serum ferritin consistently greater than 1,000 mcg/L or liver iron concentration (LIC) greater than or equal to 7 iron per gram of liver dry weight (mg Fe/g dw) |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | Initial authorization requires trial and failure of deferasirox (generic Exjade) and reauthorization requires failure of generic deferasirox (generic Exjade) if not previously trialed. For reauthorization, continued requirement for regular blood transfusions -AND- serum ferritin level greater than or equal to 500mcg/L or LIC greater than or equal to 3 mg Fe/g dw |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Fetzima

Products Affected

- **FETZIMA ORAL CAPSULE,EXT REL 24HR DOSE PACK 20 MG (2)- 40 MG (26)** **CAPSULE,EXTENDED RELEASE 24 HR 120 MG, 20 MG, 40 MG, 80 MG**
- **FETZIMA ORAL**

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of major depressive disorder and trial and failure of two other generic antidepressants. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 5 years |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Filsuvez

Products Affected

- **FILSUVEZ**

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of dystrophic epidermolysis bullosa (DEB) or junctional epidermolysis bullosa (JEB) -AND- at least one open wound. |
| Age Restrictions | Deny if less than 6 months of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | For reauthorization, attestation of improvement in targeted wound(s) - AND- member requires additional courses of treatment. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Fintepla

Products Affected

- FINTEPLA

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of Dravet syndrome or Lennox-Gastaut syndrome. For Lennox-Gastaut syndrome, therapeutic failure, contraindication, or intolerance to at least 2 standard of care treatments (e.g. lamotrigine, clobazam). |
| Age Restrictions | Deny if less than 2 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Firazyr

Products Affected

- *icatibant*
- SAJAZIR

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Member should not be on two acute therapies simultaneously and acute therapy should not be used as prophylactic therapy |
| Required Medical Information | For the treatment of acute abdominal, facial, or laryngeal attacks of hereditary angioedema (HAE) type I & II with the following (1-3): 1) Low C4 level of less than or equal to 14mg/dL or C4 below lower limit of laboratory reference range and 1 of the following (A or B). A) C1 inhibitor (C1INH) antigen level less than or equal to 19mg/dL or below lower limit of laboratory reference range. B) Normal C1INH antigen level and a low C1INH functional level below laboratory reference range. 2) Past medical history of at least 1 symptom of moderate or severe angioedema attack (e.g. airway swelling, painful facial distortion) in absence of concomitant hives. 3) Medications known to cause angioedema have been evaluated and discontinued. For the treatment of acute abdominal, facial, or laryngeal attacks of hereditary angioedema (HAE) type III with the following (4-7): 4) Documentation of clinical laboratory performance C4, C1INH antigen, or C1INH functional level are within normal limits of laboratory reference ranges. 5) Documentation of family history of HAE or FXII mutation 6) Past medical history of at least 1 symptom of moderate or severe angioedema attack (e.g. airway swelling, painful facial distortion) in absence of concomitant hives. 7) Medications known to cause angioedema have been evaluated and discontinued. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

| PA Criteria | Criteria Details |
|--------------------------------|-------------------------|
| Part B Prerequisite | No |

Firdapse

Products Affected

- **FIRDAPSE**

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | For reauthorization, attestation of positive clinical response to therapy. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Firmagon

Products Affected

- **FIRMAGON KIT W DILUENT SYRINGE**

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of advanced prostate cancer. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Flector

Products Affected

- *diclofenac epolamine*
- **FLECTOR**

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis AND one of the following (1,2 or 3): 1) trial/failure, intolerance, or contraindication to 2 oral generic NSAIDs one of which must be diclofenac 2) hypersensitivity to oral NSAIDs 3) history or high risk for adverse gastrointestinal effects associated with oral NSAID use. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 1 month |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Forteo

Products Affected

- *teriparatide subcutaneous pen injector 20 mcg/dose (620mcg/2.48ml)*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis -AND- at high risk for fracture, meeting one of the following (1. thru 4.) 1) History of previous hip or vertebral fracture. 2) T-score less than or equal to -2.5. 3) T-score between -1.0 and -2.5 -AND- meets FRAX calculation (A. or B.) A) 10-year risk of major osteoporotic fracture is greater than or equal to 20 percent or B) 10-year risk of hip fracture is greater than or equal to 3 percent. 4) Age 40 years or older with T-score between -1.0 and -2.5 -AND- History of glucocorticoid use for at least 3 months at a dose of 5mg per day or more of prednisone (or equivalent). |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 24 months |
| Other Criteria | Documentation of trial/failure or intolerance to at least one oral bisphosphonate or all are contraindicated. Coverage of human parathyroid hormone related peptide analogs beyond 24 months will not be approved. A cumulative lifetime approval of teriparatide will be limited to a coverage duration of 24 months in the absence of provider attestation that the member remains at or has returned to having a high risk for fracture |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Fotivda

Products Affected

- FOTIVDA

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis -AND- member has received at least two prior systemic therapies. |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Fruzaqla

Products Affected

- FRUZAQLA ORAL CAPSULE 1 MG, 5 MG

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis -AND- member has received previous threatment with a fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy -AND- member has received previous treatment with an anti-VEGF therapy -AND- one of the following, if member is RAS wild-type (1-2): 1) member has received previous therapy with an anti-EGFR therapy 2) prescriber attests that treatment with an anti-EGFR therapy would not be medically appropriate. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Furoscix

Products Affected

- **FUROSCIX**

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documented diagnosis of heart failure classified as NYHA Class II/III - AND- chronic heart failure medication regimen includes an oral loop diuretic (e.g. furosemide, bumetanide, torsemide) -AND- treatment with oral diuretics will replace the use of Furoscix as soon as practical. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 6 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Gabapentin

Products Affected

- *gabapentin oral capsule 100 mg, 300 mg, 400 mg*
- *gabapentin oral solution 250 mg/5 ml*
- *gabapentin oral tablet 600 mg, 800 mg*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis. When using concomitantly with an opiate agonist, attestation of an intent to monitor and address concomitant drug-drug interaction adverse events for opiate potentiators |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Gattex

Products Affected

- **GATTEX 30-VIAL**

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of short bowel syndrome (SBS) having less than 200 cm of functional small bowel -AND- Dependence on parenteral/intravenous nutrition -AND- weight of at least 10 kg. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | For reauthorization, continued dependence on parenteral nutrition/intravenous nutritional support -AND- attestation of increase in weight from baseline or decrease in intravenous parenteral nutrition requirements from baseline. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Gavreto

Products Affected

- GAVRETO

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis. For metastatic non-small cell lung cancer, disease is RET fusion-positive as detected by an FDA approved test. For advanced or metastatic thyroid cancer, all of the following (1-2): 1) disease is RET fusion-positive 2) if radioactive iodine is appropriate, the member is radioactive iodine-refractory. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Gilenya

Products Affected

- *fingolimod*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | Concomitant use with other disease modifying agents such as teriflunomide, interferons, Copaxone, Tysabri |
| Required Medical Information | Documentation of relapsing form of multiple sclerosis (e.g. relapsing-remitting, clinically isolated syndrome, or active secondary progressive disease) |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 5 years |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Glatiramer

Products Affected

- **COPAXONE SUBCUTANEOUS SYRINGE 20 MG/ML, 40 MG/ML**
 - *glatiramer subcutaneous syringe 20 mg/ml, 40 mg/ml*
- **GLATOPA SUBCUTANEOUS SYRINGE 20 MG/ML, 40 MG/ML**

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Gleevec

Products Affected

- *imatinib oral tablet 100 mg, 400 mg*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | <p>Documentation of Ph+ chronic myeloid leukemia -AND- one of the following: 1) member is newly diagnosed in chronic phase 2) member is in blast crisis, the accelerated phase or the chronic phase after failure of interferon-alpha therapy. Documentation of Ph+ acute lymphocytic leukemia -AND- one of the following: 1) for adults, member has relapsed or refractory disease 2) for pediatric patients, member is newly diagnosed and will be using imatinib in combination with a chemotherapy regimen. Documentation of adult aggressive systemic mastocytosis -AND- one of the following: 1) documentation that the member does not have D816V c-KIT status 2) member's c-KIT status is unknown. For gastrointestinal stromal tumors (GIST) one of the following: 1) member has diagnosis of KIT (CD117)-positive unresectable and/or metastatic malignant GIST 2) imatinib will be used as adjuvant treatment following resection of KIT (CD117)-positive GIST. Documentation of unresectable, recurrent or metastatic dermatofibrosarcoma protuberans. Documentation of Hypereosinophilic Syndrome/Chronic Eosinophilic Leukemia. Documentation of myeloproliferative disease -AND- disease is associated with PDGFR gene rearrangements. Documentation of myelodysplastic syndrome -AND- disease is associated with PDGFR gene rearrangements.</p> |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

| PA Criteria | Criteria Details |
|--------------------------------|-------------------------|
| Part B Prerequisite | No |

Gleostine

Products Affected

- GLEOSTINE

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of primary or metastatic brain tumor(s) -AND- member has previously received surgical and/or radiotherapeutic procedure(s). Documentation of Hodgkin's lymphoma -AND- all of the following (1-2): 1) using lomustine in combination with other chemotherapies 2) member has experienced disease progression with initial chemotherapy. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Growth Hormone

Products Affected

- **NORDITROPIN FLEXPRO**

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis, growth chart, bone age, growth velocity, response to stimulation test, when applicable to meet standard diagnostic criteria. Additionally for growth failure due to chronic kidney disease, glomerular filtration rate is less than 89ml/min per 1.73m*2. For HIV wasting and cachexia, Concurrent use of antiretroviral therapy -AND- weight loss of at least 10 percent from baseline. For short bowel syndrome, receiving management for short bowel syndrome, including specialized nutritional support -AND- less than 200 cm of functional small bowel. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | For reauthorization, attestation of growth velocity and bone age, as applicable to meet standard continuation of therapy guidelines. For reauthorization of HIV wasting and cachexia, attestation of increase in weight from start of therapy. For reauthorization of short bowel syndrome, continued dependence on parenteral nutrition/intravenous nutritional support -AND- attestation of increase in weight from baseline or decrease in intravenous parenteral nutrition requirements from baseline. |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Haegarda

Products Affected

- HAEGARDA

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | Member should not be on two prophylactic therapies simultaneously. |
| Required Medical Information | <p>For the prophylactic treatment of abdominal, facial, or laryngeal attacks of hereditary angioedema (HAE) type I & II with the following (1-4): 1) Low C4 level of less than or equal to 14mg/dL or C4 below lower limit of laboratory reference range and 1 of the following (A or B). A) C1 inhibitor (C1INH) antigen level less than or equal to 19mg/dL or below lower limit of laboratory reference range. B) Normal C1INH antigen level and a low C1INH functional level below laboratory reference range. 2) Past medical history of at least 1 symptom of moderate or severe angioedema attack (e.g. airway swelling, painful facial distortion) in absence of concomitant hives. 3) Medications known to cause angioedema have been evaluated and discontinued. 4) Documentation of member's weight. For the prophylactic treatment of acute abdominal, facial, or laryngeal attacks of hereditary angioedema (HAE) type III with the following (5-9): 5) Documentation of clinical laboratory performance C4, C1INH antigen, or C1INH functional level are within normal limits of laboratory reference ranges. 6) Documentation of family history of HAE or FXII mutation 7) Past medical history of at least 1 symptom of moderate or severe angioedema attack (e.g. airway swelling, painful facial distortion) in absence of concomitant hives. 8) Medications known to cause angioedema have been evaluated and discontinued. 9) Documentation of member's weight.</p> |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |

| PA Criteria | Criteria Details |
|----------------------------|-------------------------|
| Off Label Uses | |
| Part B Prerequisite | No |

High-risk meds

Products Affected

- *amitriptyline*
- *benztropine oral*
- *clomipramine*
- *cyproheptadine*
- *doxepin oral capsule*
- *doxepin oral concentrate*
- *doxepin oral tablet*
- *hydroxyzine hcl oral solution 10 mg/5 ml*
- *hydroxyzine hcl oral tablet*
- *imipramine hcl*
- *promethazine oral tablet*
- *trimipramine*

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------|
| Exclusion Criteria | Pending CMS Review |
| Required Medical Information | Pending CMS Review |
| Age Restrictions | Pending CMS Review |
| Prescriber Restrictions | Pending CMS Review |
| Coverage Duration | Pending CMS Review |
| Other Criteria | Pending CMS Review |
| Indications | Pending CMS Review |
| Off Label Uses | Pending CMS Review |
| Part B Prerequisite | No |

High-risk meds phenobarbital

Products Affected

- *phenobarbital*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Coverage is not provided for use in sedation/insomnia |
| Required Medical Information | For use in seizures the following are required: 1. Explanation of risk-benefit profile favoring use of the high-risk medication 2. Attestation of an intent to monitor and address treatment-related adverse events. 3. For new starts, the trial and failure or documentation of intolerance or contraindication to at least 2 non-high risk alternative drugs used for seizures (e.g. carbamazepine, lamotrigine) is required. |
| Age Restrictions | Automatic approval if less than 65 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off Label Uses | Seizure disorders |
| Part B Prerequisite | No |

Humira

Products Affected

- **CYLTEZO(CF)**
- **CYLTEZO(CF) PEN**
- **CYLTEZO(CF) PEN CROHN'S-UC-HS**
- **CYLTEZO(CF) PEN PSORIASIS-UV**
- **HUMIRA PEN**
- **HUMIRA SUBCUTANEOUS SYRINGE KIT 40 MG/0.8 ML**
- **HUMIRA(CF)**
- **HUMIRA(CF) PEN**
- **HUMIRA(CF) PEN CROHNS-UC-HS**
- **HUMIRA(CF) PEN PEDIATRIC UC**
- **HUMIRA(CF) PEN PSOR-UV-ADOL HS**
- **YUFLYMA(CF)**
- **YUFLYMA(CF) AI CROHN'S-UC-HS**
- **YUFLYMA(CF) AUTOINJECTOR**

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis. For moderate to severe rheumatoid arthritis, inadequate response or intolerance to at least one DMARD (e.g. methotrexate, leflunomide). For ankylosing spondylitis, inadequate response or intolerance to at least one nonsteroidal anti-inflammatory drug (NSAID). For moderate to severe juvenile idiopathic rheumatoid arthritis, inadequate response or intolerance to at least one DMARD (e.g., methotrexate, leflunomide) -OR- requires initial biologic therapy due to involvement of high-risk joints, high disease activity or at high risk of disabling joint damage. For moderate to severe plaque psoriasis, inadequate response or intolerance to one systemic therapy (e.g. methotrexate) -OR- inadequate response to phototherapy -OR- contraindication to phototherapy and systemic therapy. For uveitis, inadequate response or intolerance to 2 immunosuppressants. |
| Age Restrictions | Deny if less than 18 years of age for Rheumatoid Arthritis, Psoriatic Arthritis, Plaque Psoriasis, and Ankylosing Spondylitis or less than 12 years of age for Hidradenitis Suppurative or Less than 6 years of age for Crohn's disease or Less than 5 years of age for Ulcerative Colitis or less than 2 years of age for Juvenile Idiopathic Arthritis and Uveitis |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |

| PA Criteria | Criteria Details |
|----------------------------|--|
| Other Criteria | For plaque psoriasis induction therapy, doses above plan quantity limit will be approved aligned with recommended induction therapy dosing regimen. For rheumatoid arthritis therapy without concomitant methotrexate, doses above plan quantity limit will be approved aligned with recommended weekly dosing regimen. For pediatric ulcerative colitis and hidradenitis suppurativa, doses above plan quantity limit will be approved to align with recommended dosing regimen. Induction therapy or treatment regimens for other indications are aligned with plan quantity limit on Humira starter kit. Please Note: Covered preferred adalimumab products include Humira with NDC starting with 00074, Cyltezo with NDC starting 00597 and Yuflyma with NDC starting 72606. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Ibrance

Products Affected

- **IBRANCE**

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of HR-positive, HER2-negative advanced or metastatic breast cancer -AND- meets one of the following (1 or 2): 1) documentation of use with an aromatase inhibitor as initial endocrine-based therapy -OR- 2) documentation of use with fulvestrant in patients with disease progression following endocrine therapy. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Ibsrela

Products Affected

- **IBSRELA**

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of irritable bowel syndrome with constipation -AND- failure or intolerance to Linzess -AND- if member is female, failure or intolerance to lubiprostone. |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Iclusig

Products Affected

- ICLUSIG

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Treatment of newly-diagnosed chronic phase CML |
| Required Medical Information | Documentation of T3151+ chronic myeloid leukemia (CML) -OR- documentation of chronic phase CML and member has experienced resistance or intolerance to at least two prior kinase inhibitors -OR- documentation of accelerated phase or blast phase CML and no other kinase inhibitor is indicated -OR- member is using Iclusig as monotherapy and meets one of the following (1-2): 1) documentation of T3151+ acute lymphoblastic leukemia (ALL) 2) documentation of Ph+ ALL and no other tyrosine kinase inhibitor therapy is indicated -OR- member has newly diagnosed Ph+ ALL and is using Iclusig in combination with chemotherapy. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Idhifa

Products Affected

- **IDHIFA ORAL TABLET 100 MG, 50 MG**

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA approved test |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

IG

Products Affected

- **BIVIGAM**
- **GAMMAGARD LIQUID**
- **GAMMAGARD S-D (IGA**
- **GAMMAKED INJECTION SOLUTION**
- **GAMMAPLEX**
- **GAMMAPLEX (WITH SORBITOL)**
- **GAMUNEX-C INJECTION SOLUTION**
- **1 GRAM/10 ML (10 %)**
- **OCTAGAM**
- **PANZYGA**
- **PRIVIGEN**

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | <p>Documentation of diagnosis. For select diagnoses the following apply 1) For Myasthenia Gravis Syndrome, documentation that the patient is refractory to other standard therapies (e.g., cholinesterase inhibitors, corticosteroids, azathioprine) given in therapeutic doses over at least 3 months OR is intolerant/contraindication to those standard therapies. 2) For Multiple Sclerosis, patient is refractory to other standard therapies (e.g., interferons) given in therapeutic doses over at least 3 months OR is intolerant/contraindication to those standard therapies. 3) For B-cell CLL, associated with recurrent bacterial infections OR with Associated Hypogammaglobulinemia defined as IgG level less than 600mg/dL or evidence of a specific antibody deficiency. 4) For Bone Marrow Transplantation, the member is 20 years of age or older and within the first 100 days after transplantation. 5) For Dermatomyositis/Polymyositis, trial and failure, intolerance, or contraindication to standard fist line therapy (i.e. corticosteroids or immunosuppressants). 6) For Pediatric HIV, the patient is less than 13 y.o. who have entry CD4 lymphocyte count greater than or equal to 200/mcl and IgG less than 400mg/dL OR recurrent bacterial infections. 7) For Guillain-Barre syndrome, impaired function by objective assessment and/or objective findings on physical exam at the time of initial therapy and IVIG therapy must be initiated within 2 weeks of symptom onset. 8) For Autoimmune Mucocutaneous Blistering Diseases (e.g. Stevens-Johnson Syndrome), trial and failure, intolerance, or contraindication to conventional therapy (e.g. corticosteroids) or the patient has rapidly progressive disease in which a clinical response could not be affected quickly enough using conventional agents.</p> |
| Age Restrictions | |

| PA Criteria | Criteria Details |
|--------------------------------|--|
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | Covered under Part B when administered in the home to a member with a diagnosis of primary immunodeficiency disease |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off Label Uses | Myasthenia Gravis syndrome, Multiple Sclerosis, Polymyositis, Bone Marrow Transplant, Pediatric HIV, Guillain-Barre syndrome, Autoimmune Mucocutaneous Blistering Diseases |
| Part B Prerequisite | No |

Imbruvica

Products Affected

- **IMBRUVICA ORAL CAPSULE 140 MG, 280 MG, 420 MG, 70 MG**
- **IMBRUVICA ORAL SUSPENSION**
- **IMBRUVICA ORAL TABLET 140 MG,**

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis. For chronic graft versus host disease, previous treatment with at least 1 prior systemic therapy. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | For suspension, inability to swallow oral tablets or oral capsules is required. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Increlex

Products Affected

- **INCRELEX**

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------|
| Exclusion Criteria | Pending CMS Review |
| Required Medical Information | Pending CMS Review |
| Age Restrictions | Pending CMS Review |
| Prescriber Restrictions | Pending CMS Review |
| Coverage Duration | Pending CMS Review |
| Other Criteria | Pending CMS Review |
| Indications | Pending CMS Review |
| Off Label Uses | Pending CMS Review |
| Part B Prerequisite | No |

Ingrezza

Products Affected

- **INGREZZA INITIATION PK(TARDIV)**
- **INGREZZA ORAL CAPSULE 40 MG, 60 MG, 80 MG**
- **INGREZZA SPRINKLE**

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of tardive dyskinesia -OR- documentation of chorea associated with Huntington's disease. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Inlyta

Products Affected

- INLYTA

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis -AND- one of the following (1-2): 1) if using axitinib as first line therapy for advanced renal cell carcinoma, member is using axitinib in combination with avelumab or pembrolizumab 2) member has been treated with at least one prior systemic therapy. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Inqovi

Products Affected

- INQOVI

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation chronic myelomonocytic leukemia. Documentation of myelodysplastic syndrome -AND- One of the following (1 or 2): 1) French American-British MDS subtypes of refractory anemia, refractory anemia with ringed sideroblasts or refractory anemia with excess blasts. 2) International Prognostic Scoring System group of intermediate-1, intermediate-2 or high-risk. |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Inrebic

Products Affected

- INREBIC

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of intermediate-2 or high-risk myelofibrosis per an accepted risk stratification tool for myelofibrosis (e.g., International Prognostic Scoring System [IPSS]) -AND- If a new start, baseline platelet count of greater than or equal to $50 \times 10^9/L$ |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | Baseline platelet count to be provided. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Insulin Supplies

Products Affected

- ALCOHOL PADS
- ASSURE ID INSULIN SAFETY SYRINGE 1 ML 29 GAUGE X 1/2"
- GAUZE PAD TOPICAL BANDAGE 2 X 2 "
- *insulin syringe-needle u-100 syringe 0.3 ml 29 gauge, 1 ml 29 gauge x 1/2", 1/2 ml 28 gauge*
- *pen needle, diabetic needle 29 gauge x 1/2"*

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation the product is being used for the delivery of insulin into the body. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Interferon Alfa

Products Affected

- PEGASYS

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Interferon Beta

Products Affected

- AVONEX INTRAMUSCULAR PEN INJECTOR KIT
- AVONEX INTRAMUSCULAR SYRINGE KIT
- BETASERON SUBCUTANEOUS KIT
- PLEGRIDY SUBCUTANEOUS PEN INJECTOR 125 MCG/0.5 ML
- PLEGRIDY SUBCUTANEOUS SYRINGE 125 MCG/0.5 ML

| PA Criteria | Criteria Details |
|------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

IPF Agents

Products Affected

- **OFEV**
- *pirfenidone oral capsule*
- *pirfenidone oral tablet*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of idiopathic pulmonary fibrosis -AND- baseline forced vital capacity (FVC) of at least 50% and a percent predicted diffusing capacity of the lungs of carbon monoxide (DLCO) of at least 30%. For Ofev only, documentation of systemic sclerosis-associated interstitial lung disease -AND- baseline forced vital capacity (FVC) of at least 40% and a percent predicted diffusing capacity of the lungs of carbon monoxide (DLCO) of at least 30% -AND- documentation of a high-resolution chest computed tomography (CT) scan demonstrating greater than or equal to 10% pulmonary fibrosis. For Ofev only, documentation of chronic fibrosing interstitial lung disease with progressive phenotype -AND- high resolution chest computing tomography (HRCT) scan demonstrating greater than 10% fibrosing disease -AND- baseline forced vital capacity (FVC) of at least 45% and a percent predicted diffusing capacity of the lungs of carbon monoxide (DLCO) of at least 30% -AND- disease progression in previous 24 months shown by one of the following : 1. Relative decline in FVC greater than or equal to 10% predicted 2. Relative decline in FVC greater than or equal to 5% but less than 10% predicted and either worsening of respiratory symptoms or increased extent of fibrotic changes on HRCT 3. Worsening of respiratory symptoms and increasing extent of fibrotic changes on HRCT |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |

| PA Criteria | Criteria Details |
|----------------------------|-------------------------|
| Off Label Uses | |
| Part B Prerequisite | No |

Iressa

Products Affected

- *gefitinib*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | Use in tumors with EGFR mutations other than exon 19 deletions or exon 21 (L858R) substitution mutations. |
| Required Medical Information | Documentation of diagnosis -AND- the following: 1) EGFR exon 19 deletion mutations or exon 21 (L858R) mutations as detected by an FDA-approved test |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Itraconazole

Products Affected

- *itraconazole oral capsule*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis. If using for diagnosis of onychomycosis, confirmation through positive laboratory testing (e.g. KOH preparation, fungal culture, or nail biopsy) is required. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | Onychomycosis: 3 months. All other indications: 3 months initial, 12 months reauth |
| Other Criteria | Documentation of trial/failure or intolerance of amphotericin b must be provided for approval in patients with aspergillosis. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Ivermectin Oral

Products Affected

- *ivermectin oral*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of strongyloidiasis of the intestinal tract (non-disseminated disease) or onchocerciasis -AND- Member weighs greater than or equal to 15kg. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 3 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Iwilfin

Products Affected

- IWILFIN

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of high-risk neuroblastoma (HRNB) -AND- partial response to anti-glycolipid disialoganglioside (GD2) immunotherapy (e.g., dinutuximab, naxitamab). |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Jakafi

Products Affected

- JAKAFI

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of intermediate or high-risk myelofibrosis per an accepted risk stratification tool for myelofibrosis (e.g., International Prognostic Scoring System [IPSS]) and if a new start, baseline platelet count of greater than or equal to $50 \times 10^9/L$ -OR- documentation of polycythemia vera and inadequate response or intolerance to hydroxyurea -OR- Documentation of steroid refractory acute graft-versus-host disease and prior therapy with at least one systemic corticosteroid -OR- Documentation of chronic graft-versus-host disease with prior failure of at least one systemic therapy. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | Baseline platelet count to be provided. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Jaypirca

Products Affected

- **JAYPIRCA ORAL TABLET 100 MG, 50 MG**

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis. For relapsed or refractory mantle cell lymphoma, member has received at least two (2) previous lines of systemic therapy, at least one (1) of which was a BTK inhibitor. For Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia, member has received at least two (2) prior lines of therapy, including at least one (1) from all of the following classes (1-2): 1) BTK inhibitor 2) BCL-2 inhibitor. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Joenja

Products Affected

- JOENJA

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of activated phosphoinositide 3-kinase delta syndrome (APDS) with genetic confirmation of variant in PIK3CD or PIK3R1 gene. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Kalydeco

Products Affected

- **KALYDECO ORAL GRANULES IN PACKET 13.4 MG, 25 MG, 5.8 MG, 50 MG, 75 MG**
- **KALYDECO ORAL TABLET**

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of cystic fibrosis (CF) in patients who have one mutation in the cystic fibrosis transmembrane conductance regulator (CFTR gene) that is responsive to ivacaftor based on clinical and or in vitro assay (e.g. G551D, G1244E, G1349D) |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 6 months initial authorization, 12 months reauthorization |
| Other Criteria | For reauthorization, documentation supporting improvement or stabilization of FEV1 compared to baseline FEV1 -or- increase in body mass index -or- decreased pulmonary exacerbations -or- improved quality of life as demonstrated by CF Questionnaire is required. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Kerendia

Products Affected

- **KERENDIA**

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | eGFR less than or equal to 25 mL/min/1.73 m ² , serum potassium greater than 5.5 mEq/L |
| Required Medical Information | Documentation of type 2 diabetes mellitus with chronic kidney disease - AND- one of the following (1. 2. or 3.): 1) concomitant use of a sodium-glucose Cotransporter-2 (SGLT2) inhibitor 2) therapeutic failure to at least one SGLT2 inhibitor or 3) contraindication or intolerance to at least one SGLT2 inhibitor. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 6 months initial authorization, 12 months reauthorization |
| Other Criteria | For reauthorization, attestation that signs or symptoms of hyperkalemia are not present. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Kesimpta

Products Affected

- **KESIMPTA PEN**

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of relapsing form of multiple sclerosis (e.g. relapsing-remitting, clinically isolated syndrome, or active secondary progressive disease) |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | For induction therapy dosing, doses above plan quantity limit will be approved aligned with recommended induction therapy dosing regimens |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Kevzara

Products Affected

- **KEVZARA**

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------|
| Exclusion Criteria | Pending CMS Review |
| Required Medical Information | Pending CMS Review |
| Age Restrictions | Pending CMS Review |
| Prescriber Restrictions | Pending CMS Review |
| Coverage Duration | Pending CMS Review |
| Other Criteria | Pending CMS Review |
| Indications | Pending CMS Review |
| Off Label Uses | Pending CMS Review |
| Part B Prerequisite | No |

Kineret

Products Affected

- KINERET

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis. For moderate to severe rheumatoid arthritis, inadequate response or intolerance to at least one DMARD (e.g. methotrexate, leflunomide). For Deficiency of Interleukin-1 Receptor Antagonist (DIRA), therapeutic failure or intolerance to at least one (1) corticosteroid, or all corticosteroids are contraindicated. |
| Age Restrictions | Deny if less than 18 years of age for Rheumatoid Arthritis |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | For rheumatoid arthritis, patients must have therapeutic failure or intolerance to 2 of the following preferred products: a preferred adalimumab product, Enbrel, Actemra SC, Rinvoq and Xeljanz/Xeljanz XR. Please Note: preferred adalimumab products include Humira with NDC starting with 00074, Cyltezo with NDC starting 00597 and Yuflyma with NDC starting 72606. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Kisqali

Products Affected

- **KISQALI FEMARA CO-PACK ORAL TABLET 200 MG/DAY(200 MG X 1)-2.5 MG, 400 MG/DAY(200 MG X 2)-2.5 MG, 600 MG/DAY(200 MG X 3)-2.5 MG**
- **KISQALI ORAL TABLET 200 MG/DAY (200 MG X 1), 400 MG/DAY (200 MG X 2), 600 MG/DAY (200 MG X 3)**

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------|
| Exclusion Criteria | Pending CMS Review |
| Required Medical Information | Pending CMS Review |
| Age Restrictions | Pending CMS Review |
| Prescriber Restrictions | Pending CMS Review |
| Coverage Duration | Pending CMS Review |
| Other Criteria | Pending CMS Review |
| Indications | Pending CMS Review |
| Off Label Uses | Pending CMS Review |
| Part B Prerequisite | No |

Klisyri

Products Affected

- **KLISYRI**

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of actinic keratosis of the face or scalp -AND- Therapeutic failure or intolerance to 1 of the following 1) generic topical imiquimod 5% cream 2) generic fluorouracil 5% topical cream 3) generic fluorouracil topical solution |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 3 months |
| Other Criteria | For reauthorization, attestation that the member has previously experienced complete or partial clearance of actinic keratosis lesions with Klisyri -AND- additional course of therapy is required for recurrence of actinic keratosis -AND- member is restarting therapy at least 60 days after cessation of an initial Klisyri 5-day course. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Korlym

Products Affected

- *mifepristone oral tablet 300 mg*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of hyperglycemia secondary to hypercortisolism in patients with endogenous Cushing's syndrome -AND- Patient is not a candidate for surgery or where surgery has failed -AND- one of the following (1 or 2): 1) Diagnosis of diabetes with trial and failure, intolerance, or contraindication to one previous therapy for Type 2 Diabetes (e.g. metformin, sulfonylureas, insulin) or using in addition to a therapy for Type 2 diabetes. 2) Glucose intolerance |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Koselugo

Products Affected

- **KOSELUGO ORAL CAPSULE 10 MG, 25 MG**

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis -AND- for neurofibromatosis type 1 (NF1), documentation of symptomatic, inoperable plexiform neurofibromas (PN) |
| Age Restrictions | Deny if less than 2 years of age or older than 17 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Krazati

Products Affected

- **KRAZATI**

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis -AND- disease is KRAS G12C-mutated as determined by an FDA approved test -AND- member has received at least one prior systemic therapy. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Kuvan

Products Affected

- **JAVYGTOR**
- *sapropterin*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documented diagnosis of PKU -AND- documented baseline Phe level greater than 6 mg/dL -AND- clinical documentation of current weight -AND- sapropterin dihydrochloride dose does not exceed 20 mg/kg/day |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 3 months initial authorization, 12 months reauthorization |
| Other Criteria | For reauthorization, initial therapy has resulted in decrease in phenylalanine levels from baseline or current phenylalanine levels within the range of 120-360 micromol/L -AND- clinical documentation of current weight is required -AND- sapropterin dihydrochloride dose does not exceed 20 mg/kg/day. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Latuda

Products Affected

- *lurasidone oral tablet 120 mg, 20 mg, 40 mg, 60 mg, 80 mg*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis. If medication is being used for bipolar 1 disorder, documentation of trial and failure or intolerance to one other formulary medication indicated in bipolar 1 disorder (e.g. quetiapine) |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Lenvima

Products Affected

- LENVIMA

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | <p>Documentation of differentiated thyroid cancer -AND- meets all of the following (1-3): 1) disease is locally recurrent or metastatic 2) disease is progressive 3) disease is radioactive iodine refractory. Documentation of advanced renal cell carcinoma -AND- one of the following (1-2): 1) member is using lenvatinib in combination with pembrolizumab and is using lenvatinib and pembrolizumab as first-line treatment 2) member is using lenvatinib in combination with everolimus and has experienced therapeutic failure or intolerance to one prior anti-angiogenic therapy. Documentation of unresectable hepatocellular carcinoma. Documentation of endometrial cancer -AND- meets all of the following (1-5): 1) member is using lenvatinib in combination with pembrolizumab 2) disease is advanced 3) disease is not classified as microsatellite instability-high or disease is classified as mismatch repair proficient as determined by an FDA-approved test 4) member has experienced disease progression following prior systemic therapy 5) member is not a candidate for curative surgery or radiation.</p> |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Leukine

Products Affected

- LEUKINE INJECTION RECON SOLN

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis: following induction chemotherapy in patients who are 55 years or older with acute myelogenous leukemia (AML) -OR- mobilization of hematopoietic progenitor cells into peripheral blood for collection by leukapheresis and autologous transplantation -OR- acceleration of myeloid reconstitution following autologous bone marrow or peripheral blood progenitor cell transplantation -OR- acceleration of myeloid reconstitution following allogeneic BMT -OR- treatment of delayed neutrophil recovery or graft failure after autologous or allogeneic BMT -OR- following acute exposure to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome [H-ARS]). |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 6 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Libervant

Products Affected

- **LIBERVANT**

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of seizure clusters or acute repetitive seizures -AND- the member is currently receiving antiepileptic maintenance therapy. |
| Age Restrictions | Deny if less than 2 years of age or greater than 5 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Lidoderm

Products Affected

- *lidocaine topical adhesive patch, medicated 5 %*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of postherpetic neuralgia (PHN) or diabetic peripheral neuropathy (DPN) -AND- One of the following (1-3): 1) trial and failure of 1 other agent used to treat diagnosis (e.g. gabapentin for PHN, duloxetine for DPN), 2) inability to swallow oral medication, 3) unable to take an oral medication due to potential adverse events (e.g. sedation). |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off Label Uses | Diabetic peripheral neuropathy |
| Part B Prerequisite | No |

Litfulo

Products Affected

- LITFULO

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis. For severe alopecia areata, therapeutic failure/intolerance to an intralesional corticosteroid or high potency topical corticosteroid, or contraindication to all. |
| Age Restrictions | Deny if less than 12 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Livtency

Products Affected

- LIVTENCITY

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Diagnosis of CMV prophylaxis. |
| Required Medical Information | Documentation of refractory cytomegalovirus infection or disease as evidenced by antigenemia or polymerase chain reaction (PCR) test -AND- all of the following (1-3): 1) member weighs at least 35 kg, 2) member is a recipient of hematopoietic stem cell transplant -OR- solid organ transplant. 3) member has experienced therapeutic failure to one of the following: ganciclovir, valganciclovir, cidofovir, or foscarnet. |
| Age Restrictions | Deny if less than 12 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 3 months |
| Other Criteria | For reauthorization, attestation of a previous reduction in CMV DNA level -AND- documentation of one of the following (1-3): 1) new onset symptomatic CMV infection, 2) virologic relapse with treatment-emergent maribavir resistance or 3) continued antiviral treatment is required to achieve virologic clearance. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Lokelma

Products Affected

- **LOKELMA**

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of hyperkalemia as defined by serum potassium level between 5.1 and 7.4 mmol/L on at least two (2) screenings -AND- Modification of medications to reduce serum potassium levels were not successful, when applicable |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 6 months initial authorization, 12 months reauthorization |
| Other Criteria | For reauthorization, attestation of reduction in serum potassium levels following Lokelma administration and continued treatment for hyperkalemia is required. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Lonsurf

Products Affected

- LONSURF

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of metastatic colorectal cancer as a single agent or in combination with bevacizumab in patients who have previously been treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and if RAS wild-type, an anti-EGFR therapy -OR- documentation of metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, HER2/neu-targeted therapy |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Lorbrena

Products Affected

- **LORBRENA ORAL TABLET 100 MG,
25 MG**

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of ALK-positive metastatic non-small cell lung cancer (NSCLC) |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Lotronex

Products Affected

- *alosetron oral tablet 0.5 mg, 1 mg*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | For irritable bowel syndrome (IBS): Exclude if male gender |
| Required Medical Information | Documentation of chronic severe diarrhea-predominant IBS -AND- trial and failure or intolerance to one anti-diarrheal (e.g. loperamide), anti-spasmodic, or tricyclic antidepressant, or contraindication to all |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 weeks initial authorization, 12 months reauthorization |
| Other Criteria | For reauthorization, attestation that symptoms of IBS continue to persist AND positive clinical response. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Lumakras

Products Affected

- LUMAKRAS ORAL TABLET 120 MG, 320 MG

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis -AND- disease is KRAS G12C-mutated as determined by an FDA approved test -AND- member has received at least one prior systemic therapy. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Lupron Depot Ped

Products Affected

- **LUPRON DEPOT-PED (3 MONTH) INTRAMUSCULAR SYRINGE KIT 11.25 MG**
 - **LUPRON DEPOT-PED**
- **INTRAMUSCULAR KIT 7.5 MG (PED)**
 - **LUPRON DEPOT-PED INTRAMUSCULAR SYRINGE KIT**

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of central precocious puberty -AND- advancement of bone age is beyond chronological age -AND- Basal luteinizing hormone (LH) level greater than 0.2-0.3 IU/L or leuprolide-stimulating LH level greater than 3.3-5 IU/L |
| Age Restrictions | Deny if greater than 8 years of age for females or greater than 9 years of age for males unless there is medical necessity for treatment of central precocious puberty |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | For reauthorization, attestation of positive clinical response to therapy defined as pre-pubertal slowing/decline, normalization of FSH, normalization LH, normalization of bone age, normalization of estradiol level or normalization of testosterone level |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Lynparza

Products Affected

- LYNPARZA

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | <p>Documentation of diagnosis. For advanced epithelial ovarian, fallopian tube or primary peritoneal cancer, all of the following (1-2): 1) in complete or partial response to first-line platinum-based chemotherapy 2) diagnosis of deleterious or suspected deleterious BRCA mutated disease or disease is associated with homologous recombination deficiency (HRD) positive status with a deleterious or suspected deleterious BRCA mutation or genomic instability and will be using in combination with bevacizumab. For recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, all of the following (1-2): 1) deleterious or suspected deleterious germline or somatic BRCA mutation 2) in complete or partial response to platinum-based chemotherapy. For deleterious or suspected deleterious gBRCAm, HER2-negative breast cancer, 1 of the following (1-2): 1) classified as high-risk, early breast cancer and has been treated with neoadjuvant or adjuvant chemotherapy 2) has been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting and if hormone receptor (HR)-positive, has been previously treated with or considered inappropriate for treatment with endocrine therapy. For metastatic pancreatic adenocarcinoma, all of the following (1-2): 1) a deleterious or suspected deleterious gBRCA mutation 2) did not progress on at least 16 weeks of a first-line platinum-based chemotherapy regimen. For deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene mutation metastatic castration-resistant prostate cancer, all of the following (1-2): 1) progressed following prior treatment with enzalutamide or abiraterone 2) concurrently receiving a gonadotropin-releasing hormone (GnRH) analog or has had a bilateral orchiectomy. For deleterious or suspected deleterious BRCA mutation metastatic castration-resistant prostate cancer, using in combination with all of the following (1-2): 1) abiraterone 2) prednisone or prednisolone.</p> |
| Age Restrictions | |

| PA Criteria | Criteria Details |
|--------------------------------|-------------------------------|
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Lyrica

Products Affected

- *pregabalin oral capsule 100 mg, 150 mg, 200 mg, 225 mg, 25 mg, 300 mg, 50 mg, 75 mg*
- *pregabalin oral solution*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of DPN and trial/failure or intolerance to duloxetine -OR- PHN and trial/failure or intolerance to gabapentin -OR- Partial-onset seizures and trial/failure or intolerance to two AEDS -OR- Neuropathic pain associated with spinal cord injury -OR- Documentation to support a diagnosis of fibromyalgia and trial/failure or intolerance to duloxetine. When using pregabalin products concomitantly with an opiate agonist, attestation of an intent to monitor and address concomitant drug-drug interaction adverse events for opiate potentiators. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Lytgobi

Products Affected

- **LYTGOBI ORAL TABLET 12 MG/DAY (4 MG X 3), 16 MG/DAY (4 MG X 4), 20 MG/DAY (4 MG X 5)**

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis -AND- all of the following (1-2): 1) disease harbors FGFR2 fusions or other rearrangements 2) member has experienced therapeutic failure or intolerance to at least one prior therapy. |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Mavenclad

Products Affected

- MAVENCLAD (10 TABLET PACK)
- MAVENCLAD (4 TABLET PACK)
- MAVENCLAD (5 TABLET PACK)
- MAVENCLAD (6 TABLET PACK)
- MAVENCLAD (7 TABLET PACK)
- MAVENCLAD (8 TABLET PACK)
- MAVENCLAD (9 TABLET PACK)

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Concomitant use of Mavenclad and other disease modifying agents such as interferons, Copaxone, Tysabri. Treatment duration greater than 24 months. |
| Required Medical Information | Documentation of diagnosis of relapse-remitting multiples sclerosis or active secondary progressive disease -AND- therapeutic failure or intolerance to one other disease modifying therapy (e.g. Avonex, Gilenya, Copaxone) |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 24 months |
| Other Criteria | Coverage beyond 24 months will not be approved. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Mavyret

Products Affected

- MAVYRET ORAL PELLETS IN PACKET
- MAVYRET ORAL TABLET

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Criteria will be applied consistent with current AASLD/IDSA guidance |
| Age Restrictions | Deny if less than 3 years of age |
| Prescriber Restrictions | |
| Coverage Duration | Criteria/duration applied consistent with current AASLD-IDSA guidance |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Megace

Products Affected

- *megestrol oral suspension 400 mg/10 ml (40 mg/ml), 625 mg/5 ml (125 mg/ml)*
- *megestrol oral tablet*

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Mekinist

Products Affected

- **MEKINIST ORAL RECON SOLN**
- **MEKINIST ORAL TABLET 0.5 MG, 2 MG**

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | For trametinib monotherapy, documentation of unresectable or metastatic melanoma -AND- meets all of the following (1-2): 1) member has a BRAF V600E or V600K mutation 2) member is BRAF inhibitor treatment naive. For use in combination with dabrafenib, documentation of unresectable or metastatic melanoma or melanoma with lymph node(s) involvement following complete resection and member is using trametinib and dabrafenib as adjuvant therapy -AND- member has a BRAF V600E or V600K mutation. For use in combination with dabrafenib, documentation of metastatic non-small cell lung cancer, locally advanced or metastatic anaplastic thyroid cancer, or low-grade glioma -AND- member has a BRAF V600E mutation. For use in combination with dabrafenib, documentation of unresectable or metastatic solid tumors -AND- all of the following (1-3): 1) BRAF V600E mutation 2) disease has progressed following prior treatment 3) member has no satisfactory alternative treatment options. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | For Mekinist powder for oral solution, attestation of inability to swallow Mekinist (trametinib) tablets is required. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Mektovi

Products Affected

- MEKTOVI

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis. For unresectable or metastatic melanoma, all of the following (1-2): 1) BRAF V600E or V600K mutation status 2) using in combination with encorafenib. For metastatic non-small cell lung cancer, all of the following (1-2): 1) BRAF V600E mutation status 2) using in combination with encorafenib. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Metyrosine

Products Affected

- *metyrosine*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of pheochromocytoma defined by 1 of the following (1 or 2): 1) Elevated metanephrines in plasma or urine, or 2) Tumor evidence from CT scan or MRI -AND- Documentation of 1 of the following (3., 4., or 5.): 3) Planned resection surgery, 4) Resection surgery is contraindicated, or 5) malignant pheochromocytoma. -AND- therapeutic failure, contraindication, or intolerance to a selective alpha-blocker (e.g., doxazosin, prazosin, terazosin). |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Mulpleta

Products Affected

- MULPLETA

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of thrombocytopenia and chronic liver disease - AND- beneficiary is scheduled to undergo a procedure -AND- trial and failure or intolerance to Doptelet |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 1 month |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Myasthenia Gravis

Products Affected

- **ZILBRYSQ SUBCUTANEOUS
SYRINGE 16.6 MG/0.416 ML, 23
MG/0.574 ML, 32.4 MG/0.81 ML**

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of generalized myasthenia gravis (gMG) -AND- Anti-acetylcholine receptor (AChR) antibody-positive -AND- Therapeutic failure, contraindication, or intolerance to generic pyridostigmine. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 6 months initial authorization, 12 months reauthorization |
| Other Criteria | For reauthorization, attestation of gMG signs/symptoms improvement (e.g., speech, swallowing, mobility, and/or respiratory function) -OR- decreased gMG exacerbations. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Namzarin

Products Affected

- NAMZARIC

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis and trial/failure of generic memantine and generic donepezil |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Nayzilam

Products Affected

- NAYZILAM

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of seizure clusters or acute repetitive seizures -AND- the member is currently receiving antiepileptic maintenance therapy. |
| Age Restrictions | Deny if less than 12 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Nerlynx

Products Affected

- **NERLYNX**

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of early-stage, HER2-positive breast cancer -AND- meets all of the following: 1) member has received adjuvant trastuzumab-based therapy 2) member is using neratinib as a single agent. Documentation of advanced HER-2 positive, or metastatic HER2-positive breast cancer and meets all of the following 1) using neratinib in combination with capecitabine 2) member has received two or more prior anti-HER2 based regimens in the metastatic setting. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Nexavar

Products Affected

- *sorafenib*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis. For locally recurrent or metastatic, progressive, differentiated thyroid carcinoma, refractory to radioactive iodine treatment |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Nexletol

Products Affected

- NEXLETOL
- NEXLIZET

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | <p>1.HeFH supported by presence of causal mutation of FH by genetic testing OR untreated LDL-C greater than or equal to 190 mg/dL or untreated LDL-C greater than or equal to 160 mg/dL before 20 years of age with physical signs of FH (e.g. xanthomas, xanthelasma) OR diagnosis based on WHO criteria/Dutch Lipid Clinical Network criteria with score greater than 8 points, or definite Simon Broome register criteria, or definite on the Make Early Diagnosis to Prevent Early Deaths tool AND LDL-C greater than 100 mg/dL despite use of maximally tolerated statin or statin intolerance AND therapeutic failure, intolerance or contraindication to ezetimibe AND must be used with maximally tolerated statin dose or documentation of statin intolerance.</p> <p>2.Hypercholesterolemia ASCVD AND LDL-C greater than 70 mg/dL despite use of maximally tolerated statin or statin intolerance AND therapeutic failure, intolerance or contraindication to ezetimibe AND must be used with maximally tolerated statin dose or documentation of statin intolerance.</p> |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 6 months initial authorization, 12 months reauthorization |

| PA Criteria | Criteria Details |
|----------------------------|--|
| Other Criteria | For reauthorization, documentation showing an LDL-C reduction from baseline AND attestation of continued use of Nexletol or Nexlizet with a maximally tolerated statin, unless statin intolerant. Statin intolerance defined as follows: statin related rhabdomyolysis or skeletal muscle symptoms while receiving at least 2 separate trials of different statin which resolved upon discontinuation of statin or documentation of one of the following during any course of statin therapy: 1. CK increase to 10x upper limit of normal 2. LFTs increase to 3x upper limit of normal 3. Hospitalization due to severe statin-related AEs such as rhabdomyolysis. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Ninlaro

Products Affected

- NINLARO

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of multiple myeloma -AND- previous treatment with at least 1 prior therapy -AND- used in combination with lenalidomide and dexamethasone |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Nitisinone

Products Affected

- *nitisinone*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of hereditary tyrosinemia type 1 (HT-1) confirmed by biochemical or genetic testing -AND- dietary restriction of tyrosine and phenylalanine. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Northera

Products Affected

- *droxidopa oral capsule 100 mg, 200 mg, 300 mg*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of neurogenic orthostatic hypotension caused by primary autonomic failure (e.g., Parkinson's disease, multiple system atrophy, or pure autonomic failure), dopamine beta-hydroxylase deficiency or non-diabetic autonomic neuropathy -AND- Documentation of inadequate response, intolerance or contraindication to preferred generic alternative midodrine. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 3 months |
| Other Criteria | For reauthorization, attestation of increase from baseline of systolic or diastolic blood pressure upon standing -OR- attestation of decrease from baseline of neurogenic orthostatic hypotension symptoms upon standing (e.g., dizziness, feeling faint, etc.). |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Nubeqa

Products Affected

- NUBEQA

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of non-metastatic castration-resistant prostate cancer -AND- one of the following (1-2): 1) using in combination with a GnRH analog 2) member has had a bilateral orchiectomy. Documentation of metastatic hormone-sensitive prostate cancer -AND- will be using in combination with docetaxel -AND- one of the following (1-2): 1) using in combination with a GnRH analog 2) member has had a bilateral orchiectomy. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Nucala

Products Affected

- **NUCALA SUBCUTANEOUS AUTO-INJECTOR**
- **NUCALA SUBCUTANEOUS RECON SOLN**
- **NUCALA SUBCUTANEOUS SYRINGE 100 MG/ML, 40 MG/0.4 ML**

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------|
| Exclusion Criteria | Pending CMS Review |
| Required Medical Information | Pending CMS Review |
| Age Restrictions | Pending CMS Review |
| Prescriber Restrictions | Pending CMS Review |
| Coverage Duration | Pending CMS Review |
| Other Criteria | Pending CMS Review |
| Indications | Pending CMS Review |
| Off Label Uses | Pending CMS Review |
| Part B Prerequisite | No |

Nuedexta

Products Affected

- NUEDEXTA

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | For reauthorization, attestation supporting improvement in symptoms is required. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Nuplazid

Products Affected

- NUPLAZID

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of hallucinations and delusions associated with Parkinson's disease psychosis |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Nurtec

Products Affected

- NURTEC ODT

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis. For Episodic Migraine Prevention, defined as 4-14 migraine days per month, the following criteria will apply (1-3). 1) Documentation of average monthly migraine days. 2) Attestation that headaches are not caused by medication rebound or overutilization (e.g. not taking triptans exceeding more than 18 doses per month) or lifestyle factors (e.g. sleep patterns, caffeine use). 3) Trial and failure or intolerance to one agent from 2 unique prophylactic migraine medication classes: e.g. Anti-epileptic drugs (e.g. topiramate), beta-blockers (e.g. propranolol), calcium-channel blockers (e.g. verapamil), tricyclic antidepressants (e.g. amitriptyline) -OR- contraindication to all prophylactic medication classes. For acute treatment of migraine with or without aura, trial and failure of one generic triptan. |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 6 months initial authorization, 12 months reauthorization |
| Other Criteria | For reauthorization of episodic migraine prevention, attestation of reduction in migraine frequency. For reauthorization of acute treatment of migraine, attestation of reduction in migraine symptoms. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Nuvigil

Products Affected

- *armodafinil*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | <p>Diagnosis of shift work sleep disorder (SWSD) substantiated by excessive sleepiness or insomnia that is temporarily associated with a recurring work schedule that overlaps the usual time for sleep -AND- Symptoms are accompanied by a reduction of total sleep time -AND- Symptoms experienced for at least 3 months -AND- Sleep log or actigraphy monitoring for at least 14 days including both work and free days -AND- Sleep disturbance is not better explained by another current sleep disorder, medical or neurological disorder, mental disorder, medication use, or substance use disorder. Diagnosis of narcolepsy -AND- Documentation of baseline data of excessive daytime sleepiness (EDS) via the Epworth Sleepiness Scale (ESS) or Maintenance of Wakefulness Test (MWT) -AND- Documentation of the following (1, 2, or 3): 1) Hypocretin-1 deficiency defined by (A or B), A) Cerebrospinal fluid hypocretin-1 less than 110 pg/mL. B) Cerebrospinal fluid hypocretin-1 less than 1/3 of the normal value based on laboratory reference range -OR- 2) Multiple sleep latency test (MSLT) documenting MSL less than or equal to 8 minutes and 2 sleep-onset rapid eye movement periods (SOREMP) -OR- 3) MSLT documenting MSL less than or equal to 8 minutes and 1 SOREMP and Polysomnography substantiating 1 SOREMP. Diagnosis of obstructive sleep apnea/hypopnea syndrome (OSAHS) documented by objective polysomnography as established in accordance with ICSD or DSM V criteria acceptable for all indications</p> |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | For reauthorization, provider attestation of improvement in daytime sleepiness is required. |

| PA Criteria | Criteria Details |
|----------------------------|-------------------------------|
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Ocaliva

Products Affected

- OCALIVA

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | Compensated cirrhosis with evidence of portal hypertension |
| Required Medical Information | Documentation of primary biliary cholangitis -AND- trial and failure, contraindication, or intolerance to ursodiol monotherapy -AND- will use concomitantly with ursodiol unless contraindicated or intolerant. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Octreotide

Products Affected

- *octreotide acetate injection solution*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis. For acromegaly, high pretreatment insulin-like growth factor-1 (IGF-1) based on laboratory reference range -AND- therapeutic failure or cannot be treated with surgical resection, pituitary irradiation or bromocriptine mesylate. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | For reauthorization of acromegaly, decreased or normalized IGF-1 from baseline |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Odomzo

Products Affected

- ODOMZO

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of locally advanced basal cell carcinoma (laBCC) that has recurred following surgery or radiation therapy or for use in patients who are not candidates for surgery or radiation therapy |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Ogsiveo

Products Affected

- **OGSIVEO ORAL TABLET 100 MG, 150 MG, 50 MG**

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of progressing desmoid tumor(s) requiring systemic therapy. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Ojemda

Products Affected

- **OJEMDA ORAL SUSPENSION FOR RECONSTITUTION**
- **OJEMDA ORAL TABLET 500 MG/WEEK (100 MG X 5)**

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of relapsed or refractory pediatric low-grade glioma - AND- one of the following (1-2): 1) BRAF fusion or rearrangement, or 2) BRAF V600K mutation. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Ojjaara

Products Affected

- OJJAARA

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of intermediate or high-risk myelofibrosis -AND- attestation of anemia. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Olumiant

Products Affected

- OLUMIANT

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Part A covered for Covid-19 in hospitalized patients |
| Required Medical Information | Documentation of diagnosis. For moderate to severely active rheumatoid arthritis an inadequate response or intolerance to at least one non-biologic DMARD (e.g., methotrexate, leflunomide). For severe alopecia areata, inadequate response or intolerance to an intralesional corticosteroid or high potency topical corticosteroid, or contraindication to all. |
| Age Restrictions | Deny if less than 18 years of age for Rheumatoid Arthritis and Alopecia Areata |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | For rheumatoid arthritis, patients must have therapeutic failure or intolerance to 2 of the following preferred products: a preferred adalimumab product, Enbrel, Actemra SC, Rinvoq and Xeljanz/Xeljanz XR, with at least 1 being a tumor necrosis factor blocker. Please Note: preferred adalimumab products include Humira with NDC starting with 00074, Cyltezo with NDC starting 00597 and Yuflyma with NDC starting 72606. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Onfi

Products Affected

- *clobazam oral suspension*
- *clobazam oral tablet*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of seizures due to Lennox-Gastaut Syndrome -AND- documentation of adjunctive therapy -AND- therapeutic failure or intolerance of a previous antiepileptic therapy |
| Age Restrictions | Deny if less than 2 years old |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Onureg

Products Affected

- ONUREG

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of acute myeloid leukemia that has achieved first complete remission or complete remission with incomplete blood count recovery following intensive induction chemotherapy -AND- Inability to complete intensive curative therapy |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Orencia

Products Affected

- **ORENCIA CLICKJECT**
- **ORENCIA SUBCUTANEOUS SYRINGE**
125 MG/ML, 50 MG/0.4 ML, 87.5 MG/0.7 ML

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis. For moderate to severe rheumatoid arthritis, inadequate response or intolerance to at least one DMARD (e.g. methotrexate, leflunomide). For juvenile idiopathic rheumatoid arthritis, inadequate response or intolerance to at least one DMARD (e.g., methotrexate, leflunomide) -OR- requires initial biologic therapy due to involvement of high-risk joints, high disease activity or at high risk of disabling joint damage. |
| Age Restrictions | Deny if less than 18 years of age for Rheumatoid Arthritis or less than 2 years of age for Juvenile Idiopathic Arthritis and Psoriatic Arthritis |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | For rheumatoid arthritis, patients must have therapeutic failure or intolerance to 2 of the following preferred products: a preferred adalimumab product, Enbrel, Actemra SC, Rinvoq and Xeljanz/Xeljanz XR. For psoriatic arthritis, patients over 18 years of age must have therapeutic failure or intolerance to 2 of the following preferred products: a preferred adalimumab product, Enbrel, Cosentyx, Xeljanz/Xeljanz XR, Otezla and Stelara SC, Rinvoq, and Skyrizi SC. For juvenile idiopathic arthritis, patients must have therapeutic failure or intolerance to 2 of the following preferred products: a preferred adalimumab product, Enbrel, Xeljanz/Xeljanz solution and Actemra SC. Please Note: preferred adalimumab products include Humira with NDC starting with 00074, Cyltezo with NDC starting 00597 and Yuflyma with NDC starting 72606. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

| PA Criteria | Criteria Details |
|--------------------------------|-------------------------|
| Part B Prerequisite | No |

Orgovyx

Products Affected

- ORGOVYX

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of advanced prostate cancer |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | For induction therapy dosing, doses above plan quantity limit will be approved aligned with recommended induction therapy dosing regimens per indication. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Orkambi

Products Affected

- **ORKAMBI ORAL GRANULES IN PACKET**
- **ORKAMBI ORAL TABLET**

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of cystic fibrosis and homozygous F508del mutation |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 6 months initial authorization, 12 months reauthorization |
| Other Criteria | For reauthorization, documentation supporting improvement or stabilization of FEV1 compared to baseline FEV1 -or- increase in body mass index -or- decreased pulmonary exacerbations -or- improved quality of life as demonstrated by CF Questionnaire is required. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Orserdu

Products Affected

- **ORSERDU ORAL TABLET 345 MG, 86 MG**

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis -AND- all of the following (1-4): 1) member is male or a postmenopausal female 2) tumor status is ER-positive, HER2-negative 3) an ESR1 gene mutation is present in the tumor 4) member has experienced disease progression on or after an endocrine based regimen. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

OTEZLA

Products Affected

- OTEZLA ORAL TABLET 30 MG
- OTEZLA STARTER ORAL TABLETS,DOSE PACK 10 MG (4)-20 MG (4)-30 MG (47)

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis. For plaque psoriasis, all of the following (1-2): 1) if the member is greater than or equal to 6 years of age and less than 18 years, weight is greater than or equal to 20 kg and member has moderate-to-severe disease -AND- 2) inadequate response or intolerance to one systemic therapy (e.g. methotrexate) -OR- inadequate response to phototherapy -OR- contraindication to phototherapy and systemic therapy. For oral ulcers associated with Behcet's Disease, inadequate response or intolerance to one systemic therapy for prevention of recurrent oral ulcers |
| Age Restrictions | Deny if less than 6 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Panretin

Products Affected

- PANRETIN

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of cutaneous lesions in patients with AIDS-related Kaposi Sarcoma (KS) who are not receiving systemic therapy for KS. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Pemazyre

Products Affected

- PEMAZYRE

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of unresectable locally advanced cholangiocarcinoma or metastatic cholangiocarcinoma -AND- all of the following (1-2): 1) disease harbors FGFR2 fusion or other rearrangement as detected by an FDA-approved test 2) member has experienced therapeutic failure or intolerance to at least on prior therapy. Documentation of relapsed or refractory myeloid/lymphoid neoplasms -AND- disease harbors an FGFR1 rearrangement. |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Pheburane

Products Affected

- PHEBURANE

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis -AND- therapeutic failure or intolerance to generic sodium phenylbutyrate |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Piqray

Products Affected

- **PIQRAY ORAL TABLET 200 MG/DAY (200 MG X 1), 250 MG/DAY (200 MG X1-50 MG X1), 300 MG/DAY (150 MG X 2)**

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis -AND- all of the following: 1) HR-positive, HER2-negative tumor status, 2) PIK3CA mutation positive as detected by an FDA-approved test, 3) disease progression on or after an endocrine-based regimen, 4) Concomitant therapy with fulvestrant |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Pomalyst

Products Affected

- POMALYST

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of multiple myeloma, and combination use with dexamethasone, and previous trial of at least 2 therapies including lenalidomide and a proteasome inhibitor, and disease progression on or within 60 days of completion of the last therapy -OR- Documentation of AIDS-related Kaposi sarcoma (KS) after failure of highly active antiretroviral therapy (HAART) or in patients with KS who are HIV negative |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Posaconazole Tablet

Products Affected

- *posaconazole oral tablet, delayed release (dr/ec)*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis. For aspergillus or candida infection prophylaxis, high risk of developing invasive Aspergillosis or Candidiasis infection due to being severely immunocompromised (e.g., hematopoietic stem cell transplant recipients with graft versus host disease, those with hematologic malignancies with prolonged neutropenia from chemotherapy) -AND- weight greater than 40 kg. For invasive aspergillosis infection, trial/failure or contraindication to voriconazole. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Prenatal Vitamins

Products Affected

- **PRENATAL VITAMIN PLUS LOW IRON**

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of nutritional supplementation required in a female of child-bearing potential during pre-conception, pregnancy, or lactation |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Prescription Drug Combo

Products Affected

- acetaminophen-codeine oral solution 120-12 mg/5 ml
- acetaminophen-codeine oral tablet
- alprazolam oral tablet 0.25 mg, 0.5 mg, 1 mg, 2 mg
- buprenorphine
- clonazepam oral tablet 0.5 mg, 1 mg, 2 mg
- clonazepam oral tablet, disintegrating 0.125 mg, 0.25 mg, 0.5 mg, 1 mg, 2 mg
- clorazepate dipotassium oral tablet 15 mg, 3.75 mg, 7.5 mg
- **DIAZEPAM INTENSOL**
- diazepam oral solution 5 mg/5 ml (1 mg/ml)
- diazepam oral tablet
- **ENDOCET**
- fentanyl transdermal patch 72 hour 100 mcg/hr, 12 mcg/hr, 25 mcg/hr, 50 mcg/hr, 75 mcg/hr
- hydrocodone-acetaminophen oral tablet 10-325 mg, 5-325 mg, 7.5-325 mg
- hydromorphone oral liquid
- hydromorphone oral tablet 2 mg, 4 mg, 8 mg
- **LORAZEPAM INTENSOL**
- lorazepam oral tablet 0.5 mg, 1 mg, 2 mg
- methadone oral solution 10 mg/5 ml, 5 mg/5 ml
- methadone oral tablet 10 mg, 5 mg
- morphine concentrate oral solution
- morphine oral solution 10 mg/5 ml, 20 mg/5 ml (4 mg/ml)
- morphine oral tablet
- morphine oral tablet extended release 100 mg, 15 mg, 200 mg, 30 mg, 60 mg
- oxycodone oral capsule
- oxycodone oral concentrate
- oxycodone oral tablet 10 mg, 15 mg, 20 mg, 30 mg, 5 mg
- oxycodone-acetaminophen oral tablet 10-325 mg, 2.5-325 mg, 5-325 mg, 7.5-325 mg
- tramadol oral tablet 50 mg
- tramadol-acetaminophen
- zaleplon oral capsule 10 mg, 5 mg
- zolpidem oral tablet

| PA Criteria | Criteria Details |
|------------------------------|--------------------|
| Exclusion Criteria | Pending CMS Review |
| Required Medical Information | Pending CMS Review |
| Age Restrictions | Pending CMS Review |
| Prescriber Restrictions | Pending CMS Review |
| Coverage Duration | Pending CMS Review |
| Other Criteria | Pending CMS Review |
| Indications | Pending CMS Review |

| PA Criteria | Criteria Details |
|----------------------------|-------------------------|
| Off Label Uses | Pending CMS Review |
| Part B Prerequisite | No |

Prolia

Products Affected

- PROLIA

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis -And- For osteoporosis at high risk for fracture, meeting one of the following (1. thru 4.) 1) History of previous hip or vertebral fracture. 2) T-score less than or equal to -2.5. 3) T-score between -1.0 and -2.5 (i.e. osteopenia) -AND- meets FRAX calculation (A. or B.) A) 10-year risk of major osteoporotic fracture is greater than or equal to 20 percent or B) 10-year risk of hip fracture is greater than or equal to 3 percent. 4) Age 40 years or older with T-score between -1.0 and -2.5 -AND- History of glucocorticoid use for at least 3 months at a dose of 5mg per day or more of prednisone (or equivalent). |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | For osteoporosis and osteopenia, documentation of trial/failure or intolerance to at least one oral bisphosphonate or all are contraindicated. Covered under Part B for patients eligible for home health services when provider certifies that patient sustained bone fracture related to post-menopausal osteoporosis and is unable to learn the skills needed to self-administer the drug or is otherwise physically or mentally incapable of administering the drug or family/caregivers are unable or unwilling to administer the drug. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Provigil

Products Affected

- *modafinil*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | <p>Diagnosis of shift work sleep disorder (SWSD) substantiated by excessive sleepiness or insomnia that is temporarily associated with a recurring work schedule that overlaps the usual time for sleep -AND- Symptoms are accompanied by a reduction of total sleep time -AND- Symptoms experienced for at least 3 months -AND- Sleep log or actigraphy monitoring for at least 14 days including both work and free days -AND- Sleep disturbance is not better explained by another current sleep disorder, medical or neurological disorder, mental disorder, medication use, or substance use disorder. Diagnosis of narcolepsy -AND- Documentation of baseline data of excessive daytime sleepiness (EDS) via the Epworth Sleepiness Scale (ESS) or Maintenance of Wakefulness Test (MWT) -AND- Documentation of the following (1, 2, or 3): 1) Hypocretin-1 deficiency defined by (A or B), A) Cerebrospinal fluid hypocretin-1 less than 110 pg/mL. B) Cerebrospinal fluid hypocretin-1 less than 1/3 of the normal value based on laboratory reference range -OR- 2) Multiple sleep latency test (MSLT) documenting MSL less than or equal to 8 minutes and 2 sleep-onset rapid eye movement periods (SOREMP) -OR- 3) MSLT documenting MSL less than or equal to 8 minutes and 1 SOREMP and Polysomnography substantiating 1 SOREMP. Diagnosis of obstructive sleep apnea/hypopnea syndrome (OSAHS) documented by objective polysomnography as established in accordance with ICSD or DSM V criteria acceptable for all indications. Diagnosis of fatigue associated with Multiple Sclerosis (MS)</p> |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |

| | |
|----------------------------|---|
| PA Criteria | Criteria Details |
| Other Criteria | For reauthorization, provider attestation of improvement in daytime sleepiness is required. |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off Label Uses | Fatigue associated with Multiple Sclerosis (MS) |
| Part B Prerequisite | No |

Pulmonary Arterial Hypertension

Products Affected

- **ADEMPAS**
- **ALYQ**
- *ambrisentan*
- **OPSUMIT**
- **ORENITRAM ORAL TABLET EXTENDED RELEASE 0.125 MG, 0.25 MG, 1 MG, 2.5 MG, 5 MG**
- *sildenafil (pulm.hypertension) oral suspension for reconstitution*
- *sildenafil (pulm.hypertension) oral tablet*
- *tadalafil (pulm. hypertension)*
- **UPTRAVI ORAL TABLET 1,000 MCG, 1,200 MCG, 1,400 MCG, 1,600 MCG, 200 MCG, 400 MCG, 600 MCG, 800 MCG**
- **UPTRAVI ORAL TABLETS,DOSE PACK**

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------|
| Exclusion Criteria | Pending CMS Review |
| Required Medical Information | Pending CMS Review |
| Age Restrictions | Pending CMS Review |
| Prescriber Restrictions | Pending CMS Review |
| Coverage Duration | Pending CMS Review |
| Other Criteria | Pending CMS Review |
| Indications | Pending CMS Review |
| Off Label Uses | Pending CMS Review |
| Part B Prerequisite | No |

Pulmozyme

Products Affected

- PULMOZYME

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Diagnosis of cystic fibrosis -AND- Used in conjunction with standard therapies for management of cystic fibrosis to improve pulmonary function. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | Inhalation solutions covered under Part B when administered in the home setting using a covered nebulizer (i.e. DME). For reauthorization, attestation of increase in FEV1 or decrease in number of hospitalizations or pulmonary exacerbations. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Qinlock

Products Affected

- QINLOCK

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of advanced gastrointestinal stromal tumor -AND- Prior treatment with imatinib and 2 other kinase inhibitors. |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Quinine

Products Affected

- *quinine sulfate*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Treatment or prevention of leg cramps |
| Required Medical Information | Documentation of diagnosis |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 10 days |
| Other Criteria | Doses for duration greater than 10 days will not be approved |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Qulipta

Products Affected

- QULIPTA

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis of Episodic Migraine, defined as 4-14 migraine days per month OR Chronic Migraine, defined as 15 or more headaches per month, of which 8 or more are migraine days. The following criteria will apply (1-3). 1) Documentation of average monthly migraine days. 2) Attestation that headaches are not caused by medication rebound (e.g. not taking triptans exceeding more than 18 doses per month) or lifestyle factors (e.g. sleep patterns, caffeine use). 3) Trial and failure or intolerance to one agent from 2 unique prophylactic migraine medication classes: e.g. Anti-epileptic drugs (e.g. topiramate), beta-blockers (e.g. propranolol), calcium-channel blockers (e.g. verapamil), tricyclic antidepressants (e.g. amitriptyline) -OR- contraindication to all prophylactic medication classes. |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 6 months initial authorization, 12 months reauthorization |
| Other Criteria | For reauthorization, attestation of reduction in migraine frequency |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Ravicti

Products Affected

- **RAVICTI**

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | Urea cycle disorders due to N-acetylglutamate synthetase deficiency, Treatment of acute hyperammonemia in urea cycle disorders |
| Required Medical Information | Documentation of chronic management of a urea cycle disorders (UCDs) |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Regranex

Products Affected

- **REGRANEX**

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of lower-extremity diabetic neuropathic ulcer(s) that extends into the subcutaneous tissue or beyond and have an adequate blood supply -AND- being used as an adjunct to standard ulcer care practices (e.g. sharp debridement, non-weight bearing regimen, infection control) -AND- attestation of a wound care plan. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 20 weeks |
| Other Criteria | For reauthorization, one of the following (1-2): 1) documentation of decrease in ulcer(s) size without complete ulcer(s) closure -OR- 2) documentation of new lower extremity diabetic neuropathic ulcer(s) that extends into the subcutaneous tissue or beyond with an adequate blood supply, attestation of being used as an adjunct to standard ulcer care practices, and attestation of a wound care plan. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Repatha

Products Affected

- **REPATHA PUSHTRONEX**
- **REPATHA SURECLICK**
- **REPATHA SYRINGE**

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------|
| Exclusion Criteria | Pending CMS Review |
| Required Medical Information | Pending CMS Review |
| Age Restrictions | Pending CMS Review |
| Prescriber Restrictions | Pending CMS Review |
| Coverage Duration | Pending CMS Review |
| Other Criteria | Pending CMS Review |
| Indications | Pending CMS Review |
| Off Label Uses | Pending CMS Review |
| Part B Prerequisite | No |

Retevmo

Products Affected

- **RETEVMO ORAL CAPSULE 40 MG, 80 MG**

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------|
| Exclusion Criteria | Pending CMS Review |
| Required Medical Information | Pending CMS Review |
| Age Restrictions | Pending CMS Review |
| Prescriber Restrictions | Pending CMS Review |
| Coverage Duration | Pending CMS Review |
| Other Criteria | Pending CMS Review |
| Indications | Pending CMS Review |
| Off Label Uses | Pending CMS Review |
| Part B Prerequisite | No |

Revlimid

Products Affected

- *lenalidomide*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | Documentation of chronic lymphocytic leukemia outside of a controlled clinical trial |
| Required Medical Information | Diagnosis of multiple myeloma in combination with dexamethasone -OR- diagnosis of multiple myeloma, as maintenance following autologous hematopoietic stem cell transplant (auto-HSCT) -OR- diagnosis of transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q abnormality with or without additional cytogenetic abnormalities -OR- diagnosis of mantle cell lymphoma (MCL) in which disease has relapsed or progressed after two prior therapies, one of which included bortezomib -OR- diagnosis of follicular lymphoma in combination with a rituximab product -OR- diagnosis of marginal zone lymphoma in combination with a rituximab product after previous treatment. |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Rexulti

Products Affected

- REXULTI ORAL TABLET

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis. For major depressive disorder, documentation of adjunctive therapy and therapeutic failure, contraindication or intolerance to one other generic antidepressant in addition to the antidepressant currently being used for the treatment of MDD (e.g. SSRI, SNRI, NDRIs, TCA, MAOI). For schizophrenia, therapeutic failure, intolerance, or contraindication to one other generic atypical antipsychotic (e.g. quetiapine). |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Rezdiffra

Products Affected

- REZDIFFRA

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis of noncirrhotic nonalcoholic steatohepatitis (NASH) with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis) in conjunction with diet and exercise. Diagnosis of NASH confirmed by a liver biopsy or non-invasive tests (NITs) performed within the previous 6 months indicating F2 or F3 fibrosis - AND- member does not have any evidence of cirrhosis, hepatic decompensation, or hepatocellular carcinoma. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | For reauthorization, attestation of continued use in conjunction with diet and exercise -AND- member has experienced stabilization of fibrosis as demonstrated by NIT. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Rezlidhia

Products Affected

- **REZLIDHIA**

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA approved test |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Rinvoq

Products Affected

- **RINVOQ ORAL TABLET EXTENDED
RELEASE 24 HR 15 MG, 30 MG, 45 MG**

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------|
| Exclusion Criteria | Pending CMS Review |
| Required Medical Information | Pending CMS Review |
| Age Restrictions | Pending CMS Review |
| Prescriber Restrictions | Pending CMS Review |
| Coverage Duration | Pending CMS Review |
| Other Criteria | Pending CMS Review |
| Indications | Pending CMS Review |
| Off Label Uses | Pending CMS Review |
| Part B Prerequisite | No |

Rivfloza

Products Affected

- **RIVFLOZA SUBCUTANEOUS SOLUTION**
- **RIVFLOZA SUBCUTANEOUS SYRINGE 128 MG/0.8 ML, 160 MG/ML**

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of all of the following (1-3): 1) genetically confirmed diagnosis of primary hyperoxaluria type 1 (PH1), 2) relatively preserved kidney function (e.g., eGFR greater than or equal to 30 mL/min/1.73 m ²), and 3) at least two elevated urinary oxalate levels greater than 1.5 times the upper reference limit. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 6 months initial authorization, 12 months reauthorization |
| Other Criteria | For reauthorization, continued preserved kidney function (e.g., eGFR greater than or equal to 30 mL/min/1.73 m ²) -AND- reduction in urinary oxalate levels from baseline. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Rozlytrek

Products Affected

- **ROZLYTREK ORAL CAPSULE 100 MG, 200 MG**
- **ROZLYTREK ORAL PELLETS IN PACKET**

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis. For metastatic non-small cell lung cancer, the tumor status is ROS1-positive. For solid tumors with NTRK gene fusion without a known acquired resistance mutation, the tumors are metastatic or surgical resection is likely to result in severe morbidity - AND- There are no satisfactory alternative treatments or the tumors have progressed following treatment. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Rubraca

Products Affected

- RUBRACA

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis. For recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, all of the following (1-2): 1) Disease harbors a deleterious BRCA mutation (germline or somatic) 2) member is in complete or partial response to platinum-based chemotherapy. For metastatic castration-resistant prostate cancer, all of the following (1-3): 1) disease harbors a deleterious BRCA mutation (germline and/or somatic) 2) member has been treated with androgen receptor-directed therapy and taxane-based chemotherapy 3) member is concurrently receiving a gonadotropin-releasing hormone (GnRH) analog or member has had a bilateral orchiectomy. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Rydapt

Products Affected

- RYDAPT

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Use as single agent induction therapy for AML |
| Required Medical Information | Documentation of diagnosis. For a new diagnosis of acute myeloid leukemia, member is using in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation chemotherapy regimens and member is FLT3 mutation positive as detected by an FDA-approved test. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Sabril

Products Affected

- *vigabatrin*
- **VIGADRONE**
- **VIGPODER**

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of refractory complex partial seizures -AND- documentation of adjunctive therapy -AND- therapeutic failure or intolerance to at least two alternative treatments (e.g. carbamazepine, lamotrigine, levetiracetam, oxcarbazepine, tiagabine) -OR- documentation of use as monotherapy in treatment of infantile spasms |
| Age Restrictions | Deny if less than 2 years of age in treatment of refractory complex partial seizures -OR- if less than 1 month old and greater than 2 years of age in treatment of infantile spasms |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Samsca

Products Affected

- *tolvaptan*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of symptomatic hypervolemic or euvolemic hyponatremia evidenced by (1. or 2.): 1.) Serum Na less than 125 mEq/L -OR- 2.) Serum NA less than 135mEq/L with symptoms (e.g. nausea, malaise, lethargy, headache, seizures) |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 1 month |
| Other Criteria | Doses must be initiated in the hospital setting to closely monitor serum sodium. Treatment should be limited to 30 days to minimize risk of liver injury. For reauthorization, treatment is for a new episode of a clinically significant euvolemic or hypervolemic hyponatremia -AND- on of the following (1. or 2.) 1.) Serum Na less than 125 mEq/L -OR- 2.) Serum NA less than 135mEq/L with symptoms (e.g. nausea, malaise, lethargy, headache, seizures) |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Saphris

Products Affected

- *asenapine maleate*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis - AND - trial and failure of one of the following: olanzapine, quetiapine, or risperidone. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Scemblix

Products Affected

- **SCSEMBLIX ORAL TABLET 100 MG, 20 MG, 40 MG**

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis -AND- one of the following (1-2): 1) member has experienced therapeutic intolerance or failure to at least 2 prior kinase inhibitors 2) disease is positive for the T3151 mutation. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Secuado

Products Affected

- **SECUADO**

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis -AND- trial and failure of generic asenapine sublingual tablets -AND- trial/failure or intolerance to 1 of the following or all are contraindicated (1-3): 1) olanzapine, 2) quetiapine, 3) risperidone. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Siliq

Products Affected

- SILIQ

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis. For moderate to severe plaque psoriasis, inadequate response or intolerance to one systemic therapy (e.g. methotrexate) -OR- inadequate response to phototherapy -OR- contraindication to phototherapy and systemic therapy. |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | For psoriasis, patients must have therapeutic failure or intolerance to 2 preferred products: a preferred adalimumab product, Cosentyx, Otezla, Stelara SC, Enbrel, and Skyrizi SC. Please Note: preferred adalimumab products include Humira with NDC starting with 00074, Cyltezo with NDC starting 00597 and Yuflyma with NDC starting 72606. For psoriasis induction therapy, doses above plan quantity limit will be approved aligned with recommended induction therapy dosing regimen. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Simponi

Products Affected

- **SIMPONI SUBCUTANEOUS PEN INJECTOR 100 MG/ML, 50 MG/0.5 ML**
- **SIMPONI SUBCUTANEOUS SYRINGE 100 MG/ML, 50 MG/0.5 ML**

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis. Simponi 50mg: For moderate to severe rheumatoid arthritis, inadequate response or intolerance to at least one DMARD (e.g. leflunomide) and Simponi will be used in combination with methotrexate. For ankylosing spondylitis, inadequate response or intolerance to one nonsteroidal anti-inflammatory drug (NSAID). Diagnosis of psoriatic arthritis Simponi 100mg: Diagnosis of moderate to severe ulcerative colitis. |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | For rheumatoid arthritis, patients must have therapeutic failure or intolerance to 2 of the following preferred products: a preferred adalimumab product, Enbrel, Actemra SC, Rinvoq and Xeljanz/Xeljanz XR. For psoriatic arthritis, patients must have therapeutic failure or intolerance to 2 of the following preferred products: a preferred adalimumab product, Enbrel, Cosentyx, Xeljanz/Xeljanz XR, Otezla, Stelara SC, Rinvoq, and Skyrizi SC. For ankylosing spondylitis, patients must have therapeutic failure or intolerance to 2 of the following preferred products: a preferred adalimumab product, Enbrel, Cosentyx, Rinvoq, and Xeljanz/Xeljanz XR. For ulcerative colitis, patients must have therapeutic failure or intolerance to the preferred products: a preferred adalimumab product, Stelara SC, Rinvoq, and Xeljanz/Xeljanz XR. Please Note: preferred adalimumab products include Humira with NDC starting with 00074, Cyltezo with NDC starting 00597 and Yuflyma with NDC starting 72606. For ulcerative colitis induction therapy, doses above plan quantity limit will be approved aligned with recommended induction therapy dosing regimen. |

| PA Criteria | Criteria Details |
|----------------------------|-------------------------------|
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Sirturo

Products Affected

- SIRTURO

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of extensively drug resistant tuberculosis, treatment-intolerant tuberculosis, or nonresponsive multidrug-resistant tuberculosis - AND- Therapeutic failure, contraindication, or intolerance to 1 of the following: isoniazid, rifampin, rifabutin, or rifapentine -AND- Used in combination with at least 3 other drugs for tuberculosis. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 24 weeks |
| Other Criteria | For reauthorization, additional therapy required due to doses of the regimen being missed for safety reasons |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Skyclarys

Products Affected

- SKYCLARYS

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of Friedreichs ataxia confirmed by genetic testing (i.e., FXN gene mutation). |
| Age Restrictions | Deny if less than 16 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Skyrizi

Products Affected

- **SKYRIZI SUBCUTANEOUS PEN INJECTOR**
- **SKYRIZI SUBCUTANEOUS SYRINGE 150 MG/ML**
- **SKYRIZI SUBCUTANEOUS WEARABLE INJECTOR 180 MG/1.2 ML (150 MG/ML), 360 MG/2.4 ML (150 MG/ML)**

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis. For moderate to severe plaque psoriasis, inadequate response or intolerance to one systemic therapy (e.g. methotrexate) -OR- inadequate response to phototherapy -OR- contraindication to phototherapy and systemic therapy. For Crohns disease, attestation of clinical response or remission following IV administration of Skyrizi within 3 months of initiating therapy with Skyrizi SC. |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | For induction therapy, doses above plan quantity limit will be approved when aligned with recommended induction therapy dosing regimen. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Sohonos

Products Affected

- **SOHONOS ORAL CAPSULE 1 MG, 1.5 MG, 10 MG, 2.5 MG, 5 MG**

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis |
| Age Restrictions | Deny if female and less than 8 years of age -OR- if male and less than 10 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | For reauthorization, attestation of reduction in volume of new heterotopic ossification from baseline. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Solaraze

Products Affected

- *diclofenac sodium topical gel 3 %*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis -AND- trial and failure, intolerance, or contraindication to one of the following (1 or 2): 1) topical fluorouracil solution or fluorouracil 5% cream 2) topical imiquimod 5% cream |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 3 months |
| Other Criteria | For reauthorization, attestation of 30 day washout period since optimal therapeutic effect may not be evident until 30 days following cessation of therapy AND attestation of previous response to diclofenac sodium 3% topical gel therapy |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Somavert

Products Affected

- SOMAVERT

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis. For acromegaly, high pretreatment insulin-like growth factor-1 (IGF-1) based on laboratory reference range -AND- inadequate or partial response to surgery or radiotherapy or not a candidate for surgery or radiotherapy |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | For reauthorization of acromegaly, decreased or normalized IGF-1 from baseline |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Sprycel

Products Affected

- SPRYCEL

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis. For adults with Ph+ chronic myeloid leukemia, the member is newly diagnosed in the chronic phase -OR- the member is in chronic, accelerated, or myeloid or lymphoid blast phase and has resistance or intolerance to prior therapy including imatinib. For adults with Ph+ acute lymphocytic leukemia, member has had resistance or intolerance to prior therapy. For pediatric patients with Ph+ CML, the member is in the chronic phase. For pediatric patients with Ph+ acute lymphoblastic leukemia, the member is newly diagnosed and will be using in combination with chemotherapy. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Stelara

Products Affected

- **STELARA SUBCUTANEOUS SOLUTION**
- **STELARA SUBCUTANEOUS SYRINGE 45 MG/0.5 ML, 90 MG/ML**

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis -AND- documentation of member weight and prescribed dose. For moderate to severe plaque psoriasis, inadequate response or intolerance to one systemic therapy (e.g. methotrexate) -OR- inadequate response to phototherapy -OR- contraindication to phototherapy and systemic therapy. For Crohn's Disease, attestation of clinical response or remission following single induction dose of IV Stelara within 2 months of initiating therapy with Stelara SC. For Ulcerative colitis, attestation of clinical response or remission following single induction dose of IV Stelara within 2 months of initiating therapy with Stelara SC |
| Age Restrictions | Deny if less than 18 years of age for Crohn's Disease and Ulcerative Colitis or less than 6 years of age for Plaque Psoriasis and Psoriatic Arthritis |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | Must follow recommended dosing guidelines based upon weight. Induction therapy, doses above plan quantity limit will be approved aligned with recommended induction therapy dosing regimen. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Steroidogenesis Inhibitors

Products Affected

- RECORLEV
- SIGNIFOR

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis -AND- patient is not a candidate for pituitary surgery or surgery has not been curative |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | For reauthorization, attestation of decrease in urinary free cortisol levels from baseline |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Stivarga

Products Affected

- STIVARGA

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of metastatic colorectal cancer and trial of a fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy, AND an anti-VEGF therapy AND if RAS wild-type, an anti-EGFR therapy -OR- documentation of locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) after treatment with both imatinib and sunitinib -OR- documentation of hepatocellular cancer AND previous treatment with sorafenib |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Sunosi

Products Affected

- SUNOSI

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | <p>Diagnosis of narcolepsy -AND- Documentation of baseline data of excessive daytime sleepiness (EDS) via the Epworth Sleepiness Scale (ESS) or Maintenance of Wakefulness Test (MWT) -AND- Documentation of the following (1, 2, or 3): 1) Hypocretin-1 deficiency defined by (A or B), A) Cerebrospinal fluid hypocretin-1 less than 110 pg/mL. B) Cerebrospinal fluid hypocretin-1 less than 1/3 of the normal value based on laboratory reference range -OR- 2) Multiple sleep latency test (MSLT) documenting MSL less than 8 minutes and 2 sleep-onset rapid eye movement periods (SOREMP) -OR- 3) MSLT documenting MSL less than 8 minutes and 1 SOREMP and Polysomnography substantiating 1 SOREMP. Diagnosis of obstructive sleep apnea/hypopnea syndrome (OSAHS) documented by objective polysomnography as established in accordance with ICSD or DSM V criteria acceptable for all indications</p> |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | <p>For narcolepsy and OSAHS, documentation of trial and failure, contraindication or intolerance to modafinil and armodafinil. For reauthorization, provider attestation of improvement in daytime sleepiness is required.</p> |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

| PA Criteria | Criteria Details |
|--------------------------------|-------------------------|
| Part B Prerequisite | No |

Sutent

Products Affected

- *sunitinib malate*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis. For gastrointestinal stromal tumor (GIST), the member has experienced therapeutic failure, intolerance, or contraindication to imatinib. For a high risk of recurrent renal cell carcinoma, member has had a nephrectomy and sunitinib is to be used as adjuvant treatment. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Symdeko

Products Affected

- SYMDEKO

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of cystic fibrosis (CF) in patients who have either the homozygous F508del mutation or another mutation in the cystic fibrosis transmembrane conductance regulator (CFTR gene) that is responsive to tezacaftor/ivacaftor based on clinical and/or in vitro assay (e.g. E56K, R117C, A455E) |
| Age Restrictions | Deny if less than 6 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 6 months initial authorization, 12 months reauthorization |
| Other Criteria | For reauthorization, documentation supporting improvement or stabilization of FEV1 compared to baseline FEV1 -or- increase in body mass index -or- decreased pulmonary exacerbations -or- improved quality of life as demonstrated by CF Questionnaire is required. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Sympazan

Products Affected

- SYMPAZAN

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of seizures due to Lennox-Gastaut Syndrome -AND- documentation of adjunctive therapy -AND- therapeutic failure or intolerance of a previous antiepileptic therapy -AND- unable to tolerate generic clobazam |
| Age Restrictions | Deny if less than 2 years old |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Synarel

Products Affected

- SYNAREL

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis. For central precocious puberty (CPP), advancement of bone age is beyond chronological age -AND- Basal luteinizing hormone (LH) level greater than 0.2-0.3IU/L or leuprolide-stimulating LH level greater than 3.3-5 IU/L. For female with endometriosis, attestation of not pregnant if of childbearing age -AND- Therapeutic failure, contraindication or intolerance to 2 of the following standard of care treatments: NSAIDs, combination hormonal contraceptive, progestin (i.e. medroxyprogesterone injection), GnRH agonist (i.e. Leuprolide) or danazol |
| Age Restrictions | Deny if greater than 8 years of age for females or greater than 9 years of age for males unless there is medical necessity for treatment of central precocious puberty. Deny if less than 18 years of age for endometriosis. |
| Prescriber Restrictions | |
| Coverage Duration | Endometriosis: 6 months, CPP: 6 months initial authorization, 12 months reauthorization |
| Other Criteria | For reauthorization for CPP, attestation of pubertal development slowing from baseline. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Tabrecta

Products Affected

- TABRECTA

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of metastatic non-small cell lung cancer with MET exon 14 skipping mutation as detected by an FDA approved test. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Tafinlar

Products Affected

- **TAFINLAR ORAL TABLET FOR SUSPENSION**

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | For dabrafenib monotherapy, documentation of unresectable or metastatic melanoma -AND- documentation of a BRAF V600E mutation. For use in combination with trametinib, documentation of unresectable or metastatic melanoma or melanoma with lymph node(s) involvement following complete resection and member is using trametinib and dabrafenib as adjuvant therapy -AND- member has a BRAF V600E or V600K mutation. For use in combination with trametinib, documentation of metastatic non-small cell lung cancer, locally advanced or metastatic anaplastic thyroid cancer, or low-grade glioma -AND- member has a BRAF V600E mutation. For use in combination with trametinib, documentation of unresectable or metastatic solid tumors -AND- all of the following (1-3): 1) BRAF V600E mutation 2) disease has progressed following prior treatment 3) member has no satisfactory alternative treatment options. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | For Tafinlar tablets for oral suspension, attestation of inability to swallow Tafinlar (dabrafenib) capsules is required. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Tagrisso

Products Affected

- TAGRISSO

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of non-small cell lung cancer (NSCLC) and one of the following (1-4): 1) Adjuvant therapy after tumor resection -AND- disease harbors EGFR exon 19 deletions or exon 21 L858R mutations, 2) Locally advanced disease -AND- disease harbors EGFR exon 19 deletions or exon 21 L858R mutations -AND- used in combination with pemetrexed and platinum-based chemotherapy, 3) Metastatic disease -AND- using as first-line therapy -AND- disease harbors EGFR exon 19 deletions or exon 21 L858R mutations -AND- used with or without combination therapy of pemetrexed and platinum-based chemotherapy, 4) Metastatic disease -AND- using as first-line therapy -AND- disease harbors EGFR T790M mutations -AND- has progressed on or after EGFR TKI therapy. |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Takhzyro

Products Affected

- **TAKHZYRO SUBCUTANEOUS SOLUTION (150 MG/ML)**
- **TAKHZYRO SUBCUTANEOUS SYRINGE 150 MG/ML, 300 MG/2 ML**

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Member should not be on two prophylactic therapies simultaneously. |
| Required Medical Information | For the prophylactic treatment of attacks of hereditary angioedema (HAE) type I & II with the following (1-3): 1) Low C4 level of less than or equal to 14mg/dL or C4 below lower limit of laboratory reference range and 1 of the following (A or B). A) C1 inhibitor (C1INH) antigen level less than or equal to 19mg/dL or below lower limit of laboratory reference range. B) Normal C1INH antigen level and a low C1INH functional level below laboratory reference range. 2) Past medical history of at least 1 symptom of moderate or severe angioedema attack (e.g. airway swelling, painful facial distortion) in absence of concomitant hives. 3) Medications known to cause angioedema have been evaluated and discontinued. For the prophylactic treatment of attacks of hereditary angioedema (HAE) type III with the following (4-7): 4) Documentation of clinical laboratory performance C4, C1INH antigen, or C1INH functional level are within normal limits of laboratory reference ranges. 5) Documentation of family history of HAE or FXII mutation 6) Past medical history of at least 1 symptom of moderate or severe angioedema attack (e.g. airway swelling, painful facial distortion) in absence of concomitant hives. 7) Medications known to cause angioedema have been evaluated and discontinued. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

| PA Criteria | Criteria Details |
|--------------------------------|-------------------------|
| Part B Prerequisite | No |

Taltz

Products Affected

- **TALTZ AUTOINJECTOR**
- **TALTZ SYRINGE SUBCUTANEOUS SYRINGE 80 MG/ML**

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis. For moderate to severe plaque psoriasis, inadequate response or intolerance to one systemic therapy (e.g. methotrexate) -OR- inadequate response to phototherapy -OR- contraindication to phototherapy and systemic therapy. For ankylosing spondylitis, inadequate response or intolerance to one nonsteroidal anti-inflammatory drug (NSAID). For non-radiographic axial spondyloarthritis, inadequate response or intolerance to 2 NSAIDs. |
| Age Restrictions | Deny if less than 18 years of age for Psoriatic Arthritis, Ankylosing Spondylitis and non-radiographic axial spondyloarthritis or less than 6 years of age for Plaque Psoriasis |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |

| PA Criteria | Criteria Details |
|----------------------------|---|
| Other Criteria | <p>For psoriatic arthritis, patients must have therapeutic failure or intolerance to 2 of the following preferred products: Cosentyx, Enbrel, a preferred adalimumab product, Xeljanz/Xeljanz XR, Otezla, Stelara SC, Rinvoq, and Skyrizi SC. For plaque psoriasis, patients must have therapeutic failure or intolerance to 2 of the following preferred products: a preferred adalimumab product, Cosentyx, Otezla, Stelara SC, Skyrizi SC, and Enbrel. For ankylosing spondylitis, patients must have therapeutic failure or intolerance to 2 of the following preferred products: a preferred adalimumab product, Enbrel, Cosentyx, Rinvoq, and Xeljanz/Xeljanz XR. For non-radiographic axial spondyloarthritis patients must have therapeutic failure or intolerance to 2 of the following preferred products: Cimzia, Rinvoq, Cosentyx. Please Note: preferred adalimumab products include Humira with NDC starting with 00074, Cyltezo with NDC starting 00597 and Yuflyma with NDC starting 72606. For induction therapy, doses above plan quantity limit will be approved when aligned with recommended induction therapy dosing regimen.</p> |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Talzenna

Products Affected

- **TALZENNA**

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of deleterious or suspected deleterious gBRCAm, HER2-negative locally advanced or metastatic breast cancer as a single agent - OR- Documentation of HRR gene-mutated metastatic castration-resistant prostate cancer in combination with enzalutamide |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Targretin

Products Affected

- *bexarotene oral*
- *bexarotene topical*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of cutaneous manifestations of cutaneous T-cell lymphoma in patients who are refractory to at least one prior systemic therapy. |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Tascenso ODT

Products Affected

- TASCENSO ODT

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | Concomitant use with other disease modifying agents such as teriflunomide, interferons, Copaxone, Tysabri |
| Required Medical Information | Documentation of a relapsing form of multiple sclerosis (e.g. relapsing-remitting, clinically isolated syndrome, or active secondary progressive disease) -AND- Inability to swallow capsules |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 5 years |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Tasigna

Products Affected

- TASIGNA

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis. For adult patients with Ph+ chronic myeloid leukemia (CML), member's CML is in the chronic or accelerated phase and the member is no longer responding to or is intolerant to imatinib - OR- member is newly diagnosed in the chronic phase. For pediatric patients, one of the following (1-2): 1) member has chronic phase or accelerated phase Ph+ CML and is is resistant or intolerant to prior tyrosine kinase inhibitor therapy 2) member is newly diagnosed with Ph+ CML in the chronic phase. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Tasimelteon

Products Affected

- *tasimelteon*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documented diagnosis of Non-24 Sleep-Wake disorder in patient that is totally blind -AND- evidenced by all the following (1 through 4): 1) history of insomnia, excessive daytime sleepiness, or both alternating with asymptomatic episodes 2) symptoms persistent for at least 3 months 3) daily sleep logs for at least 1 month demonstrating a sleep/wake pattern that delays each day 4) sleep disturbances are not better explained by another current disorder or medication/substance use |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 3 months initial authorization, 12 months reauthorization |
| Other Criteria | For reauthorization, attestation of increased total nighttime sleep or decreased daytime nap duration for Non-24 Sleep-Wake disorder |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Tazorac

Products Affected

- *tazarotene topical cream*
- **TAZORAC TOPICAL CREAM 0.05 %**

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of 1 of the following (A or B). A) Documentation of plaque psoriasis -AND- trial and failure or intolerance to at least one topical corticosteroid (e.g. fluocinonide, mometasone, triamcinolone, betamethasone). B) Documentation of acne vulgaris -AND- trial and failure or intolerance of at least two topical acne medications (e.g. adapalene, clindamycin, sulfacetamide, erythromycin) one of which must be generic topical tretinoin |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Tazverik

Products Affected

- TAZVERIK

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of locally advanced or metastatic epithelioid sarcoma - AND- Disease is not eligible for complete resection. Documentation of relapsed or refractory follicular lymphoma -AND-Tumors are EZH2 mutation positive, as detected by FDA approved test, in a member that has received at least 2 prior systemic therapies -OR- Prescriber attests there are no satisfactory alternative treatment options. |
| Age Restrictions | For epithelioid sarcoma, deny if less than 16 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Tecfidera

Products Affected

- *dimethyl fumarate oral capsule, delayed release(dr/ec) 120 mg, 120 mg (14)- 240 mg (46), 240 mg*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | Concomitant use with other disease modifying agents such as interferons, Copaxone, Tysabri, Aubagio, Gilenya |
| Required Medical Information | Documentation of relapsing form of multiple sclerosis (e.g. relapsing-remitting, clinically isolated syndrome, or active secondary progressive disease) |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 5 years |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Tepmetko

Products Affected

- **TEPMETKO**

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of metastatic non-small cell lung cancer with a MET exon 14 skipping alteration |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Testosterone (androgens)

Products Affected

- *testosterone cypionate*
- *testosterone enanthate*
- *testosterone transdermal gel in metered-dose pump 20.25 mg/1.25 gram (1.62 %)*
- *testosterone transdermal gel in packet 1.62 % (20.25 mg/1.25 gram), 1.62 % (40.5 mg/2.5 gram)*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of primary or secondary hypogonadism in males with testicular failure due to cryptorchidism, bilateral torsions, orchitis, vanishing testis syndrome, orchidectomy, Klinefelter's syndrome, chemotherapy, radiation or toxic damage -OR- documentation of primary or secondary hypogonadism in males with multiple symptoms of hypogonadism including at least one of the following specific symptoms: height loss due to vertebral fractures, low trauma fractures, low bone density, incomplete or delayed sexual development, breast discomfort, loss of axillar and/or pubic body hair, hot flushes -OR- documentation of HIV infection in men with weight loss -OR- documentation of chronic steroid treatment in men. In all previously noted indications, members must also have documented low total testosterone level below the normal range for the laboratory -OR- a total testosterone level near the lower limit of the normal range with a low free testosterone level which is less than normal based upon the laboratory reference range -OR- the member is not producing any testosterone. Additional approvable indications include female patients with metastatic breast cancer (testosterone enanthate only), primary or secondary hypogonadism in males with testicular failure due to double orchidectomy, and delayed puberty in males (testosterone enanthate only). |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |

| PA Criteria | Criteria Details |
|----------------------------|-------------------------|
| Off Label Uses | HIV Wasting |
| Part B Prerequisite | No |

Thalomid

Products Affected

- **THALOMID ORAL CAPSULE 100 MG, 150 MG, 200 MG, 50 MG**

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Use as monotherapy for ENL treatment in the presence of moderate to severe neuritis |
| Required Medical Information | Documentation of multiple myeloma in combination with dexamethasone -OR- documentation for use in the treatment of cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL) -OR- documentation of therapy for prevention and suppression of the cutaneous manifestations of ENL recurrence |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Thrombopoiesis Stimulating Agents

Products Affected

- **PROMACTA ORAL POWDER IN PACKET 12.5 MG, 25 MG**
- **PROMACTA ORAL TABLET 12.5 MG, 25 MG, 50 MG, 75 MG**

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis of persistent or chronic immune idiopathic thrombocytopenia purpura and trial and failure of corticosteroid or immunoglobulin therapy or splenectomy -OR- documentation of thrombocytopenia in patients with chronic hepatitis C to allow the initiation and maintenance of interferon-based therapy -OR- severe aplastic anemia who have had an insufficient response to immunosuppressive therapy -OR- documentation of first line treatment for severe aplastic anemia and used in combination with at least two immunosuppressive therapies. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | Platelet count to be provided |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Tibsovo

Products Affected

- TIBSOVO

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis -AND- disease is IDH1 mutation positive as detected by an FDA-approved test. For newly-diagnosed acute myeloid leukemia, member is using as monotherapy or in combination with azacitidine -AND- member meets one of the following (1-5): 1) age is greater than or equal to 75 years of age 2) severe cardiac or pulmonary comorbidity 3) reduced renal function 4) hepatic impairment 5) or prescriber attestation that member is not a candidate for intensive induction therapy. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Topical Lidocaine

Products Affected

- *lidocaine hcl mucous membrane solution 4 % (40 mg/ml)*
- *lidocaine topical ointment*
- *lidocaine-prilocaine topical cream*

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Transmucosal Fentanyl Citrate

Products Affected

- *fentanyl citrate buccal lozenge on a handle*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of therapeutic use and the member is currently receiving and tolerant to long acting opioid therapy |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Tretinoin

Products Affected

- *tretinoin topical cream*
- *tretinoin topical gel 0.01 %, 0.025 %*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | Cosmetic use |
| Required Medical Information | Documentation of acne vulgaris -AND- trial and failure or intolerance of at least two generic topical non-retinoid acne medications (e.g. clindamycin, sulfacetamide, erythromycin) |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Trikafta

Products Affected

- **TRIKAFTA ORAL GRANULES IN PACKET, SEQUENTIAL**
- **TRIKAFTA ORAL TABLETS, SEQUENTIAL**

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of cystic fibrosis (CF) in patients who have at least one F508del mutation or another mutation in the cystic fibrosis transmembrane conductance regulator (CFTR gene) that is responsive to elexacaftor/tezacaftor/ivacaftor based on in vitro assay (e.g. E56K, R117C, A455E) |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 6 months initial authorization, 12 months reauthorization |
| Other Criteria | For reauthorization, documentation supporting improvement or stabilization of FEV1 compared to baseline FEV1 -or- increase in body mass index -or- decreased pulmonary exacerbations -or- improved quality of life as demonstrated by CF Questionnaire is required. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Trintellix

Products Affected

- **TRINTELLIX**

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of major depressive disorder -AND- Therapeutic failure, intolerance or contraindication to one generic antidepressant (e.g. SSRI, TCA, MAOI). |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Truqap

Products Affected

- TRUQAP

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis -AND- all of the following (1-3): 1) HR mutation status, HER2 mutation status, and PIK3CA/AKT1/PTEN status 2) concomitant therapy with fulvestrant 3) disease progression on at least one endocrine-based regimen in the metastatic setting -OR- recurrence on or within 12 months of completing adjuvant therapy. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Tukysa

Products Affected

- TUKYSA ORAL TABLET 150 MG, 50 MG

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis. For advanced unresectable HER2-positive breast cancer or metastatic HER2-positive breast cancer, member will be using in combination with trastuzumab and capecitabine -AND- member has received one or more prior anti-HER2 based regimens in the metastatic setting. For RAS wild-type HER2-positive unresectable or metastatic colorectal cancer, member will be using in combination with trastuzumab -AND- member has experienced disease progression following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Turalio

Products Affected

- TURALIO ORAL CAPSULE 125 MG

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of symptomatic tenosynovial giant cell tumor associated with severe morbidity and functional limitations -AND- patient is not amenable to improvement with surgery or not a candidate for surgery |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 24 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Tykerb

Products Affected

- *lapatinib*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis. For advanced HER2-positive, or metastatic HER2-positive breast cancer, the member has received prior therapy with an anthracycline, a taxane, and trastuzumab -AND- will be using in combination with capecitabine. For HR+, metastatic breast cancer, the member is post-menopausal -AND- the member's cancer over expresses the HER2 receptor -AND- the member will be using lapatinib in combination with letrozole. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Tymlos

Products Affected

- TYMLOS

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | Treatment duration greater than 24 months. |
| Required Medical Information | Documentation of diagnosis -AND- at high risk for fracture, meeting one of the following (1. thru 3.) 1) History of previous hip or vertebral fracture. 2) T-score less than or equal to -2.5. 3) T-score between -1.0 and -2.5 -AND- meets FRAX calculation (A. or B.) A) 10-year risk of major osteoporotic fracture is greater than or equal to 20 percent or B) 10-year risk of hip fracture is greater than or equal to 3 percent. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 24 months |
| Other Criteria | Documentation of trial/failure or intolerance to at least one oral bisphosphonate or all are contraindicated. Additional documentation of trial/failure, intolerance or contraindication to preferred parathyroid hormone analog teriparatide. Coverage of human parathyroid hormone related peptide analogs beyond 24 months will not be approved. A cumulative lifetime approval of Tymlos will be limited to a coverage duration of 24 months. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Ubrelvy

Products Affected

- **UBRELVY ORAL TABLET 100 MG, 50 MG**

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis of acute treatment of migraine with or without aura -AND- trial and failure of one generic triptan. |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 6 months initial authorization, 12 months reauthorization |
| Other Criteria | Patients must have therapeutic failure, intolerance, or contraindication to Nurtec ODT. For reauthorization, attestation of reduction in migraine symptoms. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Valchlor

Products Affected

- VALCHLOR

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of Stage IA or IB mycosis fungoides-type cutaneous T-cell lymphoma in patients who have received at least one prior skin-directed therapy (e.g. topical corticosteroids, topical chemotherapy, local radiation and topical retinoids). |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Valtoco

Products Affected

- VALTOCO

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of seizure clusters or acute repetitive seizures -AND- the member is currently receiving antiepileptic maintenance therapy. |
| Age Restrictions | Deny if less than 6 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Vancomycin

Products Affected

- *vancomycin oral capsule 125 mg, 250 mg*

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 3 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Vanflyta

Products Affected

- VANFLYTA

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis -AND- disease is FLT3-ITD-positive as detected by an FDA-approved test -AND- one of the following (1-3): 1) member is receiving induction therapy and is using Vanflyta in combination with standard cytarabine and anthracycline induction therapy 2) member is receiving consolidation therapy and is using Vanflyta in combination with standard cytarabine consolidation therapy 3) member is receiving maintenance therapy and is using Vanflyta as monotherapy. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Venclexta

Products Affected

- VENCLEXTA ORAL TABLET 10 MG, 100 MG, 50 MG
- VENCLEXTA STARTING PACK

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | For newly-diagnosed AML, member is using in combination with azacitidine, decitabine, cytarabine -AND- age greater than or equal to 75 years or presence of at least one comorbidity that precludes use of intensive induction chemotherapy (i.e. severe cardiac or pulmonary comorbidity, reduced renal function, hepatic impairment, or physician attestation) is required. |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Verquvo

Products Affected

- VERQUVO

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of heart failure (NYHA Class II to IV) -AND- Left ventricular ejection fraction less than 45% -AND- Hospitalization for heart failure or received outpatient IV diuretics for heart failure -AND- Used in combination with a angiotensin-converting enzyme inhibitor, angiotensin II receptor blocker or Entresto -AND- Used in combination with bisoprolol, carvedilol IR/ER or metoprolol succinate ER. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Verzenio

Products Affected

- VERZENIO

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis -AND- disease is classified as HR-positive, HER2-negative. For early breast cancer that is at high risk of recurrence and is node-positive, all of the following (1-2): 1) used in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) 2) used as adjuvant treatment. For advanced or metastatic breast cancer, used as initial endocrine-based therapy and used in combination with an aromatase inhibitor -OR- used after documented disease progression following endocrine therapy and used in combination with fulvestrant -OR- used after documented disease progression and used following endocrine therapy and prior chemotherapy in the metastatic setting and will be used as monotherapy. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Viberzi

Products Affected

- **VIBERZI**

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Severe (Child-Pugh C) hepatic impairment |
| Required Medical Information | Documentation of diarrhea predominant, irritable bowel syndrome (IBS-D) -AND- trial/failure or intolerance to one of the following medications for IBS-D or documentation of contraindication to all: antidiarrheal (e.g., loperamide), antispasmodic (e.g., dicyclomine, hyoscyamine), tricyclic antidepressant (e.g., amitriptyline, nortriptyline). |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Viibryd

Products Affected

- *vilazodone*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of major depressive disorder -AND- Therapeutic failure, intolerance or contraindication to one generic antidepressant (e.g. SSRI, TCA, MAOI). |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Vioice

Products Affected

- VIJOICE ORAL GRANULES IN PACKET MG
- VIJOICE ORAL TABLET 125 MG, 250 MG/DAY (200 MG X1-50 MG X1), 50

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of severe manifestations of PIK3CA Related Overgrowth Spectrum (PROS) |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Vittrakvi

Products Affected

- VITRAKVI ORAL CAPSULE 100 MG, 25 MG
- VITRAKVI ORAL SOLUTION

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation -AND- Tumors are metastatic or surgical resection is likely to result in severe morbidity - AND- There are no satisfactory alternative treatments or tumors have progressed following treatment. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Vivjoa

Products Affected

- VIVJOA

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of recurrent vulvovaginal candidiasis defined as at least 3 episodes of vulvovaginal candidiasis in less than one year -AND Documentation the member is NOT of reproductive potential defined as postmenopausal or another reason for permanent infertility (e.g., tubal ligation, hysterectomy, salpingo-oophorectomy) -AND- the member has experienced therapeutic failure, contraindication, or intolerance to a six-month maintenance course of oral fluconazole. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 14 weeks |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Vizimpro

Products Affected

- VIZIMPRO

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of metastatic non-small cell lung cancer -AND- one of the following (1 or 2): 1. Epidermal growth factor (EGFR) exon 19 deletions - OR- 2. Epidermal growth factor receptor (EGFR) exon 21 L858R substitution mutations. |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Vonjo

Products Affected

- VONJO

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of intermediate or high-risk myelofibrosis -AND- attestation of a platelet count of less than $50 \times 10^9/L$. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Voriconazole

Products Affected

- *voriconazole intravenous*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis -AND- attestation that the beneficiary cannot take oral voriconazole |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 3 months |
| Other Criteria | For reauthorization, attestation of continued indicators of active disease (e.g. histopathology, positive cultures) is required |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Vosevi

Products Affected

- VOSEVI

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Criteria will be applied consistent with current AASLD/IDSA guidance - AND- the member has a contraindication to or is otherwise not a candidate for one of the following regimens recommended by the AASLD/IDSA guidelines containing the following agents: sofosbuvir/velpatasvir (i.e. Epclusa authorized generic), Mavyret. |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | Criteria/duration applied consistent with current AASLD-IDSA guidance |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Votrient

Products Affected

- *pazopanib*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | Documentation of adipocytic soft tissue sarcoma or gastrointestinal stromal tumor |
| Required Medical Information | Documentation of diagnosis. For advanced soft-tissue sarcoma, trial/failure of at least one prior chemotherapy regimen. |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Vraylar

Products Affected

- VRAYLAR ORAL CAPSULE

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | For a diagnosis of schizophrenia and bipolar I disorder, therapeutic failure, intolerance, or contraindication to one other generic atypical antipsychotic (e.g. quetiapine). For major depressive disorder, documentation of adjunctive therapy and therapeutic failure, contraindication or intolerance to one other generic antidepressant in addition to the antidepressant currently being used for the treatment of MDD (e.g. SSRI, SNRI, NDRIs, TCA, MAOI). |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Vumerity

Products Affected

- VUMERITY

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | Concomitant use with other disease modifying agents such as interferons, Copaxone, Tysabri, Aubagio, Gilenya |
| Required Medical Information | Documentation of relapsing form of multiple sclerosis (e.g. relapsing-remitting, clinically isolated syndrome, or active secondary progressive disease) -AND- Therapeutic failure or intolerance to generic dimethyl fumarate |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 5 years |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Welireg

Products Affected

- WELIREG

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis. For von Hippel Lindau (VHL) syndrome, one of the following diagnoses not requiring immediate surgery (1, 2, or 3): 1) Renal cell carcinoma (RCC) 2) CNS hemangioblastoma 3) Pancreatic neuroendocrine tumor. For advanced RCC, prior treatment with a vascular endothelial growth factor tyrosine kinase inhibitor (VEGF-TKI) -AND- a programmed death receptor-1 (PD-1) or a programmed death-ligand (PD-L1) inhibitor. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Xalkori

Products Affected

- **XALKORI ORAL CAPSULE**
- **XALKORI ORAL PELLETT 150 MG, 20 MG, 50 MG**

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis. For metastatic non-small cell lung cancer (NSCLC), disease is ALK-positive or ROS1-positive. For relapsed or refractory anaplastic large cell lymphoma (ALCL), disease is ALK-positive. For unresectable, recurrent, or refractory inflammatory myofibroblastic tumor (IMT), disease is ALK-positive. |
| Age Restrictions | Deny if less than 18 years of age for NSCLC. Deny if less than 1 year of age or greater than 21 years of age for ALCL. |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | For crizotinib oral pellets and NSCLC, inability to swallow capsules is required. For crizotinib oral pellets and ALCL / IMT, inability to swallow oral capsules -OR- body surface area less than 1.34 m ² is required. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Xcopri

Products Affected

- **XCOPRI**
- **XCOPRI MAINTENANCE PACK**
- **XCOPRI TITRATION PACK**

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of partial-onset seizures -AND- Therapeutic failure, intolerance or contraindication to 1 other anti-epileptic drug (e.g. carbamazepine, levetiracetam) |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Xdemvy

Products Affected

- XDEMVI

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis confirmed by identification of Demodex infection via microscopic examination of pulled eyelashes -OR- identification of collarettes via slit-lamp evaluation. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 6 weeks |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Xeljanz

Products Affected

- XELJANZ ORAL TABLET
- XELJANZ XR

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis. For moderate to severely active rheumatoid arthritis and an inadequate response or intolerance to methotrexate. Xeljanz immediate release for juvenile idiopathic arthritis, inadequate response or intolerance to at least one DMARD (e.g., methotrexate, leflunomide) -OR- requires initial biologic therapy due to involvement of high-risk joints, high disease activity or at high risk of disabling joint damage. For ankylosing spondylitis, inadequate response or intolerance to at least one nonsteroidal anti-inflammatory drug (NSAID). |
| Age Restrictions | Deny if less than 18 years of age for rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, ankylosing spondylitis. For Xeljanz regular release tablet, deny if less than 2 years of age for juvenile idiopathic arthritis |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | The member has experienced inadequate response or intolerance to at least 1 tumor necrosis factor (TNF) blocker. Doses greater than 10 mg per day for Xeljanz and 11 mg per day for Xeljanz XR will not be approved for rheumatoid arthritis and psoriatic arthritis. Doses greater than 20mg per day for Xeljanz and 22 mg per day for Xeljanz XR will not be approved for ulcerative colitis. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Xeljanz Solution

Products Affected

- XELJANZ ORAL SOLUTION

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------|
| Exclusion Criteria | Pending CMS Review |
| Required Medical Information | Pending CMS Review |
| Age Restrictions | Pending CMS Review |
| Prescriber Restrictions | Pending CMS Review |
| Coverage Duration | Pending CMS Review |
| Other Criteria | Pending CMS Review |
| Indications | Pending CMS Review |
| Off Label Uses | Pending CMS Review |
| Part B Prerequisite | No |

Xenazine

Products Affected

- *tetrabenazine oral tablet 12.5 mg, 25 mg*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis -AND- attestation that the beneficiary is not actively suicidal |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | In patients with comorbid depression, attestation of adequate treatment for depression is required. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Xermelo

Products Affected

- XERMELO

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of carcinoid syndrome diarrhea AND used in combination with a somatostatin analog AND trial and failure of somatostatin analog monotherapy |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 3 months initial authorization, 12 months reauthorization |
| Other Criteria | For reauthorization, attestation of reduction in average number of daily bowel movements -AND- the member will continue to use in combination with a somatostatin analog. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Xgeva

Products Affected

- XGEVA

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis. For hypercalcemia of malignancy, refractory to bisphosphonates. For giant cell tumor of bone, unresectable or surgical resection is likely to result in severe morbidity -AND- one of the following (1. or 2.)- 1.) the member is 18 years old or older -OR- 2.) the member is a skeletally mature adolescent (e.g. has at least one mature long bone) |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Xifaxan

Products Affected

- XIFAXAN ORAL TABLET 550 MG

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of 1 or 2. 1) Diagnosis of hepatic encephalopathy AND trial/failure, intolerance, or contraindication to lactulose. 2) Diagnosis of Irritable Bowel Syndrome with Diarrhea (IBS-D) AND trial/failure, intolerance to one of the following medications for IBS-D or documentation of contraindication to all: antidiarrheal (e.g., loperamide), antispasmodic (e.g., dicyclomine, hyoscyamine), tricyclic antidepressant (e.g., amitriptyline, nortriptyline). |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | Hepatic encephalopathy: 1 year. IBS-D: 14 days. |
| Other Criteria | No more than three courses of rifaximin for the treatment of IBS-D will be approved per lifetime. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Xolair

Products Affected

- XOLAIR

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | <p>Documentation of the following (1-2): 1) Chronic Spontaneous Urticaria, 2) trial/failure or intolerance of a second-generation non-sedating H1 antihistamine at the maximum recommended doses (e.g. cetirizine, fexofenadine, loratadine, desloratadine, levocetirizine). -OR- Documentation of the following (3-9): 3) moderate to severe persistent asthma, 4) a positive skin test or in vitro reactivity to a perennial aeroallergen, 5) Baseline IgE titer greater than or equal to 30 IU/mL, 6) documented pretreatment FEV1 less than 80% predicted in adults or less than 90% predicted in children and adolescents or FEV1 reversibility of at least 12% and 200mL after albuterol administration, 7) history of at least 2 asthma exacerbations requiring oral or injectable corticosteroid treatment in past 12 mos or at least 1 asthma exacerbation requiring hospitalization in past 12 mos, 8) inadequately controlled symptoms despite a 3-month trial of both of the following (a-b) a) medium-dose inhaled corticosteroid or systemic steroid b) a long-acting beta-agonist or leukotriene antagonist, 9) currently on 1 of the following (c, d, e): c) a long-acting beta2-agonist, d) leukotriene modifier, or e) theophylline. -OR- Documentation of the following (10-11): 10) chronic rhinosinusitis with nasal polyps (CRSwNP), 11) will use concomitantly with nasal corticosteroid maintenance treatment, -OR- Documentation of the following (12-17): 12) IgE mediated food allergy, 13) diagnosis confirmed by skin prick test or food-specific antibodies, 14) previous allergic reaction to food, 15) using for the reduction of allergic reactions (type 1), including anaphylaxis, 16) will be used in conjunction with food allergen avoidance, 17) member has a documented prescription for epinephrine.</p> |
| Age Restrictions | |
| Prescriber Restrictions | |

| PA Criteria | Criteria Details |
|----------------------------|---|
| Coverage Duration | 12 months |
| Other Criteria | For asthma reauthorization, attestation of one of the following is required (1-4): 1) decreased rescue medication or oral corticosteroid use, 2) decreased frequency of asthma exacerbations, 3) increased pulmonary function from baseline (e.g. FEV1), or 4) reduction in reported asthma related symptoms. For CSU reauthorization, improved CSU symptoms. For CRSwNP reauthorization, attestation of decrease in nasal polyp score or reduction in nasal congestion/obstruction severity score. For IgE-mediated food allergy reauthorization, member requires continuation of therapy and will continue food allergen avoidance. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Xolremdi

Products Affected

- **XOLREMDI**

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of WHIM syndrome (warts, hypogammaglobulinemia, infections, myelokathexis). |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | For reauthorization, attestation of reduction in incidence of infections is required. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Xospata

Products Affected

- XOSPATA

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis -AND- member is FLT3 mutation-positive. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Xpovio

Products Affected

- **XPOVIO ORAL TABLET 100 MG/WEEK (50 MG X 2), 40 MG/WEEK (40 MG X 1), 40MG TWICE WEEK (40 MG X 2), 60 MG/WEEK (60 MG X 1), 60MG TWICE WEEK (120 MG/WEEK), 80 MG/WEEK (40 MG X 2), 80MG TWICE WEEK (160 MG/WEEK)**

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of use in combination with dexamethasone for relapse or refractory multiple myeloma with failure, intolerance or contraindication to 5 therapies (e.g. bortezomib, carfilzomib, lenalidomide, pomalidomide and daratumumab) -OR- Documentation of use in combination with both bortezomib and dexamethasone for multiple myeloma after receiving 1 prior multiple myeloma therapy -OR- Documentation of relapsing or refractory diffuse large B-cell lymphoma with failure, intolerance or contraindication to at least 2 lines of systemic therapy |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Xtandi

Products Affected

- **XTANDI ORAL CAPSULE**
- **XTANDI ORAL TABLET 40 MG, 80 MG**

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis. For castration-resistant prostate cancer and metastatic castration sensitive-prostate cancer, the member is using in combination with a GnRH analog or the member has had a bilateral orchiectomy. For non-metastatic castration-sensitive prostate cancer, the member has biochemical recurrence at high risk for metastasis. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Xyrem

Products Affected

- *sodium oxybate*
- **XYREM**

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | <p>Diagnosis of narcolepsy -AND- Documentation of baseline data of excessive daytime sleepiness (EDS) via the Epworth Sleepiness Scale (ESS) or Maintenance of Wakefulness Test (MWT) - AND- Documentation of the following (1, 2, or 3): 1) Hypocretin-1 deficiency defined by (A or B), A) Cerebrospinal fluid hypocretin-1 less than 110 pg/mL. B) Cerebrospinal fluid hypocretin-1 less than 1/3 of the normal value based on laboratory reference range -OR- 2) Multiple sleep latency test (MSLT) documenting MSL less than 8 minutes and 2 sleep-onset rapid eye movement periods (SOREMP) -OR- 3) MSLT documenting MSL less than 8 minutes and 1 SOREMP and Polysomnography substantiating 1 SOREMP. If the member has a diagnosis of cataplexy provision of baseline number of cataplexy episodes is required.</p> |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | <p>If no diagnosis of cataplexy- trial and failure, intolerance, or contraindication to generic modafinil AND a generic CNS stimulant indicated for use in narcolepsy (e.g. methylphenidate, amphetamine salts) is required. For reauthorization, attestation supporting improvement in symptoms of narcolepsy and cataplexy (if applicable) is required.</p> |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Yonsa

Products Affected

- YONSA

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis -AND- using in combination with methylprednisolone. |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Zavesca

Products Affected

- *miglustat*
- YARGESA

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of mild to moderate type 1 Gaucher disease confirmed by the following (A. or B.) A. (1, 2, 3, 4, or, 5): 1)Hepatomegaly. 2)Splenomegaly. 3)Bone disease (i.e. osteonecrosis, osteopenia, secondary pathologic fractures, bone infarct). 4)Bone marrow complications as defined by anemia with hemoglobin less than or equal to 11.5 g/dL for females or 12.5 g/dL for males or thrombocytopenia with platelet count less than or equal to 120,000/mm ³ -OR- 5)Symptomatic disease (e.g. bone pain, exertional limitation, cachexia). -OR- B. Attestation of deficiency in glucocerebrosidase activity in peripheral leukocytes or genetic testing confirms mutant alleles. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | Attestation enzyme replacement therapy (e.g. Cerezyme, Elelyso, or VPRIV) is not a therapeutic option |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Zavzpret

Products Affected

- ZAVZPRET

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of acute migraine headaches with or without aura -AND- Therapeutic failure, contraindication or intolerance to one generic triptan -AND- Inability to swallow capsules/tablets |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 6 months initial authorization, 12 months reauthorization |
| Other Criteria | For reauthorization, attestation of reduction in migraine symptoms. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Zejula

Products Affected

- ZEJULA ORAL TABLET

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis. For advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer, member is in complete or partial response to first-line platinum-based therapy. For recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, all of the following (1-2): 1) disease harbors a deleterious or suspected deleterious germline BRCA mutation 2) member is in a complete or partial response to platinum-based chemotherapy. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Zelboraf

Products Affected

- TAFINLAR ORAL CAPSULE
- ZELBORAF

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------|
| Exclusion Criteria | Pending CMS Review |
| Required Medical Information | Pending CMS Review |
| Age Restrictions | Pending CMS Review |
| Prescriber Restrictions | Pending CMS Review |
| Coverage Duration | Pending CMS Review |
| Other Criteria | Pending CMS Review |
| Indications | Pending CMS Review |
| Off Label Uses | Pending CMS Review |
| Part B Prerequisite | No |

Zeposia

Products Affected

- ZEPOSIA
- ZEPOSIA STARTER KIT (28-DAY)
- ZEPOSIA STARTER PACK (7-DAY)

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | Concomitant use of Zeposia and other disease modifying agents such as interferons, Copaxone, Tysabri. |
| Required Medical Information | Documentation of diagnosis. For moderate to severe active ulcerative colitis, inadequate response or intolerance to one systemic therapy (e.g. methotrexate, cyclosporine). |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | Ulcerative Colitis: 12 months, Multiple Sclerosis: 24 months |
| Other Criteria | For moderate to severe active ulcerative colitis, patients must have therapeutic failure or intolerance to 2 of the following preferred products: a preferred adalimumab product, Rinvoq, Xeljanz/Xeljanz XR and Stelara SC. Please Note: preferred adalimumab products include Humira with NDC starting with 00074, Cyltezo with NDC starting 00597 and Yuflyma with NDC starting 72606. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Zolinza

Products Affected

- ZOLINZA

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of cutaneous manifestations in patients with cutaneous T-cell lymphoma (CTCL) who have progressive, persistent, or recurrent disease on or following 2 systemic therapies. Systemic therapies include bexarotene, interferon alpha, extracorporeal photochemotherapy, PUVA, single agent or combination chemotherapies (e.g. cyclophosphamide, vinblastine, romidepsin) |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Zonisade

Products Affected

- ZONISADE

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of partial-onset seizures -AND- Documentation of adjunctive therapy -AND- Inability to swallow capsules -AND- Therapeutic failure/intolerance to 2 or contraindication to all of the following (1-6): 1) generic carbamazepine suspension/chewable tablet/extended-release capsule, 2) generic gabapentin capsules/solution, 3) generic lacosamide solution, 4) generic levetiracetam solution, 5) generic oxcarbazepine suspension, 6) generic pregabalin capsules/solution. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Ztalmy

Products Affected

- ZTALMY

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of seizures associated with CDKL5 deficiency confirmed by genetic testing -AND- therapeutic failure or intolerance to 2 previous antiepileptic therapies |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Zurzuvaе

Products Affected

- ZURZUVAE ORAL CAPSULE 20 MG, 25 MG, 30 MG

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis of moderate to severe postpartum depression -AND- less than or equal to 12 months postpartum. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 30 days |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Zydelig

Products Affected

- ZYDELIG

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | First line treatment. Combination use with benadmustine and/or rituximab for the treatment of FL. |
| Required Medical Information | Documentation of relapsed chronic lymphocytic leukemia -AND- all of the following (1-2): 1) will be used in combination with rituximab 2) use of rituximab alone would be appropriate due to other due to other comorbidities. |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Zykadia

Products Affected

- ZYKADIA

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis -AND- ALK mutations, as detected by an FDA approved test. |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Zytiga

Products Affected

- *abiraterone oral tablet 250 mg, 500 mg*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis -AND- using in combination with prednisone. |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

Index of Drugs

| | | | |
|---|-----|---|-----|
| <i>abiraterone oral tablet 250 mg, 500 mg</i> | 337 | AUSTEDO XR TITRATION KT(WK1-4) ORAL TABLET, EXT REL 24HR DOSE PACK 6 MG (14)-12 MG (14)-24 MG (14) | 21 |
| <i>acetaminophen-codeine oral solution 120-12 mg/5 ml</i> | 210 | AUVELITY | 22 |
| <i>acetaminophen-codeine oral tablet</i> | 210 | AVONEX INTRAMUSCULAR PEN INJECTOR KIT | 126 |
| <i>acitretin</i> | 1 | AVONEX INTRAMUSCULAR SYRINGE KIT | 126 |
| ACTEMRA ACTPEN | 2 | AYVAKIT | 23 |
| ACTEMRA SUBCUTANEOUS | 2 | BAFIERTAM | 24 |
| ACTIMMUNE | 3 | BALVERSA | 25 |
| ADBRY SUBCUTANEOUS SYRINGE | 4 | BENLYSTA SUBCUTANEOUS | 27 |
| ADEMPAS | 215 | <i>benztropine oral</i> | 108 |
| AIMOVIG AUTOINJECTOR SUBCUTANEOUS AUTO-INJECTOR 140 MG/ML, 70 MG/ML | 8 | BERINERT INTRAVENOUS KIT | 28 |
| AJOVY AUTOINJECTOR | 9 | BESREMI | 30 |
| AJOVY SYRINGE | 9 | BETASERON SUBCUTANEOUS KIT | 126 |
| AKEEGA | 10 | <i>bexarotene oral</i> | 265 |
| ALCOHOL PADS | 124 | <i>bexarotene topical</i> | 265 |
| ALECENSA | 11 | BIVIGAM | 116 |
| <i>alosetron oral tablet 0.5 mg, 1 mg</i> | 157 | BOSULIF ORAL CAPSULE 100 MG, 50 MG | 31 |
| <i>alprazolam oral tablet 0.25 mg, 0.5 mg, 1 mg, 2 mg</i> | 210 | BOSULIF ORAL TABLET 100 MG, 400 MG, 500 MG | 31 |
| ALUNBRIG ORAL TABLET 180 MG, 30 MG, 90 MG | 13 | BRAFTOVI | 32 |
| ALUNBRIG ORAL TABLETS,DOSE PACK | 13 | BRUKINSA | 33 |
| ALYQ | 215 | <i>buprenorphine</i> | 210 |
| <i>ambrisentan</i> | 215 | BYDUREON BCISE | 104 |
| <i>amitriptyline</i> | 108 | CABLIVI INJECTION KIT | 35 |
| <i>apomorphine</i> | 15 | CABOMETYX | 36 |
| ARIKAYCE | 16 | CALQUENCE | 37 |
| <i>aripiprazole oral solution</i> | 18 | CALQUENCE (ACALABRUTINIB MAL) | 37 |
| <i>aripiprazole oral tablet,disintegrating</i> | 18 | CAMZYOS | 38 |
| <i>armodafinil</i> | 186 | CAPLYTA | 39 |
| <i>asenapine maleate</i> | 235 | CAPRELSA ORAL TABLET 100 MG, 300 MG | 40 |
| ASSURE ID INSULIN SAFETY SYRINGE 1 ML 29 GAUGE X 1/2" | 124 | <i>carglumic acid</i> | 41 |
| AUGTYRO | 20 | CAYSTON | 42 |
| AUSTEDO ORAL TABLET 12 MG, 6 MG, 9 MG | 21 | CERDELGA | 43 |
| AUSTEDO XR ORAL TABLET EXTENDED RELEASE 24 HR 12 MG, 24 MG, 30 MG, 36 MG, 42 MG, 48 MG, 6 MG | 21 | CIBINQO | 46 |
| | | CIMZIA | 47 |
| | | CIMZIA POWDER FOR RECONST | 47 |
| | | CINRYZE | 49 |
| | | <i>clobazam oral suspension</i> | 195 |

| | | | |
|--|-----|--|-----|
| <i>clobazam oral tablet</i> | 195 | <i>dihydroergotamine nasal</i> | 62 |
| <i>clomipramine</i> | 108 | <i>dimethyl fumarate oral capsule, delayed release(dr/ec) 120 mg, 120 mg (14)- 240 mg (46), 240 mg</i> | 271 |
| <i>clonazepam oral tablet 0.5 mg, 1 mg, 2 mg</i> | 210 | DOPTELET (10 TAB PACK) | 63 |
| <i>clonazepam oral tablet, disintegrating 0.125 mg, 0.25 mg, 0.5 mg, 1 mg, 2 mg</i> | 210 | DOPTELET (15 TAB PACK) | 63 |
| <i>clorazepate dipotassium oral tablet 15 mg, 3.75 mg, 7.5 mg</i> | 210 | DOPTELET (30 TAB PACK) | 63 |
| COMETRIQ ORAL CAPSULE 100 MG/DAY(80 MG X1-20 MG X1), 140 MG/DAY(80 MG X1-20 MG X3), 60 MG/DAY (20 MG X 3/DAY) | 51 | <i>doxepin oral capsule</i> | 108 |
| COPAXONE SUBCUTANEOUS SYRINGE 20 MG/ML, 40 MG/ML | 100 | <i>doxepin oral concentrate</i> | 108 |
| COPIKTRA | 52 | <i>doxepin oral tablet</i> | 108 |
| CORLANOR ORAL SOLUTION | 53 | <i>droxidopa oral capsule 100 mg, 200 mg, 300 mg</i> | 180 |
| CORLANOR ORAL TABLET 5 MG, 7.5 MG | 53 | DUPIXENT PEN SUBCUTANEOUS PEN INJECTOR 200 MG/1.14 ML, 300 MG/2 ML | 64 |
| COSENTYX (2 SYRINGES) | 54 | DUPIXENT SYRINGE SUBCUTANEOUS SYRINGE 100 MG/0.67 ML, 200 MG/1.14 ML, 300 MG/2 ML | 64 |
| COSENTYX PEN (2 PENS) | 54 | EMGALITY PEN | 67 |
| COSENTYX SUBCUTANEOUS SYRINGE 75 MG/0.5 ML | 54 | EMGALITY SYRINGE SUBCUTANEOUS SYRINGE 120 MG/ML, 300 MG/3 ML (100 MG/ML X 3) | 67 |
| COSENTYX UNOREADY PEN | 54 | ENBREL MINI | 69 |
| COTELLIC | 55 | ENBREL SUBCUTANEOUS SOLUTION | 69 |
| CYLTEZO(CF) | 110 | ENBREL SUBCUTANEOUS SYRINGE 25 MG/0.5 ML (0.5), 50 MG/ML (1 ML) .. | 69 |
| CYLTEZO(CF) PEN | 110 | ENBREL SURECLICK | 69 |
| CYLTEZO(CF) PEN CROHN'S-UC-HS | 110 | ENDOCET | 210 |
| CYLTEZO(CF) PEN PSORIASIS-UV .. | 110 | EPIDIOLEX | 71 |
| <i>ciproheptadine</i> | 108 | EPRONTIA | 72 |
| CYSTARAN | 56 | <i>ergotamine-caffeine</i> | 73 |
| <i>dalfampridine</i> | 14 | ERIVEDGE | 74 |
| DAURISMO ORAL TABLET 100 MG, 25 MG | 58 | ERLEADA ORAL TABLET 240 MG, 60 MG | 75 |
| DAYBUE | 59 | <i>erlotinib</i> | 66 |
| <i>deferasirox oral tablet, dispersible</i> | 60 | EVENITY SUBCUTANEOUS SYRINGE 210MG/2.34ML (105MG/1.17MLX2) | 76 |
| <i>deferiprone</i> | 83 | <i>everolimus (antineoplastic) oral tablet 10 mg, 2.5 mg, 5 mg, 7.5 mg</i> | 6 |
| DIACOMIT ORAL CAPSULE 250 MG, 500 MG | 61 | <i>everolimus (antineoplastic) oral tablet for suspension 2 mg, 3 mg, 5 mg</i> | 6 |
| DIACOMIT ORAL POWDER IN PACKET 250 MG, 500 MG | 61 | EVRYSDI | 77 |
| DIAZEPAM INTENSOL | 210 | | |
| <i>diazepam oral solution 5 mg/5 ml (1 mg/ml)</i> | 210 | | |
| <i>diazepam oral tablet</i> | 210 | | |
| <i>diclofenac epolamine</i> | 91 | | |
| <i>diclofenac sodium topical gel 3 %</i> | 245 | | |

| | | | |
|--|-----|--|-----|
| FABHALTA | 78 | <i>gefitinib</i> | 129 |
| FANAPT ORAL TABLET | 79 | GILOTRIF | 66 |
| FANAPT ORAL TABLETS,DOSE | | <i>glatiramer subcutaneous syringe 20 mg/ml,</i> | |
| PACK | 79 | <i>40 mg/ml</i> | 100 |
| FASENRA PEN | 80 | GLATOPA SUBCUTANEOUS | |
| FASENRA SUBCUTANEOUS | | SYRINGE 20 MG/ML, 40 MG/ML | 100 |
| SYRINGE 10 MG/0.5 ML, 30 MG/ML | 80 | GLEOSTINE | 103 |
| <i>fentanyl citrate buccal lozenge on a handle</i> | | <i>guanfacine oral tablet extended release 24</i> | |
| | 279 | <i>hr</i> | 5 |
| <i>fentanyl transdermal patch 72 hour 100</i> | | HAEGARDA | 106 |
| <i>mcg/hr, 12 mcg/hr, 25 mcg/hr, 50 mcg/hr,</i> | | HUMIRA PEN | 110 |
| <i>75 mcg/hr</i> | 210 | HUMIRA SUBCUTANEOUS | |
| FETZIMA ORAL CAPSULE,EXT REL | | SYRINGE KIT 40 MG/0.8 ML | 110 |
| 24HR DOSE PACK 20 MG (2)- 40 MG | | HUMIRA(CF) | 110 |
| (26) | 84 | HUMIRA(CF) PEN | 110 |
| FETZIMA ORAL | | HUMIRA(CF) PEN CROHNS-UC-HS .. | 110 |
| CAPSULE,EXTENDED RELEASE 24 | | HUMIRA(CF) PEN PEDIATRIC UC | 110 |
| HR 120 MG, 20 MG, 40 MG, 80 MG | 84 | HUMIRA(CF) PEN PSOR-UV-ADOL | |
| FILSUVEZ | 85 | HS | 110 |
| <i> fingolimod</i> | 99 | <i>hydrocodone-acetaminophen oral tablet</i> | |
| FINTEPLA | 86 | <i>10-325 mg, 5-325 mg, 7.5-325 mg</i> | 210 |
| FIRDAPSE | 89 | <i>hydromorphone oral liquid</i> | 210 |
| FIRMAGON KIT W DILUENT | | <i>hydromorphone oral tablet 2 mg, 4 mg, 8</i> | |
| SYRINGE | 90 | <i>mg</i> | 210 |
| FLECTOR | 91 | <i>hydroxyzine hcl oral solution 10 mg/5 ml</i> .. | 108 |
| FOTIVDA | 93 | <i>hydroxyzine hcl oral tablet</i> | 108 |
| FRUZAQLA ORAL CAPSULE 1 MG, 5 | | IBRANCE | 112 |
| MG | 94 | IBSRELA | 113 |
| FUROSCIX | 95 | <i>icatibant</i> | 87 |
| <i>gabapentin oral capsule 100 mg, 300 mg,</i> | | ICLUSIG | 114 |
| <i>400 mg</i> | 96 | IDHIFA ORAL TABLET 100 MG, 50 | |
| <i>gabapentin oral solution 250 mg/5 ml</i> | 96 | MG | 115 |
| <i>gabapentin oral tablet 600 mg, 800 mg</i> | 96 | <i>imatinib oral tablet 100 mg, 400 mg</i> | 101 |
| GAMMAGARD LIQUID | 116 | IMBRUVICA ORAL CAPSULE 140 | |
| GAMMAGARD S-D (IGA < 1 | | MG, 70 MG | 118 |
| MCG/ML) | 116 | IMBRUVICA ORAL SUSPENSION | 118 |
| GAMMAKED INJECTION | | IMBRUVICA ORAL TABLET 140 MG, | |
| SOLUTION 1 GRAM/10 ML (10 %) | 116 | 280 MG, 420 MG | 118 |
| GAMMAPLEX | 116 | <i>imipramine hcl</i> | 108 |
| GAMMAPLEX (WITH SORBITOL) | 116 | INCRELEX | 119 |
| GAMUNEX-C INJECTION | | INGREZZA INITIATION | |
| SOLUTION 1 GRAM/10 ML (10 %) | 116 | PK(TARDIV) | 120 |
| GATTEX 30-VIAL | 97 | INGREZZA ORAL CAPSULE 40 MG, | |
| GAUZE PAD TOPICAL BANDAGE 2 | | 60 MG, 80 MG | 120 |
| X 2 " | 124 | INGREZZA SPRINKLE | 120 |
| GAVRETO | 98 | INLYTA | 121 |

| | | | |
|--|-----|--|-----|
| INQOVI | 122 | LITFULO | 152 |
| INREBIC | 123 | LIVTENCITY | 153 |
| <i>insulin syringe-needle u-100 syringe 0.3 ml</i> | | LOKELMA | 154 |
| <i>29 gauge, 1 ml 29 gauge x 1/2", 1/2 ml 28</i> | | LONSURF | 155 |
| <i>gauge</i> | 124 | LORAZEPAM INTENSOL | 210 |
| <i>itraconazole oral capsule</i> | 130 | <i>lorazepam oral tablet 0.5 mg, 1 mg, 2 mg</i> .. | 210 |
| <i>ivermectin oral</i> | 131 | LORBRENA ORAL TABLET 100 MG, | |
| IWILFIN | 132 | 25 MG | 156 |
| JAKAFI | 133 | LUMAKRAS ORAL TABLET 120 MG, | |
| JAVYGTOR | 146 | 320 MG | 158 |
| JAYPIRCA ORAL TABLET 100 MG, | | LUPRON DEPOT-PED (3 MONTH) | |
| 50 MG | 134 | INTRAMUSCULAR SYRINGE KIT | |
| JOENJA | 135 | 11.25 MG | 159 |
| KALYDECO ORAL GRANULES IN | | LUPRON DEPOT-PED | |
| PACKET 13.4 MG, 25 MG, 5.8 MG, 50 | | INTRAMUSCULAR KIT 7.5 MG (PED) | |
| MG, 75 MG | 136 | | 159 |
| KALYDECO ORAL TABLET | 136 | LUPRON DEPOT-PED | |
| KERENDIA | 137 | INTRAMUSCULAR SYRINGE KIT | 159 |
| KESIMPTA PEN | 138 | <i>lurasidone oral tablet 120 mg, 20 mg, 40</i> | |
| KEVZARA | 139 | <i>mg, 60 mg, 80 mg</i> | 147 |
| KINERET | 140 | LYNPARZA | 160 |
| KISQALI FEMARA CO-PACK ORAL | | LYTGOBI ORAL TABLET 12 | |
| TABLET 200 MG/DAY(200 MG X 1)- | | MG/DAY (4 MG X 3), 16 MG/DAY (4 | |
| 2.5 MG, 400 MG/DAY(200 MG X 2)-2.5 | | MG X 4), 20 MG/DAY (4 MG X 5) | 163 |
| MG, 600 MG/DAY(200 MG X 3)-2.5 | | MAVENCLAD (10 TABLET PACK) | 164 |
| MG | 141 | MAVENCLAD (4 TABLET PACK) | 164 |
| KISQALI ORAL TABLET 200 | | MAVENCLAD (5 TABLET PACK) | 164 |
| MG/DAY (200 MG X 1), 400 MG/DAY | | MAVENCLAD (6 TABLET PACK) | 164 |
| (200 MG X 2), 600 MG/DAY (200 MG X | | MAVENCLAD (7 TABLET PACK) | 164 |
| 3) | 141 | MAVENCLAD (8 TABLET PACK) | 164 |
| KLISYRI | 142 | MAVENCLAD (9 TABLET PACK) | 164 |
| KOSELUGO ORAL CAPSULE 10 MG, | | MAVYRET ORAL PELLETS IN | |
| 25 MG | 144 | PACKET | 165 |
| KRAZATI | 145 | MAVYRET ORAL TABLET | 165 |
| <i>lapatinib</i> | 286 | <i>megestrol oral suspension 400 mg/10 ml</i> | |
| <i>lenalidomide</i> | 224 | <i>(40 mg/ml), 625 mg/5 ml (125 mg/ml)</i> | 166 |
| LENVIMA | 148 | <i>megestrol oral tablet</i> | 166 |
| LEUKINE INJECTION RECON SOLN | | MEKINIST ORAL RECON SOLN | 167 |
| | 149 | MEKINIST ORAL TABLET 0.5 MG, 2 | |
| LIBERVANT | 150 | MG | 167 |
| <i>lidocaine hcl mucous membrane solution 4</i> | | MEKTOVI | 168 |
| <i>% (40 mg/ml)</i> | 278 | <i>methadone oral solution 10 mg/5 ml, 5</i> | |
| <i>lidocaine topical adhesive patch,medicated</i> | | <i>mg/5 ml</i> | 210 |
| <i>5 %</i> | 151 | <i>methadone oral tablet 10 mg, 5 mg</i> | 210 |
| <i>lidocaine topical ointment</i> | 278 | <i>metyrosine</i> | 169 |
| <i>lidocaine-prilocaine topical cream</i> | 278 | <i>mifepristone oral tablet 300 mg</i> | 143 |

| | | | |
|--|-----|--|-----|
| <i>miglustat</i> | 326 | ORENCIA SUBCUTANEOUS | |
| <i>modafinil</i> | 213 | SYRINGE 125 MG/ML, 50 MG/0.4 ML, | |
| <i>morphine concentrate oral solution</i> | 210 | 87.5 MG/0.7 ML | 197 |
| <i>morphine oral solution 10 mg/5 ml, 20</i> | | ORENITRAM ORAL TABLET | |
| <i>mg/5 ml (4 mg/ml)</i> | 210 | EXTENDED RELEASE 0.125 MG, 0.25 | |
| <i>morphine oral tablet</i> | 210 | MG, 1 MG, 2.5 MG, 5 MG | 215 |
| <i>morphine oral tablet extended release 100</i> | | ORGOVYX | 199 |
| <i>mg, 15 mg, 200 mg, 30 mg, 60 mg</i> | 210 | ORKAMBI ORAL GRANULES IN | |
| MOUNJARO | 104 | PACKET | 200 |
| MULPLETA | 170 | ORKAMBI ORAL TABLET | 200 |
| NAMZARIC | 172 | ORSERDU ORAL TABLET 345 MG, | |
| NAYZILAM | 173 | 86 MG | 201 |
| NERLYNX | 174 | OTEZLA ORAL TABLET 30 MG | 202 |
| NEXLETOL | 176 | OTEZLA STARTER ORAL | |
| NEXLIZET | 176 | TABLETS,DOSE PACK 10 MG (4)-20 | |
| NINLARO | 178 | MG (4)-30 MG (47) | 202 |
| <i>nitisinone</i> | 179 | <i>oxycodone oral capsule</i> | 210 |
| NORDITROPIN FLEXPRO | 105 | <i>oxycodone oral concentrate</i> | 210 |
| NUBEQA | 181 | <i>oxycodone oral tablet 10 mg, 15 mg, 20</i> | |
| NUCALA SUBCUTANEOUS AUTO- | | <i>mg, 30 mg, 5 mg</i> | 210 |
| INJECTOR | 182 | <i>oxycodone-acetaminophen oral tablet 10-</i> | |
| NUCALA SUBCUTANEOUS RECON | | <i>325 mg, 2.5-325 mg, 5-325 mg, 7.5-325 mg</i> | |
| SOLN | 182 | | 210 |
| NUCALA SUBCUTANEOUS | | OZEMPIC SUBCUTANEOUS PEN | |
| SYRINGE 100 MG/ML, 40 MG/0.4 ML | 182 | INJECTOR 0.25 MG OR 0.5 MG (2 | |
| NUDEXTA | 183 | MG/3 ML), 1 MG/DOSE (4 MG/3 ML), | |
| NUPLAZID | 184 | 2 MG/DOSE (8 MG/3 ML) | 104 |
| NURTEC ODT | 185 | PANRETIN | 203 |
| OCALIVA | 188 | PANZYGA | 116 |
| OCTAGAM | 116 | <i>pazopanib</i> | 305 |
| <i>octreotide acetate injection solution</i> | 189 | PEGASYS | 125 |
| ODOMZO | 190 | PEMAZYRE | 204 |
| OFEV | 127 | <i>pen needle, diabetic needle 29 gauge x 1/2"</i> | |
| OGSIVEO ORAL TABLET 100 MG, | | | 124 |
| 150 MG, 50 MG | 191 | PHEBURANE | 205 |
| OJEMDA ORAL SUSPENSION FOR | | <i>phenobarbital</i> | 109 |
| RECONSTITUTION | 192 | PIQRAY ORAL TABLET 200 | |
| OJEMDA ORAL TABLET 500 | | MG/DAY (200 MG X 1), 250 MG/DAY | |
| MG/WEEK (100 MG X 5) | 192 | (200 MG X1-50 MG X1), 300 MG/DAY | |
| OJJAARA | 193 | (150 MG X 2) | 206 |
| OLUMIANT | 194 | <i>pirfenidone oral capsule</i> | 127 |
| ONUREG | 196 | <i>pirfenidone oral tablet</i> | 127 |
| OPSUMIT | 215 | PLEGRIDY SUBCUTANEOUS PEN | |
| ORENCIA CLICKJECT | 197 | INJECTOR 125 MCG/0.5 ML | 126 |
| | | PLEGRIDY SUBCUTANEOUS | |
| | | SYRINGE 125 MCG/0.5 ML | 126 |

| | | | |
|--|-----|--|-----|
| POMALYST | 207 | RUBRACA | 231 |
| <i>posaconazole oral tablet, delayed release (dr/ec)</i> | 208 | <i>rufinamide</i> | 26 |
| <i>pregabalin oral capsule 100 mg, 150 mg, 200 mg, 225 mg, 25 mg, 300 mg, 50 mg, 75 mg</i> | 162 | RYBELSUS | 104 |
| <i>pregabalin oral solution</i> | 162 | RYDAPT | 232 |
| PRENATAL VITAMIN PLUS LOW IRON | 209 | SAJAZIR | 87 |
| PRIVIGEN | 116 | <i>sapropterin</i> | 146 |
| PROLASTIN-C INTRAVENOUS SOLUTION | 12 | SCEMBLIX ORAL TABLET 100 MG, 20 MG, 40 MG | 236 |
| PROLIA | 212 | SECUADO | 237 |
| PROMACTA ORAL POWDER IN PACKET 12.5 MG, 25 MG | 276 | SIGNIFOR | 249 |
| PROMACTA ORAL TABLET 12.5 MG, 25 MG, 50 MG, 75 MG | 276 | <i>sildenafil (pulm.hypertension) oral suspension for reconstitution</i> | 215 |
| <i>promethazine oral tablet</i> | 108 | <i>sildenafil (pulm.hypertension) oral tablet</i> .. | 215 |
| PULMOZYME | 216 | SILIQ | 238 |
| <i>pyrimethamine</i> | 57 | SIMPONI SUBCUTANEOUS PEN INJECTOR 100 MG/ML, 50 MG/0.5 ML | 239 |
| QINLOCK | 217 | ML | 239 |
| <i>quinine sulfate</i> | 218 | SIMPONI SUBCUTANEOUS SYRINGE 100 MG/ML, 50 MG/0.5 ML | 239 |
| QULIPTA | 219 | SIRTURO | 241 |
| RAVICTI | 220 | SKYCLARYS | 242 |
| RECORLEV | 249 | SKYRIZI SUBCUTANEOUS PEN INJECTOR | 243 |
| REGRANEX | 221 | SKYRIZI SUBCUTANEOUS SYRINGE 150 MG/ML | 243 |
| REPATHA PUSHTRONEX | 222 | SKYRIZI SUBCUTANEOUS WEARABLE INJECTOR 180 MG/1.2 ML (150 MG/ML), 360 MG/2.4 ML (150 MG/ML) | 243 |
| REPATHA SURECLICK | 222 | <i>sodium oxybate</i> | 324 |
| REPATHA SYRINGE | 222 | <i>sodium phenylbutyrate</i> | 34 |
| RETEVMO ORAL CAPSULE 40 MG, 80 MG | 223 | <i>sofosbuvir-velpatasvir</i> | 70 |
| REXULTI ORAL TABLET | 225 | SOHONOS ORAL CAPSULE 1 MG, 1.5 MG, 10 MG, 2.5 MG, 5 MG | 244 |
| REZDIFFRA | 226 | SOMAVERT | 246 |
| REZLIDHIA | 227 | <i>sorafenib</i> | 175 |
| RINVOQ ORAL TABLET EXTENDED RELEASE 24 HR 15 MG, 30 MG, 45 MG | 228 | SPRYCEL | 247 |
| RIVFLOZA SUBCUTANEOUS SOLUTION | 229 | STELARA SUBCUTANEOUS SOLUTION | 248 |
| RIVFLOZA SUBCUTANEOUS SYRINGE 128 MG/0.8 ML, 160 MG/ML | 229 | STELARA SUBCUTANEOUS SYRINGE 45 MG/0.5 ML, 90 MG/ML .. | 248 |
| ROZLYTREK ORAL CAPSULE 100 MG, 200 MG | 230 | STIVARGA | 250 |
| ROZLYTREK ORAL PELLETS IN PACKET | 230 | <i>sunitinib malate</i> | 253 |
| | | SUNOSI | 251 |
| | | SYMDEKO | 254 |
| | | SYMPAZAN | 255 |

| | | | |
|---|-----|--|-----|
| SYNAREL | 256 | TRIKAFTA ORAL GRANULES IN | |
| TABRECTA | 257 | PACKET, SEQUENTIAL | 281 |
| <i>tadalafil (pulm. hypertension)</i> | 215 | TRIKAFTA ORAL TABLETS, | |
| <i>tadalafil oral tablet 2.5 mg, 5 mg</i> | 45 | SEQUENTIAL | 281 |
| TAFINLAR ORAL CAPSULE | 329 | <i>trimipramine</i> | 108 |
| TAFINLAR ORAL TABLET FOR | | TRINTELLIX | 282 |
| SUSPENSION | 258 | TRULICITY | 104 |
| TAGRISSE | 259 | TRUQAP | 283 |
| TAKHZYRO SUBCUTANEOUS | | TUKYSA ORAL TABLET 150 MG, 50 | |
| SOLUTION | 260 | MG | 284 |
| TAKHZYRO SUBCUTANEOUS | | TURALIO ORAL CAPSULE 125 MG.. | 285 |
| SYRINGE 150 MG/ML, 300 MG/2 ML | | TYMLOS | 287 |
| (150 MG/ML) | 260 | UBRELVY ORAL TABLET 100 MG, | |
| TALTZ AUTOINJECTOR | 262 | 50 MG | 288 |
| TALTZ SYRINGE SUBCUTANEOUS | | UPTRAVI ORAL TABLET 1,000 MCG, | |
| SYRINGE 80 MG/ML | 262 | 1,200 MCG, 1,400 MCG, 1,600 MCG, | |
| TALZENNA | 264 | 200 MCG, 400 MCG, 600 MCG, 800 | |
| TASCENSO ODT | 266 | MCG | 215 |
| TASIGNA | 267 | UPTRAVI ORAL TABLETS,DOSE | |
| <i>tasimelteon</i> | 268 | PACK | 215 |
| <i>tazarotene topical cream</i> | 269 | VALCHLOR | 289 |
| TAZORAC TOPICAL CREAM 0.05 % | 269 | VALTOCO | 290 |
| TAZVERIK | 270 | <i>vancomycin oral capsule 125 mg, 250 mg.</i> | 291 |
| TEPMETKO | 272 | VANFLYTA | 292 |
| <i>teriflunomide</i> | 19 | VENCLEXTA ORAL TABLET 10 MG, | |
| <i>teriparatide subcutaneous pen injector 20</i> | | 100 MG, 50 MG | 293 |
| <i>mcg/dose (620mcg/2.48ml)</i> | 92 | VENCLEXTA STARTING PACK | 293 |
| <i>testosterone cypionate</i> | 273 | VERQUVO | 294 |
| <i>testosterone enanthate</i> | 273 | VERZENIO | 295 |
| <i>testosterone transdermal gel in metered-</i> | | VIBERZI | 296 |
| <i>dose pump 20.25 mg/1.25 gram (1.62 %)</i> .. | 273 | <i>vigabatrin</i> | 233 |
| <i>testosterone transdermal gel in packet 1.62</i> | | VIGADRONE | 233 |
| <i>% (20.25 mg/1.25 gram), 1.62 % (40.5</i> | | VIGPODER | 233 |
| <i>mg/2.5 gram)</i> | 273 | VIJOICE ORAL GRANULES IN | |
| <i>tetrabenazine oral tablet 12.5 mg, 25 mg</i> ... | 314 | PACKET | 298 |
| THALOMID ORAL CAPSULE 100 | | VIJOICE ORAL TABLET 125 MG, 250 | |
| MG, 150 MG, 200 MG, 50 MG | 275 | MG/DAY (200 MG X1-50 MG X1), 50 | |
| TIBSOVO | 277 | MG | 298 |
| TOBI PODHALER | 44 | <i>vilazodone</i> | 297 |
| <i>tobramycin in 0.225 % nacl</i> | 44 | VITRAKVI ORAL CAPSULE 100 MG, | |
| <i>tobramycin inhalation</i> | 44 | 25 MG | 299 |
| <i>tolvaptan</i> | 234 | VITRAKVI ORAL SOLUTION | 299 |
| <i>tramadol oral tablet 50 mg</i> | 210 | VIVJOA | 300 |
| <i>tramadol-acetaminophen</i> | 210 | VIZIMPRO | 301 |
| <i>tretinoin topical cream</i> | 280 | VONJO | 302 |
| <i>tretinoin topical gel 0.01 %, 0.025 %</i> | 280 | <i>voriconazole intravenous</i> | 303 |

| | | | |
|--|-----|---|-----|
| VOSEVI | 304 | ZILBRYSQ SUBCUTANEOUS | |
| VOWST | 82 | SYRINGE 16.6 MG/0.416 ML, 23 | |
| VRAYLAR ORAL CAPSULE | 306 | MG/0.574 ML, 32.4 MG/0.81 ML | 171 |
| VUMERITY | 307 | ZOLINZA | 331 |
| VYNDAQEL | 17 | <i>zolpidem oral tablet</i> | 210 |
| WELIREG | 308 | ZONISADE | 332 |
| XALKORI ORAL CAPSULE | 309 | ZTALMY | 333 |
| XALKORI ORAL PELLETT 150 MG, 20 | | ZURZUVAE ORAL CAPSULE 20 MG, | |
| MG, 50 MG | 309 | 25 MG, 30 MG | 334 |
| XCOPRI | 310 | ZYDELIG | 335 |
| XCOPRI MAINTENANCE PACK | 310 | ZYKADIA | 336 |
| XCOPRI TITRATION PACK | 310 | | |
| XDEMVY | 311 | | |
| XELJANZ ORAL SOLUTION | 313 | | |
| XELJANZ ORAL TABLET | 312 | | |
| XELJANZ XR | 312 | | |
| XERMELO | 315 | | |
| XGEVA | 316 | | |
| XIFAXAN ORAL TABLET 550 MG | 317 | | |
| XOLAIR | 318 | | |
| XOLREMDI | 320 | | |
| XOSPATA | 321 | | |
| XPOVIO ORAL TABLET 100 | | | |
| MG/WEEK (50 MG X 2), 40 | | | |
| MG/WEEK (40 MG X 1), 40MG | | | |
| TWICE WEEK (40 MG X 2), 60 | | | |
| MG/WEEK (60 MG X 1), 60MG | | | |
| TWICE WEEK (120 MG/WEEK), 80 | | | |
| MG/WEEK (40 MG X 2), 80MG | | | |
| TWICE WEEK (160 MG/WEEK) | 322 | | |
| XTANDI ORAL CAPSULE | 323 | | |
| XTANDI ORAL TABLET 40 MG, 80 | | | |
| MG | 323 | | |
| XYREM | 324 | | |
| YARGESA | 326 | | |
| YONSA | 325 | | |
| YUFLYMA(CF) | 110 | | |
| YUFLYMA(CF) AI CROHN'S-UC-HS | 110 | | |
| YUFLYMA(CF) AUTOINJECTOR | 110 | | |
| <i>zaleplon oral capsule 10 mg, 5 mg</i> | 210 | | |
| ZAVZPRET | 327 | | |
| ZEJULA ORAL TABLET | 328 | | |
| ZELBORAF | 329 | | |
| ZEPOSIA | 330 | | |
| ZEPOSIA STARTER KIT (28-DAY) | 330 | | |
| ZEPOSIA STARTER PACK (7-DAY) | 330 | | |

GnRH Agonists

Products Affected

- **ELIGARD 22.5 MG (3 MONTH) SUBCUTANEOUS SYRINGE**
- **ELIGARD 30 MG (4 MONTH) SUBCUTANEOUS SYRINGE**
- **ELIGARD 45 MG (6 MONTH) SUBCUTANEOUS SYRINGE**
- **ELIGARD 7.5 MG (1 MONTH) SUBCUTANEOUS SYRINGE**
- **TRELSTAR 11.25 MG IM SUSPENSION**
- **TRELSTAR 22.5 MG IM SUSPENSION**
- **TRELSTAR 3.75 MG IM SUSPENSION**

Details

| | |
|-----------------|---|
| Criteria | Require a trial of Lupron Depot (Step 1 drug) in the last 180 days when being utilized for the same medically accepted indication |
|-----------------|---|

Herpetic Keratitis

Products Affected

- ZIRGAN 0.15 % EYE GEL

Details

| | |
|-----------------|---|
| Criteria | Require a 1 month trial of generic trifluridine eye drops (Step 1 drug) in the last 90 days |
|-----------------|---|

Pulmonary Antiinflammatory

Products Affected

- *fluticasone propionate 100 mcg/actuation blister powder for inhalation*
- *fluticasone propionate 110 mcg/actuation hfa aerosol inhaler*
- *fluticasone propionate 220 mcg/actuation hfa aerosol inhaler*
- *fluticasone propionate 250 mcg/actuation blister powder for inhalation*
- *fluticasone propionate 44 mcg/actuation hfa aerosol inhaler*
- *fluticasone propionate 50 mcg/actuation blister powder for inhalation*

Details

| | |
|-----------------|---|
| Criteria | Require a 1 month trial of Qvar and Asmanex/Asmanex HFA (Step 1 drugs) in the last 180 days |
|-----------------|---|

Rytary

Products Affected

- **RYTARY 23.75 MG-95 MG
CAPSULE,EXTENDED RELEASE**
- **RYTARY 36.25 MG-145 MG
CAPSULE,EXTENDED RELEASE**
- **RYTARY 48.75 MG-195 MG
CAPSULE,EXTENDED RELEASE**
- **RYTARY 61.25 MG-245 MG
CAPSULE,EXTENDED RELEASE**

Details

| | |
|-----------------|---|
| Criteria | Require a trial of generic carbidopa/levodopa product (Step 1 drug) in the last 90 days |
|-----------------|---|

Index of Drugs

**ELIGARD 22.5 MG (3 MONTH)
SUBCUTANEOUS SYRINGE..... 1**

**ELIGARD 30 MG (4 MONTH)
SUBCUTANEOUS SYRINGE..... 1**

**ELIGARD 45 MG (6 MONTH)
SUBCUTANEOUS SYRINGE..... 1**

**ELIGARD 7.5 MG (1 MONTH)
SUBCUTANEOUS SYRINGE..... 1**

*fluticasone propionate 100 mcg/actuation
blister powder for inhalation..... 3*

*fluticasone propionate 110 mcg/actuation
hfa aerosol inhaler..... 3*

*fluticasone propionate 220 mcg/actuation
hfa aerosol inhaler..... 3*

*fluticasone propionate 250 mcg/actuation
blister powder for inhalation..... 3*

*fluticasone propionate 44 mcg/actuation
hfa aerosol inhaler..... 3*

*fluticasone propionate 50 mcg/actuation
blister powder for inhalation..... 3*

**RYTARY 23.75 MG-95 MG
CAPSULE,EXTENDED RELEASE.....4**

**RYTARY 36.25 MG-145 MG
CAPSULE,EXTENDED RELEASE.....4**

**RYTARY 48.75 MG-195 MG
CAPSULE,EXTENDED RELEASE.....4**

**RYTARY 61.25 MG-245 MG
CAPSULE,EXTENDED RELEASE.....4**

**TRELSTAR 11.25 MG IM
SUSPENSION..... 1**

TRELSTAR 22.5 MG IM SUSPENSION.. 1

TRELSTAR 3.75 MG IM SUSPENSION.. 1

ZIRGAN 0.15 % EYE GEL..... 2